{"PMC7175784": [["The problem of RNA modification system in host cellsWe have stated that SARS-CoV-2 is an RNA virus.", [["cells", "ANATOMY", 47, 52], ["SARS", "DISEASE", 72, 76], ["host cells", "CELL", 42, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 72, 82], ["host cells", "CELL_TYPE", 42, 52], ["SARS-CoV", "SPECIES", 72, 80], ["RNA modification system in host cells", "PROBLEM", 15, 52], ["SARS", "PROBLEM", 72, 76], ["CoV", "TEST", 77, 80], ["an RNA virus", "PROBLEM", 86, 98], ["RNA modification", "OBSERVATION", 15, 31], ["host cells", "OBSERVATION", 42, 52], ["RNA virus", "OBSERVATION", 89, 98]]], ["The classic theories, principles and formula of evolutionary biology are based on the central dogma, which assumes the DNA-to-RNA-to-protein chain.", [["DNA", "CELLULAR_COMPONENT", 119, 122], ["DNA-to-RNA-to-protein chain", "PROTEIN", 119, 146], ["the DNA", "TEST", 115, 122], ["RNA", "TEST", 126, 129], ["central dogma", "OBSERVATION", 86, 99]]], ["The basic notion is that the mutations on DNA could be inherited rather than the modifications on RNA.", [["DNA", "CELLULAR_COMPONENT", 42, 45], ["RNA", "RNA", 98, 101], ["the mutations on DNA", "PROBLEM", 25, 45], ["the modifications on RNA", "PROBLEM", 77, 101]]], ["For example, despite the numerous types of RNA modifications in higher eukaryotes, these organisms do not suffer from extraordinarily high mutation rates because the modified RNAs could not be transmitted to the next generation.", [["modified RNAs", "RNA", 166, 179], ["RNA modifications", "TREATMENT", 43, 60], ["extraordinarily high mutation rates", "PROBLEM", 118, 153], ["the modified RNAs", "PROBLEM", 162, 179], ["RNA modifications", "OBSERVATION", 43, 60], ["higher eukaryotes", "OBSERVATION_MODIFIER", 64, 81], ["high mutation", "OBSERVATION", 134, 147]]], ["However, for RNA viruses, their RNA is actually their genetic information.", [["RNA viruses", "PROBLEM", 13, 24]]], ["Whether the evolutionary principles could be applied to RNA viruses should be seriously debated.", [["RNA viruses", "PROBLEM", 56, 67]]], ["The host cells have multiple RNA modification systems/enzymes.", [["cells", "ANATOMY", 9, 14], ["host cells", "CELL", 4, 14], ["host cells", "CELL_TYPE", 4, 14], ["enzymes", "PROTEIN", 54, 61], ["enzymes", "TEST", 54, 61], ["host cells", "OBSERVATION", 4, 14]]], ["The changes in viral RNA (by host cells) would permanently change its genetic information and be transmitted to the next \u2018generation\u2019, which is similar to genetic mutations in higher organisms.", [["cells", "ANATOMY", 34, 39], ["host cells", "CELL", 29, 39], ["viral RNA", "RNA", 15, 24], ["host cells", "CELL_TYPE", 29, 39], ["The changes in viral RNA", "PROBLEM", 0, 24], ["genetic mutations in higher organisms", "PROBLEM", 155, 192], ["viral RNA", "OBSERVATION", 15, 24]]], ["Technically, one could not distinguish genetic mutations and RNA modifications from the RNA-sequencing data of RNA viruses.", [["genetic mutations", "PROBLEM", 39, 56], ["RNA modifications", "PROBLEM", 61, 78], ["the RNA", "TEST", 84, 91], ["sequencing data", "TEST", 92, 107], ["RNA viruses", "PROBLEM", 111, 122]]], ["So, what is the point of detecting positive/negative selection based on the mutations in the virus population?", [["positive/negative selection", "PROBLEM", 35, 62], ["the mutations", "PROBLEM", 72, 85]]], ["These mutations are possibly conferred by the host cell\u2019s RNA modification systems.", [["cell", "ANATOMY", 51, 55], ["cell", "CELL", 51, 55], ["These mutations", "PROBLEM", 0, 15], ["host cell", "OBSERVATION", 46, 55]]], ["How could the randomly occurring RNA modification events have preference on missense or synonymous sites?The problem of RNA modification system in host cellsThe recent study by Tang et al. [10] claimed that the divergence between SARS-CoV-2 and RaTG13 (a bat SARS-related coronavirus) is 14-times larger than the divergence between human and chimpanzee.", [["cells", "ANATOMY", 152, 157], ["SARS", "DISEASE", 259, 263], ["host cells", "CELL", 147, 157], ["SARS-CoV-2", "ORGANISM", 230, 240], ["RaTG13", "GENE_OR_GENE_PRODUCT", 245, 251], ["bat SARS-related coronavirus", "ORGANISM", 255, 283], ["human", "ORGANISM", 332, 337], ["chimpanzee", "ORGANISM", 342, 352], ["host cells", "CELL_TYPE", 147, 157], ["RaTG13", "DNA", 245, 251], ["human", "SPECIES", 332, 337], ["chimpanzee", "SPECIES", 342, 352], ["SARS-CoV", "SPECIES", 230, 238], ["human", "SPECIES", 332, 337], ["RNA modification events", "PROBLEM", 33, 56], ["missense or synonymous sites", "PROBLEM", 76, 104], ["RNA modification system in host cells", "PROBLEM", 120, 157], ["The recent study", "TEST", 157, 173], ["SARS", "TEST", 230, 234], ["CoV", "TEST", 235, 238], ["RaTG13", "TEST", 245, 251], ["a bat SARS", "TEST", 253, 263], ["coronavirus", "PROBLEM", 272, 283], ["RNA modification", "OBSERVATION", 120, 136], ["host cells", "OBSERVATION", 147, 157]]], ["The authors concluded that only the neutral evolving sites should be considered rather than all different sites.", [["the neutral evolving sites", "PROBLEM", 32, 58]]], ["Let us assume that both SARS-CoV-2 and RaTG13 undergo the RNA modification by host cells, and the modified viral RNA is inheritable, then their sequence (SARS-CoV-2 and RaTG13) could become quite different within a short time scale.", [["cells", "ANATOMY", 83, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 34], ["RaTG13", "GENE_OR_GENE_PRODUCT", 39, 45], ["host cells", "CELL", 78, 88], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["RaTG13", "GENE_OR_GENE_PRODUCT", 169, 175], ["SARS-CoV-2", "DNA", 24, 34], ["RaTG13", "DNA", 39, 45], ["host cells", "CELL_TYPE", 78, 88], ["modified viral RNA", "RNA", 98, 116], ["RaTG13", "DNA", 169, 175], ["both SARS", "TEST", 19, 28], ["CoV", "TEST", 29, 32], ["RaTG13", "TREATMENT", 39, 45], ["the RNA modification", "TREATMENT", 54, 74], ["the modified viral RNA", "PROBLEM", 94, 116], ["their sequence", "TEST", 138, 152], ["SARS", "TEST", 154, 158], ["CoV", "TEST", 159, 162], ["viral RNA", "OBSERVATION", 107, 116]]], ["When dS might be largely contributed by the RNA modification system of host cells, this estimation could be inaccurate.", [["cells", "ANATOMY", 76, 81], ["host cells", "CELL", 71, 81], ["dS", "DNA", 5, 7], ["host cells", "CELL_TYPE", 71, 81], ["this estimation", "TEST", 83, 98], ["host cells", "OBSERVATION", 71, 81]]], ["In the dN and dS calculation, it is necessary to rule out any mismatch sites that might be produced by RNA modification.", [["dS calculation", "TEST", 14, 28], ["any mismatch sites", "PROBLEM", 58, 76], ["mismatch", "OBSERVATION", 62, 70]]], ["Does \u2018u\u2019 include the nucleotide changes conferred by the host\u2019s modification enzymes?", [["nucleotide", "CHEMICAL", 21, 31], ["nucleotide", "CHEMICAL", 21, 31], ["host\u2019s modification enzymes", "PROTEIN", 57, 84], ["the nucleotide changes", "PROBLEM", 17, 39]]], ["Therefore, the authors' logic chain is questionable.The problem of RNA modification system in host cellsMore importantly, the single nucleotide polymorphism and modified RNAs are technically indistinguishable.", [["cells", "ANATOMY", 99, 104], ["host cells", "CELL", 94, 104], ["host cells", "CELL_TYPE", 94, 104], ["modified RNAs", "RNA", 161, 174], ["RNA modification system in host cells", "PROBLEM", 67, 104], ["the single nucleotide polymorphism and modified RNAs", "PROBLEM", 122, 174], ["RNA modification", "OBSERVATION", 67, 83], ["host cells", "OBSERVATION", 94, 104]]], ["The software and algorithms only align the sequences but do not tell you whether the observed mismatch is a single nucleotide polymorphism or RNA modification site.", [["RNA modification site", "DNA", 142, 163], ["a single nucleotide polymorphism", "PROBLEM", 106, 138], ["RNA modification site", "PROBLEM", 142, 163], ["mismatch", "OBSERVATION", 94, 102]]], ["This is a biological problem rather than technical problem, and could not be solved by adjusting or improving the alignment parameters or filtering criteria.The problem of RNA modification system in host cellsOne may argue that some studies have analyzed RNA modifications by using classic evolutionary theory, but note that the viral RNA is modified by the host cell rather than by the virus itself, and their equivalence (modified by the host or modified by itself) should be formally proven before conducting any analyses.The problem of RNA modification system in host cellsIndeed, the coronaviruses isolated from the hosts (like human, bat or pangolin) are only compared with SARS-CoV-2.", [["cells", "ANATOMY", 204, 209], ["cell", "ANATOMY", 363, 367], ["cells", "ANATOMY", 572, 577], ["host cells", "CELL", 199, 209], ["host cell", "CELL", 358, 367], ["host cells", "CELL", 567, 577], ["coronaviruses", "ORGANISM", 589, 602], ["human", "ORGANISM", 633, 638], ["bat", "ORGANISM", 640, 643], ["pangolin", "GENE_OR_GENE_PRODUCT", 647, 655], ["SARS-CoV-2", "ORGANISM", 680, 690], ["host cells", "CELL_TYPE", 199, 209], ["viral RNA", "RNA", 329, 338], ["host cells", "CELL_TYPE", 567, 577], ["human", "SPECIES", 633, 638], ["human", "SPECIES", 633, 638], ["SARS-CoV", "SPECIES", 680, 688], ["a biological problem", "PROBLEM", 8, 28], ["RNA modification system in host cells", "PROBLEM", 172, 209], ["some studies", "TEST", 228, 240], ["the viral RNA", "PROBLEM", 325, 338], ["RNA modification system in host cells", "PROBLEM", 540, 577], ["the coronaviruses", "PROBLEM", 585, 602], ["SARS", "TEST", 680, 684], ["CoV", "TEST", 685, 688], ["RNA modification", "OBSERVATION", 172, 188], ["host cells", "OBSERVATION", 199, 209], ["viral RNA", "OBSERVATION", 329, 338], ["host cell", "OBSERVATION", 358, 367], ["RNA modification", "OBSERVATION", 540, 556], ["host cells", "OBSERVATION", 567, 577], ["coronaviruses", "OBSERVATION", 589, 602]]], ["Therefore, RNA virus sequence is compared with the SARS2 RNA, and hence, the used strategy is almost sound.", [["SARS2", "GENE_OR_GENE_PRODUCT", 51, 56], ["SARS2 RNA", "RNA", 51, 60], ["RNA virus sequence", "TEST", 11, 29], ["the SARS2 RNA", "TEST", 47, 60]]], ["So, these studies compared virus to virus or RNA to RNA and conclude the potential host or carrier based on the highest percent of identity or potential concluded recombination events.", [["these studies", "TEST", 4, 17], ["virus", "PROBLEM", 36, 41], ["recombination events", "PROBLEM", 163, 183]]], ["However, as we have stated, the sequence similarity could be largely and even randomly skewed by the hosts' RNA modification systems.", [["RNA modification systems", "PROBLEM", 108, 132]]], ["Therefore, aligning RNA with RNA is fine, but the concern is how to distinguish whether the observed divergence (or mismatch sites) really reflects the phylogeny of the viruses.", [["aligning RNA with RNA", "PROBLEM", 11, 32], ["mismatch sites", "PROBLEM", 116, 130], ["viruses", "OBSERVATION", 169, 176]]], ["It could simply be shaped by the arbitrary modification of the host\u2019s enzymes.The problem of RNA modification system in host cellsThe next concern caused by RNA modification system is the \u2018batch effect\u2019.", [["cells", "ANATOMY", 125, 130], ["host cells", "CELL", 120, 130], ["host\u2019s enzymes", "PROTEIN", 63, 77], ["host cells", "CELL_TYPE", 120, 130], ["the host\u2019s enzymes", "TEST", 59, 77], ["RNA modification system in host cells", "PROBLEM", 93, 130], ["RNA modification system", "TREATMENT", 157, 180], ["could simply be", "UNCERTAINTY", 3, 18], ["shaped", "OBSERVATION_MODIFIER", 19, 25], ["RNA modification", "OBSERVATION", 93, 109], ["host cells", "OBSERVATION", 120, 130]]], ["In population genetics, DNA mutations take place randomly among different individuals.", [["DNA", "CELLULAR_COMPONENT", 24, 27], ["DNA mutations", "PROBLEM", 24, 37]]], ["But when RNA viruses are modified by host cells, the modification enzymes are likely to modify multiple sites at a time.", [["cells", "ANATOMY", 42, 47], ["host cells", "CELL", 37, 47], ["host cells", "CELL_TYPE", 37, 47], ["modification enzymes", "PROTEIN", 53, 73], ["RNA viruses", "PROBLEM", 9, 20], ["the modification enzymes", "TEST", 49, 73]]], ["Since the genes of an RNA virus (like the 12 genes of SARS-CoV-2) are linked, they are prone to be modified \u2018in a batch\u2019.", [["SARS-CoV-2", "ORGANISM", 54, 64], ["an RNA virus", "PROBLEM", 19, 31], ["RNA virus", "OBSERVATION", 22, 31]]], ["In contrast, in higher organisms, it is not possible to see numerous individual-specific mutations linked within an entire haplotype unless it is driven by selective sweep.", [["not possible", "UNCERTAINTY", 40, 52]]], ["This reality again challenges the application of traditional theories to RNA viruses.The problem of RNA modification system in host cellsIn our opinion, the RNA viruses should obey a different evolutionary theory.", [["cells", "ANATOMY", 132, 137], ["host cells", "CELL", 127, 137], ["host cells", "CELL_TYPE", 127, 137], ["traditional theories", "TREATMENT", 49, 69], ["RNA viruses", "PROBLEM", 73, 84], ["RNA modification system in host cells", "PROBLEM", 100, 137], ["the RNA viruses", "PROBLEM", 153, 168], ["RNA modification", "OBSERVATION", 100, 116], ["host cells", "OBSERVATION", 127, 137]]], ["So far, the functional experiments are more important and reliable than the pure evolutionary analyses in this case of RNA virus.", [["RNA virus", "PROBLEM", 119, 128]]], ["When traditional evolutionary principles are jeopardized by additional mutation forces, the functional experiments work well as they did in the past.Problems raised from the RNA replication processApart from being modified by the host RNA modification systems, there are other concerns about whether the evolutionary theories could be applied to the RNA viruses like SARS-CoV-2.Problems raised from the RNA replication processFirst, for cellular organisms, the DNA mutations are majorly introduced during the DNA replication process.", [["cellular organisms", "ANATOMY", 437, 455], ["SARS", "DISEASE", 367, 371], ["SARS-CoV-2", "ORGANISM", 367, 377], ["cellular", "CELL", 437, 445], ["DNA", "CELLULAR_COMPONENT", 461, 464], ["DNA", "CELLULAR_COMPONENT", 509, 512], ["SARS-CoV", "SPECIES", 367, 375], ["additional mutation forces", "PROBLEM", 60, 86], ["Problems raised", "PROBLEM", 149, 164], ["the RNA replication process", "PROBLEM", 170, 197], ["the evolutionary theories", "PROBLEM", 300, 325], ["the RNA viruses", "PROBLEM", 346, 361], ["CoV", "TEST", 372, 375], ["Problems raised", "PROBLEM", 378, 393], ["the RNA replication process", "PROBLEM", 399, 426], ["cellular organisms", "PROBLEM", 437, 455], ["the DNA mutations", "PROBLEM", 457, 474], ["the DNA replication process", "TREATMENT", 505, 532], ["RNA replication", "OBSERVATION", 174, 189], ["RNA replication", "OBSERVATION", 403, 418]]], ["The mutation rate is largely connected with the fidelity of DNA replication.", [["DNA", "CELLULAR_COMPONENT", 60, 63], ["The mutation rate", "TEST", 0, 17], ["DNA replication", "TREATMENT", 60, 75]]], ["The next step is the natural selection force acting on these mutations, after which the deleterious mutations are purged and those beneficial mutations are maintained.", [["the deleterious mutations", "PROBLEM", 84, 109]]], ["However, RNA viruses either undergo the reverse-transcription process (like HIV) or the RNA replication process (like SARS-CoV-2).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 118, 128], ["HIV", "SPECIES", 76, 79], ["RNA viruses", "PROBLEM", 9, 20], ["HIV", "PROBLEM", 76, 79], ["the RNA replication process", "PROBLEM", 84, 111], ["RNA replication", "OBSERVATION", 88, 103]]], ["For RNA viruses, every newly transcribed RNA molecule is a potential offspring of the original virus.", [["RNA viruses", "PROBLEM", 4, 15], ["every newly transcribed RNA molecule", "PROBLEM", 17, 53], ["the original virus", "PROBLEM", 82, 100], ["viruses", "OBSERVATION", 8, 15], ["RNA molecule", "OBSERVATION", 41, 53], ["virus", "OBSERVATION", 95, 100]]], ["The mismatches introduced during reverse transcription or RNA replication would be maintained and kept in the offspring.", [["The mismatches", "TREATMENT", 0, 14], ["reverse transcription", "TREATMENT", 33, 54], ["RNA replication", "TREATMENT", 58, 73], ["mismatches", "OBSERVATION", 4, 14]]], ["Before applying the evolutionary formula to RNA viruses, one should state whether RNA replication has similar mismatching rates as DNA replication.", [["DNA", "CELLULAR_COMPONENT", 131, 134], ["RNA viruses", "PROBLEM", 44, 55], ["RNA replication", "PROBLEM", 82, 97], ["DNA replication", "TREATMENT", 131, 146]]], ["Intuitively, DNA\u2013DNA pairing (DNA replication), DNA\u2013RNA pairing (transcription) and RNA\u2013RNA pairing (such as RNA replication) should have different mismatching rates.", [["DNA\u2013DNA", "CELLULAR_COMPONENT", 13, 20], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["DNA\u2013RNA", "RNA", 48, 55], ["RNA\u2013RNA", "RNA", 84, 91], ["DNA\u2013DNA pairing (DNA replication", "TREATMENT", 13, 45], ["DNA\u2013RNA pairing", "TREATMENT", 48, 63], ["RNA\u2013RNA pairing", "TREATMENT", 84, 99], ["RNA replication", "TREATMENT", 109, 124], ["different mismatching rates", "PROBLEM", 138, 165]]], ["Thus, when applying theories to SARS-CoV-2, should the authors consider the potentially different mutation rates during the reverse transcription or RNA replication processes?", [["SARS", "DISEASE", 32, 36], ["SARS-CoV", "SPECIES", 32, 40], ["different mutation rates", "PROBLEM", 88, 112], ["the reverse transcription", "TREATMENT", 120, 145], ["RNA replication processes", "PROBLEM", 149, 174]]], ["Even the problem of technically indistinguishable RNA modification and the \u2018de novo\u2019 RNA mutation is not mentioned by the authors at all, let alone the mutations introduced during the RNA replication process.", [["let", "GENE_OR_GENE_PRODUCT", 138, 141], ["technically indistinguishable RNA modification", "PROBLEM", 20, 66], ["the \u2018de novo\u2019 RNA mutation", "PROBLEM", 71, 97], ["the mutations", "PROBLEM", 148, 161], ["RNA modification", "OBSERVATION", 50, 66]]], ["At least, the authors could briefly introduce the reproduction mode of SARS-CoV-2 rather than \u2018mechanically\u2019 apply the formula to an organism which they are not familiar with.Problems raised from the RNA replication processSecond, the DNA generated from the reversetranscription is only an intermediate, and could not be packaged into the envelope protein.", [["SARS", "DISEASE", 71, 75], ["DNA", "CELLULAR_COMPONENT", 235, 238], ["RNA replication processSecond", "DNA", 200, 229], ["envelope protein", "PROTEIN", 339, 355], ["the DNA", "PROBLEM", 231, 238]]], ["The same goes for the negative-strand RNA generated by the positive-strand RNA during the RNA replication.", [["negative-strand RNA", "RNA", 22, 41], ["positive-strand RNA", "RNA", 59, 78], ["the positive-strand RNA", "PROBLEM", 55, 78], ["the RNA replication", "TREATMENT", 86, 105], ["strand RNA", "OBSERVATION", 68, 78]]], ["So that the DNA/negative-strand RNA and any changes on it could not be directly transferred to the next host cell.", [["cell", "ANATOMY", 109, 113], ["DNA", "CELLULAR_COMPONENT", 12, 15], ["cell", "CELL", 109, 113], ["DNA/negative-strand RNA", "RNA", 12, 35], ["the DNA", "TEST", 8, 15], ["strand RNA", "PROBLEM", 25, 35], ["negative", "OBSERVATION", 16, 24], ["strand RNA", "OBSERVATION_MODIFIER", 25, 35]]], ["However, if a DNA intermediate could transcribe N RNA molecules, and a mutation takes place when N/2 RNA molecules have been transcribed, then only part of the offspring would have this mutation.", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["N RNA molecules", "PROTEIN", 48, 63], ["N/2 RNA molecules", "RNA", 97, 114], ["a DNA intermediate could transcribe N RNA molecules", "PROBLEM", 12, 63], ["a mutation", "PROBLEM", 69, 79], ["N/2 RNA molecules", "PROBLEM", 97, 114], ["this mutation", "PROBLEM", 181, 194]]], ["How could theories on DNA mutations be applied to a transiently existing DNA intermediate or negative-strand RNA?Problems raised from the RNA replication processThese factors may shed concerns on the accuracy and validity of the results of previous works.", [["DNA", "CELLULAR_COMPONENT", 22, 25], ["DNA", "CELLULAR_COMPONENT", 73, 76], ["negative-strand RNA", "RNA", 93, 112], ["DNA mutations", "PROBLEM", 22, 35], ["strand RNA", "PROBLEM", 102, 112], ["Problems raised", "PROBLEM", 113, 128], ["the RNA replication process", "PROBLEM", 134, 161], ["the accuracy", "TEST", 196, 208], ["RNA replication", "OBSERVATION", 138, 153]]], ["Hopefully, our opinions could be seen and discussed by other researchers and benefit the studies on the evolution and origin of SARS-CoV-2.ConclusionWe are concerned with the validity of applying classic evolutionary theories and formula to the evolution of RNA viruses.", [["SARS", "DISEASE", 128, 132], ["SARS-CoV-2", "ORGANISM", 128, 138], ["SARS-CoV", "SPECIES", 128, 136], ["the studies", "TEST", 85, 96], ["SARS", "PROBLEM", 128, 132], ["CoV", "TEST", 133, 136], ["RNA viruses", "PROBLEM", 258, 269], ["RNA viruses", "OBSERVATION", 258, 269]]], ["We have raised several confounding factors like the RNA replication process and the RNA modification systems of the hosts, which might jeopardize the validity of the application of classic methods to analyze the SARS-CoV-2 data.", [["the RNA replication process", "PROBLEM", 48, 75], ["classic methods", "TREATMENT", 181, 196], ["the SARS", "TEST", 208, 216], ["RNA replication", "OBSERVATION", 52, 67]]], ["However, we neither criticize any studies nor prove any ideas wrong.", [["any studies", "TEST", 30, 41]]], ["We hope our concerns could be considered by the broad community and could contribute to the accurate identification of the origins of SARS-CoV-2.Future perspectiveWe anticipate and speculate that the field of virus evolution could be incorporated with more novel evolutionary theories that distinguish cellular organisms, DNA viruses and RNA viruses, due to their distinct features of nucleotide components, mutation rates, and reproductive patterns.", [["cellular organisms", "ANATOMY", 302, 320], ["SARS", "DISEASE", 134, 138], ["nucleotide", "CHEMICAL", 385, 395], ["nucleotide", "CHEMICAL", 385, 395], ["SARS-CoV-2", "ORGANISM", 134, 144], ["cellular", "CELL", 302, 310], ["DNA", "CELLULAR_COMPONENT", 322, 325], ["SARS-CoV", "SPECIES", 134, 142], ["CoV", "TEST", 139, 142], ["virus evolution", "PROBLEM", 209, 224], ["cellular organisms", "PROBLEM", 302, 320], ["DNA viruses and RNA viruses", "PROBLEM", 322, 349], ["nucleotide components", "PROBLEM", 385, 406], ["mutation rates", "TEST", 408, 422], ["RNA viruses", "OBSERVATION", 338, 349], ["nucleotide components", "OBSERVATION", 385, 406]]]], "PMC7126760": [["IntroductionMullis et al. developed the polymerase chain reaction (PCR) in 1986 to clone specified deoxyribonucleic acid (DNA) fragments in vitro by using temperature cycling [1].", [["deoxyribonucleic acid", "CHEMICAL", 99, 120], ["deoxyribonucleic acid", "SIMPLE_CHEMICAL", 99, 120], ["DNA", "CELLULAR_COMPONENT", 122, 125], ["deoxyribonucleic acid (DNA) fragments", "DNA", 99, 136], ["the polymerase chain reaction", "PROBLEM", 36, 65], ["PCR", "TEST", 67, 70], ["deoxyribonucleic acid (DNA) fragments", "TREATMENT", 99, 136], ["temperature cycling", "TEST", 155, 174]]], ["A real-time PCR (RT-PCR) machine was introduced in 1997 by integrating a fluorometer with a temperature cycler [2], [3].", [["A real-time PCR (RT-PCR) machine", "TREATMENT", 0, 32], ["a temperature cycler", "TREATMENT", 90, 110]]], ["This RT-PCR system identifies DNA amplification by detecting the fluorescence-labeling dye in the PCR mix during the early phase of reaction.", [["DNA", "CELLULAR_COMPONENT", 30, 33], ["This RT-PCR system", "TEST", 0, 18], ["DNA amplification", "TEST", 30, 47], ["the fluorescence", "TEST", 61, 77], ["the PCR mix", "TREATMENT", 94, 105], ["reaction", "PROBLEM", 132, 140]]], ["In addition, the recorded time history of fluorescence intensity can be used to determine the concentration of target DNA fragments in the PCR mix before thermal cycling.", [["DNA", "CELLULAR_COMPONENT", 118, 121], ["target DNA fragments", "DNA", 111, 131], ["fluorescence intensity", "PROBLEM", 42, 64], ["target DNA fragments", "PROBLEM", 111, 131], ["the PCR mix", "TREATMENT", 135, 146]]], ["However, an RT-PCR machine requires using a complex thermal controller for repetitively heating and cooling samples, usually for 35\u201350 cycles.", [["samples", "ANATOMY", 108, 115], ["an RT-PCR machine", "TREATMENT", 9, 26], ["a complex thermal controller", "TREATMENT", 42, 70], ["repetitively heating and cooling samples", "TREATMENT", 75, 115]]], ["Restricted by the large size, costliness, and long amplification time, using traditional PCR thermocyclers have been limited to principal hospitals and laboratories.", [["traditional PCR thermocyclers", "TREATMENT", 77, 106], ["large", "OBSERVATION_MODIFIER", 18, 23], ["size", "OBSERVATION_MODIFIER", 24, 28]]], ["Recently, new platforms have been advanced by simplifying the equipment structure and reducing the amplification times.IntroductionA promising solution is to induce natural convection with temperature gradients, thereby enhancing the amplification of DNA [4].", [["DNA", "CELLULAR_COMPONENT", 251, 254], ["IntroductionA promising solution", "TREATMENT", 119, 151], ["temperature gradients", "PROBLEM", 189, 210]]], ["When the reagents in a sample circulate repeatedly among temperature zones because of the natural convection effect, the sample is anticipated to undergo three steps of a PCR cycle (i.e., nucleic acid denaturation, annealing, and extension) in a single circulation.", [["sample", "ANATOMY", 23, 29], ["nucleic acid", "CHEMICAL", 188, 200], ["a PCR cycle", "TEST", 169, 180], ["nucleic acid denaturation", "PROBLEM", 188, 213], ["natural convection", "OBSERVATION", 90, 108]]], ["Therefore, convective PCR can substantially shorten the amplification time from multiple hours to 30\u201340 min [5], [6].", [["convective PCR", "TEST", 11, 25]]], ["By using this mechanism, a dedicated thermocycler, the most expensive module of the conventional PCR, is not required.", [["the conventional PCR", "TEST", 80, 100]]], ["The real-time convective PCR (RT-cPCR) apparatus could also be devised by combining fluorescence detectors.", [["convective PCR", "TEST", 14, 28]]], ["However, the current RT-cPCR systems adopt two or even more individual temperature controllers and elaborate designs necessitating a specific shape of tubing or additional chambers to circulate the sample fluids thoroughly [7], [8], [9], [10], [11].", [["[8]", "SIMPLE_CHEMICAL", 228, 231], ["[9]", "SIMPLE_CHEMICAL", 233, 236], ["[10]", "SIMPLE_CHEMICAL", 238, 242], ["a specific shape of tubing", "TREATMENT", 131, 157], ["additional chambers", "TREATMENT", 161, 180], ["the sample fluids", "TEST", 194, 211]]], ["Current RT-cPCR systems also require skillful manipulation for certain operations such as loading and unloading reagents from thin tubing as well as sealing both tube ends without trapping air bubbles in the tube, thus causing detection errors.IntroductionChou et al. designed and fabricated a novel capillary convective PCR (ccPCR) platform with a capillary tube mounted on a heater at a constant temperature of 95 \u00b0C [12], [13], [14].", [["tube", "ANATOMY", 162, 166], ["tube", "ANATOMY", 208, 212], ["capillary", "ANATOMY", 300, 309], ["capillary tube", "ANATOMY", 349, 363], ["tube", "TISSUE", 162, 166], ["tube", "TISSUE", 208, 212], ["capillary", "TISSUE", 300, 309], ["capillary tube", "TISSUE", 349, 363], ["Current RT-cPCR systems", "TREATMENT", 0, 23], ["skillful manipulation", "TREATMENT", 37, 58], ["certain operations", "TREATMENT", 63, 81], ["loading and unloading reagents", "TREATMENT", 90, 120], ["thin tubing", "TREATMENT", 126, 137], ["sealing both tube ends", "TREATMENT", 149, 171], ["trapping air bubbles in the tube", "PROBLEM", 180, 212], ["a novel capillary convective PCR", "TREATMENT", 292, 324], ["a capillary tube", "TREATMENT", 347, 363], ["a heater", "TREATMENT", 375, 383], ["a constant temperature", "TEST", 387, 409], ["tube", "OBSERVATION", 162, 166], ["air bubbles", "OBSERVATION", 189, 200], ["tube", "OBSERVATION", 208, 212], ["capillary tube", "OBSERVATION", 349, 363]]], ["When using this platform, no complex microfluidic chip design, special tubing, or vessels are required.", [["vessels", "ANATOMY", 82, 89], ["vessels", "MULTI-TISSUE_STRUCTURE", 82, 89], ["complex microfluidic chip design", "PROBLEM", 29, 61], ["special tubing", "TREATMENT", 63, 77], ["microfluidic chip", "OBSERVATION", 37, 54], ["vessels", "ANATOMY", 82, 89]]], ["The constantly heated capillary base drives the lowest part of the sample fluids and raises them by convection while denaturing the template simultaneously.", [["capillary", "ANATOMY", 22, 31], ["sample fluids", "ANATOMY", 67, 80], ["capillary", "TISSUE", 22, 31], ["capillary", "ANATOMY_MODIFIER", 22, 31], ["base", "ANATOMY_MODIFIER", 32, 36]]], ["During the ascending of the sample, its temperature falls because of cooling from the surrounding air.", [["sample", "ANATOMY", 28, 34], ["its temperature falls", "PROBLEM", 36, 57], ["ascending", "OBSERVATION_MODIFIER", 11, 20], ["air", "OBSERVATION", 98, 101]]], ["As the sample reaches the cool temperature zone near the top of the tube, it undergoes annealing and extension, after which the DNA template descends and is heated again.", [["sample", "ANATOMY", 7, 13], ["tube", "TISSUE", 68, 72], ["DNA", "CELLULAR_COMPONENT", 128, 131], ["the cool temperature zone", "PROBLEM", 22, 47], ["the DNA template descends", "TREATMENT", 124, 149], ["cool", "OBSERVATION_MODIFIER", 26, 30], ["temperature", "OBSERVATION_MODIFIER", 31, 42], ["zone", "OBSERVATION_MODIFIER", 43, 47], ["top", "OBSERVATION_MODIFIER", 57, 60], ["tube", "OBSERVATION", 68, 72], ["annealing", "OBSERVATION_MODIFIER", 87, 96], ["descends", "OBSERVATION_MODIFIER", 141, 149]]], ["Thus, PCR cycles are achieved by natural convection.", [["PCR cycles", "TREATMENT", 6, 16], ["natural convection", "OBSERVATION", 33, 51]]], ["This study adopted a concept similar to that of Chou et al. to form a real-time convective PCR machine in a capillary tube instrumented with a CCD-based fluorometer.", [["capillary tube", "ANATOMY", 108, 122], ["capillary tube", "TISSUE", 108, 122], ["This study", "TEST", 0, 10], ["a real-time convective PCR machine", "TREATMENT", 68, 102], ["a capillary tube instrumented", "TREATMENT", 106, 135], ["a CCD-based fluorometer", "TREATMENT", 141, 164], ["capillary tube", "OBSERVATION", 108, 122]]], ["In such a simple platform without costly and delicate thermocyclers and additional complex hardware, this study demonstrates that correct primer and amplicon design are essential to perform DNA amplification successfully.", [["DNA", "CELLULAR_COMPONENT", 190, 193], ["costly and delicate thermocyclers", "PROBLEM", 34, 67], ["additional complex hardware", "TREATMENT", 72, 99], ["this study", "TEST", 101, 111], ["DNA amplification", "TREATMENT", 190, 207], ["complex", "OBSERVATION_MODIFIER", 83, 90], ["hardware", "OBSERVATION", 91, 99]]], ["Moreover, the computer-aided analysis was implemented using the computational fluid dynamics (CFD) simulations to resolve the flow pattern in the capillary of an RT-cPCR machine and to determine the time required for completing an RT-cPCR cycle.", [["capillary", "ANATOMY", 146, 155], ["capillary", "TISSUE", 146, 155], ["the computational fluid dynamics", "TEST", 60, 92], ["the flow pattern", "TEST", 122, 138], ["an RT-cPCR cycle", "TREATMENT", 228, 244], ["flow pattern", "OBSERVATION", 126, 138], ["capillary", "ANATOMY_MODIFIER", 146, 155]]], ["To assess the performance of the prototype, a single DNA template, HBV 122 base pairs, with known concentrations and a single labeling dye, SYBR Green I, was used in the PCR mixes undergoing the same thermal cycling in both the prototype and commercial RT-PCR machines for comparing their measured and predicted fluorescence intensities emitted from the glass capillaries.", [["capillaries", "ANATOMY", 360, 371], ["DNA", "CELLULAR_COMPONENT", 53, 56], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 140, 152], ["capillaries", "TISSUE", 360, 371], ["DNA template", "DNA", 53, 65], ["HBV 122 base pairs", "DNA", 67, 85], ["SYBR Green I", "PROTEIN", 140, 152], ["a single DNA template", "TREATMENT", 44, 65], ["HBV 122 base pairs", "PROBLEM", 67, 85], ["known concentrations", "PROBLEM", 92, 112], ["a single labeling dye", "PROBLEM", 117, 138], ["commercial RT-PCR machines", "TREATMENT", 242, 268], ["fluorescence intensities", "TEST", 312, 336], ["glass capillaries", "OBSERVATION", 354, 371]]], ["We claim that the current RT-cPCR machine can offer a new DNA amplification method with ease of operation and low cost that is well suited for point-of-care applications in less-developed countries.Experimental apparatus", [["DNA", "CELLULAR_COMPONENT", 58, 61], ["the current RT-cPCR machine", "TREATMENT", 14, 41], ["a new DNA amplification method", "TREATMENT", 52, 82], ["operation and low cost", "TREATMENT", 96, 118], ["Experimental apparatus", "PROBLEM", 198, 220]]]], "90f8e5799643143ccaba3439564ff331512661dd": [["Rehabilitation of Orthopaedics and Arthroplasty PatientInitially, in the confusion of the first few days of lockdown, there was utter chaos.", [["confusion", "DISEASE", 73, 82], ["Arthroplasty", "TREATMENT", 35, 47], ["Arthroplasty", "OBSERVATION", 35, 47]]], ["The established protocols were sidelined and patients asked to care on their own with dictum being \"stay home and stay safe\".", [["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53]]], ["Patients faced additional challenges to their recovery path on discharges.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Limited health care services in adjoining native areas, including no rehabilitation services available compound the scenario [3] .", [["rehabilitation services", "TREATMENT", 69, 92]]], ["The majority may respond well to the rehabilitation protocols adopted in pre-Covid era [4] .", [["the rehabilitation protocols", "TREATMENT", 33, 61]]], ["Recurrent episodes depending on the disease load may require lockdown restrictions for the next two years.", [["Recurrent episodes", "PROBLEM", 0, 18], ["the disease load", "PROBLEM", 32, 48], ["lockdown restrictions", "TREATMENT", 61, 82]]], ["The induction of patient into an orthopaedic or arthroplasty programme should be a systematic team approach with the inclusion of established patient-specific home-based rehabilitation protocol.", [["patient", "ORGANISM", 17, 24], ["patient", "ORGANISM", 142, 149], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 142, 149], ["an orthopaedic or arthroplasty programme", "TREATMENT", 30, 70], ["rehabilitation protocol", "TREATMENT", 170, 193], ["arthroplasty", "OBSERVATION", 48, 60]]], ["Plans that need consideration [3] are: Physical therapy will be even more crucial in the medium to long-term response to assist the orthopaedic and arthroplasty patient to regain optimal function and to help them return to their previous level of activities [3] .", [["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["Physical therapy", "TREATMENT", 39, 55], ["the orthopaedic and arthroplasty", "TREATMENT", 128, 160]]]], "3a5a9f9cb7f5e0d081ab22433a8342fdae418829": [["J o u r n a l P r e -p r o o fStates identified diabetes as the most common risk factor for SARS-CoV-2 infection [8] .", [["diabetes", "DISEASE", 48, 56], ["SARS-CoV-2 infection", "DISEASE", 92, 112], ["SARS-CoV-2", "ORGANISM", 92, 102], ["SARS-CoV-2", "SPECIES", 92, 102], ["fStates", "PROBLEM", 29, 36], ["diabetes", "PROBLEM", 48, 56], ["SARS", "PROBLEM", 92, 96], ["CoV-2 infection", "PROBLEM", 97, 112], ["diabetes", "OBSERVATION", 48, 56]]], ["In this editorial, we review the clinical observations related to diabetes and COVID-19 in China, Italy, and the United States.", [["diabetes", "DISEASE", 66, 74], ["diabetes", "PROBLEM", 66, 74], ["COVID", "TREATMENT", 79, 84]]], ["We next review the pathogenesis of and immune response to SARS-CoV-2 infection.", [["SARS", "DISEASE", 58, 62], ["infection", "DISEASE", 69, 78], ["SARS-CoV-2", "ORGANISM", 58, 68], ["SARS-CoV-2", "SPECIES", 58, 68], ["immune response", "PROBLEM", 39, 54], ["SARS", "PROBLEM", 58, 62], ["CoV", "PROBLEM", 63, 66], ["2 infection", "PROBLEM", 67, 78], ["infection", "OBSERVATION", 69, 78]]], ["We then outline proposed mechanisms that may predispose individuals with diabetes both to infection and severe disease.", [["diabetes", "DISEASE", 73, 81], ["infection", "DISEASE", 90, 99], ["diabetes", "PROBLEM", 73, 81], ["infection", "PROBLEM", 90, 99], ["severe disease", "PROBLEM", 104, 118], ["infection", "OBSERVATION", 90, 99], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["disease", "OBSERVATION", 111, 118]]], ["Finally, we highlight areas that warrant further investigation and discuss management considerations for clinicians.Clinical Observations in China, Italy, and the United StatesThe first cluster of cases of pneumonia of unknown etiology appeared in Wuhan, China, in late December of 2019 [9] .", [["pneumonia", "DISEASE", 206, 215], ["further investigation", "TEST", 41, 62], ["pneumonia", "PROBLEM", 206, 215], ["pneumonia", "OBSERVATION", 206, 215]]], ["Subsequent analysis identified the novel betacoronavirus, SARS-CoV-2, the seventh member of the coronavirus family that infects humans and includes severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), as the causative agent of COVID-19 [10] .", [["acute respiratory syndrome coronavirus", "DISEASE", 155, 193], ["SARS-CoV)", "DISEASE", 195, 204], ["Middle East respiratory syndrome coronavirus", "DISEASE", 209, 253], ["SARS-CoV-2", "ORGANISM", 58, 68], ["coronavirus", "ORGANISM", 96, 107], ["humans", "ORGANISM", 128, 134], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 148, 193], ["SARS-CoV", "ORGANISM", 195, 203], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 209, 253], ["MERS-CoV", "ORGANISM", 255, 263], ["coronavirus", "SPECIES", 96, 107], ["humans", "SPECIES", 128, 134], ["SARS-CoV-2", "SPECIES", 58, 68], ["humans", "SPECIES", 128, 134], ["severe acute respiratory syndrome coronavirus", "SPECIES", 148, 193], ["SARS-CoV", "SPECIES", 195, 203], ["Middle East respiratory syndrome coronavirus", "SPECIES", 209, 253], ["MERS-CoV", "SPECIES", 255, 263], ["Subsequent analysis", "TEST", 0, 19], ["the novel betacoronavirus", "PROBLEM", 31, 56], ["SARS", "TEST", 58, 62], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 148, 193], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 209, 253], ["COVID", "TEST", 292, 297], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["acute", "OBSERVATION_MODIFIER", 155, 160], ["respiratory syndrome coronavirus", "OBSERVATION", 161, 193], ["Middle", "ANATOMY_MODIFIER", 209, 215], ["respiratory syndrome", "OBSERVATION", 221, 241]]], ["An early single-center observational study in Wuhan of individuals with severe COVID-19 pneumonia described a high prevalence of chronic illness and a 22% prevalence of type 2 diabetes in individuals who did not survive the infection [2] .", [["COVID", "DISEASE", 79, 84], ["pneumonia", "DISEASE", 88, 97], ["chronic illness", "DISEASE", 129, 144], ["type 2 diabetes", "DISEASE", 169, 184], ["infection", "DISEASE", 224, 233], ["individuals", "ORGANISM", 188, 199], ["observational study", "TEST", 23, 42], ["severe COVID", "PROBLEM", 72, 84], ["pneumonia", "PROBLEM", 88, 97], ["chronic illness", "PROBLEM", 129, 144], ["type 2 diabetes", "PROBLEM", 169, 184], ["the infection", "PROBLEM", 220, 233], ["pneumonia", "OBSERVATION", 88, 97], ["high prevalence", "OBSERVATION_MODIFIER", 110, 125], ["chronic", "OBSERVATION_MODIFIER", 129, 136], ["illness", "OBSERVATION", 137, 144], ["infection", "OBSERVATION", 224, 233]]], ["Another early large observational study identified type 2 diabetes as a common underlying condition in patients with severe illness (16.2%), second only to hypertension (23.7%) [3] .", [["type 2 diabetes", "DISEASE", 51, 66], ["illness", "DISEASE", 124, 131], ["hypertension", "DISEASE", 156, 168], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["observational study", "TEST", 20, 39], ["type 2 diabetes", "PROBLEM", 51, 66], ["severe illness", "PROBLEM", 117, 131], ["hypertension", "PROBLEM", 156, 168], ["large", "OBSERVATION_MODIFIER", 14, 19], ["diabetes", "OBSERVATION", 58, 66], ["hypertension", "OBSERVATION", 156, 168]]], ["A meta-analysis that included these and other studies found that the incidence of diabetes was two-fold higher in those that developed severe disease compared with patients that experienced non-severe disease [5] .", [["diabetes", "DISEASE", 82, 90], ["patients", "ORGANISM", 164, 172], ["patients", "SPECIES", 164, 172], ["A meta-analysis", "TEST", 0, 15], ["other studies", "TEST", 40, 53], ["diabetes", "PROBLEM", 82, 90], ["severe disease", "PROBLEM", 135, 149], ["non-severe disease", "PROBLEM", 190, 208], ["diabetes", "OBSERVATION", 82, 90], ["severe", "OBSERVATION_MODIFIER", 135, 141], ["disease", "OBSERVATION", 142, 149]]], ["Subsequent studies have demonstrated an association between diabetes and poor prognosis and increased mortality.", [["diabetes", "DISEASE", 60, 68], ["Subsequent studies", "TEST", 0, 18], ["diabetes", "PROBLEM", 60, 68], ["poor prognosis", "PROBLEM", 73, 87], ["increased mortality", "PROBLEM", 92, 111], ["diabetes", "OBSERVATION", 60, 68], ["increased", "OBSERVATION_MODIFIER", 92, 101], ["mortality", "OBSERVATION", 102, 111]]], ["A recent retrospective cohort study of 174 patients admitted to Wuhan Union Hospital with COVID-19 found that 21.2% of patients had diabetes, and further identified diabetes as a risk factor for severe disease based on radiographic findings and biomarkers of inflammation and end-organ damage [11] .Clinical Observations in China, Italy, and the United StatesThese findings are consistent with a summary report of over 72,000 cases across China from the Chinese Center for Disease Control (CDC) that showed an increased fatality rate of 7.3% in individuals with diabetes compared to an overall fatality rate of 2.3% [12] .", [["organ", "ANATOMY", 280, 285], ["diabetes", "DISEASE", 132, 140], ["diabetes", "DISEASE", 165, 173], ["inflammation", "DISEASE", 259, 271], ["end-organ damage", "DISEASE", 276, 292], ["diabetes", "DISEASE", 562, 570], ["patients", "ORGANISM", 43, 51], ["patients", "ORGANISM", 119, 127], ["organ", "ORGAN", 280, 285], ["patients", "SPECIES", 43, 51], ["patients", "SPECIES", 119, 127], ["A recent retrospective cohort study", "TEST", 0, 35], ["COVID", "TEST", 90, 95], ["diabetes", "PROBLEM", 132, 140], ["diabetes", "PROBLEM", 165, 173], ["a risk factor", "PROBLEM", 177, 190], ["severe disease", "PROBLEM", 195, 209], ["radiographic findings", "TEST", 219, 240], ["inflammation", "PROBLEM", 259, 271], ["end-organ damage", "PROBLEM", 276, 292], ["an increased fatality rate", "PROBLEM", 507, 533], ["diabetes", "PROBLEM", 562, 570], ["an overall fatality rate", "TEST", 583, 607], ["diabetes", "OBSERVATION", 132, 140], ["diabetes", "OBSERVATION", 165, 173], ["inflammation", "OBSERVATION", 259, 271], ["increased", "OBSERVATION_MODIFIER", 510, 519], ["fatality", "OBSERVATION_MODIFIER", 520, 528]]], ["Additionally, a recent multicenter retrospective cohort study of COVID-19 confirmed inpatients from Jinyintan Hospital and Wuhan Pulmonary Hospital found a statistically significant association between diabetes and increased mortality [13] .J o u r n a l P r e -p r o o fIn Italy, the severity of disease and strain on the healthcare system related to has been noteworthy, with one recent estimated case fatality rate of 7.2% [14] .", [["diabetes", "DISEASE", 202, 210], ["inpatients", "ORGANISM", 84, 94], ["COVID", "TEST", 65, 70], ["diabetes", "PROBLEM", 202, 210], ["increased mortality", "PROBLEM", 215, 234], ["disease", "PROBLEM", 297, 304], ["strain on the healthcare system", "PROBLEM", 309, 340], ["fatality rate", "TEST", 404, 417], ["Pulmonary", "ANATOMY", 129, 138], ["disease", "OBSERVATION", 297, 304]]], ["While factors unique to the Italian population may contribute to the higher case fatality rate, such as a relatively older population, emerging data has also highlighted the role that underlying chronic cardiometabolic disease has on the severity of illness.", [["cardiometabolic disease", "DISEASE", 203, 226], ["underlying chronic cardiometabolic disease", "PROBLEM", 184, 226], ["illness", "PROBLEM", 250, 257], ["chronic", "OBSERVATION_MODIFIER", 195, 202], ["cardiometabolic disease", "OBSERVATION", 203, 226]]], ["A retrospective case series of patients admitted to the intensive care unit (ICU) with COVID-19 in the Lombardy region found hypertension (49%), cardiovascular disease (21%), and diabetes (17%) to be common underlying medical conditions [15] .", [["cardiovascular", "ANATOMY", 145, 159], ["hypertension", "DISEASE", 125, 137], ["cardiovascular disease", "DISEASE", 145, 167], ["diabetes", "DISEASE", 179, 187], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["COVID", "TEST", 87, 92], ["hypertension", "PROBLEM", 125, 137], ["cardiovascular disease", "PROBLEM", 145, 167], ["diabetes", "PROBLEM", 179, 187], ["hypertension", "OBSERVATION", 125, 137], ["cardiovascular", "ANATOMY", 145, 159], ["disease", "OBSERVATION", 160, 167]]], ["The Italian National Institute of Health reported the prevalence of diabetes in patients that died while infected with SARS-CoV-2 to be 35.5%, suggesting that diabetes may be a significant risk factor for mortality [16] .J o u r n a l P r e -p r o o fThe first case of COVID-19 in the United States was confirmed on January 20, 2020, in Snohomish County, Washington [17] .", [["diabetes", "DISEASE", 68, 76], ["SARS", "DISEASE", 119, 123], ["diabetes", "DISEASE", 159, 167], ["patients", "ORGANISM", 80, 88], ["SARS-CoV-2", "ORGANISM", 119, 129], ["patients", "SPECIES", 80, 88], ["SARS-CoV", "SPECIES", 119, 127], ["diabetes", "PROBLEM", 68, 76], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["diabetes", "PROBLEM", 159, 167], ["mortality", "TEST", 205, 214], ["COVID", "TEST", 269, 274], ["diabetes", "OBSERVATION", 68, 76]]], ["Two early case series of critically ill patients admitted to ICUs in the Seattle-area found an incidence of diabetes of 58% and 33.3%, respectively [18, 19] .J o u r n a l P r e -p r o o fWhile more robust studies need to be completed, preliminary data from the United States CDC on March 28, 2020, estimated diabetes to be the most prevalent underlying health condition in individuals infected with SARS-CoV-2 at 10.9%, and further estimated that 32% of patients requiring ICU admission had diabetes [8] .", [["critically ill", "DISEASE", 25, 39], ["diabetes", "DISEASE", 108, 116], ["diabetes", "DISEASE", 309, 317], ["SARS", "DISEASE", 400, 404], ["diabetes", "DISEASE", 492, 500], ["patients", "ORGANISM", 40, 48], ["SARS-CoV-2", "ORGANISM", 400, 410], ["patients", "ORGANISM", 455, 463], ["patients", "SPECIES", 40, 48], ["patients", "SPECIES", 455, 463], ["SARS-CoV", "SPECIES", 400, 408], ["diabetes", "PROBLEM", 108, 116], ["robust studies", "TEST", 199, 213], ["estimated diabetes", "PROBLEM", 299, 317], ["SARS", "TEST", 400, 404], ["CoV", "TEST", 405, 408], ["diabetes", "PROBLEM", 492, 500], ["diabetes", "OBSERVATION", 108, 116]]], ["What remains to be fully elucidated, given the nature and study designs of initial reports, is whether the reported associations are independent from potential confounding factors such as gender and age that are associated with both COVID-19 and diabetes.", [["diabetes", "DISEASE", 246, 254], ["diabetes", "PROBLEM", 246, 254]]], ["Additionally, the extent that admission to the hospital or ICU, or medications used in the ICU (such as steroids), may be contributing to the increased prevalence of diabetes and other metabolic syndrome-related comorbidities needs to be determined.Pathogenesis and Immune Response to SARS-CoV-2 InfectionCoronaviruses are positive-sense, single-stranded RNA viruses, with a large 27 to 32 kilobase genome packaged inside a capsid formed by nucleocapsid protein (N).", [["steroids", "CHEMICAL", 104, 112], ["diabetes", "DISEASE", 166, 174], ["metabolic syndrome", "DISEASE", 185, 203], ["SARS", "DISEASE", 285, 289], ["steroids", "CHEMICAL", 104, 112], ["SARS-CoV-2", "ORGANISM", 285, 295], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 305, 318], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 441, 465], ["27 to 32 kilobase genome", "DNA", 381, 405], ["nucleocapsid protein", "PROTEIN", 441, 461], ["N", "PROTEIN", 463, 464], ["SARS-CoV", "SPECIES", 285, 293], ["medications", "TREATMENT", 67, 78], ["steroids", "TREATMENT", 104, 112], ["diabetes", "PROBLEM", 166, 174], ["other metabolic syndrome", "PROBLEM", 179, 203], ["related comorbidities", "PROBLEM", 204, 225], ["Pathogenesis", "PROBLEM", 249, 261], ["SARS", "TEST", 285, 289], ["CoV", "TEST", 290, 293], ["InfectionCoronaviruses", "PROBLEM", 296, 318], ["single-stranded RNA viruses", "PROBLEM", 339, 366], ["diabetes", "OBSERVATION", 166, 174], ["metabolic syndrome", "OBSERVATION", 185, 203], ["Immune Response", "OBSERVATION", 266, 281], ["RNA viruses", "OBSERVATION", 355, 366], ["large", "OBSERVATION_MODIFIER", 375, 380], ["27 to 32 kilobase", "OBSERVATION_MODIFIER", 381, 398], ["capsid formed", "OBSERVATION_MODIFIER", 424, 437], ["nucleocapsid protein", "OBSERVATION", 441, 461]]], ["An envelope surrounds this helical structure and is associated with three structural proteins: membrane protein (M) and envelope protein (E), which are both involved in virion assembly, and spike protein (S), which mediates entry into host cells [20, 21] .", [["virion", "ANATOMY", 169, 175], ["cells", "ANATOMY", 240, 245], ["membrane protein (M)", "GENE_OR_GENE_PRODUCT", 95, 115], ["envelope protein (E)", "GENE_OR_GENE_PRODUCT", 120, 140], ["virion", "CELLULAR_COMPONENT", 169, 175], ["spike protein (S)", "GENE_OR_GENE_PRODUCT", 190, 207], ["cells", "CELL", 240, 245], ["structural proteins", "PROTEIN", 74, 93], ["membrane protein", "PROTEIN", 95, 111], ["M", "PROTEIN", 113, 114], ["envelope protein", "PROTEIN", 120, 136], ["E", "PROTEIN", 138, 139], ["spike protein", "PROTEIN", 190, 203], ["S", "PROTEIN", 205, 206], ["host cells", "CELL_TYPE", 235, 245], ["membrane protein", "TEST", 95, 111], ["envelope protein (E", "TEST", 120, 139], ["spike protein (S)", "PROBLEM", 190, 207], ["envelope", "OBSERVATION_MODIFIER", 3, 11], ["helical structure", "OBSERVATION_MODIFIER", 27, 44], ["host cells", "OBSERVATION", 235, 245]]], ["The S protein is further characterized by a receptor-J o u r n a l P r e -p r o o f binding domain (RBD) S1 subunit that facilitates binding to the host angiotensin-converting enzyme 2 (ACE2) receptor for both SARS-CoV and SARS-CoV-2, and an S2 subunit that is responsible for membrane fusion [22] [23] [24] .", [["membrane", "ANATOMY", 277, 285], ["angiotensin", "CHEMICAL", 153, 164], ["f binding domain (RBD) S1", "GENE_OR_GENE_PRODUCT", 82, 107], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 153, 184], ["ACE2", "GENE_OR_GENE_PRODUCT", 186, 190], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 210, 218], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 223, 233], ["S2", "GENE_OR_GENE_PRODUCT", 242, 244], ["membrane", "CELLULAR_COMPONENT", 277, 285], ["S protein", "PROTEIN", 4, 13], ["J o u r n a l P r e -p r o o f binding domain (RBD) S1 subunit", "PROTEIN", 53, 115], ["host angiotensin-converting enzyme 2 (ACE2) receptor", "PROTEIN", 148, 200], ["S2 subunit", "PROTEIN", 242, 252], ["SARS-CoV", "SPECIES", 210, 218], ["The S protein", "TEST", 0, 13], ["binding domain (RBD) S1 subunit", "PROBLEM", 84, 115], ["angiotensin", "TEST", 153, 164], ["converting enzyme", "TEST", 165, 182], ["both SARS", "PROBLEM", 205, 214], ["CoV", "TEST", 215, 218], ["SARS", "TEST", 223, 227], ["CoV", "TEST", 228, 231], ["an S2 subunit", "TREATMENT", 239, 252], ["membrane fusion", "TEST", 277, 292]]], ["The RBD of MERS-CoV attaches to host cells via dipeptidyl peptidase 4 (DPP4) rather than ACE2 [25] .", [["cells", "ANATOMY", 37, 42], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 11, 19], ["host cells", "CELL", 32, 42], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 47, 69], ["DPP4", "GENE_OR_GENE_PRODUCT", 71, 75], ["ACE2", "GENE_OR_GENE_PRODUCT", 89, 93], ["RBD", "PROTEIN", 4, 7], ["MERS", "PROTEIN", 11, 15], ["host cells", "CELL_TYPE", 32, 42], ["dipeptidyl peptidase 4", "PROTEIN", 47, 69], ["DPP4", "PROTEIN", 71, 75], ["ACE2", "PROTEIN", 89, 93], ["MERS-CoV", "SPECIES", 11, 19], ["dipeptidyl peptidase", "TREATMENT", 47, 67], ["ACE2", "TEST", 89, 93], ["RBD", "OBSERVATION", 4, 7], ["host cells", "OBSERVATION", 32, 42]]], ["A recent study demonstrated that certain structural changes of the RBD unique to SARS-CoV-2 results in enhanced ACE2 receptor binding affinity in comparison to SARS-CoV [26] .", [["RBD", "DISEASE", 67, 70], ["SARS", "DISEASE", 81, 85], ["SARS", "DISEASE", 160, 164], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 81, 91], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 112, 125], ["RBD", "PROTEIN", 67, 70], ["ACE2", "PROTEIN", 112, 116], ["SARS-CoV", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 160, 168], ["A recent study", "TEST", 0, 14], ["the RBD", "PROBLEM", 63, 70], ["SARS", "TEST", 81, 85], ["CoV", "TEST", 86, 89], ["enhanced ACE2 receptor binding affinity", "PROBLEM", 103, 142], ["SARS", "TEST", 160, 164]]], ["Host cell factors further mediate viral entry through two serine proteases, TMPRSS2 and furin, which activate the S protein for membrane fusion through cleavage and assist in viral processing, respectively [21 22, 24] .Pathogenesis and Immune Response to SARS-CoV-2 InfectionOnce infection with SARS-CoV-2 has occurred, a complex, orchestrated response of the innate and adaptive immune system ensues that correlates clinically to three proposed phases: a viremia phase, an acute phase, and a recovery phase [27] .", [["cell", "ANATOMY", 5, 9], ["membrane", "ANATOMY", 128, 136], ["SARS", "DISEASE", 255, 259], ["infection", "DISEASE", 280, 289], ["SARS", "DISEASE", 295, 299], ["viremia", "DISEASE", 456, 463], ["serine", "CHEMICAL", 58, 64], ["Host cell", "CELL", 0, 9], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 76, 83], ["furin", "GENE_OR_GENE_PRODUCT", 88, 93], ["membrane", "CELLULAR_COMPONENT", 128, 136], ["SARS-CoV-2 InfectionOnce", "ORGANISM", 255, 279], ["SARS-CoV-2", "ORGANISM", 295, 305], ["Host cell factors", "PROTEIN", 0, 17], ["serine proteases", "PROTEIN", 58, 74], ["TMPRSS2", "PROTEIN", 76, 83], ["furin", "PROTEIN", 88, 93], ["S protein", "PROTEIN", 114, 123], ["SARS-CoV", "SPECIES", 255, 263], ["SARS-CoV", "SPECIES", 295, 303], ["Host cell factors", "PROBLEM", 0, 17], ["two serine proteases", "TREATMENT", 54, 74], ["TMPRSS2", "TEST", 76, 83], ["furin", "TREATMENT", 88, 93], ["the S protein", "TREATMENT", 110, 123], ["membrane fusion through cleavage", "TREATMENT", 128, 160], ["Pathogenesis", "PROBLEM", 219, 231], ["SARS", "TEST", 255, 259], ["CoV", "TEST", 260, 263], ["InfectionOnce infection", "PROBLEM", 266, 289], ["SARS", "PROBLEM", 295, 299], ["a viremia phase", "TEST", 454, 469], ["Immune Response", "OBSERVATION", 236, 251]]], ["The innate immune response involves the recognition of viral pathogen-associated molecular patterns by pattern recognition receptors (i.e., Toll-like receptors), resulting in the expression of type I interferons and inflammatory factors that potentiate macrophage and natural killer cell defense mechanisms [20] .", [["macrophage", "ANATOMY", 253, 263], ["killer cell", "ANATOMY", 276, 287], ["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 103, 132], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 140, 159], ["type I interferons", "GENE_OR_GENE_PRODUCT", 193, 211], ["macrophage", "CELL", 253, 263], ["natural killer cell", "CELL", 268, 287], ["pattern recognition receptors", "PROTEIN", 103, 132], ["Toll-like receptors", "PROTEIN", 140, 159], ["type I interferons", "PROTEIN", 193, 211], ["inflammatory factors", "PROTEIN", 216, 236], ["viral pathogen", "PROBLEM", 55, 69], ["type I interferons", "PROBLEM", 193, 211], ["inflammatory factors", "PROBLEM", 216, 236], ["macrophage", "PROBLEM", 253, 263], ["natural killer cell defense mechanisms", "TREATMENT", 268, 306], ["immune response", "OBSERVATION", 11, 26], ["viral pathogen", "OBSERVATION", 55, 69], ["natural killer cell", "OBSERVATION", 268, 287]]], ["Dendritic cells are tissue phagocytes that bridge the innate and adaptive immune response by activating Tlymphocytes and B-lymphocytes through antigen-presentation [20] .", [["Dendritic cells", "ANATOMY", 0, 15], ["tissue phagocytes", "ANATOMY", 20, 37], ["Tlymphocytes", "ANATOMY", 104, 116], ["B-lymphocytes", "ANATOMY", 121, 134], ["Dendritic cells", "CELL", 0, 15], ["tissue phagocytes", "CELL", 20, 37], ["Tlymphocytes", "CELL", 104, 116], ["B-lymphocytes", "CELL", 121, 134], ["antigen", "GENE_OR_GENE_PRODUCT", 143, 150], ["Dendritic cells", "CELL_TYPE", 0, 15], ["tissue phagocytes", "CELL_TYPE", 20, 37], ["Tlymphocytes", "CELL_TYPE", 104, 116], ["B-lymphocytes", "CELL_TYPE", 121, 134], ["Dendritic cells", "PROBLEM", 0, 15], ["tissue phagocytes", "PROBLEM", 20, 37], ["activating Tlymphocytes", "TEST", 93, 116], ["B-lymphocytes", "TEST", 121, 134], ["antigen", "TEST", 143, 150], ["tissue phagocytes", "OBSERVATION", 20, 37]]], ["The adaptive immune system is essential for control of the persistent phase of infection and involves the production of neutralizing monoclonal antibodies to viral envelope glycoproteins by CD4+ T cells and the killing of viral-infected cells by cytotoxic CD8+ T cells [20] .", [["CD4+ T cells", "ANATOMY", 190, 202], ["cells", "ANATOMY", 237, 242], ["cytotoxic CD8+ T cells", "ANATOMY", 246, 268], ["infection", "DISEASE", 79, 88], ["CD4", "GENE_OR_GENE_PRODUCT", 190, 193], ["cells", "CELL", 237, 242], ["CD8", "GENE_OR_GENE_PRODUCT", 256, 259], ["neutralizing monoclonal antibodies", "PROTEIN", 120, 154], ["viral envelope glycoproteins", "PROTEIN", 158, 186], ["CD4", "PROTEIN", 190, 193], ["T cells", "CELL_TYPE", 195, 202], ["viral-infected cells", "CELL_TYPE", 222, 242], ["cytotoxic CD8+ T cells", "CELL_TYPE", 246, 268], ["The adaptive immune system", "TREATMENT", 0, 26], ["infection", "PROBLEM", 79, 88], ["neutralizing monoclonal antibodies", "PROBLEM", 120, 154], ["viral envelope glycoproteins", "PROBLEM", 158, 186], ["CD4", "TEST", 190, 193], ["T cells", "PROBLEM", 195, 202], ["viral-infected cells", "PROBLEM", 222, 242], ["cytotoxic CD8", "TEST", 246, 259], ["persistent", "OBSERVATION_MODIFIER", 59, 69], ["phase", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 79, 88], ["infected cells", "OBSERVATION", 228, 242]]], ["In the acute phase of infection, SARS-CoV and SARS-CoV-2 invade CD4+ and CD8+ T-lymphocytes resulting in apoptosis and lymphocytopenia, a marker that is associated with severe outcomes [22, 27] .Pathogenesis and Immune Response to SARS-CoV-2 InfectionThe specifics of the humoral response to SARS-CoV-2 infection is under investigation.", [["CD4+ and CD8+", "ANATOMY", 64, 77], ["T-lymphocytes", "ANATOMY", 78, 91], ["infection", "DISEASE", 22, 31], ["SARS", "DISEASE", 33, 37], ["lymphocytopenia", "DISEASE", 119, 134], ["SARS", "DISEASE", 231, 235], ["SARS", "DISEASE", 292, 296], ["infection", "DISEASE", 303, 312], ["SARS-CoV", "ORGANISM", 33, 41], ["SARS-CoV-2", "ORGANISM", 46, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 64, 67], ["CD8", "GENE_OR_GENE_PRODUCT", 73, 76], ["T-lymphocytes", "CELL", 78, 91], ["SARS-CoV-2", "ORGANISM", 231, 241], ["SARS-CoV-2", "ORGANISM", 292, 302], ["CD4", "PROTEIN", 64, 67], ["CD8", "PROTEIN", 73, 76], ["T-lymphocytes", "CELL_TYPE", 78, 91], ["CoV-2", "SPECIES", 297, 302], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV-2", "SPECIES", 292, 302], ["infection", "PROBLEM", 22, 31], ["SARS", "TEST", 33, 37], ["CoV", "TEST", 38, 41], ["SARS", "TEST", 46, 50], ["CoV", "TEST", 51, 54], ["CD4", "TEST", 64, 67], ["CD8", "TEST", 73, 76], ["apoptosis", "PROBLEM", 105, 114], ["lymphocytopenia", "PROBLEM", 119, 134], ["a marker", "TEST", 136, 144], ["severe outcomes", "PROBLEM", 169, 184], ["Pathogenesis", "PROBLEM", 195, 207], ["SARS", "PROBLEM", 231, 235], ["CoV", "PROBLEM", 236, 239], ["2 Infection", "PROBLEM", 240, 251], ["SARS", "PROBLEM", 292, 296], ["CoV-2 infection", "PROBLEM", 297, 312], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["phase", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 22, 31], ["lymphocytes", "ANATOMY", 80, 91], ["apoptosis", "OBSERVATION_MODIFIER", 105, 114], ["lymphocytopenia", "OBSERVATION", 119, 134], ["associated with", "UNCERTAINTY", 153, 168], ["severe", "OBSERVATION_MODIFIER", 169, 175], ["Immune Response", "OBSERVATION", 212, 227], ["Infection", "OBSERVATION", 242, 251], ["infection", "OBSERVATION", 303, 312]]], ["A study of 173 hospitalized patients with reverse transcription polymerase chain reaction (RT-PCR) confirmed SARS-CoV-2 infection showed a seroconversion rate for total antibody, IgM, and IgG of 93.1%, 82.7%, and 64.7%, respectively, and noted that the few patients with negative antibody findings did not have later stage blood samples available for analysis [28] .", [["blood samples", "ANATOMY", 323, 336], ["infection", "DISEASE", 120, 129], ["patients", "ORGANISM", 28, 36], ["SARS-CoV-2", "ORGANISM", 109, 119], ["IgM", "GENE_OR_GENE_PRODUCT", 179, 182], ["IgG", "GENE_OR_GENE_PRODUCT", 188, 191], ["patients", "ORGANISM", 257, 265], ["blood samples", "ORGANISM_SUBSTANCE", 323, 336], ["IgM", "PROTEIN", 179, 182], ["IgG", "PROTEIN", 188, 191], ["patients", "SPECIES", 28, 36], ["patients", "SPECIES", 257, 265], ["A study", "TEST", 0, 7], ["reverse transcription polymerase chain reaction", "PROBLEM", 42, 89], ["RT-PCR", "TEST", 91, 97], ["SARS", "PROBLEM", 109, 113], ["CoV", "TEST", 114, 117], ["2 infection", "PROBLEM", 118, 129], ["a seroconversion rate", "TEST", 137, 158], ["total antibody", "TEST", 163, 177], ["IgM", "TEST", 179, 182], ["IgG", "TEST", 188, 191], ["negative antibody findings", "PROBLEM", 271, 297], ["later stage blood samples", "PROBLEM", 311, 336], ["analysis", "TEST", 351, 359]]], ["However, a subsequent study that analyzed the plasma of 175 patients who had recovered from mild COVID-19 illness showed that 30% of participants generated a very low level of neutralizing antibody and that elderly patients were more likely to generate a robust antibody response than J o u r n a l P r e -p r o o f younger patients [29] .", [["plasma", "ANATOMY", 46, 52], ["plasma", "ORGANISM_SUBSTANCE", 46, 52], ["patients", "ORGANISM", 60, 68], ["participants", "ORGANISM", 133, 145], ["patients", "ORGANISM", 215, 223], ["patients", "ORGANISM", 324, 332], ["neutralizing antibody", "PROTEIN", 176, 197], ["patients", "SPECIES", 60, 68], ["participants", "SPECIES", 133, 145], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 324, 332], ["a subsequent study", "TEST", 9, 27], ["mild COVID-19 illness", "PROBLEM", 92, 113], ["a very low level of neutralizing antibody", "PROBLEM", 156, 197], ["mild", "OBSERVATION_MODIFIER", 92, 96]]], ["The implications of this regarding susceptibility to recurrent infection warrants further investigation, and ongoing studies are expected to shed more light on this topic.DiabetesIndividuals with diabetes are more susceptible to a broad range of infections [30] .", [["infection", "DISEASE", 63, 72], ["Diabetes", "DISEASE", 171, 179], ["diabetes", "DISEASE", 196, 204], ["infections", "DISEASE", 246, 256], ["recurrent infection", "PROBLEM", 53, 72], ["further investigation", "TEST", 82, 103], ["ongoing studies", "TEST", 109, 124], ["DiabetesIndividuals", "PROBLEM", 171, 190], ["diabetes", "PROBLEM", 196, 204], ["infections", "PROBLEM", 246, 256], ["recurrent", "OBSERVATION_MODIFIER", 53, 62], ["infection", "OBSERVATION", 63, 72], ["infections", "OBSERVATION", 246, 256]]], ["In addition, several infections may result in less well-controlled diabetes.", [["infections", "DISEASE", 21, 31], ["diabetes", "DISEASE", 67, 75], ["several infections", "PROBLEM", 13, 31], ["less well-controlled diabetes", "PROBLEM", 46, 75], ["several", "OBSERVATION_MODIFIER", 13, 20], ["infections", "OBSERVATION", 21, 31], ["less well-controlled", "OBSERVATION_MODIFIER", 46, 66], ["diabetes", "OBSERVATION", 67, 75]]], ["Numerous factors contribute to the immune dysfunction in individuals with diabetes, including hyperglycemia, inhibition of neutrophil chemotaxis, altered cytokine production, phagocytic cell dysfunction,Diabetesimpaired T-cell mediated immune responses, and ineffective microbial clearance [31] [32] [33] [34] [35] .DiabetesThe relationship between these known mechanisms of immune dysfunction in patients with diabetes and infection with SARS-CoV-2 will require further investigation.", [["neutrophil", "ANATOMY", 123, 133], ["phagocytic cell", "ANATOMY", 175, 190], ["T-cell", "ANATOMY", 220, 226], ["immune dysfunction", "DISEASE", 35, 53], ["diabetes", "DISEASE", 74, 82], ["hyperglycemia", "DISEASE", 94, 107], ["Diabetes", "DISEASE", 316, 324], ["immune dysfunction", "DISEASE", 375, 393], ["diabetes", "DISEASE", 411, 419], ["infection", "DISEASE", 424, 433], ["SARS", "DISEASE", 439, 443], ["neutrophil", "CELL", 123, 133], ["phagocytic cell", "CELL", 175, 190], ["Diabetesimpaired T-cell", "CELL", 203, 226], ["[31] [32] [33] [34] [35]", "SIMPLE_CHEMICAL", 290, 314], ["patients", "ORGANISM", 397, 405], ["SARS-CoV-2", "ORGANISM", 439, 449], ["cytokine", "PROTEIN", 154, 162], ["patients", "SPECIES", 397, 405], ["SARS-CoV", "SPECIES", 439, 447], ["Numerous factors", "PROBLEM", 0, 16], ["the immune dysfunction", "PROBLEM", 31, 53], ["diabetes", "PROBLEM", 74, 82], ["hyperglycemia", "PROBLEM", 94, 107], ["neutrophil chemotaxis", "PROBLEM", 123, 144], ["altered cytokine production", "PROBLEM", 146, 173], ["phagocytic cell dysfunction", "PROBLEM", 175, 202], ["ineffective microbial clearance", "TEST", 258, 289], ["Diabetes", "PROBLEM", 316, 324], ["immune dysfunction", "PROBLEM", 375, 393], ["diabetes", "PROBLEM", 411, 419], ["infection", "PROBLEM", 424, 433], ["SARS", "PROBLEM", 439, 443], ["further investigation", "TEST", 463, 484], ["immune dysfunction", "OBSERVATION", 35, 53], ["neutrophil chemotaxis", "OBSERVATION", 123, 144], ["cytokine production", "OBSERVATION", 154, 173], ["phagocytic cell dysfunction", "OBSERVATION", 175, 202], ["immune dysfunction", "OBSERVATION", 375, 393], ["infection", "OBSERVATION", 424, 433]]], ["One recent study involving patients admitted for COVID-19 suggested that hypertension and diabetes resulted in delayed clearance of SARS-CoV-2 [36] .", [["COVID-19", "CHEMICAL", 49, 57], ["hypertension", "DISEASE", 73, 85], ["diabetes", "DISEASE", 90, 98], ["SARS", "DISEASE", 132, 136], ["COVID-19", "CHEMICAL", 49, 57], ["patients", "ORGANISM", 27, 35], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 132, 142], ["patients", "SPECIES", 27, 35], ["One recent study", "TEST", 0, 16], ["COVID", "TEST", 49, 54], ["hypertension", "PROBLEM", 73, 85], ["diabetes", "PROBLEM", 90, 98], ["delayed clearance of SARS", "PROBLEM", 111, 136], ["CoV", "TEST", 137, 140], ["hypertension", "OBSERVATION", 73, 85], ["diabetes", "OBSERVATION", 90, 98]]], ["(DPP4 H/M ), the cellular binding site for MERS-CoV, and induced diabetes through a high-fat diet [37] .", [["cellular", "ANATOMY", 17, 25], ["diabetes", "DISEASE", 65, 73], ["DPP4 H/M", "GENE_OR_GENE_PRODUCT", 1, 9], ["cellular", "CELL", 17, 25], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 43, 51], ["cellular binding site", "DNA", 17, 38], ["MERS-CoV", "SPECIES", 43, 51], ["the cellular binding site", "PROBLEM", 13, 38], ["MERS", "PROBLEM", 43, 47], ["CoV", "PROBLEM", 48, 51], ["induced diabetes", "PROBLEM", 57, 73], ["a high-fat diet", "TREATMENT", 82, 97]]], ["The diabetic DPP4 H/M mice developed more severe disease and were found to have a dysregulated immune response after infection characterized by delayed and decreased recruitment of CD4+ T cells and inflammatory monocytes and macrophages in lung tissue.", [["CD4+", "ANATOMY", 181, 185], ["T cells", "ANATOMY", 186, 193], ["inflammatory monocytes", "ANATOMY", 198, 220], ["macrophages", "ANATOMY", 225, 236], ["lung tissue", "ANATOMY", 240, 251], ["diabetic", "DISEASE", 4, 12], ["infection", "DISEASE", 117, 126], ["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 181, 184], ["T cells", "CELL", 186, 193], ["inflammatory monocytes", "CELL", 198, 220], ["macrophages", "CELL", 225, 236], ["lung tissue", "TISSUE", 240, 251], ["CD4", "PROTEIN", 181, 184], ["T cells", "CELL_TYPE", 186, 193], ["inflammatory monocytes", "CELL_TYPE", 198, 220], ["macrophages", "CELL_TYPE", 225, 236], ["mice", "SPECIES", 22, 26], ["H/M mice", "SPECIES", 18, 26], ["more severe disease", "PROBLEM", 37, 56], ["a dysregulated immune response", "PROBLEM", 80, 110], ["infection", "PROBLEM", 117, 126], ["inflammatory monocytes", "PROBLEM", 198, 220], ["macrophages in lung tissue", "PROBLEM", 225, 251], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["disease", "OBSERVATION", 49, 56], ["dysregulated", "OBSERVATION_MODIFIER", 82, 94], ["immune response", "OBSERVATION", 95, 110], ["decreased", "OBSERVATION_MODIFIER", 156, 165], ["recruitment", "OBSERVATION_MODIFIER", 166, 177], ["inflammatory monocytes", "OBSERVATION", 198, 220], ["macrophages", "OBSERVATION", 225, 236], ["lung", "ANATOMY", 240, 244], ["tissue", "ANATOMY_MODIFIER", 245, 251]]], ["In addition to the decreased overall CD4+ T cell response, infected diabetic mice also displayed a more prominent Th17 response with increased levels of IL-17a, indicating that an alteration in cytokine profiles could be partly responsible for disease severity.", [["CD4+ T cell", "ANATOMY", 37, 48], ["diabetic", "DISEASE", 68, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["mice", "ORGANISM", 77, 81], ["Th17", "CELL", 114, 118], ["IL-17a", "GENE_OR_GENE_PRODUCT", 153, 159], ["CD4", "PROTEIN", 37, 40], ["IL-17a", "PROTEIN", 153, 159], ["cytokine", "PROTEIN", 194, 202], ["mice", "SPECIES", 77, 81], ["mice", "SPECIES", 77, 81], ["infected diabetic mice", "PROBLEM", 59, 81], ["an alteration in cytokine profiles", "PROBLEM", 177, 211], ["disease severity", "PROBLEM", 244, 260], ["decreased", "OBSERVATION_MODIFIER", 19, 28], ["cell response", "OBSERVATION", 44, 57], ["infected", "OBSERVATION_MODIFIER", 59, 67], ["diabetic", "OBSERVATION", 68, 76], ["more prominent", "OBSERVATION_MODIFIER", 99, 113], ["Th17 response", "OBSERVATION", 114, 127], ["increased", "OBSERVATION_MODIFIER", 133, 142], ["alteration", "OBSERVATION", 180, 190], ["cytokine profiles", "OBSERVATION", 194, 211], ["could be partly responsible for", "UNCERTAINTY", 212, 243]]], ["This study is consistent with prior evidence that diabetes results in a shift toward Th17 responses and diminished regulatory T cells resulting in exaggerated inflammatory cascades [22, 34] .", [["regulatory T cells", "ANATOMY", 115, 133], ["diabetes", "DISEASE", 50, 58], ["Th17", "CELL", 85, 89], ["T cells", "CELL", 126, 133], ["regulatory T cells", "CELL_TYPE", 115, 133], ["This study", "TEST", 0, 10], ["diabetes", "PROBLEM", 50, 58], ["Th17 responses", "TEST", 85, 99], ["diminished regulatory T cells", "PROBLEM", 104, 133], ["exaggerated inflammatory cascades", "PROBLEM", 147, 180], ["consistent with", "UNCERTAINTY", 14, 29], ["diabetes", "OBSERVATION", 50, 58], ["diminished", "OBSERVATION_MODIFIER", 104, 114], ["regulatory T cells", "OBSERVATION", 115, 133], ["exaggerated", "OBSERVATION_MODIFIER", 147, 158], ["inflammatory", "OBSERVATION_MODIFIER", 159, 171]]], ["Notably, some patients infected with COVID-19 have developed a fatal hyperinflammatory syndrome resembling secondary hemophagocytic lymphohistiocytosis, thought to be mediated by pro-inflammatory cytokines such as IL-2, IL-6, IL-12, TNF-\u03b1, and IFN-\u03b3 [9, 38] .J o u r n a l P r e -p r o o fAnother area of both scientific and clinical interest has centered on the relationship between ACE2 receptor expression and specific diseases such as diabetes.", [["hyperinflammatory syndrome", "DISEASE", 69, 95], ["hemophagocytic lymphohistiocytosis", "DISEASE", 117, 151], ["diabetes", "DISEASE", 439, 447], ["patients", "ORGANISM", 14, 22], ["IL-2", "GENE_OR_GENE_PRODUCT", 214, 218], ["IL-6", "GENE_OR_GENE_PRODUCT", 220, 224], ["IL-12", "GENE_OR_GENE_PRODUCT", 226, 231], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 233, 238], ["IFN-\u03b3", "SIMPLE_CHEMICAL", 244, 249], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 384, 397], ["pro-inflammatory cytokines", "PROTEIN", 179, 205], ["IL-12", "PROTEIN", 226, 231], ["TNF", "PROTEIN", 233, 236], ["IFN", "PROTEIN", 244, 247], ["ACE2", "PROTEIN", 384, 388], ["patients", "SPECIES", 14, 22], ["COVID", "TEST", 37, 42], ["a fatal hyperinflammatory syndrome", "PROBLEM", 61, 95], ["secondary hemophagocytic lymphohistiocytosis", "PROBLEM", 107, 151], ["pro-inflammatory cytokines", "TEST", 179, 205], ["IL", "TEST", 214, 216], ["IL", "TEST", 220, 222], ["IL", "TEST", 226, 228], ["TNF", "TEST", 233, 236], ["IFN", "TEST", 244, 247], ["ACE2 receptor expression", "TREATMENT", 384, 408], ["specific diseases", "PROBLEM", 413, 430], ["diabetes", "PROBLEM", 439, 447], ["infected", "OBSERVATION", 23, 31], ["fatal", "OBSERVATION_MODIFIER", 63, 68], ["hyperinflammatory syndrome", "OBSERVATION", 69, 95], ["secondary", "OBSERVATION_MODIFIER", 107, 116], ["hemophagocytic lymphohistiocytosis", "OBSERVATION", 117, 151], ["both", "ANATOMY_MODIFIER", 305, 309], ["scientific", "OBSERVATION", 310, 320], ["diabetes", "OBSERVATION", 439, 447]]], ["ACE2 is a transmembrane glycoprotein expressed on cells throughout the human body, including upper respiratory tract epithelium, type II alveolar pneumocytes, cardiac myocytes, and pancreatic islet cells.", [["transmembrane", "ANATOMY", 10, 23], ["cells", "ANATOMY", 50, 55], ["body", "ANATOMY", 77, 81], ["upper respiratory tract epithelium", "ANATOMY", 93, 127], ["alveolar pneumocytes", "ANATOMY", 137, 157], ["cardiac myocytes", "ANATOMY", 159, 175], ["pancreatic islet cells", "ANATOMY", 181, 203], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 50, 55], ["human", "ORGANISM", 71, 76], ["body", "ORGANISM_SUBDIVISION", 77, 81], ["tract epithelium", "TISSUE", 111, 127], ["type II alveolar pneumocytes", "CELL", 129, 157], ["cardiac myocytes", "CELL", 159, 175], ["pancreatic islet cells", "CELL", 181, 203], ["ACE2", "PROTEIN", 0, 4], ["transmembrane glycoprotein", "PROTEIN", 10, 36], ["type II alveolar pneumocytes", "CELL_TYPE", 129, 157], ["cardiac myocytes", "CELL_TYPE", 159, 175], ["pancreatic islet cells", "CELL_TYPE", 181, 203], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["a transmembrane glycoprotein", "TREATMENT", 8, 36], ["upper respiratory tract epithelium", "PROBLEM", 93, 127], ["type II alveolar pneumocytes", "PROBLEM", 129, 157], ["cardiac myocytes", "PROBLEM", 159, 175], ["pancreatic islet cells", "PROBLEM", 181, 203], ["upper", "ANATOMY_MODIFIER", 93, 98], ["respiratory tract", "ANATOMY", 99, 116], ["alveolar pneumocytes", "OBSERVATION", 137, 157], ["cardiac myocytes", "ANATOMY", 159, 175], ["pancreatic", "ANATOMY", 181, 191], ["islet cells", "OBSERVATION", 192, 203]]], ["The renin-angiotensin-aldosterone (RAAS) signaling pathway comprises both angiotensinconverting enzyme (ACE), which metabolizes angiotensin I (Ang I) to angiotensin II (Ang II), and ACE2, which converts Ang II to angiotensin (1-7) (Ang 1-7) [39] .", [["angiotensin", "CHEMICAL", 10, 21], ["aldosterone", "CHEMICAL", 22, 33], ["angiotensin I", "CHEMICAL", 128, 141], ["Ang", "CHEMICAL", 143, 146], ["angiotensin II", "CHEMICAL", 153, 167], ["Ang II", "CHEMICAL", 169, 175], ["Ang II", "CHEMICAL", 203, 209], ["angiotensin (1-7)", "CHEMICAL", 213, 230], ["Ang 1-7", "CHEMICAL", 232, 239], ["aldosterone", "CHEMICAL", 22, 33], ["renin-angiotensin-aldosterone", "GENE_OR_GENE_PRODUCT", 4, 33], ["RAAS", "GENE_OR_GENE_PRODUCT", 35, 39], ["angiotensinconverting enzyme", "GENE_OR_GENE_PRODUCT", 74, 102], ["ACE", "GENE_OR_GENE_PRODUCT", 104, 107], ["angiotensin I", "GENE_OR_GENE_PRODUCT", 128, 141], ["Ang I", "GENE_OR_GENE_PRODUCT", 143, 148], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 153, 167], ["Ang II", "GENE_OR_GENE_PRODUCT", 169, 175], ["ACE2", "GENE_OR_GENE_PRODUCT", 182, 186], ["Ang II", "GENE_OR_GENE_PRODUCT", 203, 209], ["angiotensin (1-7", "GENE_OR_GENE_PRODUCT", 213, 229], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 232, 239], ["renin", "PROTEIN", 4, 9], ["angiotensinconverting enzyme", "PROTEIN", 74, 102], ["ACE", "PROTEIN", 104, 107], ["angiotensin I", "PROTEIN", 128, 141], ["Ang I", "PROTEIN", 143, 148], ["angiotensin II", "PROTEIN", 153, 167], ["Ang II", "PROTEIN", 169, 175], ["ACE2", "PROTEIN", 182, 186], ["Ang II", "PROTEIN", 203, 209], ["The renin-angiotensin-aldosterone (RAAS", "TREATMENT", 0, 39], ["signaling pathway", "PROBLEM", 41, 58], ["both angiotensinconverting enzyme (ACE)", "TREATMENT", 69, 108], ["angiotensin II (Ang II)", "TREATMENT", 153, 176], ["ACE2", "TEST", 182, 186], ["angiotensin", "TEST", 213, 224]]], ["Ang II has both vasoconstrictive and inflammatory properties, which are counter-balanced by the vasodilatory and anti-inflammatory properties of Ang 1-7 [39, 40] .", [["Ang II", "CHEMICAL", 0, 6], ["Ang", "CHEMICAL", 145, 148], ["Ang II", "GENE_OR_GENE_PRODUCT", 0, 6], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 145, 152], ["Ang II", "PROTEIN", 0, 6], ["both vasoconstrictive and inflammatory properties", "PROBLEM", 11, 60], ["the vasodilatory", "TREATMENT", 92, 108], ["Ang", "TEST", 145, 148], ["vasoconstrictive", "OBSERVATION_MODIFIER", 16, 32], ["inflammatory", "OBSERVATION_MODIFIER", 37, 49]]], ["The ratio of the activity of ACE and ACE2, which are both highly expressed in the lung, has been shown to have implications on lung oxygenation and lung injury in acute respiratory distress syndrome (ARDS) [39, 41, 42] .J o u r n a l P r e -p r o o fExperimental models following the SARS-CoV epidemic showed that Spike protein binding results in decreased expression of ACE2 receptors in the lung, suggesting that lung injury may be mediated by a higher proportion of Ang II relative to Ang 1-7 [43] .", [["lung", "ANATOMY", 82, 86], ["lung", "ANATOMY", 127, 131], ["lung", "ANATOMY", 148, 152], ["respiratory", "ANATOMY", 169, 180], ["lung", "ANATOMY", 393, 397], ["lung", "ANATOMY", 415, 419], ["lung injury", "DISEASE", 148, 159], ["acute respiratory distress syndrome", "DISEASE", 163, 198], ["ARDS", "DISEASE", 200, 204], ["SARS", "DISEASE", 284, 288], ["lung injury", "DISEASE", 415, 426], ["Ang II", "CHEMICAL", 469, 475], ["Ang 1-7", "CHEMICAL", 488, 495], ["ACE", "GENE_OR_GENE_PRODUCT", 29, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 37, 41], ["lung", "ORGAN", 82, 86], ["lung", "ORGAN", 127, 131], ["lung", "ORGAN", 148, 152], ["SARS-CoV", "ORGANISM", 284, 292], ["Spike", "GENE_OR_GENE_PRODUCT", 314, 319], ["ACE2 receptors", "GENE_OR_GENE_PRODUCT", 371, 385], ["lung", "ORGAN", 393, 397], ["lung", "ORGAN", 415, 419], ["Ang II", "GENE_OR_GENE_PRODUCT", 469, 475], ["Ang 1-7", "GENE_OR_GENE_PRODUCT", 488, 495], ["ACE", "PROTEIN", 29, 32], ["ACE2", "PROTEIN", 37, 41], ["Spike protein", "PROTEIN", 314, 327], ["ACE2 receptors", "PROTEIN", 371, 385], ["Ang II", "PROTEIN", 469, 475], ["SARS-CoV", "SPECIES", 284, 292], ["ACE", "TEST", 29, 32], ["ACE2", "TEST", 37, 41], ["lung oxygenation", "TEST", 127, 143], ["lung injury", "PROBLEM", 148, 159], ["acute respiratory distress syndrome", "PROBLEM", 163, 198], ["ARDS", "PROBLEM", 200, 204], ["a l P", "TEST", 230, 235], ["fExperimental models", "PROBLEM", 249, 269], ["the SARS", "TEST", 280, 288], ["CoV epidemic", "PROBLEM", 289, 301], ["Spike protein binding", "PROBLEM", 314, 335], ["ACE2 receptors in the lung", "PROBLEM", 371, 397], ["lung injury", "PROBLEM", 415, 426], ["Ang", "TEST", 488, 491], ["activity", "OBSERVATION_MODIFIER", 17, 25], ["lung", "ANATOMY", 82, 86], ["lung", "ANATOMY", 127, 131], ["oxygenation", "OBSERVATION", 132, 143], ["lung", "ANATOMY", 148, 152], ["injury", "OBSERVATION", 153, 159], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory distress", "OBSERVATION", 169, 189], ["decreased", "OBSERVATION_MODIFIER", 347, 356], ["ACE2 receptors", "OBSERVATION", 371, 385], ["lung", "ANATOMY", 393, 397], ["lung", "ANATOMY", 415, 419], ["injury", "OBSERVATION", 420, 426]]], ["Thus, the ACE2 receptor appears to have conflicting roles related to the pathophysiology of SARS-CoV-2 infection: one where ACE2 facilitates disease as the binding site for SARS-CoV-2, and another where reduced expression of ACE2 may contribute to severe lung injury after infection [40] .J o u r n a l P r e -p r o o fThe effects that diabetes has on ACE2 expression in specific tissues need to be studied in more detail.", [["lung", "ANATOMY", 255, 259], ["tissues", "ANATOMY", 380, 387], ["SARS", "DISEASE", 92, 96], ["infection", "DISEASE", 103, 112], ["lung injury", "DISEASE", 255, 266], ["infection", "DISEASE", 273, 282], ["diabetes", "DISEASE", 336, 344], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 10, 23], ["SARS-CoV-2", "ORGANISM", 92, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 124, 128], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 173, 183], ["ACE2", "GENE_OR_GENE_PRODUCT", 225, 229], ["lung", "ORGAN", 255, 259], ["ACE2", "GENE_OR_GENE_PRODUCT", 352, 356], ["tissues", "TISSUE", 380, 387], ["ACE2 receptor", "PROTEIN", 10, 23], ["ACE2", "PROTEIN", 124, 128], ["ACE2", "PROTEIN", 225, 229], ["ACE2", "PROTEIN", 352, 356], ["SARS-CoV", "SPECIES", 92, 100], ["SARS-CoV", "SPECIES", 173, 181], ["the ACE2 receptor", "TREATMENT", 6, 23], ["SARS", "PROBLEM", 92, 96], ["CoV-2 infection", "PROBLEM", 97, 112], ["ACE2 facilitates disease", "PROBLEM", 124, 148], ["the binding site", "PROBLEM", 152, 168], ["SARS", "PROBLEM", 173, 177], ["ACE2", "PROBLEM", 225, 229], ["severe lung injury", "PROBLEM", 248, 266], ["infection", "PROBLEM", 273, 282], ["The effects", "PROBLEM", 319, 330], ["diabetes", "PROBLEM", 336, 344], ["ACE2 expression", "TREATMENT", 352, 367], ["severe", "OBSERVATION_MODIFIER", 248, 254], ["lung", "ANATOMY", 255, 259], ["injury", "OBSERVATION", 260, 266], ["diabetes", "OBSERVATION", 336, 344]]], ["Experimental models have primarily focused on ACE2 in the kidney of type 1 and type 2 diabetic mice and have shown increased ACE2 expression in early disease followed by decreased expression in later disease that coincides with the development of nephropathy [44] [45] [46] [47] .", [["kidney", "ANATOMY", 58, 64], ["diabetic", "DISEASE", 86, 94], ["nephropathy", "DISEASE", 247, 258], ["ACE2", "GENE_OR_GENE_PRODUCT", 46, 50], ["kidney", "ORGAN", 58, 64], ["mice", "ORGANISM", 95, 99], ["ACE2", "GENE_OR_GENE_PRODUCT", 125, 129], ["ACE2", "PROTEIN", 46, 50], ["ACE2", "PROTEIN", 125, 129], ["mice", "SPECIES", 95, 99], ["mice", "SPECIES", 95, 99], ["Experimental models", "PROBLEM", 0, 19], ["ACE2", "TEST", 46, 50], ["increased ACE2 expression", "PROBLEM", 115, 140], ["early disease", "PROBLEM", 144, 157], ["decreased expression in later disease", "PROBLEM", 170, 207], ["nephropathy", "PROBLEM", 247, 258], ["kidney", "ANATOMY", 58, 64], ["increased", "OBSERVATION_MODIFIER", 115, 124], ["ACE2 expression", "OBSERVATION", 125, 140], ["early", "OBSERVATION_MODIFIER", 144, 149], ["disease", "OBSERVATION", 150, 157]]], ["Similarly, ACE2 has been shown to be decreased in the tubules of individuals with diabetic nephropathy [48] .", [["tubules", "ANATOMY", 54, 61], ["diabetic nephropathy", "DISEASE", 82, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 11, 15], ["tubules", "TISSUE", 54, 61], ["ACE2", "PROTEIN", 11, 15], ["ACE2", "TEST", 11, 15], ["diabetic nephropathy", "PROBLEM", 82, 102], ["shown to be", "UNCERTAINTY", 25, 36], ["decreased", "OBSERVATION_MODIFIER", 37, 46], ["diabetic", "OBSERVATION_MODIFIER", 82, 90], ["nephropathy", "OBSERVATION", 91, 102]]], ["An experimental model that investigated the effect of diabetes on the expression of ACE2 in tissues throughout the body found that the ratio of ACE2/ACE activity in the lung was decreased in late-stage diabetes [49] .", [["tissues", "ANATOMY", 92, 99], ["body", "ANATOMY", 115, 119], ["lung", "ANATOMY", 169, 173], ["diabetes", "DISEASE", 54, 62], ["diabetes", "DISEASE", 202, 210], ["ACE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["tissues", "TISSUE", 92, 99], ["body", "ORGANISM_SUBDIVISION", 115, 119], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["ACE", "GENE_OR_GENE_PRODUCT", 149, 152], ["lung", "ORGAN", 169, 173], ["ACE2", "PROTEIN", 84, 88], ["ACE2", "PROTEIN", 144, 148], ["ACE", "PROTEIN", 149, 152], ["diabetes", "PROBLEM", 54, 62], ["ACE2 in tissues", "PROBLEM", 84, 99], ["the ratio", "TEST", 131, 140], ["ACE2", "TEST", 144, 148], ["ACE activity in the lung", "PROBLEM", 149, 173], ["late-stage diabetes", "PROBLEM", 191, 210], ["diabetes", "OBSERVATION", 54, 62], ["lung", "ANATOMY", 169, 173], ["decreased", "OBSERVATION_MODIFIER", 178, 187], ["late", "OBSERVATION_MODIFIER", 191, 195], ["-stage", "OBSERVATION_MODIFIER", 195, 201], ["diabetes", "OBSERVATION", 202, 210]]], ["Conversely, a recent phenome-wide Mendelian randomization study that investigated the association of disease states and ACE2 expression found that type 2 diabetes is causally associated with increased ACE2 expression in the lung [50] .", [["lung", "ANATOMY", 224, 228], ["type 2 diabetes", "DISEASE", 147, 162], ["ACE2", "GENE_OR_GENE_PRODUCT", 120, 124], ["ACE2", "GENE_OR_GENE_PRODUCT", 201, 205], ["lung", "ORGAN", 224, 228], ["ACE2", "PROTEIN", 120, 124], ["ACE2", "PROTEIN", 201, 205], ["a recent phenome", "TEST", 12, 28], ["wide Mendelian randomization study", "TEST", 29, 63], ["disease states", "PROBLEM", 101, 115], ["ACE2 expression", "PROBLEM", 120, 135], ["type 2 diabetes", "PROBLEM", 147, 162], ["increased ACE2 expression in the lung", "PROBLEM", 191, 228], ["disease", "OBSERVATION", 101, 108], ["ACE2 expression", "OBSERVATION", 201, 216], ["lung", "ANATOMY", 224, 228]]], ["Further investigation into the effects that both diabetes and SARS-CoV-2 infection have on ACE2 is warranted to guide therapeutic approaches.Gaps in Our Knowledge Requiring InvestigationAs discussed above, emerging information suggests that patients with diabetes are more susceptible to SARS-CoV-2 infection and are at risk of increased morbidity and mortality associated with COVID-19.", [["diabetes", "DISEASE", 49, 57], ["SARS", "DISEASE", 62, 66], ["infection", "DISEASE", 73, 82], ["diabetes", "DISEASE", 255, 263], ["SARS-CoV-2 infection", "DISEASE", 288, 308], ["COVID-19", "CHEMICAL", 378, 386], ["SARS-CoV-2", "ORGANISM", 62, 72], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["patients", "ORGANISM", 241, 249], ["SARS-CoV-2", "ORGANISM", 288, 298], ["ACE2", "PROTEIN", 91, 95], ["patients", "SPECIES", 241, 249], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 288, 296], ["Further investigation", "TEST", 0, 21], ["both diabetes", "PROBLEM", 44, 57], ["SARS", "PROBLEM", 62, 66], ["CoV-2 infection", "PROBLEM", 67, 82], ["ACE2", "TREATMENT", 91, 95], ["therapeutic approaches", "TREATMENT", 118, 140], ["diabetes", "PROBLEM", 255, 263], ["SARS", "PROBLEM", 288, 292], ["CoV-2 infection", "PROBLEM", 293, 308], ["increased morbidity", "PROBLEM", 328, 347], ["COVID", "TEST", 378, 383], ["diabetes", "OBSERVATION", 49, 57], ["infection", "OBSERVATION", 299, 308], ["increased", "OBSERVATION_MODIFIER", 328, 337], ["morbidity", "OBSERVATION", 338, 347]]], ["However, it has been argued that the presence of diabetes may not predispose to an increased risk of SARS-CoV-2 infection, but rather a rapid progression and worse outcome of COVID-19 [16] .", [["diabetes", "DISEASE", 49, 57], ["SARS", "DISEASE", 101, 105], ["infection", "DISEASE", 112, 121], ["COVID-19", "CHEMICAL", 175, 183], ["SARS-CoV-2", "ORGANISM", 101, 111], ["SARS-CoV", "SPECIES", 101, 109], ["diabetes", "PROBLEM", 49, 57], ["SARS", "PROBLEM", 101, 105], ["CoV-2 infection", "PROBLEM", 106, 121], ["a rapid progression", "PROBLEM", 134, 153], ["COVID", "TEST", 175, 180], ["diabetes", "OBSERVATION", 49, 57], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["SARS", "OBSERVATION", 101, 105], ["infection", "OBSERVATION", 112, 121], ["rapid", "OBSERVATION_MODIFIER", 136, 141], ["progression", "OBSERVATION_MODIFIER", 142, 153]]], ["Thus, appropriately controlled large studies in both the inpatient and outpatient settings are needed to quantify the magnitude of these associations before and after therapy, and to assess whether such associations are causal or due to underlying confounding.", [["therapy", "TREATMENT", 167, 174], ["underlying confounding", "PROBLEM", 237, 259]]], ["For example, studies suggesting increased susceptibility to SARS-CoV-2 infection in individuals with diabetes could be confounded by a greater degree of testing in this population due to more frequent visits to the emergency department or hospitalizations for coexisting complications of diabetes such as other components of the metabolic syndrome and cardiovascular disease.", [["cardiovascular", "ANATOMY", 352, 366], ["SARS-CoV-2 infection", "DISEASE", 60, 80], ["diabetes", "DISEASE", 101, 109], ["diabetes", "DISEASE", 288, 296], ["metabolic syndrome", "DISEASE", 329, 347], ["cardiovascular disease", "DISEASE", 352, 374], ["SARS-CoV-2", "ORGANISM", 60, 70], ["individuals", "ORGANISM", 84, 95], ["cardiovascular", "ANATOMICAL_SYSTEM", 352, 366], ["CoV-", "SPECIES", 65, 69], ["SARS-CoV", "SPECIES", 60, 68], ["studies", "TEST", 13, 20], ["increased susceptibility", "PROBLEM", 32, 56], ["SARS", "PROBLEM", 60, 64], ["CoV-2 infection", "PROBLEM", 65, 80], ["diabetes", "PROBLEM", 101, 109], ["coexisting complications", "PROBLEM", 260, 284], ["diabetes", "PROBLEM", 288, 296], ["the metabolic syndrome", "PROBLEM", 325, 347], ["cardiovascular disease", "PROBLEM", 352, 374], ["suggesting", "UNCERTAINTY", 21, 31], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["susceptibility", "OBSERVATION_MODIFIER", 42, 56], ["infection", "OBSERVATION", 71, 80], ["greater degree", "OBSERVATION_MODIFIER", 135, 149], ["diabetes", "OBSERVATION", 288, 296], ["metabolic syndrome", "OBSERVATION", 329, 347], ["cardiovascular disease", "OBSERVATION", 352, 374]]], ["Thus, it is necessary to clarify whether patients with diabetes are highly prone to SARS-CoV-2 infection or poor outcomes from COVID-19.Gaps in Our Knowledge Requiring InvestigationIt should be noted that challenges have been encountered with the quality and availability of PCR-based diagnostic tests that are currently used to make the diagnosis.", [["diabetes", "DISEASE", 55, 63], ["SARS", "DISEASE", 84, 88], ["infection", "DISEASE", 95, 104], ["patients", "ORGANISM", 41, 49], ["CoV-2", "ORGANISM", 89, 94], ["patients", "SPECIES", 41, 49], ["diabetes", "PROBLEM", 55, 63], ["SARS", "PROBLEM", 84, 88], ["CoV", "PROBLEM", 89, 92], ["2 infection", "PROBLEM", 93, 104], ["poor outcomes", "PROBLEM", 108, 121], ["COVID", "TEST", 127, 132], ["Investigation", "TEST", 168, 181], ["PCR", "TEST", 275, 278], ["diagnostic tests", "TEST", 285, 301]]], ["Furthermore, the first antibody-based tests for diagnosing recent infection (IgM) or more remote infection (IgG), and possibly immunity, are only now emerging.", [["infection", "DISEASE", 66, 75], ["infection", "DISEASE", 97, 106], ["IgM", "PROTEIN", 77, 80], ["IgG", "PROTEIN", 108, 111], ["the first antibody", "TEST", 13, 31], ["recent infection (IgM)", "PROBLEM", 59, 81], ["more remote infection (IgG)", "PROBLEM", 85, 112], ["infection", "OBSERVATION", 66, 75], ["infection", "OBSERVATION", 97, 106]]], ["Initial antibody-based tests, mainly enzyme-linked immunosorbent assays (ELISAs), were characterized by a lack of specificity due to crossreactivity with other coronaviruses.", [["Initial antibody", "TEST", 0, 16], ["based tests", "TEST", 17, 28], ["enzyme", "TEST", 37, 43], ["immunosorbent assays", "TEST", 51, 71], ["ELISAs", "TEST", 73, 79], ["crossreactivity", "PROBLEM", 133, 148], ["other coronaviruses", "PROBLEM", 154, 173]]], ["These deficiencies need to be corrected for the tests to be clinically useful, and their availability needs to significantly increase since they are not currently available for screening the asymptomatic population.Gaps in Our Knowledge Requiring InvestigationThe deployment of large-scale antibody testing is imperative not only to understand the frequency of infection in specific subpopulations (such as individuals with diabetes) but also to obtain an accurate assessment of the case fatality rate of COVID-19.", [["infection", "DISEASE", 361, 370], ["diabetes", "DISEASE", 424, 432], ["COVID-19", "CHEMICAL", 505, 513], ["These deficiencies", "PROBLEM", 0, 18], ["the tests", "TEST", 44, 53], ["Investigation", "TEST", 247, 260], ["large-scale antibody testing", "TEST", 278, 306], ["infection", "PROBLEM", 361, 370], ["diabetes", "PROBLEM", 424, 432], ["an accurate assessment", "TEST", 453, 475], ["COVID", "TEST", 505, 510], ["large", "OBSERVATION_MODIFIER", 278, 283], ["infection", "OBSERVATION", 361, 370]]], ["Serological testing could provide necessary read-outs regarding the efficacy of vaccines or other medications currently in clinical trials.", [["Serological testing", "TEST", 0, 19], ["vaccines", "TREATMENT", 80, 88], ["other medications", "TREATMENT", 92, 109]]], ["Taking all the above into account, more accurate and widely available diagnostic tools are needed to expand the study sample and Due to the fact that ACE2 is the cellular receptor of SARS-CoV-2, many investigators have expressed concern whether patients treated with ACE inhibitors (ACEIs), angiotensin II type-I receptor blockers (ARBs), or other drugs that increase ACE2 expression may exhibit a worse prognosis and have questioned whether physicians should discontinue these drugs in patients that take them for hypertension or complications of diabetes [52, 53] .", [["cellular", "ANATOMY", 162, 170], ["SARS", "DISEASE", 183, 187], ["ACE inhibitors", "CHEMICAL", 267, 281], ["ACEIs", "CHEMICAL", 283, 288], ["angiotensin II type-I receptor blockers", "CHEMICAL", 291, 330], ["ARBs", "CHEMICAL", 332, 336], ["hypertension", "DISEASE", 515, 527], ["diabetes", "DISEASE", 548, 556], ["ACE2", "GENE_OR_GENE_PRODUCT", 150, 154], ["cellular", "CELL", 162, 170], ["SARS-CoV-2", "ORGANISM", 183, 193], ["patients", "ORGANISM", 245, 253], ["ACE", "GENE_OR_GENE_PRODUCT", 267, 270], ["ACEIs", "SIMPLE_CHEMICAL", 283, 288], ["angiotensin II type-I receptor blockers", "GENE_OR_GENE_PRODUCT", 291, 330], ["ARBs", "SIMPLE_CHEMICAL", 332, 336], ["ACE2", "GENE_OR_GENE_PRODUCT", 368, 372], ["patients", "ORGANISM", 487, 495], ["ACE2", "PROTEIN", 150, 154], ["ACE2", "PROTEIN", 368, 372], ["patients", "SPECIES", 245, 253], ["patients", "SPECIES", 487, 495], ["the study sample", "TEST", 108, 124], ["ACE inhibitors", "TREATMENT", 267, 281], ["ACEIs", "TREATMENT", 283, 288], ["angiotensin II type-I receptor blockers", "TREATMENT", 291, 330], ["ARBs", "TREATMENT", 332, 336], ["other drugs", "TREATMENT", 342, 353], ["these drugs", "TREATMENT", 472, 483], ["hypertension", "PROBLEM", 515, 527], ["diabetes", "PROBLEM", 548, 556]]], ["On the other hand, some evidence emphasizes the protective effects of ACE2 on the cardiovascular system and in ARDS [39, 42] .", [["cardiovascular system", "ANATOMY", 82, 103], ["ARDS", "DISEASE", 111, 115], ["ACE2", "GENE_OR_GENE_PRODUCT", 70, 74], ["cardiovascular", "ANATOMICAL_SYSTEM", 82, 96], ["system", "ANATOMICAL_SYSTEM", 97, 103], ["ACE2", "PROTEIN", 70, 74], ["ARDS", "PROBLEM", 111, 115], ["cardiovascular system", "ANATOMY", 82, 103], ["ARDS", "OBSERVATION", 111, 115]]], ["SARS-CoV-2-induced impaired ACE2 activity may hypothetically attenuate the cardioprotective role of ACE2, exaggerate inflammation, and contribute to severe lung injury in COVID-19.", [["lung", "ANATOMY", 156, 160], ["SARS", "DISEASE", 0, 4], ["inflammation", "DISEASE", 117, 129], ["lung injury", "DISEASE", 156, 167], ["CoV-2", "GENE_OR_GENE_PRODUCT", 5, 10], ["ACE2", "GENE_OR_GENE_PRODUCT", 28, 32], ["ACE2", "GENE_OR_GENE_PRODUCT", 100, 104], ["lung", "ORGAN", 156, 160], ["ACE2", "PROTEIN", 28, 32], ["ACE2", "PROTEIN", 100, 104], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["impaired ACE2 activity", "PROBLEM", 19, 41], ["inflammation", "PROBLEM", 117, 129], ["severe lung injury", "PROBLEM", 149, 167], ["COVID", "TEST", 171, 176], ["inflammation", "OBSERVATION", 117, 129], ["severe", "OBSERVATION_MODIFIER", 149, 155], ["lung", "ANATOMY", 156, 160], ["injury", "OBSERVATION", 161, 167]]], ["As discussed above, ACE2 in humans is not well understood, but evidence suggesting that ACE2 expression may be reduced in the elderly, or individuals with hypertension or diabetes, provides an argument for the continuation of ACEIs/ARBs and for clinical trials investigating the therapeutic effects of initiating these medications in severe cases of COVID-19 [40] .", [["hypertension", "DISEASE", 155, 167], ["diabetes", "DISEASE", 171, 179], ["COVID-19", "CHEMICAL", 350, 358], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["humans", "ORGANISM", 28, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["ACE2", "PROTEIN", 20, 24], ["ACE2", "PROTEIN", 88, 92], ["humans", "SPECIES", 28, 34], ["humans", "SPECIES", 28, 34], ["ACE2 expression", "PROBLEM", 88, 103], ["hypertension", "PROBLEM", 155, 167], ["diabetes", "PROBLEM", 171, 179], ["ACEIs", "TREATMENT", 226, 231], ["ARBs", "TREATMENT", 232, 236], ["clinical trials", "TREATMENT", 245, 260], ["these medications", "TREATMENT", 313, 330], ["COVID", "TEST", 350, 355], ["reduced", "OBSERVATION_MODIFIER", 111, 118]]], ["Furthermore, different RAAS inhibitors may demonstrate different effects on ACE2 levels and COVID-19 outcomes, and the discontinuation of ACEIs and ARBs may result in adverse health outcomes related to poor control of chronic conditions [54] [55] [56] [57] .", [["ACEIs", "CHEMICAL", 138, 143], ["ARBs", "CHEMICAL", 148, 152], ["RAAS", "GENE_OR_GENE_PRODUCT", 23, 27], ["ACE2", "GENE_OR_GENE_PRODUCT", 76, 80], ["ACEIs", "SIMPLE_CHEMICAL", 138, 143], ["ARBs", "SIMPLE_CHEMICAL", 148, 152], ["ACE2", "PROTEIN", 76, 80], ["different RAAS inhibitors", "TREATMENT", 13, 38], ["ACE2 levels", "TEST", 76, 87], ["COVID", "TEST", 92, 97], ["ACEIs", "TREATMENT", 138, 143], ["ARBs", "TREATMENT", 148, 152], ["adverse health outcomes", "PROBLEM", 167, 190], ["poor control of chronic conditions", "PROBLEM", 202, 236]]], ["This is an area of active investigation from both an epidemiological risk factor perspective as well as from a novel drug development point of view.Gaps in Our Knowledge Requiring InvestigationMoreover, multicenter observational studies should be conducted to estimate the prevalence and the case fatality ratio of the disease, which appears to be different among different populations.", [["multicenter observational studies", "TEST", 203, 236], ["the disease", "PROBLEM", 315, 326], ["area", "OBSERVATION_MODIFIER", 11, 15], ["active", "OBSERVATION_MODIFIER", 19, 25], ["disease", "OBSERVATION", 319, 326], ["appears to be", "UNCERTAINTY", 334, 347]]], ["Potential explanations for the observed differences include measurement errors (since the denominator of the ratio is affected by the quality and number of measurements in each case), genetic susceptibility of the populations of interest, and differential virulence of the J o u r n a l P r e -p r o o f known haplotypes/variants of the virus.", [["known haplotypes/variants", "PROBLEM", 304, 329], ["the virus", "PROBLEM", 333, 342], ["virus", "OBSERVATION", 337, 342]]], ["In addition, more experimental and rigorous clinical trials are of vital importance to clarify and further explore the findings of the observational studies.", [["the observational studies", "TEST", 131, 156]]], ["Furthermore, trials using multi-omics approaches and big data analytics are urgently needed to examine the characteristics of these subpopulations and to identify potential risk factors, i.e., sex, race, ethnicity, presence of preexisting disorders, or comorbidities.Gaps in Our Knowledge Requiring InvestigationInterventional trials should also focus on the efficacy and safety of the different types of RAAS inhibitors and elucidate their role and mechanism of action in the disease milieu.", [["RAAS", "GENE_OR_GENE_PRODUCT", 405, 409], ["multi-omics approaches", "TREATMENT", 26, 48], ["big data analytics", "TEST", 53, 71], ["potential risk factors", "PROBLEM", 163, 185], ["preexisting disorders", "PROBLEM", 227, 248], ["comorbidities", "PROBLEM", 253, 266], ["Investigation", "TEST", 299, 312], ["Interventional trials", "TREATMENT", 312, 333], ["RAAS inhibitors", "TREATMENT", 405, 420]]], ["Whether different classes of antidiabetic drugs that may affect the levels of ACE2 (such as DPP4 inhibitors) can reduce the risk of infection or modify disease progression should be investigated [52, 58] .", [["infection", "DISEASE", 132, 141], ["ACE2", "GENE_OR_GENE_PRODUCT", 78, 82], ["DPP4", "GENE_OR_GENE_PRODUCT", 92, 96], ["ACE2", "PROTEIN", 78, 82], ["antidiabetic drugs", "TREATMENT", 29, 47], ["ACE2 (such as DPP4 inhibitors", "TREATMENT", 78, 107], ["infection", "PROBLEM", 132, 141], ["modify disease progression", "PROBLEM", 145, 171], ["antidiabetic drugs", "OBSERVATION", 29, 47], ["infection", "OBSERVATION", 132, 141]]], ["A more in-depth understanding of the disease is crucial for the development of effective vaccines and therapeutic strategies against SARS-CoV-2.Gaps in Our Knowledge Requiring InvestigationThe potential benefits of several other agents against SARS-CoV-2 are currently being investigated (i.e., hydroxychloroquine, chloroquine, azithromycin, corticosteroids, antiinflammatory agents, antiviral drugs, convalescent plasma transfusion) and numerous compounds are in development.", [["plasma", "ANATOMY", 414, 420], ["SARS", "DISEASE", 133, 137], ["SARS", "DISEASE", 244, 248], ["hydroxychloroquine", "CHEMICAL", 295, 313], ["chloroquine", "CHEMICAL", 315, 326], ["azithromycin", "CHEMICAL", 328, 340], ["hydroxychloroquine", "CHEMICAL", 295, 313], ["chloroquine", "CHEMICAL", 315, 326], ["azithromycin", "CHEMICAL", 328, 340], ["corticosteroids", "CHEMICAL", 342, 357], ["SARS-CoV-2", "ORGANISM", 133, 143], ["SARS-CoV-2", "ORGANISM", 244, 254], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 295, 313], ["chloroquine", "SIMPLE_CHEMICAL", 315, 326], ["azithromycin", "SIMPLE_CHEMICAL", 328, 340], ["corticosteroids", "SIMPLE_CHEMICAL", 342, 357], ["convalescent", "ORGANISM", 401, 413], ["plasma", "ORGANISM_SUBSTANCE", 414, 420], ["SARS-CoV", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 244, 252], ["the disease", "PROBLEM", 33, 44], ["effective vaccines", "TREATMENT", 79, 97], ["therapeutic strategies", "TREATMENT", 102, 124], ["SARS", "PROBLEM", 133, 137], ["Investigation", "TEST", 176, 189], ["several other agents", "TREATMENT", 215, 235], ["SARS", "PROBLEM", 244, 248], ["hydroxychloroquine", "TREATMENT", 295, 313], ["chloroquine", "TREATMENT", 315, 326], ["azithromycin", "TREATMENT", 328, 340], ["corticosteroids", "TREATMENT", 342, 357], ["antiinflammatory agents", "TREATMENT", 359, 382], ["antiviral drugs", "TREATMENT", 384, 399], ["convalescent plasma transfusion", "TREATMENT", 401, 432], ["disease", "OBSERVATION", 37, 44]]], ["Randomized clinical trials should be designed to examine the safety and efficacy of these drugs on chemoprophylaxis and treatment, including patients with diabetes, and the possibility of a quick interim analysis from these studies should be considered [59] [60] [61] .", [["diabetes", "DISEASE", 155, 163], ["[59] [60]", "CHEMICAL", 253, 262], ["patients", "ORGANISM", 141, 149], ["[59] [60] [61]", "SIMPLE_CHEMICAL", 253, 267], ["patients", "SPECIES", 141, 149], ["these drugs", "TREATMENT", 84, 95], ["chemoprophylaxis", "TREATMENT", 99, 115], ["treatment", "TREATMENT", 120, 129], ["diabetes", "PROBLEM", 155, 163], ["a quick interim analysis", "TEST", 188, 212], ["these studies", "TEST", 218, 231]]], ["With global attention focused on the COVID-19 pandemic and urgent requests for emergency access to potential therapies, there is an understandable temptation to use drugs without fully proven safety and efficacy against the disease.", [["emergency access", "TREATMENT", 79, 95], ["potential therapies", "TREATMENT", 99, 118], ["drugs", "TREATMENT", 165, 170], ["the disease", "PROBLEM", 220, 231], ["disease", "OBSERVATION", 224, 231]]], ["As a result, a greater emphasis on the drug-evaluation process and evidence-based decision making is needed to protect patients not only from possibly ineffective drugs but also potentially unsafe treatments, which may induce complications and have side effects [62] .Trials with long-term follow up are essential to evaluate the effects of different therapeutic strategies on patient-centered outcomes such as intermediateterm and long-term mortality.", [["patients", "ORGANISM", 119, 127], ["patient", "ORGANISM", 377, 384], ["patients", "SPECIES", 119, 127], ["patient", "SPECIES", 377, 384], ["the drug-evaluation process", "TEST", 35, 62], ["ineffective drugs", "TREATMENT", 151, 168], ["unsafe treatments", "TREATMENT", 190, 207], ["different therapeutic strategies", "TREATMENT", 341, 373], ["intermediateterm and long-term mortality", "TREATMENT", 411, 451], ["long-term", "OBSERVATION_MODIFIER", 432, 441]]], ["Studies should also be designed to examine the long-term cardiometabolic sequelae of SARS-CoV-2 infection among individuals that have recovered from COVID-19.", [["SARS-CoV-2 infection", "DISEASE", 85, 105], ["SARS-CoV-2", "ORGANISM", 85, 95], ["individuals", "ORGANISM", 112, 123], ["SARS-CoV", "SPECIES", 85, 93], ["the long-term cardiometabolic sequelae", "PROBLEM", 43, 81], ["SARS", "PROBLEM", 85, 89], ["CoV", "PROBLEM", 90, 93], ["2 infection", "PROBLEM", 94, 105], ["COVID", "TEST", 149, 154], ["SARS", "OBSERVATION", 85, 89]]], ["Of note, one small study evaluated 25 individuals 12 years after recovery from SARS-CoV infection and found a higher amount of altered glucose and lipid metabolism and significant differences in serum metabolomes compared to age-matched healthy controls [63] .J o u r n a l P r e -p r o o fMetabolism has issued a call for papers and letters to the editor to enhance the scientific dialogue and facilitate dissemination of critically needed useful information in this area.", [["serum", "ANATOMY", 195, 200], ["SARS-CoV infection", "DISEASE", 79, 97], ["glucose", "CHEMICAL", 135, 142], ["glucose", "CHEMICAL", 135, 142], ["SARS-CoV", "ORGANISM", 79, 87], ["glucose", "SIMPLE_CHEMICAL", 135, 142], ["lipid", "SIMPLE_CHEMICAL", 147, 152], ["serum", "ORGANISM_SUBSTANCE", 195, 200], ["SARS-CoV", "SPECIES", 79, 87], ["small study", "TEST", 13, 24], ["SARS", "PROBLEM", 79, 83], ["CoV infection", "PROBLEM", 84, 97], ["altered glucose", "PROBLEM", 127, 142], ["lipid metabolism", "PROBLEM", 147, 163], ["significant differences in serum metabolomes", "PROBLEM", 168, 212], ["fMetabolism", "PROBLEM", 289, 300], ["infection", "OBSERVATION", 88, 97], ["lipid metabolism", "OBSERVATION", 147, 163], ["significant", "OBSERVATION_MODIFIER", 168, 179]]], ["At the same time, it should be acknowledged that the urgent need for information about this global public health crisis has led to an increased number of published papers and data with several limitations (including sampling issues, methodological constraints, limited peer-review process, and potential publication and researcher bias) that may affect the validity of the findings and their interpretation [64] .", [["sampling issues", "TEST", 216, 231], ["increased", "OBSERVATION_MODIFIER", 134, 143]]], ["It is essential for future studies to have predefined and standardized criteria regarding study hypothesis, sample population, clinical syndromes, disease severity, and patient-centered outcomes both for observational and interventional studies.", [["patient", "ORGANISM", 169, 176], ["patient", "SPECIES", 169, 176], ["future studies", "TEST", 20, 34], ["study hypothesis", "TEST", 90, 106], ["sample population", "PROBLEM", 108, 125], ["clinical syndromes", "PROBLEM", 127, 145], ["disease severity", "PROBLEM", 147, 163], ["observational and interventional studies", "TEST", 204, 244]]], ["Thus, in order to elucidate the impact of diabetes mellitus as a risk factor for COVID-19 as well as to explore the best prophylactic and therapeutic strategies for this high-risk population, it is critical to design and conduct high-quality, robust observational studies and clinical trials.Implications for CliniciansGiven the current situation, the paucity of robust scientific evidence, and the lack of specific treatments, COVID-19 has become a crucial worldwide health problem.", [["diabetes mellitus", "DISEASE", 42, 59], ["COVID-19", "CHEMICAL", 428, 436], ["diabetes mellitus", "PROBLEM", 42, 59], ["COVID", "TEST", 81, 86], ["therapeutic strategies", "TREATMENT", 138, 160], ["this high-risk population", "PROBLEM", 165, 190], ["robust observational studies", "TEST", 243, 271], ["specific treatments", "TREATMENT", 407, 426], ["COVID", "TEST", 428, 433], ["diabetes", "OBSERVATION", 42, 50]]], ["At present, quarantine, isolation, social distancing, and stringent restrictions on domestic and international travel are the most effective preventive strategies, along with practicing good hygiene.", [["isolation", "TREATMENT", 24, 33]]], ["However, due to a potential lack of access to medications and supplies, individuals with diabetes may experience difficulties in acquiring essential medical supplies as well as consumable medical devices such as insulin, alcohol wipes, glucose test strips, etc. As a result, metabolic dysregulation and inadequate control of coexisting cardiometabolic conditions, such as hypertension and dyslipidemia, may occur in patients with diabetes [65] .Implications for CliniciansNotably, ACE2 is also expressed in pancreatic and liver tissues, both of which may be potential targets for SARS-CoV-2, leading to further worsening of hyperglycemia during the COVID-19 infection.", [["pancreatic", "ANATOMY", 507, 517], ["liver tissues", "ANATOMY", 522, 535], ["diabetes", "DISEASE", 89, 97], ["alcohol", "CHEMICAL", 221, 228], ["glucose", "CHEMICAL", 236, 243], ["cardiometabolic conditions", "DISEASE", 336, 362], ["hypertension", "DISEASE", 372, 384], ["dyslipidemia", "DISEASE", 389, 401], ["diabetes", "DISEASE", 430, 438], ["hyperglycemia", "DISEASE", 624, 637], ["infection", "DISEASE", 658, 667], ["alcohol", "CHEMICAL", 221, 228], ["glucose", "CHEMICAL", 236, 243], ["insulin", "GENE_OR_GENE_PRODUCT", 212, 219], ["alcohol", "SIMPLE_CHEMICAL", 221, 228], ["glucose", "SIMPLE_CHEMICAL", 236, 243], ["patients", "ORGANISM", 416, 424], ["ACE2", "GENE_OR_GENE_PRODUCT", 481, 485], ["pancreatic", "TISSUE", 507, 517], ["liver tissues", "TISSUE", 522, 535], ["SARS-CoV-2", "ORGANISM", 580, 590], ["COVID-19", "ORGANISM", 649, 657], ["ACE2", "PROTEIN", 481, 485], ["patients", "SPECIES", 416, 424], ["SARS-CoV", "SPECIES", 580, 588], ["COVID-19", "SPECIES", 649, 657], ["medications", "TREATMENT", 46, 57], ["diabetes", "PROBLEM", 89, 97], ["essential medical supplies", "TREATMENT", 139, 165], ["consumable medical devices", "TREATMENT", 177, 203], ["insulin", "TREATMENT", 212, 219], ["glucose test strips", "TEST", 236, 255], ["metabolic dysregulation", "PROBLEM", 275, 298], ["coexisting cardiometabolic conditions", "PROBLEM", 325, 362], ["hypertension", "PROBLEM", 372, 384], ["dyslipidemia", "PROBLEM", 389, 401], ["diabetes", "PROBLEM", 430, 438], ["SARS", "PROBLEM", 580, 584], ["CoV", "TEST", 585, 588], ["hyperglycemia", "PROBLEM", 624, 637], ["the COVID-19 infection", "PROBLEM", 645, 667], ["metabolic dysregulation", "OBSERVATION", 275, 298], ["cardiometabolic conditions", "OBSERVATION", 336, 362], ["hypertension", "OBSERVATION", 372, 384], ["dyslipidemia", "OBSERVATION", 389, 401], ["pancreatic", "ANATOMY", 507, 517], ["liver", "ANATOMY", 522, 527], ["worsening", "OBSERVATION_MODIFIER", 611, 620], ["hyperglycemia", "OBSERVATION", 624, 637], ["infection", "OBSERVATION", 658, 667]]], ["According to this hypothesis, both COVID-19 as an acute illness and SARS-CoV-2 per se may worsen glycemic control [22, 66] .", [["acute illness", "DISEASE", 50, 63], ["SARS", "DISEASE", 68, 72], ["SARS-CoV", "SPECIES", 68, 76], ["COVID", "TEST", 35, 40], ["an acute illness", "PROBLEM", 47, 63], ["SARS", "PROBLEM", 68, 72], ["CoV", "TEST", 73, 76], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["illness", "OBSERVATION", 56, 63]]], ["Given that individuals with diabetes, especially those with comorbidities and complications, are considered high-risk patients, it is evident that risk factors such as hyperglycemia and hypertension should be optimized.J o u r n a l P r e -p r o o fClinicians should be proactive in addressing the needs of patients using telemedicine technologies, including phone calls and video visits if available.", [["diabetes", "DISEASE", 28, 36], ["hyperglycemia", "DISEASE", 168, 181], ["hypertension", "DISEASE", 186, 198], ["patients", "ORGANISM", 118, 126], ["patients", "ORGANISM", 307, 315], ["patients", "SPECIES", 118, 126], ["patients", "SPECIES", 307, 315], ["diabetes", "PROBLEM", 28, 36], ["comorbidities", "PROBLEM", 60, 73], ["complications", "PROBLEM", 78, 91], ["risk factors", "PROBLEM", 147, 159], ["hyperglycemia", "PROBLEM", 168, 181], ["hypertension", "PROBLEM", 186, 198], ["fClinicians", "PROBLEM", 248, 259], ["telemedicine technologies", "TREATMENT", 322, 347], ["hypertension", "OBSERVATION", 186, 198]]], ["The United States government has notably decreased regulatory thresholds to make video health visits easier to provide during this pandemic.", [["decreased regulatory thresholds", "PROBLEM", 41, 72]]], ["We anticipate that establishing care through these technologically advanced means may have a lasting impact on how we treat and follow up with patients with diabetes in the long-term.", [["diabetes", "DISEASE", 157, 165], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["diabetes", "PROBLEM", 157, 165]]], ["Both patients and physicians will be adopting and benefiting from novel technological advancements [67] [68] [69] .J o u r n a l P r e -p r o o fInnovative public health interventions are also being explored, such as a mobile phone contact tracing App that could be used as a strategy to mitigate pre-symptomatic transmission, also considering the limitations of this theoretical model (minimum number of registers, potential privacy compliance issues, ethical requirements) [70] .", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["fInnovative public health interventions", "TREATMENT", 144, 183], ["privacy compliance issues", "TREATMENT", 426, 451]]], ["Health care providers, in general, should use telemedicine and telehealth services to minimize physical contact and simultaneously provide individualized care, support, and feedback.", [["telehealth services", "TREATMENT", 63, 82]]], ["Moreover, they should also ensure close monitoring, maintenance of healthy lifestyle practices, treatment adherence, and aim to remotely address rising health issues in an efficient and timely manner.", [["close monitoring", "TEST", 34, 50], ["healthy lifestyle practices", "TREATMENT", 67, 94], ["treatment adherence", "TREATMENT", 96, 115], ["rising health issues", "PROBLEM", 145, 165]]], ["Due to this uncertain situation and the extremely challenging circumstances, individuals may not only undergo physical health deterioration, but also may experience various anxieties, psychological pressure, distress, and vulnerability.", [["this uncertain situation", "PROBLEM", 7, 31], ["various anxieties", "PROBLEM", 165, 182], ["psychological pressure", "TEST", 184, 206], ["distress", "PROBLEM", 208, 216], ["vulnerability", "PROBLEM", 222, 235]]], ["A multidisciplinary group of experienced professionals both from health and social services should assist patients with diabetes as well as their families and caregivers, taking advantage of the new communication-based social networking platforms.J o u r n a l P r e -p r o o fThe immediate management considerations surrounding medications such as ACEIs and ARBs continues to be debated and investigated.", [["diabetes", "DISEASE", 120, 128], ["ACEIs", "CHEMICAL", 349, 354], ["ARBs", "CHEMICAL", 359, 363], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 106, 114], ["diabetes", "PROBLEM", 120, 128], ["fThe immediate management", "TREATMENT", 276, 301], ["surrounding medications", "TREATMENT", 317, 340], ["ACEIs", "TREATMENT", 349, 354], ["ARBs", "TREATMENT", 359, 363]]], ["Due to lack of strong evidence and given the beneficial organ-protective effects of ACEIs and ARBs, as well as the potential adverse outcomes of SARS-CoV-2 on the cardiovascular system [5, 56, 71] , the Heart Failure Society of America, the American College of Cardiology, and the American Heart Association, as well as the European Society of Cardiology recommend against the discontinuation of RAAS inhibitors [72, 73] .", [["organ", "ANATOMY", 56, 61], ["cardiovascular", "ANATOMY", 163, 177], ["ACEIs", "CHEMICAL", 84, 89], ["SARS", "DISEASE", 145, 149], ["Heart Failure", "DISEASE", 203, 216], ["organ", "ORGAN", 56, 61], ["ACEIs", "SIMPLE_CHEMICAL", 84, 89], ["ARBs", "SIMPLE_CHEMICAL", 94, 98], ["cardiovascular", "ANATOMICAL_SYSTEM", 163, 177], ["ACEIs", "TREATMENT", 84, 89], ["ARBs", "TREATMENT", 94, 98], ["SARS", "PROBLEM", 145, 149], ["CoV", "TEST", 150, 153], ["RAAS inhibitors", "TREATMENT", 396, 411], ["cardiovascular system", "ANATOMY", 163, 184], ["Heart", "ANATOMY", 203, 208], ["Failure", "OBSERVATION", 209, 216]]], ["It should be noted that several clinical trials are underway to examine the safety and efficacy of RAAS inhibitors in COVID-19.J o u r n a l P r e -p r o o fThere have been a number of reports regarding the role of corticosteroids during severe acute illness due to SARS-CoV-2 [2, 13, 74, 75] .", [["corticosteroids", "CHEMICAL", 215, 230], ["acute illness", "DISEASE", 245, 258], ["SARS", "DISEASE", 266, 270], ["corticosteroids", "CHEMICAL", 215, 230], ["RAAS", "SIMPLE_CHEMICAL", 99, 103], ["corticosteroids", "SIMPLE_CHEMICAL", 215, 230], ["SARS-CoV", "SPECIES", 266, 274], ["RAAS inhibitors", "TREATMENT", 99, 114], ["COVID", "TEST", 118, 123], ["corticosteroids", "TREATMENT", 215, 230], ["severe acute illness", "PROBLEM", 238, 258], ["SARS", "PROBLEM", 266, 270], ["CoV", "TEST", 271, 274]]], ["Corticosteroids may attenuate pulmonary J o u r n a l P r e -p r o o f inflammation and subsequent acute lung injury by reducing the inflammatory response and modulating the activity of the immune system [76] .", [["pulmonary", "ANATOMY", 30, 39], ["lung", "ANATOMY", 105, 109], ["inflammation", "DISEASE", 71, 83], ["lung injury", "DISEASE", 105, 116], ["lung", "ORGAN", 105, 109], ["Corticosteroids", "TREATMENT", 0, 15], ["inflammation", "PROBLEM", 71, 83], ["subsequent acute lung injury", "PROBLEM", 88, 116], ["the inflammatory response", "PROBLEM", 129, 154], ["pulmonary", "ANATOMY", 30, 39], ["inflammation", "OBSERVATION", 71, 83], ["acute", "OBSERVATION_MODIFIER", 99, 104], ["lung", "ANATOMY", 105, 109], ["injury", "OBSERVATION", 110, 116], ["inflammatory", "OBSERVATION_MODIFIER", 133, 145]]], ["However, concerns exist whether corticosteroid use is associated with viral rebound, prolonged replication, and increased rates of mechanical ventilation and mortality [77] [78] [79] .", [["corticosteroid", "SIMPLE_CHEMICAL", 32, 46], ["viral rebound", "PROBLEM", 70, 83], ["prolonged replication", "TREATMENT", 85, 106], ["mechanical ventilation", "TREATMENT", 131, 153], ["mechanical ventilation", "OBSERVATION", 131, 153]]], ["Therefore, according to the WHO, corticosteroid treatment is not routinely recommended as a therapeutic option for COVID-19 pneumonia outside of clinical trials [80] .J o u r n a l P r e -p r o o fAt this point, we would also like to note that based on the currently proposed mechanisms of SARS-CoV-2 pathogenesis, APN01, a recombinant soluble human ACE2 (rhACE2), recently received regulatory approvals to be studied in the context of a Phase II clinical trial to treat patients with severe COVID-19.", [["pneumonia", "DISEASE", 124, 133], ["SARS", "DISEASE", 290, 294], ["APN01", "CHEMICAL", 315, 320], ["COVID-19", "CHEMICAL", 492, 500], ["corticosteroid", "SIMPLE_CHEMICAL", 33, 47], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 290, 300], ["APN01", "SIMPLE_CHEMICAL", 315, 320], ["human", "ORGANISM", 344, 349], ["ACE2", "GENE_OR_GENE_PRODUCT", 350, 354], ["rhACE2", "GENE_OR_GENE_PRODUCT", 356, 362], ["patients", "ORGANISM", 471, 479], ["APN01", "PROTEIN", 315, 320], ["recombinant soluble human ACE2", "PROTEIN", 324, 354], ["rhACE2", "PROTEIN", 356, 362], ["human", "SPECIES", 344, 349], ["patients", "SPECIES", 471, 479], ["human", "SPECIES", 344, 349], ["corticosteroid treatment", "TREATMENT", 33, 57], ["a therapeutic option", "TREATMENT", 90, 110], ["COVID", "TEST", 115, 120], ["pneumonia", "PROBLEM", 124, 133], ["SARS", "PROBLEM", 290, 294], ["CoV", "TEST", 295, 298], ["APN01", "TREATMENT", 315, 320], ["a recombinant soluble human ACE2 (rhACE2", "TREATMENT", 322, 362], ["regulatory approvals", "TREATMENT", 383, 403], ["severe COVID", "PROBLEM", 485, 497], ["pneumonia", "OBSERVATION", 124, 133], ["SARS", "OBSERVATION", 290, 294]]], ["APN01 alleviates the detrimental effects of acute inflammation in the lungs and may exhibit a protective role against acute lung injury and ARDS induced by SARS-CoV-2.", [["lungs", "ANATOMY", 70, 75], ["lung", "ANATOMY", 124, 128], ["APN01", "CHEMICAL", 0, 5], ["inflammation", "DISEASE", 50, 62], ["acute lung injury", "DISEASE", 118, 135], ["ARDS", "DISEASE", 140, 144], ["APN01", "CHEMICAL", 0, 5], ["APN01", "SIMPLE_CHEMICAL", 0, 5], ["lungs", "ORGAN", 70, 75], ["lung", "ORGAN", 124, 128], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 156, 166], ["SARS-CoV", "SPECIES", 156, 164], ["APN01", "TREATMENT", 0, 5], ["acute inflammation in the lungs", "PROBLEM", 44, 75], ["acute lung injury", "PROBLEM", 118, 135], ["ARDS", "PROBLEM", 140, 144], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["inflammation", "OBSERVATION", 50, 62], ["lungs", "ANATOMY", 70, 75], ["acute", "OBSERVATION_MODIFIER", 118, 123], ["lung", "ANATOMY", 124, 128], ["injury", "OBSERVATION", 129, 135], ["ARDS", "OBSERVATION", 140, 144]]], ["Due to the similarity of APN01 with human ACE2, the virus binds to the soluble APN01 and inhibits entry into human cells by serving as a decoy receptor [81] .", [["cells", "ANATOMY", 115, 120], ["APN01", "GENE_OR_GENE_PRODUCT", 25, 30], ["human", "ORGANISM", 36, 41], ["ACE2", "GENE_OR_GENE_PRODUCT", 42, 46], ["APN01", "GENE_OR_GENE_PRODUCT", 79, 84], ["human", "ORGANISM", 109, 114], ["cells", "CELL", 115, 120], ["APN01", "PROTEIN", 25, 30], ["human ACE2", "PROTEIN", 36, 46], ["APN01", "PROTEIN", 79, 84], ["human cells", "CELL_TYPE", 109, 120], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 109, 114], ["APN01", "TREATMENT", 25, 30], ["human ACE2", "TREATMENT", 36, 46], ["the virus binds", "PROBLEM", 48, 63], ["the soluble APN01", "TEST", 67, 84]]], ["In our opinion, and based on mechanisms of action, we believe that this is the most promising compound among all medications currently in development.", [["all medications", "TREATMENT", 109, 124]]], ["In this context, it should also be noted that the activity of TMPRSS2, a molecule downstream of ACE2, is essential for viral entry into primary target cells in addition to viral spread and pathogenesis in the infected host.", [["cells", "ANATOMY", 151, 156], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 62, 69], ["ACE2", "GENE_OR_GENE_PRODUCT", 96, 100], ["cells", "CELL", 151, 156], ["TMPRSS2", "PROTEIN", 62, 69], ["ACE2", "PROTEIN", 96, 100], ["primary target cells", "CELL_TYPE", 136, 156], ["the activity of TMPRSS2", "PROBLEM", 46, 69], ["ACE2", "TEST", 96, 100], ["viral entry into primary target cells", "PROBLEM", 119, 156], ["viral spread", "PROBLEM", 172, 184], ["pathogenesis in the infected host", "PROBLEM", 189, 222], ["target cells", "OBSERVATION", 144, 156], ["viral spread", "OBSERVATION", 172, 184], ["infected host", "OBSERVATION", 209, 222]]], ["According to recent data, camostat mesylate, a transmembrane serine protease serine 2 inhibitor developed for the treatment of acute pancreatitis, is active against TMPRSS2 and prevents cellular entry of the virus [24] .", [["cellular", "ANATOMY", 186, 194], ["camostat mesylate", "CHEMICAL", 26, 43], ["pancreatitis", "DISEASE", 133, 145], ["camostat mesylate", "CHEMICAL", 26, 43], ["serine", "CHEMICAL", 61, 67], ["serine", "CHEMICAL", 77, 83], ["camostat mesylate", "SIMPLE_CHEMICAL", 26, 43], ["transmembrane", "CELLULAR_COMPONENT", 47, 60], ["serine protease serine 2", "GENE_OR_GENE_PRODUCT", 61, 85], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 165, 172], ["cellular", "CELL", 186, 194], ["TMPRSS2", "PROTEIN", 165, 172], ["camostat mesylate", "TREATMENT", 26, 43], ["a transmembrane serine protease serine 2 inhibitor", "TREATMENT", 45, 95], ["acute pancreatitis", "PROBLEM", 127, 145], ["TMPRSS2", "PROBLEM", 165, 172], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["pancreatitis", "OBSERVATION", 133, 145]]], ["Data regarding additional drugs of this class, such as nafamostat, are also expected in the near future from planned trials [82] .", [["nafamostat", "CHEMICAL", 55, 65], ["nafamostat", "CHEMICAL", 55, 65], ["nafamostat", "SIMPLE_CHEMICAL", 55, 65], ["nafamostat", "TREATMENT", 55, 65]]], ["The above drugs are promising therapeutic agents, and further data are urgently needed as no specific treatment for COVID-19 is currently approved.J o u r n a l P r e -p r o o fThe ongoing COVID-19 pandemic is rapidly evolving.", [["COVID-19", "CHEMICAL", 116, 124], ["COVID-19", "CHEMICAL", 116, 124], ["COVID-19", "SIMPLE_CHEMICAL", 116, 124], ["The above drugs", "TREATMENT", 0, 15], ["therapeutic agents", "TREATMENT", 30, 48], ["further data", "TEST", 54, 66], ["COVID", "TEST", 116, 121], ["COVID", "TEST", 189, 194], ["pandemic", "PROBLEM", 198, 206], ["rapidly", "OBSERVATION_MODIFIER", 210, 217]]], ["Fast, efficient, but also unbiased, reliable, and valid studies are of paramount importance to provide evidence-based information and guidance to these unanswered questions.", [["valid studies", "TEST", 50, 63]]], ["At the same time, close monitoring of the data is crucial to identify the best strategies in terms of prevention, early diagnosis, and treatment of this globally challenging health problem.", [["close monitoring of the data", "TEST", 18, 46], ["treatment", "TREATMENT", 135, 144], ["this globally challenging health problem", "PROBLEM", 148, 188]]], ["Given that several viruses of increasing infectivity, virulence, and lethality have emerged over the past three decades from hot spots around the world, coordinated public health efforts centered on preventing the transmission of zoonotic diseases to humans as well as early detection of potential threats are needed to avoid similar J o u r n a l P r e -p r o o f future outbreaks.", [["zoonotic diseases", "DISEASE", 230, 247], ["humans", "ORGANISM", 251, 257], ["humans", "SPECIES", 251, 257], ["humans", "SPECIES", 251, 257], ["increasing infectivity", "PROBLEM", 30, 52], ["virulence", "PROBLEM", 54, 63], ["lethality", "PROBLEM", 69, 78], ["hot spots", "PROBLEM", 125, 134], ["zoonotic diseases", "PROBLEM", 230, 247], ["outbreaks", "PROBLEM", 372, 381], ["several", "OBSERVATION_MODIFIER", 11, 18], ["viruses", "OBSERVATION", 19, 26], ["increasing", "OBSERVATION_MODIFIER", 30, 40], ["infectivity", "OBSERVATION_MODIFIER", 41, 52]]], ["It is never too early to start building the foundations to more effectively prevent and address future threats as we are fighting this evolving and dangerous pandemic.", [["dangerous pandemic", "PROBLEM", 148, 166]]]], "PMC2837645": [["BackgroundThe recurrence of poultry outbreaks of highly pathogenic avian influenza of the H5N1 subtype (HPAI H5N1) in some parts of the world, and the occasional spillover of infection to humans, is a significant global health concern.", [["avian influenza", "DISEASE", 67, 82], ["H5N1", "DISEASE", 90, 94], ["HPAI H5N1", "DISEASE", 104, 113], ["infection", "DISEASE", 175, 184], ["avian influenza", "ORGANISM", 67, 82], ["H5N1 subtype", "ORGANISM", 90, 102], ["HPAI H5N1", "ORGANISM", 104, 113], ["humans", "ORGANISM", 188, 194], ["avian influenza", "SPECIES", 67, 82], ["H5N1", "SPECIES", 90, 94], ["HPAI H5N1", "SPECIES", 104, 113], ["humans", "SPECIES", 188, 194], ["HPAI H5N1", "SPECIES", 104, 113], ["humans", "SPECIES", 188, 194], ["the H5N1 subtype (HPAI H5N1", "PROBLEM", 86, 113], ["the occasional spillover of infection", "PROBLEM", 147, 184], ["recurrence", "OBSERVATION_MODIFIER", 14, 24], ["poultry", "OBSERVATION_MODIFIER", 28, 35], ["highly", "OBSERVATION_MODIFIER", 49, 55], ["pathogenic", "OBSERVATION_MODIFIER", 56, 66], ["avian influenza", "OBSERVATION", 67, 82], ["H5N1 subtype", "OBSERVATION", 90, 102], ["occasional", "OBSERVATION_MODIFIER", 151, 161], ["spillover", "OBSERVATION", 162, 171], ["infection", "OBSERVATION", 175, 184], ["significant", "OBSERVATION_MODIFIER", 201, 212], ["global", "OBSERVATION_MODIFIER", 213, 219]]], ["Poultry rearing is an important enterprise in countries across the greater Mekong region.", [["important", "OBSERVATION_MODIFIER", 22, 31], ["enterprise", "OBSERVATION", 32, 42], ["greater", "OBSERVATION_MODIFIER", 67, 74], ["Mekong", "ANATOMY_MODIFIER", 75, 81], ["region", "ANATOMY_MODIFIER", 82, 88]]], ["In Vietnam, poultry rearing is closely linked with people's livelihoods and traditional culture [1,2].BackgroundFive epidemic waves of HPAI H5N1 occurred in Vietnam between late 2003 and mid-2008, causing the second highest human case incidence and case-fatality rates in the world.", [["HPAI H5N1", "DISEASE", 135, 144], ["people", "ORGANISM", 51, 57], ["HPAI H5N1", "ORGANISM", 135, 144], ["human", "ORGANISM", 224, 229], ["people", "SPECIES", 51, 57], ["HPAI H5N1", "SPECIES", 135, 144], ["human", "SPECIES", 224, 229], ["HPAI H5N1", "SPECIES", 135, 144], ["human", "SPECIES", 224, 229], ["traditional culture", "TEST", 76, 95], ["HPAI H5N1", "PROBLEM", 135, 144], ["epidemic", "OBSERVATION_MODIFIER", 117, 125], ["HPAI H5N1", "OBSERVATION", 135, 144]]], ["The proximity of poultry flocks to water courses and paddy fields, and keeping of other poultry species all have an important role in sustaining and perpetuating infection [3-7].", [["infection", "DISEASE", 162, 171], ["water courses", "TREATMENT", 35, 48], ["other poultry species", "PROBLEM", 82, 103], ["perpetuating infection", "PROBLEM", 149, 171], ["poultry flocks", "OBSERVATION", 17, 31], ["infection", "OBSERVATION", 162, 171]]], ["Poultry outbreaks are primarily reported in the Red and Mekong river deltas, and the majority of outbreaks are recorded in the predominant small-holder chicken and duck flocks.", [["chicken", "ORGANISM", 152, 159], ["duck", "ORGANISM", 164, 168], ["chicken", "SPECIES", 152, 159], ["duck", "SPECIES", 164, 168], ["Mekong river deltas", "SPECIES", 56, 75], ["chicken", "SPECIES", 152, 159], ["Poultry outbreaks", "PROBLEM", 0, 17], ["majority", "OBSERVATION_MODIFIER", 85, 93], ["outbreaks", "OBSERVATION", 97, 106], ["predominant", "OBSERVATION_MODIFIER", 127, 138], ["small", "OBSERVATION_MODIFIER", 139, 144], ["holder chicken", "OBSERVATION", 145, 159], ["duck flocks", "OBSERVATION", 164, 175]]], ["Agro-ecological factors related to poultry husbandry, trade and social-cultural customs are suggested to be associated with the maintenance of the HPAI H5N1 infection cycle in Vietnam [3,6-8].", [["infection", "DISEASE", 157, 166], ["HPAI H5N1", "ORGANISM", 147, 156], ["HPAI H5N1", "SPECIES", 147, 156], ["HPAI H5N1", "SPECIES", 147, 156], ["Agro-ecological factors", "PROBLEM", 0, 23], ["the HPAI H5N1 infection cycle", "TREATMENT", 143, 172]]], ["The daily outbreak incidence during the first two epidemic waves (2003-2004 and 2004-2005) peaked around the annual \"Tet\" holiday festivities in February, when poultry movement is increased [6,9].", [["increased", "OBSERVATION_MODIFIER", 180, 189]]], ["However, the temporal distribution of H5N1 outbreaks has changed since the introduction of vaccination in 2005, and since mid-2008 reported outbreaks have not shown a regular pattern [10].BackgroundIn both human and animal populations, the structure of contact between individuals contributes to the incursion and spread of contagious diseases [11-13].", [["H5N1", "DISEASE", 38, 42], ["H5N1", "ORGANISM", 38, 42], ["human", "ORGANISM", 206, 211], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211], ["H5N1 outbreaks", "PROBLEM", 38, 52], ["vaccination", "TREATMENT", 91, 102], ["contagious diseases", "PROBLEM", 324, 343], ["temporal", "OBSERVATION_MODIFIER", 13, 21], ["distribution", "OBSERVATION_MODIFIER", 22, 34], ["H5N1", "OBSERVATION", 38, 42], ["both", "ANATOMY_MODIFIER", 201, 205], ["human", "ANATOMY", 206, 211], ["animal", "OBSERVATION_MODIFIER", 216, 222], ["populations", "OBSERVATION_MODIFIER", 223, 234], ["incursion", "OBSERVATION_MODIFIER", 300, 309], ["spread", "OBSERVATION_MODIFIER", 314, 320], ["contagious", "OBSERVATION_MODIFIER", 324, 334]]], ["In the case of avian influenza, the movement of live birds is a risk factor for the dissemination of the virus to poultry flocks [14].", [["avian influenza", "DISEASE", 15, 30], ["avian influenza", "ORGANISM", 15, 30], ["birds", "ORGANISM", 53, 58], ["avian influenza", "SPECIES", 15, 30], ["avian influenza", "PROBLEM", 15, 30], ["a risk factor", "PROBLEM", 62, 75], ["the virus", "PROBLEM", 101, 110], ["influenza", "OBSERVATION", 21, 30]]], ["In particular, live bird markets have long been considered to be an important link in the pathways that lead to the emergence and reintroduction of infection.", [["infection", "DISEASE", 148, 157], ["infection", "PROBLEM", 148, 157], ["infection", "OBSERVATION", 148, 157]]], ["These markets facilitate the congregation of large populations of animals- that have originated from a diversity of sources in a fairly large geographical area -- in relatively small spaces [15-17].", [["large populations of animals", "PROBLEM", 45, 73], ["a fairly large geographical area", "PROBLEM", 127, 159], ["large", "OBSERVATION_MODIFIER", 45, 50], ["populations", "OBSERVATION_MODIFIER", 51, 62], ["fairly", "OBSERVATION_MODIFIER", 129, 135], ["large", "OBSERVATION_MODIFIER", 136, 141], ["geographical", "OBSERVATION_MODIFIER", 142, 154], ["area", "OBSERVATION_MODIFIER", 155, 159], ["small", "OBSERVATION_MODIFIER", 177, 182]]], ["This becomes particularly noteworthy as avian influenza surveillance studies in the United States and in Southeast (SE) Asia have provided evidence of presence of virus lineages in live bird markets [18-23].", [["virus lineages", "PROBLEM", 163, 177], ["virus lineages", "OBSERVATION", 163, 177]]], ["Similarly, a virological survey in ten live bird markets in Ha Noi has shown that the HPAI H5N1 virus was already circulating in healthy geese as early as 2001 [18].", [["HPAI H5N1 virus", "ORGANISM", 86, 101], ["HPAI H5N1 virus", "SPECIES", 86, 101], ["HPAI H5N1 virus", "SPECIES", 86, 101], ["the HPAI H5N1 virus", "PROBLEM", 82, 101]]], ["Also, evidence suggests that live bird markets can be suitable environments for potential virus re-assortment and transmission [18,24].", [["evidence suggests", "UNCERTAINTY", 6, 23]]], ["The viruses found in 2005 in Ha Noi's live bird markets have been reported to be genetically related to virus isolated in Hong Kong in 1997, but are genetically distinct from those isolated in northern Vietnam in early 2004 [18,25,26].", [["The viruses", "PROBLEM", 0, 11], ["virus", "PROBLEM", 104, 109], ["viruses", "OBSERVATION", 4, 11]]], ["This supports the hypothesis that separate virus introductions via trade of live poultry might be responsible for different outbreak periods.", [["the hypothesis", "PROBLEM", 14, 28], ["separate virus introductions", "TREATMENT", 34, 62], ["virus", "OBSERVATION", 43, 48]]], ["This is further supported by a recent molecular study of HPAI H5N1 viruses that suggested that outbreaks in the north of Vietnam are likely to be attributable to multiple introductions of virus primarily through transboundary trade with southern China [27].BackgroundFactors such as (1) culturally-driven seasonal patterns of poultry demand and (2) the close inter-linkage of poultry production with other seasonal agricultural activities (3) and disease control interventions are expected to influence the production levels of different species and therefore their marketing patterns [1,2].", [["HPAI H5N1 viruses", "DISEASE", 57, 74], ["HPAI H5N1 viruses", "ORGANISM", 57, 74], ["HPAI H5N1", "SPECIES", 57, 66], ["HPAI H5N1 viruses", "SPECIES", 57, 74], ["a recent molecular study", "TEST", 29, 53], ["HPAI H5N1 viruses", "PROBLEM", 57, 74], ["multiple introductions of virus", "PROBLEM", 162, 193], ["BackgroundFactors", "TEST", 257, 274], ["culturally", "TEST", 287, 297], ["poultry production", "PROBLEM", 376, 394], ["disease control interventions", "TREATMENT", 447, 476], ["different species", "PROBLEM", 528, 545], ["likely to be", "UNCERTAINTY", 133, 145], ["poultry demand", "OBSERVATION", 326, 340]]], ["In relation to disease control, policies applied during the outbreak waves included movement restrictions, restrictions to breeding of certain poultry, and market bans that were fundamentally similar to the ones applied in Hong Kong LBM's after 1997 [6,28].", [["disease control", "TREATMENT", 15, 30], ["movement restrictions", "TREATMENT", 84, 105], ["disease", "OBSERVATION", 15, 22]]], ["The intended effect of restrictions to live poultry trade was to reduce the exposure of humans at markets, market contamination and opportunities for virus recombination [24,29,30].BackgroundTo date, the relationship between small-holder poultry production and trade, and in particular, between small-scale poultry holders, poultry traders and live bird markets has been insufficiently studied and documented in HPAI H5N1-affected SE Asian countries.", [["SE", "DISEASE", 431, 433], ["humans", "ORGANISM", 88, 94], ["HPAI H5N1", "ORGANISM", 412, 421], ["humans", "SPECIES", 88, 94], ["humans", "SPECIES", 88, 94], ["HPAI H5N1", "SPECIES", 412, 421], ["virus recombination", "TREATMENT", 150, 169], ["small-holder poultry production", "PROBLEM", 225, 256], ["small", "OBSERVATION_MODIFIER", 225, 230], ["small", "OBSERVATION_MODIFIER", 295, 300]]], ["This information is difficult to obtain but is essential for understanding outbreak recurrence associated with poultry trade.", [["understanding outbreak recurrence", "PROBLEM", 61, 94]]], ["The objective of the present study is to better understand the flow of live poultry, as investigated in a poultry trade network of northern Vietnam, and explore its potential role in the risk for HPAI H5N1 introduction and spread and the resulting implications for disease control policies.Relationship between trade attributes of LPT's ::: ResultsThe characteristics of LPT's are presented in Table 1.", [["H5N1", "DISEASE", 201, 205], ["HPAI H5N1", "ORGANISM", 196, 205], ["HPAI H5N1", "SPECIES", 196, 205], ["the present study", "TEST", 17, 34], ["HPAI H5N1 introduction", "TREATMENT", 196, 218], ["disease control policies", "TREATMENT", 265, 289], ["LPT's", "PROBLEM", 371, 376]]], ["The LPT's that sell and buy poultry on the same day often leave the LBM and distribute poultry to several destinations other than slaughter; this trade type is performed by individuals more experienced in poultry trade.", [["The LPT's", "TEST", 0, 9], ["LBM", "OBSERVATION", 68, 71]]], ["The number of communes visited by LPT's was not large (maximum: 4) nor was the number of contact flocks in them (maximum: 10).", [["LPT's", "TEST", 34, 39], ["large", "OBSERVATION_MODIFIER", 48, 53], ["contact flocks", "OBSERVATION", 89, 103]]], ["The communes included in the current study have significantly larger numbers of flocks and smaller commune areas when compared to other areas in the country (P < 0.001).", [["the current study", "TEST", 25, 42], ["smaller commune areas", "PROBLEM", 91, 112], ["significantly", "OBSERVATION_MODIFIER", 48, 61], ["larger", "OBSERVATION_MODIFIER", 62, 68], ["numbers", "OBSERVATION_MODIFIER", 69, 76], ["flocks", "OBSERVATION", 80, 86], ["smaller", "OBSERVATION_MODIFIER", 91, 98], ["commune", "OBSERVATION_MODIFIER", 99, 106], ["areas", "OBSERVATION_MODIFIER", 107, 112]]], ["Our results also suggest that more experienced LPT's tend to trade in retail markets (\u03c72 for trend = 12.20; p = 0.007) and that LPT's operating at wholesale markets tend to contact larger flocks (\u03c72 for trend = 300.86, p < 0.001) and trade more poultry than those operating at retail markets (\u03c72 for trend = 60.49; p < 0.001).", [["LPT's", "TEST", 47, 52], ["LPT", "TEST", 128, 131]]], ["The frequencies of the number of poultry traded do not differ by species of poultry (\u03c72 for trend = 1.58; p = 0.2) but the chicken flocks contacted by LPT's tend to have large numbers of poultry than duck and Muscovy duck flocks (\u03c72 for trend 57.56; p < 0.001).Trade behaviour of LPT's and occurrence of HPAI outbreaks ::: ResultsA total of 43% (n = 56) communes with complete trade information (N = 131) had recorded HPAI outbreaks in poultry from 2003 through to 2006.", [["HPAI", "DISEASE", 304, 308], ["HPAI", "DISEASE", 418, 422], ["chicken", "ORGANISM", 123, 130], ["duck", "ORGANISM", 200, 204], ["Muscovy duck", "ORGANISM", 209, 221], ["chicken", "SPECIES", 123, 130], ["duck", "SPECIES", 200, 204], ["Muscovy duck", "SPECIES", 209, 221], ["chicken", "SPECIES", 123, 130], ["duck", "SPECIES", 200, 204], ["Muscovy duck", "SPECIES", 209, 221], ["the chicken flocks", "PROBLEM", 119, 137], ["large numbers of poultry", "PROBLEM", 170, 194], ["Muscovy duck flocks", "TEST", 209, 228], ["LPT's", "PROBLEM", 280, 285], ["HPAI outbreaks", "PROBLEM", 304, 318], ["ResultsA total", "TEST", 323, 337], ["recorded HPAI outbreaks", "PROBLEM", 409, 432], ["large", "OBSERVATION_MODIFIER", 170, 175], ["numbers", "OBSERVATION", 176, 183], ["Muscovy", "ANATOMY", 209, 216], ["duck flocks", "OBSERVATION", 217, 228]]], ["There were only two positive communes in 2005-6 out of the 131 with disease data.Trade behaviour of LPT's and occurrence of HPAI outbreaks ::: ResultsThe results of the univariable and multivariable analysis of LPT attributes associated with HPAI outbreaks during 2003 to 2006 are presented in Tables 2 and 3 respectively.", [["HPAI", "DISEASE", 124, 128], ["HPAI", "DISEASE", 242, 246], ["disease data", "TEST", 68, 80], ["multivariable analysis", "TEST", 185, 207], ["LPT", "PROBLEM", 211, 214], ["HPAI outbreaks", "PROBLEM", 242, 256], ["two", "OBSERVATION_MODIFIER", 16, 19], ["positive", "OBSERVATION_MODIFIER", 20, 28], ["communes", "OBSERVATION_MODIFIER", 29, 37]]], ["None of the tested biologically plausible first-order interactions resulted in improvement of model fit.", [["model fit", "OBSERVATION", 94, 103]]], ["The goodness-of-fit test showed a suboptimal fitness of the model (p = 0.177).", [["fit test", "TEST", 16, 24]]], ["The potential impact of clustering of data due to multiple measurements from each LPT resulted in an intra-cluster correlation coefficient of 0.547 (p < 0.001).Networks of poultry trade and occurrence of HPAI outbreaks Trader-commune network (Network 1) ::: ResultsThe geographical distribution of the communes included in the analysis of associations with commune infection status is shown in Figure 1.", [["HPAI", "DISEASE", 204, 208], ["infection", "DISEASE", 365, 374], ["commune infection status", "PROBLEM", 357, 381]]], ["The 2-mode trader-commune network contains 308 nodes of which 191 are in the commune class and 117 in the LPT class, located in the following LBM's: Bac Thang Long, Cho Ni, Cho Phu Lo, Cho To, Da Ton, Ha Vi, Sui, and Yen Thuong.", [["Cho Ni", "CHEMICAL", 165, 171], ["Cho", "CHEMICAL", 173, 176], ["Ni", "CHEMICAL", 169, 171], ["308 nodes", "OBSERVATION", 43, 52]]], ["There were 474 flocks identified by LPT's in the set of communes; the average number of traded flocks is 2.48 per commune (average value of the links in commune class: 2.48, STD: 3.01, range: 1-29) and 4.05 per LPT (average value of the links in LPT class STD: 1.83, range: 1-10).", [["LPT's", "TEST", 36, 41], ["STD", "TEST", 174, 177], ["LPT", "TEST", 211, 214], ["STD", "TEST", 256, 259]]], ["There are 303 links between nodes and the density of the network is 2.12%.", [["nodes", "ANATOMY", 28, 33], ["nodes", "MULTI-TISSUE_STRUCTURE", 28, 33], ["nodes", "OBSERVATION", 28, 33], ["density", "OBSERVATION_MODIFIER", 42, 49]]], ["On average 1.58 traders operate per commune (average degree of the commune class; STD: 1.2, range: 1-10).", [["STD", "TEST", 82, 85]]], ["LPT's trade on average in 2.59 communes (average degree of the trader class; STD: 1.3, range: 1-8).", [["LPT's trade", "TEST", 0, 11], ["STD", "TEST", 77, 80]]], ["The network is very fragmented with 30 components, but there is a highly connected core of communes, consisting of a giant weak component and a sparse periphery (containing numerous isolated components of small size).", [["a giant weak component", "PROBLEM", 115, 137], ["a sparse periphery", "PROBLEM", 142, 160], ["very", "OBSERVATION_MODIFIER", 15, 19], ["fragmented", "OBSERVATION", 20, 30], ["30 components", "OBSERVATION_MODIFIER", 36, 49], ["highly", "OBSERVATION_MODIFIER", 66, 72], ["communes", "OBSERVATION", 91, 99], ["giant", "OBSERVATION_MODIFIER", 117, 122], ["weak", "OBSERVATION_MODIFIER", 123, 127], ["component", "OBSERVATION_MODIFIER", 128, 137], ["sparse", "OBSERVATION_MODIFIER", 144, 150], ["periphery", "OBSERVATION_MODIFIER", 151, 160], ["numerous", "OBSERVATION_MODIFIER", 173, 181], ["isolated", "OBSERVATION_MODIFIER", 182, 190], ["components", "OBSERVATION_MODIFIER", 191, 201], ["small", "OBSERVATION_MODIFIER", 205, 210], ["size", "OBSERVATION_MODIFIER", 211, 215]]], ["The giant component includes 138 nodes (44.8%) linking 90 communes and 48 traders, the second component includes 43 nodes (14.0%), 21 communes and 22 traders and the other 28 components have 10 or less nodes with 19 components of five or less nodes.Commune-Commune networks (Network 2 and 3) ::: ResultsThis network is as equally fragmented as Network 1, consisting of 30 components; the locations of the communes in the two main components are shown in Figure 2.Commune-Commune networks (Network 2 and 3) ::: ResultsThe symmetric binary 1-mode commune network includes 191 nodes, has 1.77% density and 322 links.", [["nodes", "ANATOMY", 33, 38], ["nodes", "ANATOMY", 202, 207], ["nodes", "ANATOMY", 243, 248], ["nodes", "TEST", 33, 38], ["nodes", "TEST", 116, 121], ["less nodes with 19 components of five or less nodes", "PROBLEM", 197, 248], ["giant", "OBSERVATION_MODIFIER", 4, 9], ["component", "OBSERVATION_MODIFIER", 10, 19], ["138 nodes", "OBSERVATION_MODIFIER", 29, 38], ["43 nodes", "OBSERVATION", 113, 121], ["less", "OBSERVATION_MODIFIER", 197, 201], ["nodes", "OBSERVATION", 202, 207], ["19 components", "OBSERVATION_MODIFIER", 213, 226], ["less", "OBSERVATION_MODIFIER", 238, 242], ["nodes", "OBSERVATION", 243, 248], ["communes", "OBSERVATION", 405, 413], ["two", "OBSERVATION_MODIFIER", 421, 424], ["main", "OBSERVATION_MODIFIER", 425, 429], ["symmetric", "OBSERVATION_MODIFIER", 521, 530], ["nodes", "OBSERVATION", 574, 579], ["1.77% density", "OBSERVATION_MODIFIER", 585, 598]]], ["The average degree is 3.3 (STD: 2.3, range: 0-15) so that an average commune is connected to more than three other communes via common LPT's.", [["The average degree", "TEST", 0, 18], ["STD", "TEST", 27, 30], ["average", "OBSERVATION_MODIFIER", 4, 11], ["degree", "OBSERVATION_MODIFIER", 12, 18]]], ["The giant weak component includes 90 nodes (47.1%), and a second component has 21 nodes (11%).", [["nodes", "ANATOMY", 37, 42], ["nodes", "ANATOMY", 82, 87], ["The giant weak component", "PROBLEM", 0, 24], ["21 nodes", "PROBLEM", 79, 87], ["giant", "OBSERVATION_MODIFIER", 4, 9], ["weak", "OBSERVATION_MODIFIER", 10, 14], ["component", "OBSERVATION_MODIFIER", 15, 24], ["nodes", "OBSERVATION", 37, 42], ["21 nodes", "OBSERVATION", 79, 87]]], ["The remaining 28 components have 7 or less nodes with 25 components of five or less nodes.", [["nodes", "ANATOMY", 43, 48], ["nodes", "ANATOMY", 84, 89], ["less nodes with 25 components of five or less nodes", "PROBLEM", 38, 89], ["remaining", "OBSERVATION_MODIFIER", 4, 13], ["28 components", "OBSERVATION_MODIFIER", 14, 27], ["less", "OBSERVATION_MODIFIER", 38, 42], ["nodes", "OBSERVATION", 43, 48], ["25 components", "OBSERVATION_MODIFIER", 54, 67], ["five", "OBSERVATION_MODIFIER", 71, 75], ["less", "OBSERVATION_MODIFIER", 79, 83], ["nodes", "OBSERVATION", 84, 89]]], ["Network 2 contains 64 cliques: 34 3-cliques, 23 4-cliques, 5 5-cliques, 1 6-clique and 1 8-clique.Commune-Commune networks (Network 2 and 3) ::: ResultsThe clique overlap network (Network 3) contains the same number of communes, 191, with a density of 1.6% and 298 links.", [["1 6-clique and 1 8-clique", "DNA", 72, 97], ["a density", "TEST", 239, 248]]], ["The average number of communes that share a clique with any other is 3.12 (mean degree: 3.12 STD: 2.53 Range: 0-15).Commune-Commune networks (Network 2 and 3) ::: ResultsApplying significance tests to the subset of communes with attribute data, there was no significant difference in the mean degree of the nodes of Network 2 and 3 between the ones infected during at least one of the epidemic waves or in any single one (Table 4).", [["STD", "TEST", 93, 96], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["no", "UNCERTAINTY", 255, 257], ["significant", "OBSERVATION_MODIFIER", 258, 269], ["difference", "OBSERVATION_MODIFIER", 270, 280], ["mean degree", "OBSERVATION_MODIFIER", 288, 299], ["nodes", "OBSERVATION", 307, 312], ["infected", "OBSERVATION", 349, 357]]], ["The test of autocorrelation for Network 2 and 3 showed that the proportion of links between infected and non-infected communes (Type 2) is significantly lower than expected for the variable \"Infected 2003-2006\" (P = 0.039 and P = 0.06, respectively).", [["The test", "TEST", 0, 8], ["Network", "TEST", 32, 39], ["P", "TEST", 212, 213], ["P", "TEST", 226, 227], ["infected", "OBSERVATION_MODIFIER", 92, 100], ["non-infected", "OBSERVATION_MODIFIER", 105, 117], ["significantly", "OBSERVATION_MODIFIER", 139, 152], ["lower", "OBSERVATION_MODIFIER", 153, 158]]], ["The number of Type 1 and 3 links was not significantly different for the same variable (data not shown).", [["significantly different", "OBSERVATION_MODIFIER", 41, 64]]], ["Being a member of the giant component in Network 2 is significantly associated with not having been infected in any wave (\u03c72 test: 14.14, 1 df, p < 0.001).LBM-commune network (Network4) ::: ResultsThe geographical location of the catchment areas of each LBM is presented in Figure 3.", [["infected", "OBSERVATION", 100, 108], ["catchment", "OBSERVATION_MODIFIER", 230, 239], ["areas", "OBSERVATION_MODIFIER", 240, 245]]], ["There are five communes linked to more than one LBM: two linked to Ha Vi and Bac Thang Long, one linked to Ha Vi and Cho Ni and two linked to Bac Than Long and Yen Thuong and Cho To, respectively.", [["Cho", "CHEMICAL", 117, 120], ["Ni", "CHEMICAL", 121, 123], ["Ha Vi", "GENE_OR_GENE_PRODUCT", 107, 112], ["Cho Ni", "TEST", 117, 123], ["five", "OBSERVATION_MODIFIER", 10, 14], ["communes", "OBSERVATION", 15, 23]]], ["This network consists of 199 nodes, representing links between 191 communes and 8 LBM's where the 117 LPT's of Network 1 were located.LBM-commune network (Network4) ::: ResultsIn terms of trade volume, the two distinctive types of LBM, wholesale and retail, in Network 4 determine the network structure with one component linking the two wholesale LBM's and two retail LBM's as well as four isolated components corresponding to the catchment areas of the other four retail LBM's.", [["nodes", "ANATOMY", 29, 34], ["LBM's", "TEST", 82, 87], ["two retail LBM's", "TREATMENT", 358, 374], ["four isolated components", "PROBLEM", 386, 410], ["nodes", "OBSERVATION", 29, 34], ["distinctive", "OBSERVATION_MODIFIER", 210, 221], ["types", "OBSERVATION_MODIFIER", 222, 227], ["LBM", "OBSERVATION", 231, 234], ["retail LBM", "OBSERVATION", 362, 372], ["catchment", "OBSERVATION_MODIFIER", 432, 441]]], ["In Ha Vi market, poultry from 315 flocks in 141 communes were traded mainly in the south of Ha Noi and scattered communes north of the capital, whereas in Bac Thang Long market poultry from 89 flocks in 31 communes were traded in a small area north of Ha Noi (Figure 3).", [["scattered", "OBSERVATION_MODIFIER", 103, 112], ["communes", "OBSERVATION", 113, 121], ["capital", "ANATOMY", 135, 142], ["small", "OBSERVATION_MODIFIER", 232, 237], ["area", "OBSERVATION_MODIFIER", 238, 242]]], ["The other six retail markets are local with small catchment areas in terms of number of flocks (range: 9-18) and communes (1-6).DiscussionTo the best of our knowledge, this study represents the first investigation of the association between poultry trade and HPAI outbreaks in northern Vietnam.", [["HPAI", "DISEASE", 259, 263], ["small catchment areas", "PROBLEM", 44, 65], ["this study", "TEST", 168, 178], ["six", "OBSERVATION_MODIFIER", 10, 13], ["retail", "OBSERVATION_MODIFIER", 14, 20], ["markets", "OBSERVATION_MODIFIER", 21, 28], ["local", "OBSERVATION_MODIFIER", 33, 38], ["small", "OBSERVATION_MODIFIER", 44, 49], ["catchment", "OBSERVATION_MODIFIER", 50, 59], ["areas", "OBSERVATION_MODIFIER", 60, 65], ["number", "OBSERVATION_MODIFIER", 78, 84]]], ["The results of this study highlight the advantage of combining a descriptive study with a network analysis of the characteristics of the poultry trade pattern of LPT's, and demonstrate that this methodology can improve our understanding of the epidemiology of HPAI H5N1 in affected countries.", [["H5N1", "DISEASE", 265, 269], ["HPAI H5N1", "ORGANISM", 260, 269], ["HPAI H5N1", "SPECIES", 260, 269], ["HPAI H5N1", "SPECIES", 260, 269], ["this study", "TEST", 15, 25], ["a descriptive study", "TEST", 63, 82], ["a network analysis", "TEST", 88, 106], ["LPT's", "TEST", 162, 167]]], ["Although trade is usually difficult to quantify, the network analysis provided insight into the relational nature of the live poultry trade and its potential relationship with the spread and maintenance of AI in northern Vietnam.DiscussionThis study supports previous research findings indicating that LBM's may constitute an important source of infection for poultry [18,20].", [["infection", "DISEASE", 346, 355], ["the network analysis", "TEST", 49, 69], ["This study", "TEST", 239, 249], ["LBM's", "PROBLEM", 302, 307], ["infection", "PROBLEM", 346, 355], ["infection", "OBSERVATION", 346, 355]]], ["In particular, our analyses indicate that new LPT's (i.e. those trading for less than a year) and those operating in authorised retail LBM's have increased odds of sourcing poultry from flocks located in communes with past history of H5N1 outbreaks during 2003 to 2006, when compared to older LPT's (i.e. those trading for more than a year) and to those operating in wholesale markets.", [["H5N1", "DISEASE", 234, 238], ["our analyses", "TEST", 15, 27], ["new LPT's", "PROBLEM", 42, 51], ["H5N1", "PROBLEM", 234, 238], ["new", "OBSERVATION_MODIFIER", 42, 45], ["increased", "OBSERVATION_MODIFIER", 146, 155], ["H5N1", "OBSERVATION", 234, 238]]], ["This suggests that individuals who are relatively new to the poultry trading business are more likely to operate in areas with previous infection history, perhaps due to their inexperience.", [["infection", "DISEASE", 136, 145], ["previous infection history", "PROBLEM", 127, 153], ["new", "OBSERVATION_MODIFIER", 50, 53], ["more likely", "UNCERTAINTY", 90, 101], ["infection", "OBSERVATION", 136, 145]]], ["It is also possible that experienced traders consciously avoid high disease risk areas, thereby providing new traders with an opportunity to set up their business in these areas.", [["high disease risk areas", "PROBLEM", 63, 86], ["also possible", "UNCERTAINTY", 6, 19]]], ["Although this finding does not allow inferences in relation to the source of the outbreaks amongst infected communes, it provides evidence for advocating modifiable practices directed towards new traders at retail markets.", [["advocating modifiable practices", "TREATMENT", 143, 174]]], ["These could include the dissemination of historical and up-to-date information on the geographical distribution of outbreaks and the development of more biosecure poultry trading practices such as crate cleaning and disinfection.DiscussionFurther, while it is a legal requirement that traders visiting an LBM for the purpose of selling poultry report to the market inspectors (MI) at the LBM's veterinary check point, those that leave the LBM with poultry are currently not required to report.", [["MI", "DISEASE", 377, 379], ["crate cleaning", "TREATMENT", 197, 211], ["disinfection", "PROBLEM", 216, 228], ["MI", "PROBLEM", 377, 379]]], ["As identified in our study, poultry are in some occasions introduced back to other flocks which present a risk for further virus transmission.", [["our study", "TEST", 17, 26], ["further virus transmission", "PROBLEM", 115, 141], ["virus", "OBSERVATION", 123, 128]]], ["The implementation of a poultry traceability scheme would provide a mechanism for monitoring and regulating the traffic of live poultry in and out of the LBM's.DiscussionThe links between specific communes in northern Vietnam were described using social network analysis.", [["a poultry traceability scheme", "TREATMENT", 22, 51], ["monitoring", "TEST", 82, 92]]], ["The LPT-commune network and the commune-commune networks showed low density of links and a typical core-periphery structure.", [["LPT-commune network", "DNA", 4, 23], ["commune-commune networks", "DNA", 32, 56], ["The LPT", "TEST", 0, 7], ["low density of links", "PROBLEM", 64, 84], ["low density", "OBSERVATION_MODIFIER", 64, 75], ["typical", "OBSERVATION_MODIFIER", 91, 98], ["core", "OBSERVATION_MODIFIER", 99, 103], ["periphery", "ANATOMY_MODIFIER", 104, 113]]], ["While the presence of low density of links is beneficial from a disease control point of view, the presence of a highly connected core may pose considerable challenges for the geographical containment of disease when infected birds flow through these trade channels.", [["birds", "ORGANISM", 226, 231], ["low density of links", "PROBLEM", 22, 42], ["a highly connected core", "PROBLEM", 111, 134], ["disease", "PROBLEM", 204, 211], ["infected birds flow", "PROBLEM", 217, 236], ["low density", "OBSERVATION_MODIFIER", 22, 33], ["geographical", "OBSERVATION_MODIFIER", 176, 188], ["containment", "OBSERVATION_MODIFIER", 189, 200], ["disease", "OBSERVATION", 204, 211]]], ["Furthermore, we found that increasing numbers of LPT's operating in communes does not increase the risk of AI outbreaks during the period 2003-2006 nor does being linked to many other communes via the same LPT's.", [["increasing numbers of LPT's", "PROBLEM", 27, 54], ["AI outbreaks", "PROBLEM", 107, 119], ["increasing", "OBSERVATION_MODIFIER", 27, 37], ["numbers", "OBSERVATION_MODIFIER", 38, 45]]], ["Although centrality measures at node level (such as the degree and membership of the giant component) have been suggested to be of practical use in the development of effective targeted disease control strategies [13,31], the investigation of the links within and between subgroups of nodes has provided better insight into the relationship between the disease status and network structure.", [["node", "ANATOMY", 32, 36], ["nodes", "ANATOMY", 285, 290], ["node", "MULTI-TISSUE_STRUCTURE", 32, 36], ["nodes", "MULTI-TISSUE_STRUCTURE", 285, 290], ["network", "MULTI-TISSUE_STRUCTURE", 372, 379], ["centrality measures at node level", "PROBLEM", 9, 42], ["effective targeted disease control strategies", "PROBLEM", 167, 212], ["centrality", "OBSERVATION_MODIFIER", 9, 19], ["node", "OBSERVATION", 32, 36], ["effective", "OBSERVATION_MODIFIER", 167, 176], ["targeted", "OBSERVATION_MODIFIER", 177, 185], ["disease", "OBSERVATION", 186, 193], ["nodes", "OBSERVATION", 285, 290], ["disease", "OBSERVATION", 353, 360]]], ["The randomly permuted networks indicate that the observed number of links between communes of similar disease status is higher than the random distribution of links between communes, whereas the observed number of links between infected and non-infected communes is lower than expected.", [["similar disease status", "PROBLEM", 94, 116], ["infected and non-infected communes", "PROBLEM", 228, 262], ["similar", "OBSERVATION_MODIFIER", 94, 101], ["disease", "OBSERVATION", 102, 109], ["higher", "OBSERVATION_MODIFIER", 120, 126], ["infected", "OBSERVATION_MODIFIER", 228, 236], ["non-infected", "OBSERVATION_MODIFIER", 241, 253], ["communes", "OBSERVATION", 254, 262], ["lower", "OBSERVATION_MODIFIER", 266, 271]]], ["These results suggest that there is a separation in terms of the LPT's trading between infected and non-infected communes.", [["the LPT", "TEST", 61, 68], ["infected and non-infected communes", "PROBLEM", 87, 121], ["separation", "OBSERVATION_MODIFIER", 38, 48], ["infected", "OBSERVATION_MODIFIER", 87, 95], ["non-infected", "OBSERVATION_MODIFIER", 100, 112], ["communes", "OBSERVATION", 113, 121]]], ["Since in our network analysis the links between communes are defined by trading events of LPT's, these results indicate that the observed outbreak pattern in 2003-06 appeared to be associated to subgroups of LPT's, with communes linked by them having the same disease status.", [["LPT's", "TEST", 90, 95], ["LPT's", "PROBLEM", 208, 213], ["the same disease status", "PROBLEM", 251, 274]]], ["This finding was also supported by the analysis of the clique-overlap membership matrix.DiscussionThe LBM-commune network showed that only a few communes (n = 5) traded poultry in both retail and wholesale markets.", [["matrix", "CELLULAR_COMPONENT", 81, 87], ["the analysis", "TEST", 35, 47], ["membership matrix", "OBSERVATION", 70, 87]]], ["Nevertheless, all of these communes experienced AI outbreaks during 2003 to 2006, in contrast to 40.5% infection level amongst the other communes (n = 126).", [["infection", "DISEASE", 103, 112], ["AI outbreaks", "PROBLEM", 48, 60]]], ["In addition, the travel distances from communes linked to retail markets are quite short compared to those linked to wholesale markets.", [["short", "OBSERVATION_MODIFIER", 83, 88]]], ["This is consistent with the local emphasis of trade, where most of the LPT's in retail markets transport poultry in motorcycles fitted with baskets.", [["consistent with", "UNCERTAINTY", 8, 23], ["local", "OBSERVATION_MODIFIER", 28, 33]]], ["Evidence from other livestock diseases suggests that fast long-range dissemination of infectious diseases can occur through live animal trade at large livestock markets [13].", [["livestock diseases", "DISEASE", 20, 38], ["infectious diseases", "DISEASE", 86, 105], ["other livestock diseases", "PROBLEM", 14, 38], ["fast long-range dissemination of infectious diseases", "PROBLEM", 53, 105], ["livestock diseases", "OBSERVATION", 20, 38], ["infectious", "OBSERVATION", 86, 96]]], ["Our descriptive analysis has shown that LPT's operating in wholesale markets tend to contact larger flocks and trade more poultry than those operating in retail markets.", [["Our descriptive analysis", "TEST", 0, 24], ["LPT's", "PROBLEM", 40, 45], ["larger flocks", "OBSERVATION", 93, 106]]], ["LPT's in wholesale markets generally travel by motorcycles with fitted crates, vans or lorries that enable larger distances and transport more animals than those operating in retail markets.", [["LPT's", "PROBLEM", 0, 5], ["vans", "TREATMENT", 79, 83], ["larger", "OBSERVATION_MODIFIER", 107, 113]]], ["Consequently, large wholesale markets can source and disseminate large quantities of poultry throughout a large area of northern Vietnam on the same day, further complicating disease control operations if infection were to flow through these channels.", [["infection", "DISEASE", 205, 214], ["further complicating disease control operations", "TREATMENT", 154, 201], ["infection", "PROBLEM", 205, 214], ["large", "OBSERVATION_MODIFIER", 14, 19], ["wholesale markets", "OBSERVATION", 20, 37], ["large", "OBSERVATION_MODIFIER", 65, 70], ["quantities", "OBSERVATION_MODIFIER", 71, 81], ["poultry", "OBSERVATION_MODIFIER", 85, 92], ["large", "OBSERVATION_MODIFIER", 106, 111], ["area", "OBSERVATION_MODIFIER", 112, 116]]], ["The dispersion of infection over a relatively large geographical space could be assisted by the trade with flocks in the few communes in the giant weak component that are geographically distant from its core.DiscussionOur results should be interpreted taking account the study's assumptions and limitations.", [["infection", "DISEASE", 18, 27], ["infection", "PROBLEM", 18, 27], ["a relatively large geographical space", "PROBLEM", 33, 70], ["the giant weak component", "PROBLEM", 137, 161], ["the study's assumptions", "TEST", 267, 290], ["dispersion", "OBSERVATION_MODIFIER", 4, 14], ["infection", "OBSERVATION", 18, 27], ["relatively", "OBSERVATION_MODIFIER", 35, 45], ["large", "OBSERVATION_MODIFIER", 46, 51], ["geographical space", "OBSERVATION", 52, 70], ["few", "OBSERVATION_MODIFIER", 121, 124], ["communes", "OBSERVATION_MODIFIER", 125, 133], ["giant", "OBSERVATION_MODIFIER", 141, 146], ["weak", "OBSERVATION_MODIFIER", 147, 151], ["component", "OBSERVATION_MODIFIER", 152, 161], ["geographically", "OBSERVATION_MODIFIER", 171, 185], ["distant", "OBSERVATION_MODIFIER", 186, 193]]], ["Firstly, potential biases may have been introduced during the selection of LBM's and the LPT's.", [["LBM's", "TEST", 75, 80], ["the LPT's", "TEST", 85, 94]]], ["For example, by the time we carried out our surveys, only LBM's in the five outer districts of the capital city were allowed to trade poultry.", [["our surveys", "TEST", 40, 51], ["LBM's", "PROBLEM", 58, 63], ["capital", "ANATOMY_MODIFIER", 99, 106]]], ["Nevertheless, market selection was based on a history of recurrent HPAI H5N1 outbreaks, and on regional importance with respect to the magnitude of poultry production and trade within the Red River delta.", [["H5N1", "DISEASE", 72, 76], ["Red River delta", "ORGANISM", 188, 203], ["HPAI H5N1", "SPECIES", 67, 76], ["Red River delta", "SPECIES", 188, 203], ["recurrent HPAI H5N1 outbreaks", "PROBLEM", 57, 86], ["recurrent", "OBSERVATION_MODIFIER", 57, 66], ["HPAI", "OBSERVATION_MODIFIER", 67, 71], ["H5N1", "OBSERVATION", 72, 76]]], ["In relation to the LPT's, the \"buy only\" was underrepresented because individuals leaving the LBM with live poultry do not have to report at the market veterinary check point.", [["the LPT's", "TEST", 15, 24]]], ["Secondly, while we conducted our survey during a period when poultry trade and therefore potential outbreak risk were both expected to be at their peak, the trade pattern may vary across seasons and years.", [["poultry", "SPECIES", 61, 68]]], ["Also, HPAI H5N1 disease control measures may change the trade pattern of live birds in and around the affected areas [28,32].", [["HPAI H5N1", "ORGANISM", 6, 15], ["HPAI H5N1", "SPECIES", 6, 15], ["HPAI H5N1 disease control measures", "TREATMENT", 6, 40], ["HPAI", "OBSERVATION_MODIFIER", 6, 10], ["H5N1", "OBSERVATION", 11, 15]]], ["However, it is very difficult to deal with the uncertainty of the contact structure and its stability over time and through AI outbreaks.", [["the contact structure", "PROBLEM", 62, 83], ["contact structure", "OBSERVATION", 66, 83], ["stability", "OBSERVATION_MODIFIER", 92, 101]]], ["Even if the observed contact structure was different than prior to the AI outbreaks, it would be very difficult to ascertain whether this change was due to the impact of the disease, the control measure or pure changes in the trading behaviour caused by other reasons unaccounted for in this study (e.g. market value, changes in production).", [["the disease", "PROBLEM", 170, 181], ["pure changes", "PROBLEM", 206, 218], ["this study", "TEST", 287, 297], ["disease", "OBSERVATION", 174, 181]]], ["Only by simulating stochastically alternative network structures the impact of a wider range of outputs on the disease status could have been analyzed.", [["network structures", "MULTI-TISSUE_STRUCTURE", 46, 64], ["the disease status", "PROBLEM", 107, 125]]], ["However, there is not a network model that could represent a \"standard\" contact structure of live poultry trade in this area to which to compare the observed one.", [["a \"standard\" contact structure", "PROBLEM", 59, 89], ["could represent", "UNCERTAINTY", 43, 58]]], ["Thus, the poultry trade networks presented by this study are representative of the time period of peak poultry trade in North Vietnam and of the year when the study was conducted.", [["this study", "TEST", 46, 56], ["the study", "TEST", 155, 164]]], ["Thirdly, our analyses are based on the assumption that the AI risk profile of a given LPT-flock link is associated with the historical infection status of the commune where the flock was located.", [["infection", "DISEASE", 135, 144], ["our analyses", "TEST", 9, 21], ["the historical infection status", "PROBLEM", 120, 151], ["infection", "OBSERVATION", 135, 144]]], ["This relationship is convenient because it enables the use of publicly available disease surveillance data aggregated at commune level.", [["publicly available disease surveillance data", "PROBLEM", 62, 106]]], ["However, assuming that all flocks are a single population at risk could introduce systematic error to the interpretation of results.", [["all flocks", "PROBLEM", 23, 33]]], ["Factors such as commune area size and number of flocks in the communes may have an impact on the validity of this assumption by influencing the geographic dissemination of the virus within a commune.", [["commune area size", "PROBLEM", 16, 33], ["the virus", "PROBLEM", 172, 181], ["size", "OBSERVATION_MODIFIER", 29, 33], ["number", "OBSERVATION_MODIFIER", 38, 44]]], ["Currently in Vietnam, disease control policies based on flock depopulation consider village level depopulation as the main control measure for containing local virus dissemination, and thereby make the assumption that flocks in a village are a single population at risk.", [["disease control policies", "TREATMENT", 22, 46], ["flock depopulation", "TREATMENT", 56, 74], ["village level depopulation", "TREATMENT", 84, 110], ["local virus dissemination", "PROBLEM", 154, 179]]], ["This decision represents a compromise between the logistic constraints of disease control and the known heterogeneity of poultry flocks among the approximately 16,000 communes of Vietnam.", [["a compromise", "PROBLEM", 25, 37], ["disease control", "TREATMENT", 74, 89], ["poultry flocks", "PROBLEM", 121, 135], ["heterogeneity", "OBSERVATION_MODIFIER", 104, 117], ["poultry flocks", "OBSERVATION", 121, 135]]], ["Moreover, analysis of population and area data of the communes included in this study, together with the known infectious properties of AI viruses, suggests that poultry flocks within communes may indeed be homogenous with respect to HPAIV H5N1 risk.", [["H5N1", "DISEASE", 240, 244], ["AI viruses", "ORGANISM", 136, 146], ["HPAIV H5N1", "ORGANISM", 234, 244], ["HPAIV H5N1", "SPECIES", 234, 244], ["population", "PROBLEM", 22, 32], ["area data", "TEST", 37, 46], ["this study", "TEST", 75, 85], ["AI viruses", "PROBLEM", 136, 146], ["poultry flocks", "PROBLEM", 162, 176], ["HPAIV H5N1 risk", "PROBLEM", 234, 249], ["infectious", "OBSERVATION", 111, 121], ["poultry flocks", "OBSERVATION", 162, 176], ["HPAIV H5N1", "OBSERVATION", 234, 244]]], ["Finally, the validity of a social network analysis based on our ego-centric data collection methods may have been influenced by sampling errors and lack of representativeness [33].", [["a social network analysis", "TEST", 25, 50], ["our ego-centric data collection methods", "TEST", 60, 99]]], ["The statistical analysis could not include all nodes of the networks due to the lack of response of some LPT's and inability to correctly identify some communes named by them.", [["The statistical analysis", "TEST", 0, 24], ["some LPT's", "PROBLEM", 100, 110], ["nodes", "OBSERVATION", 47, 52]]], ["The estimation of the standard errors and significance levels were affected by the fact that there were very few infected communes during the later AI epidemic wave (2005-06).DiscussionTaking these limitations into account, the results of this study indicate that the association of some LPT's to specific communes within the catchment area of authorised LBM's may support transmission of AI infection.", [["AI infection", "DISEASE", 389, 401], ["AI", "ORGANISM", 389, 391], ["significance levels", "TEST", 42, 61], ["very few infected communes", "PROBLEM", 104, 130], ["this study", "TEST", 239, 249], ["some LPT's", "PROBLEM", 283, 293], ["AI infection", "PROBLEM", 389, 401], ["very", "OBSERVATION_MODIFIER", 104, 108], ["few", "OBSERVATION_MODIFIER", 109, 112], ["infected", "OBSERVATION", 113, 121], ["catchment", "OBSERVATION_MODIFIER", 326, 335], ["area", "OBSERVATION_MODIFIER", 336, 340], ["infection", "OBSERVATION", 392, 401]]], ["This is particularly important where inadequate protection conferred by vaccination allows residual infection to remain in communes linked by LPT's of the trade network.", [["infection", "DISEASE", 100, 109], ["trade network", "MULTI-TISSUE_STRUCTURE", 155, 168], ["residual infection", "PROBLEM", 91, 109], ["infection", "OBSERVATION", 100, 109]]], ["These findings may support the need to promote policies encouraging more biosecure practices of LPT's operating through authorised LBM's.", [["LPT's", "TREATMENT", 96, 101]]], ["These could include a) the dissemination of information with respect to the geographic locations of high outbreak risk communes and b) the implementation of a formal data recording scheme for all incoming and outgoing LPT's.", [["outgoing LPT's", "TEST", 209, 223]]], ["The former could be implemented by providing maps describing areas with previous history of outbreaks, and making them available, for example, at market veterinary checkpoints.", [["outbreaks", "PROBLEM", 92, 101]]], ["Data recording systems should include regular data capture by the MIs concerning contextual characteristics of contact flocks (i.e. geographical location and type) and demographic characteristics of the trade (i.e. number of poultry traded and type).", [["Data recording systems", "TEST", 0, 22], ["the MIs", "PROBLEM", 62, 69], ["contact flocks", "PROBLEM", 111, 125], ["contact flocks", "OBSERVATION", 111, 125]]], ["These interventions should be combined with enhanced flock-level biosecurity and disease monitoring and evaluation strategies to mitigate the risks associated with the modification of the LPTs' trade patterns.", [["These interventions", "TREATMENT", 0, 19], ["enhanced flock-level biosecurity", "TREATMENT", 44, 76], ["disease monitoring", "TEST", 81, 99], ["evaluation strategies", "TEST", 104, 125]]], ["These interventions would have important implications for disease control efforts.", [["These interventions", "TREATMENT", 0, 19], ["disease control efforts", "TREATMENT", 58, 81]]], ["In addition, providing MIs with a data collection tool would formalise market access and contribute to their empowerment.", [["a data collection tool", "TEST", 32, 54]]], ["These benefits would extend to the national-level by promoting enhanced knowledge of disease control operational managers regarding the live poultry trade structure in authorized LBM's.ConclusionsOur study provides evidence which is potentially important for informing policies intended to encourage more biosecure practices of LPT operating at authorised LBM's.", [["disease control operational managers", "TREATMENT", 85, 121], ["Our study", "TEST", 196, 205]]], ["Our study, which combined descriptive and network analyses, showed that:Conclusions\u2022 Less experienced traders (i.e. operating for less than a year) and those trading in retail markets are more likely to trade with areas with a history of HPAI H5N1 infection.Conclusions\u2022 Some LPT's introduce poultry to other flocks as part of their normal trade practice.Conclusions\u2022 Larger quantities of poultry are transported from a wider geographical area to wholesale markets when compared to retail markets.Conclusions\u2022 The association of some LPT's with a limited set of communes within the catchment area of authorised LBM's may support HPAI H5N1 transmission and may contribute to perpetuating HPAI H5N1 virus circulation among certain groups of communes.ConclusionsGiven the above, current disease prevention and control interventions would benefit from dissemination of information about outbreak risk and the implementation of a formal data recording scheme at LBM's for all incoming and outgoing LPT's.Study population, data collection and dataset for analysis ::: MethodsIn March 2007, a total of 12 live bird markets (LBM) were formally operating in greater Ha Noi: ten retail markets (Cho Ni, Cho Phu Lo, Cho To, Da Ton, Sui, Yen Thuong, Dong Ngac, Ngoc Hoi, Ngu Hiep and Tan Trieu) and two wholesale markets (Ha Vi and Bac Thang Long) that were located in the five outer districts of the capital city.", [["H5N1 infection", "DISEASE", 243, 257], ["H5N1", "DISEASE", 634, 638], ["Cho", "CHEMICAL", 1185, 1188], ["HPAI H5N1", "ORGANISM", 238, 247], ["HPAI H5N1", "ORGANISM", 629, 638], ["HPAI H5N1 virus", "ORGANISM", 687, 702], ["HPAI H5N1", "SPECIES", 238, 247], ["HPAI H5N1 virus", "SPECIES", 687, 702], ["HPAI H5N1", "SPECIES", 238, 247], ["poultry", "SPECIES", 389, 396], ["HPAI H5N1", "SPECIES", 629, 638], ["HPAI H5N1 virus", "SPECIES", 687, 702], ["Our study", "TEST", 0, 9], ["network analyses", "TEST", 42, 58], ["HPAI H5N1 infection", "PROBLEM", 238, 257], ["Conclusions", "TEST", 258, 269], ["Some LPT's", "TREATMENT", 271, 281], ["Larger quantities of poultry", "PROBLEM", 368, 396], ["some LPT's", "PROBLEM", 529, 539], ["HPAI H5N1 transmission", "PROBLEM", 629, 651], ["perpetuating HPAI H5N1 virus circulation", "PROBLEM", 674, 714], ["current disease prevention", "TREATMENT", 776, 802], ["control interventions", "TREATMENT", 807, 828], ["outgoing LPT's", "TEST", 984, 998], ["Study population", "TEST", 999, 1015], ["Sui", "PROBLEM", 1221, 1224], ["more likely", "UNCERTAINTY", 188, 199], ["H5N1", "OBSERVATION_MODIFIER", 243, 247], ["infection", "OBSERVATION", 248, 257], ["normal", "OBSERVATION", 333, 339], ["Larger", "OBSERVATION_MODIFIER", 368, 374], ["quantities", "OBSERVATION_MODIFIER", 375, 385], ["poultry", "OBSERVATION_MODIFIER", 389, 396], ["wider", "OBSERVATION_MODIFIER", 420, 425], ["geographical", "OBSERVATION_MODIFIER", 426, 438], ["area", "OBSERVATION_MODIFIER", 439, 443], ["wholesale markets", "OBSERVATION", 447, 464], ["catchment", "OBSERVATION_MODIFIER", 582, 591], ["area", "OBSERVATION_MODIFIER", 592, 596], ["may contribute to", "UNCERTAINTY", 656, 673], ["disease", "OBSERVATION", 784, 791], ["capital", "ANATOMY_MODIFIER", 1389, 1396]]], ["A cross-sectional survey was carried out in all 12 markets between December 2006 and March 2007, which corresponds to peak poultry movement in Vietnam, due to high poultry demand around the traditional annual \"Tet\" festival holiday period.", [["A cross-sectional survey", "TEST", 0, 24], ["high poultry demand", "PROBLEM", 159, 178], ["peak poultry movement", "OBSERVATION", 118, 139]]], ["This is estimated to represent approximately 75% of the total number of poultry traded during a day in the northern provinces of Vietnam.Study population, data collection and dataset for analysis ::: MethodsThe Market inspectors (MI) of the participating markets collected the data as they occupy a position of authority and accessibility to the LBM's and are the institutional link with the best knowledge of the local conditions of the LBM's.", [["Study population", "TEST", 137, 153], ["the LBM's", "TREATMENT", 342, 351], ["approximately", "OBSERVATION_MODIFIER", 31, 44], ["75%", "OBSERVATION_MODIFIER", 45, 48], ["total", "OBSERVATION_MODIFIER", 56, 61], ["number", "OBSERVATION_MODIFIER", 62, 68], ["poultry", "OBSERVATION_MODIFIER", 72, 79], ["traded", "OBSERVATION_MODIFIER", 80, 86]]], ["In Vietnam, official LBM's have at least one veterinary health worker who performs the activities of a MI.", [["MI", "DISEASE", 103, 105], ["a MI", "PROBLEM", 101, 105]]], ["Based on a previous assessment of the trading pattern at each LBM it was noticed that despite LBM's usually operating daily, there is typically one day of the week when poultry trade is more intense [34].", [["a previous assessment", "TEST", 9, 30], ["intense", "OBSERVATION_MODIFIER", 191, 198]]], ["During that day it is expected that most LPT's would be present.", [["most LPT's", "PROBLEM", 36, 46]]], ["In that study it was also noticed that, with few exceptions, the same traders were operating in each market on a given day.Study population, data collection and dataset for analysis ::: MethodsData collection has followed an ego-centric approach whereby all trading activities of selected LPT's were collected.", [["Study population", "TEST", 123, 139], ["MethodsData collection", "TREATMENT", 186, 208], ["an ego-centric approach", "TREATMENT", 222, 245], ["selected LPT's", "TEST", 280, 294]]], ["The survey elicited information from a total of 157 incoming and outgoing LPT's concerning (1) their poultry trade activities outside and inside the LBM and (2) their relationship with other intermediaries and poultry flocks.", [["outgoing LPT's", "TEST", 65, 79]]], ["The questionnaire included questions regarding the usual number of poultry collected per flock in a day, the total number of poultry present at the flock(s), species of poultry reared in the flock(s) and the location of the flocks.", [["flocks", "OBSERVATION", 224, 230]]], ["The data on avian influenza outbreaks in Vietnam from 2003 through to 2006 was provided by the Epidemiology Unit of the Department of Animal Health, Ministry of Agriculture and Rural Development of Vietnam; the characteristics of this dataset are explained elsewhere [6].Statistical analyses ::: MethodsBased on previous knowledge of poultry husbandry practices at commune level and the available data from northern Vietnam on commune size and number of flocks per commune, the commune was considered an epidemiological compartment for disease status purposes [34].", [["influenza outbreaks", "DISEASE", 18, 37], ["avian", "ORGANISM", 12, 17], ["avian influenza", "SPECIES", 12, 27], ["size", "OBSERVATION_MODIFIER", 435, 439]]], ["For the statistical analysis of associations of LPT trade attributes with commune infection status during 2003 to 2006, and for the analysis of the poultry trade network we used the information generated from the \"buy and sell\" and \"buy only\" LPT's.", [["infection", "DISEASE", 82, 91], ["the statistical analysis", "TEST", 4, 28], ["LPT", "PROBLEM", 48, 51], ["commune infection status", "PROBLEM", 74, 98], ["the analysis", "TEST", 128, 140]]], ["This corresponded to a total of 142 LPT's (out of 157 initially interviewed) who had visited a total of 191 communes.", [["LPT's", "TEST", 36, 41]]], ["Of the communes reported by LPT's it was possible to link the commune names to location data for 117(82%) LPT's.Statistical analyses ::: MethodsThese LPT's considered in the analyses were operating in eight LBM's (Bac Thang Long, Cho Ni, Cho Phu Lo, Cho To, Da Ton, Ha Vi, Sui, and Yen Thuong).", [["location data", "TEST", 79, 92], ["LPT's", "TEST", 106, 111], ["Methods", "TREATMENT", 137, 144], ["These LPT's", "TEST", 144, 155], ["Sui", "PROBLEM", 273, 276]]], ["From a total of 191 communes initially available we were able to ascertain AI outbreak status for the three waves for 131(68.5%) communes.Statistical analyses ::: MethodsAssociations between attributes of the LPT's were tested using the chi-squared test for trend when at least one of the attributes had more than two ordered categories.", [["the LPT's", "TEST", 205, 214], ["the chi-squared test", "TEST", 233, 253]]], ["In addition, the association between attributes of the LPT's and the H5N1 infection status of communes where flocks were located was tested by fitting a random effect logistic regression model.", [["infection", "DISEASE", 74, 83], ["H5N1", "SPECIES", 69, 73], ["the LPT's", "PROBLEM", 51, 60], ["the H5N1 infection", "PROBLEM", 65, 83], ["flocks", "PROBLEM", 109, 115], ["H5N1", "OBSERVATION_MODIFIER", 69, 73], ["infection", "OBSERVATION", 74, 83]]], ["The H5N1 infection status of the commune in the period 2003 to 2006 (\"no outbreak\" vs. \"infection at least once\") was considered as the outcome variable.", [["infection", "DISEASE", 9, 18], ["infection", "DISEASE", 88, 97], ["H5N1", "ORGANISM", 4, 8], ["The H5N1 infection", "PROBLEM", 0, 18], ["\"infection", "PROBLEM", 87, 97], ["H5N1", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 9, 18], ["infection", "OBSERVATION", 88, 97]]], ["The effect of clustering due to multiple measurements at LPT's was assessed by including this variable as a random effect in the model.", [["multiple measurements at LPT's", "TEST", 32, 62]]], ["The statistical analysis was carried out in two phases using the LPT ID as the unit of analysis.", [["The statistical analysis", "TEST", 0, 24], ["analysis", "TEST", 87, 95]]], ["Firstly, all LPT trade behaviour attributes were screened statistically using univariable logistic regression with commune infection status based on a p-value of 0.20, using the likelihood-ratio test.", [["infection", "DISEASE", 123, 132], ["commune infection status", "PROBLEM", 115, 139], ["a p-value", "TEST", 149, 158], ["the likelihood-ratio test", "TEST", 174, 199]]], ["All continuous-scale variables were re-categorized into their quartiles.", [["All continuous-scale variables", "TREATMENT", 0, 30]]], ["Secondly, all factors significant in the screening phase were considered for inclusion through a manual backward stepwise variable selection process using a multivariable logistic regression model.", [["the screening phase", "TEST", 37, 56], ["a manual backward stepwise variable selection process", "TREATMENT", 95, 148], ["a multivariable logistic regression model", "TREATMENT", 155, 196]]], ["The criterion for removal of risk factors was based on the likelihood ratio statistic with a significance level of p > 0.05.", [["removal", "TREATMENT", 18, 25], ["risk factors", "PROBLEM", 29, 41], ["p", "TEST", 115, 116]]], ["The screening for the presence of confounding variables in the final model was performed by stepwise removal of variables which at some stage were not significant at p-value level of 0.05, and noting the impact on the coefficients of the remaining variables in the model.", [["The screening", "TEST", 0, 13], ["confounding variables", "PROBLEM", 34, 55], ["stepwise removal of variables", "TREATMENT", 92, 121]]], ["All statistical analyses were performed using STATA 9.2 (Stata\u00ae Corporation 2005).Statistical analyses ::: MethodsSocial network analysis was used to describe the connectivity pattern within the dataset consisting of records of paired trading events.", [["All statistical analyses", "TEST", 0, 24], ["STATA", "TEST", 46, 51], ["MethodsSocial network analysis", "TEST", 107, 137]]], ["Each pair represented the link between a particular LPT or LBM and the commune in which the source flock of the purchased poultry was located.", [["LBM", "OBSERVATION", 59, 62], ["source flock", "OBSERVATION", 92, 104], ["purchased poultry", "OBSERVATION", 112, 129]]], ["Two symmetric 2-mode networks, valued and binary (Network 1), were built linking LPT's and communes so that two communes are linked via a LPT if they reported to have sourced from flocks in both communes during the study period.", [["symmetric", "OBSERVATION_MODIFIER", 4, 13], ["2-mode", "OBSERVATION_MODIFIER", 14, 20]]], ["In this network nodes are divided into classes, LPT and communes, and in the case of the valued network includes the number of flocks in a commune the LPT traded with.", [["network nodes", "ANATOMY", 8, 21], ["network nodes", "MULTI-TISSUE_STRUCTURE", 8, 21], ["nodes", "OBSERVATION", 16, 21]]], ["The 2-mode trader-commune network was converted to a 1-mode binary symmetric network of communes linked via a common trader (Network 2).", [["The 2-mode trader-commune network", "TREATMENT", 0, 33]]], ["Basic descriptive measures of Network 1 and 2 were extracted: size, number of links, density and average non-normalized degree per class.", [["size", "OBSERVATION_MODIFIER", 62, 66], ["number", "OBSERVATION_MODIFIER", 68, 74], ["density", "OBSERVATION", 85, 92], ["average", "OBSERVATION_MODIFIER", 97, 104], ["non-normalized degree", "OBSERVATION_MODIFIER", 105, 126]]], ["The non-normalized degree measures the absolute number of unique links of a given node to the other node class.", [["node", "ANATOMY", 82, 86], ["node", "ANATOMY", 100, 104], ["node", "MULTI-TISSUE_STRUCTURE", 82, 86], ["degree", "OBSERVATION_MODIFIER", 19, 25], ["absolute", "OBSERVATION_MODIFIER", 39, 47], ["number", "OBSERVATION_MODIFIER", 48, 54], ["node", "OBSERVATION", 82, 86], ["node", "OBSERVATION", 100, 104]]], ["The components of the network were extracted and a binary variable was created identifying the communes included in the giant weak component (Yes/No).", [["components", "OBSERVATION_MODIFIER", 4, 14], ["giant", "OBSERVATION_MODIFIER", 120, 125], ["weak", "OBSERVATION_MODIFIER", 126, 130], ["component", "OBSERVATION_MODIFIER", 131, 140]]], ["A component is a maximal connected sub-graph where all nodes (i.e. communes) are connected through paths [37].", [["a maximal connected sub-graph", "TREATMENT", 15, 44], ["all nodes", "PROBLEM", 51, 60], ["component", "OBSERVATION_MODIFIER", 2, 11], ["maximal", "OBSERVATION_MODIFIER", 17, 24], ["sub", "OBSERVATION_MODIFIER", 35, 38], ["all", "OBSERVATION_MODIFIER", 51, 54], ["nodes", "OBSERVATION", 55, 60]]], ["Cliques of minimum size 3 were extracted and a symmetrised binary clique-overlap network (Network 3) was built where two communes are linked if they share at least one clique.", [["a symmetrised binary clique", "TEST", 45, 72], ["minimum", "OBSERVATION_MODIFIER", 11, 18], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["A clique is a maximal complete sub-graph where each node is connected to all other nodes and the clique is not contained in any other clique [38].", [["node", "ANATOMY", 52, 56], ["nodes", "ANATOMY", 83, 88], ["node", "OBSERVATION", 52, 56], ["nodes", "OBSERVATION", 83, 88]]], ["This provided information about which nodes are more closely linked to one another than to other nodes of the network in tightly knit groups within the network [37,39].", [["nodes", "ANATOMY", 38, 43], ["nodes", "OBSERVATION", 38, 43], ["nodes", "OBSERVATION", 97, 102]]], ["Communes with degree greater than one were identified as a proxy for the identification of communes which are within the catchment area of more than one market.Statistical analyses ::: MethodsTo test the association of some network parameters and variables of commune infection status in three consecutive epidemic waves (\"infection in 2003-4\", \"infection in 2004-5\" and \"infection in 2005-6\" and \"infection in any of the three waves\"), several statistical tests adapted to network data were applied.", [["infection", "DISEASE", 268, 277], ["infection", "DISEASE", 323, 332], ["infection", "DISEASE", 346, 355], ["infection", "DISEASE", 372, 381], ["infection", "DISEASE", 398, 407], ["Methods", "TREATMENT", 185, 192], ["some network parameters", "PROBLEM", 219, 242], ["commune infection status", "PROBLEM", 260, 284], ["\"infection", "PROBLEM", 322, 332], ["infection", "PROBLEM", 346, 355], ["\"infection", "PROBLEM", 371, 381], ["\"infection", "PROBLEM", 397, 407], ["several statistical tests", "TEST", 437, 462], ["degree", "OBSERVATION_MODIFIER", 14, 20], ["greater", "OBSERVATION_MODIFIER", 21, 28], ["communes", "OBSERVATION", 91, 99], ["catchment", "OBSERVATION_MODIFIER", 121, 130], ["area", "OBSERVATION_MODIFIER", 131, 135], ["infection", "OBSERVATION", 268, 277], ["infection", "OBSERVATION", 323, 332], ["infection", "OBSERVATION", 346, 355], ["infection", "OBSERVATION", 372, 381], ["infection", "OBSERVATION", 398, 407]]], ["The means of the degree distribution between infected and non-infected communes in the three outbreak waves were compared using the t-test with a permutation-based significance test involving 10,000 random permutations.", [["infected and non-infected communes", "PROBLEM", 45, 79], ["the t-test", "TEST", 128, 138], ["a permutation-based significance test", "TEST", 144, 181], ["degree", "OBSERVATION_MODIFIER", 17, 23], ["distribution", "OBSERVATION_MODIFIER", 24, 36], ["infected", "OBSERVATION_MODIFIER", 45, 53], ["non-infected", "OBSERVATION_MODIFIER", 58, 70], ["communes", "OBSERVATION_MODIFIER", 71, 79]]], ["The association between the density of the links in Network 2 and 3 and disease status of the commune was tested by applying a randomization test of autocorrelation for a symmetric adjacency matrix using two classes and 10,000 random permutations.", [["a randomization test", "TEST", 125, 145], ["a symmetric adjacency matrix", "PROBLEM", 169, 197], ["density", "OBSERVATION", 28, 35], ["symmetric", "OBSERVATION_MODIFIER", 171, 180], ["adjacency matrix", "OBSERVATION", 181, 197]]], ["The test of autocorrelation for Network 2 and 3 compared the observed number of links between two groups of nodes and the expected number obtained through random permutations of the network.", [["The test", "TEST", 0, 8], ["nodes", "OBSERVATION", 108, 113]]], ["The use of randomization tests of autocorrelation within symmetric adjacency matrices allows statistical significance testing of associations between dyadic binary variables such as represented by the links within the network and the disease status attributes of the commune nodes.", [["commune nodes", "ANATOMY", 267, 280], ["commune nodes", "MULTI-TISSUE_STRUCTURE", 267, 280], ["randomization tests", "TEST", 11, 30], ["the disease status", "PROBLEM", 230, 248], ["the commune nodes", "PROBLEM", 263, 280], ["symmetric", "OBSERVATION_MODIFIER", 57, 66], ["adjacency matrices", "OBSERVATION", 67, 85], ["commune nodes", "OBSERVATION", 267, 280]]], ["The three types of links based on the different variables of disease status are: Type 1 - between infected communes, Type 2 - between infected and non-infected communes, and Type 3 - between non-infected communes.", [["Type 1 - between infected communes", "PROBLEM", 81, 115], ["Type 2", "PROBLEM", 117, 123], ["infected and non-infected communes", "PROBLEM", 134, 168], ["infected", "OBSERVATION_MODIFIER", 98, 106], ["communes", "OBSERVATION", 107, 115], ["infected", "OBSERVATION_MODIFIER", 134, 142], ["non-infected communes", "OBSERVATION", 147, 168], ["non-infected", "OBSERVATION_MODIFIER", 191, 203], ["communes", "OBSERVATION", 204, 212]]], ["The association between disease status and membership in the giant component and the degree of commune in the Network 4 were tested using the Pearson's Chi-square test and the Fisher exact test (using the latter when the number of observations in any cell was less than 5).Statistical analyses ::: MethodsAll social network analyses were performed using UCINET 6.135 (\u00a9Analytic Technologies, Inc. 1999).", [["cell", "ANATOMY", 251, 255], ["cell", "CELL", 251, 255], ["disease status", "PROBLEM", 24, 38], ["the Pearson's Chi-square test", "TEST", 138, 167], ["the Fisher exact test", "TEST", 172, 193], ["Methods", "TREATMENT", 298, 305], ["giant", "OBSERVATION_MODIFIER", 61, 66]]], ["Maps of the study area and the location of the communes included in the networks were produced using ArcView 9.2 (\u00a9ESRI).Authors' contributionsRJSM designed the study, conducted the analysis and drafted the manuscript.", [["Maps", "TEST", 0, 4], ["the study area", "TEST", 8, 22], ["ArcView", "TEST", 101, 108], ["the study", "TEST", 157, 166], ["the analysis", "TEST", 178, 190]]], ["AO-P conducted the analysis and drafted the manuscript.", [["P", "DNA", 3, 4], ["the analysis", "TEST", 15, 27]]], ["DUP conceived the study, supervised the study and critically revised the manuscript.", [["the study", "TEST", 14, 23], ["the study", "TEST", 36, 45]]], ["JO conceived the study and critically revised the manuscript.", [["the study", "TEST", 13, 22]]], ["KLLT and QHD conducted the field work and performed data collection.", [["KLLT", "TREATMENT", 0, 4]]]], "d5ff9f6e59831b6ed4fd7b1b2ab8c826c2b0e733": [["A lockdown is a social distancing intervention that aims to minimise physical contact between individuals and groups in order to reduce transmission of a communicable disease [1] .", [["communicable disease", "DISEASE", 154, 174], ["a social distancing intervention", "TREATMENT", 14, 46], ["a communicable disease", "PROBLEM", 152, 174]]], ["Social distancing measures are typically introduced in an attempt to reduce and/or delay the peak of an epidemic/pandemic, to minimise the potential for surges in health care utilisation and to protect vulnerable groups.", [["pandemic", "PROBLEM", 113, 121]]], ["In the context of COVID-19, the World Health Organization has encouraged use of the term 'physical distancing' instead of social distancing to highlight that the aim of this intervention is only to reduce physical contact, not social contact which is often still possible through telephone and video calls, and social media [2] .", [["COVID", "TEST", 18, 23], ["this intervention", "TREATMENT", 169, 186]]], ["There are a range of physical distancing measures, which can be broadly categorised as operating at the individual (eg, to support self-isolation of confirmed or suspected cases) or population levels (eg, closing of schools or workplaces) [1] .", [["population levels", "PROBLEM", 182, 199], ["range", "OBSERVATION_MODIFIER", 12, 17]]]], "fac9ef6ba1ca4bdb16baad83f0146e6a5c3b906f": [["B. Mass spectrometry (MS) analysis with isotopic distribution of conditional ligands by LCMS-IT-TOF.", [["B. Mass spectrometry", "TEST", 0, 20], ["MS) analysis", "TEST", 22, 34], ["conditional ligands", "PROBLEM", 65, 84], ["LCMS", "TEST", 88, 92], ["Mass", "OBSERVATION", 3, 7]]], ["The mass to charge ratios (m/z) of peptides were measured after liquid chromatography (LC) separation on a C18 column.", [["The mass", "PROBLEM", 0, 8], ["charge ratios", "TEST", 12, 25], ["peptides", "PROBLEM", 35, 43], ["liquid chromatography", "TEST", 64, 85], ["a C18 column", "TREATMENT", 105, 117], ["mass", "OBSERVATION", 4, 8]]], ["As both isomers of the photocleavable 3-amino-3-(2nitro) phenyl-propanoic acid (Anp) used during solid phase peptide synthesis of the conditional ligand, 2 diasteroisomers could usually be identified.", [["3-amino-3-(2nitro) phenyl-propanoic acid", "CHEMICAL", 38, 78], ["Anp", "CHEMICAL", 80, 83], ["3-amino-3-(2nitro) phenyl-propanoic acid", "CHEMICAL", 38, 78], ["Anp", "CHEMICAL", 80, 83], ["3-amino-3-(2nitro) phenyl-propanoic acid", "SIMPLE_CHEMICAL", 38, 78], ["Anp", "SIMPLE_CHEMICAL", 80, 83], ["2 diasteroisomers", "SIMPLE_CHEMICAL", 154, 171], ["the photocleavable", "TREATMENT", 19, 37], ["amino", "TEST", 40, 45], ["2nitro) phenyl-propanoic acid (Anp)", "TREATMENT", 49, 84], ["solid phase peptide synthesis", "TREATMENT", 97, 126]]], ["In some cases, however, the two isomers failed to separate during chromatography.", [["chromatography", "TEST", 66, 80]]], ["The data displayed is for one of the two isomers, mostly for doubly charged molecules (M 2+ ), together with the amino acid sequences of conditional ligands where the letter J represents Anp.B. Mass spectrometry (MS) analysis with isotopic distribution of conditional ligands by LCMS-A.", [["amino acid", "CHEMICAL", 113, 123], ["amino acid", "CHEMICAL", 113, 123], ["M 2+", "SIMPLE_CHEMICAL", 87, 91], ["amino acid", "AMINO_ACID", 113, 123], ["amino acid sequences", "PROTEIN", 113, 133], ["doubly charged molecules", "PROBLEM", 61, 85], ["the amino acid sequences", "TEST", 109, 133], ["conditional ligands", "PROBLEM", 137, 156], ["Anp.B. Mass spectrometry", "PROBLEM", 187, 211]]], ["Cells were first analyzed for their size and granularity based on their forward scatter area (FSC-A) and side scatter area (SSC-A) profile.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["FSC", "TEST", 94, 97], ["side scatter area", "TEST", 105, 122], ["size", "OBSERVATION_MODIFIER", 36, 40], ["granularity", "OBSERVATION", 45, 56]]], ["Doublets were excluded using side-scatter height (SSC-H) vs side-scatter width (SSC-W) and forward-scatter height (FSC-H) vs forwardscatter width (FSC-W) parameters.", [["Doublets", "TEST", 0, 8], ["side-scatter height", "TEST", 29, 48], ["side-scatter width", "TEST", 60, 78], ["SSC", "TEST", 80, 83], ["scatter height", "TEST", 99, 113], ["FSC", "TEST", 115, 118], ["forwardscatter width", "TEST", 125, 145], ["FSC", "TEST", 147, 150], ["scatter width", "OBSERVATION_MODIFIER", 65, 78]]], ["Cells present in all three gates were analyzed for their time vs forward scatter area (FSC-A) to exclude cells that were read at the beginning and end of the flow cytometry run.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 105, 110], ["Cells", "CELL", 0, 5], ["cells", "CELL", 105, 110], ["Cells", "TEST", 0, 5], ["forward scatter area", "TEST", 65, 85], ["FSC", "TEST", 87, 90], ["cells", "PROBLEM", 105, 110], ["the flow cytometry", "TEST", 154, 172], ["flow cytometry", "OBSERVATION", 158, 172]]], ["Viable cells were gated based on their negative staining with the Live/Dead\u00ae dye (Invitrogen), and these cells were finally analyzed for anti-human CD8 antibodies and HLA-tetramer stainings.", [["cells", "ANATOMY", 7, 12], ["cells", "ANATOMY", 105, 110], ["cells", "CELL", 7, 12], ["Dead\u00ae dye", "SIMPLE_CHEMICAL", 71, 80], ["cells", "CELL", 105, 110], ["CD8", "GENE_OR_GENE_PRODUCT", 148, 151], ["anti-human CD8 antibodies", "PROTEIN", 137, 162], ["Viable cells", "PROBLEM", 0, 12], ["the Live/Dead\u00ae dye", "TREATMENT", 62, 80], ["these cells", "TEST", 99, 110], ["anti-human CD8 antibodies", "TEST", 137, 162], ["HLA", "TEST", 167, 170]]], ["All data were analyzed using FlowJo (Tree Star C. Culturing of PBMCs to develop antigen-specific T cell lines.", [["PBMCs", "ANATOMY", 63, 68], ["T cell lines", "ANATOMY", 97, 109], ["PBMCs", "CELL", 63, 68], ["T cell lines", "CELL", 97, 109], ["PBMCs", "CELL_TYPE", 63, 68], ["antigen-specific T cell lines", "CELL_LINE", 80, 109], ["All data", "TEST", 0, 8], ["PBMCs", "PROBLEM", 63, 68], ["antigen", "TEST", 80, 87], ["cell lines", "OBSERVATION", 99, 109]]], ["PBMCs isolated from healthy volunteers' blood were stimulated by antigens from EBV-LMP2419-427 (TYGPVFMSL) or HCMV-IE-142-50 (KEVNSQLSL) and cultured in 25 U/mL IL-2, 5% AB serum in RPMI for 14 days.", [["PBMCs", "ANATOMY", 0, 5], ["blood", "ANATOMY", 40, 45], ["serum", "ANATOMY", 173, 178], ["EBV-LMP2419-427", "CHEMICAL", 79, 94], ["PBMCs", "CELL", 0, 5], ["volunteers", "ORGANISM", 28, 38], ["blood", "ORGANISM_SUBSTANCE", 40, 45], ["EBV", "ORGANISM", 79, 82], ["LMP2419-427", "CELL", 83, 94], ["TYGPVFMSL", "CELL", 96, 105], ["HCMV", "ORGANISM", 110, 114], ["IE-142-50", "CELL", 115, 124], ["KEVNSQLSL", "CELL", 126, 135], ["IL-2", "GENE_OR_GENE_PRODUCT", 161, 165], ["AB", "ORGANISM_SUBSTANCE", 170, 172], ["serum", "ORGANISM_SUBSTANCE", 173, 178], ["PBMCs", "CELL_TYPE", 0, 5], ["EBV-LMP2419-427", "SPECIES", 79, 94], ["HCMV-IE-142-50", "SPECIES", 110, 124], ["PBMCs", "TEST", 0, 5], ["EBV", "TEST", 79, 82], ["LMP2419", "TEST", 83, 90], ["TYGPVFMSL", "TEST", 96, 105], ["HCMV", "TEST", 110, 114], ["IL", "TEST", 161, 163], ["5% AB serum in RPMI", "TEST", 167, 186]]], ["HLA tetramer staining for antigen-specific T cells was performed on day 0, 7, 10 and 14 days post stimulation.", [["T cells", "ANATOMY", 43, 50], ["HLA tetramer", "GENE_OR_GENE_PRODUCT", 0, 12], ["antigen", "GENE_OR_GENE_PRODUCT", 26, 33], ["T cells", "CELL", 43, 50], ["T cells", "CELL_TYPE", 43, 50], ["HLA tetramer staining", "TEST", 0, 21], ["antigen", "TEST", 26, 33]]]], "16c4edd6e88329857e998769ed6e1f7758a48893": [["INTRODUCTIONThe pathogenetic links between viral infection and renal disease are often difficult to establish.", [["renal", "ANATOMY", 63, 68], ["viral infection", "DISEASE", 43, 58], ["renal disease", "DISEASE", 63, 76], ["renal", "ORGAN", 63, 68], ["viral infection", "PROBLEM", 43, 58], ["renal disease", "PROBLEM", 63, 76], ["viral", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["renal", "ANATOMY", 63, 68], ["disease", "OBSERVATION", 69, 76]]], ["The criteria for proving causality are complex and include (besides recognition of the clinical syndrome) serological diagnosis, identification of specific viral antigenemia, and detection in glomerular structures of viral antigens and host antibodies.", [["glomerular structures", "ANATOMY", 192, 213], ["glomerular structures", "TISSUE", 192, 213], ["viral antigens", "PROTEIN", 217, 231], ["host antibodies", "PROTEIN", 236, 251], ["the clinical syndrome", "PROBLEM", 83, 104], ["serological diagnosis", "TEST", 106, 127], ["specific viral antigenemia", "PROBLEM", 147, 173], ["viral antigens", "PROBLEM", 217, 231], ["host antibodies", "TEST", 236, 251], ["viral antigenemia", "OBSERVATION", 156, 173], ["viral antigens", "OBSERVATION", 217, 231]]], ["According to Koch's postulates, the etiological link should be confirmed by complete cure following eradication of the virus, but this is not always possible.", [["the virus", "PROBLEM", 115, 124], ["virus", "OBSERVATION", 119, 124], ["not always possible", "UNCERTAINTY", 138, 157]]], ["The concentration of viral antigens is higher in tissue than in the circulation, where antigens are complexed with specific autoantibodies.", [["tissue", "ANATOMY", 49, 55], ["tissue", "TISSUE", 49, 55], ["viral antigens", "PROTEIN", 21, 35], ["antigens", "PROTEIN", 87, 95], ["autoantibodies", "PROTEIN", 124, 138], ["The concentration of viral antigens", "TEST", 0, 35], ["specific autoantibodies", "PROBLEM", 115, 138], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["viral antigens", "OBSERVATION", 21, 35], ["higher", "OBSERVATION_MODIFIER", 39, 45], ["circulation", "ANATOMY", 68, 79]]], ["Virological and molecular analy sis of pathologic tissues by in situ hybridiza tion, polymerase chain reaction and ultra structural analysis led to successful detection and identifica tion of the virus.", [["tissues", "ANATOMY", 50, 57], ["tissues", "TISSUE", 50, 57], ["Virological", "TEST", 0, 11], ["pathologic tissues", "PROBLEM", 39, 57], ["polymerase chain reaction", "PROBLEM", 85, 110], ["ultra structural analysis", "TEST", 115, 140], ["successful detection", "TEST", 148, 168], ["the virus", "PROBLEM", 192, 201], ["pathologic tissues", "OBSERVATION", 39, 57], ["virus", "OBSERVATION", 196, 201]]], ["It should be noted that tubular uptake of viral particles is common and does not necessarily establish an etiological link with renal disease.", [["tubular", "ANATOMY", 24, 31], ["renal", "ANATOMY", 128, 133], ["renal disease", "DISEASE", 128, 141], ["tubular", "TISSUE", 24, 31], ["renal", "ORGAN", 128, 133], ["tubular uptake of viral particles", "PROBLEM", 24, 57], ["renal disease", "PROBLEM", 128, 141], ["tubular", "OBSERVATION_MODIFIER", 24, 31], ["uptake", "OBSERVATION", 32, 38], ["viral particles", "OBSERVATION", 42, 57], ["renal", "ANATOMY", 128, 133], ["disease", "OBSERVATION", 134, 141]]], ["Improvement of the renal disease concomitant with clearance of the suspected antigen, or recurrence of glomerulonephritis following reinfection, are additional clinical criteria.VIRUSES AND MECHANISMS INVOLVED IN VIRAL NEPHROPATHYDifferent mechanisms are operative in different viral nephropathies (Box 1).", [["renal", "ANATOMY", 19, 24], ["renal disease", "DISEASE", 19, 32], ["glomerulonephritis", "DISEASE", 103, 121], ["nephropathies", "DISEASE", 284, 297], ["renal", "ORGAN", 19, 24], ["the renal disease", "PROBLEM", 15, 32], ["the suspected antigen", "PROBLEM", 63, 84], ["glomerulonephritis", "PROBLEM", 103, 121], ["reinfection", "PROBLEM", 132, 143], ["VIRAL NEPHROPATHYDifferent mechanisms", "PROBLEM", 213, 250], ["different viral nephropathies", "PROBLEM", 268, 297], ["renal", "ANATOMY", 19, 24], ["disease", "OBSERVATION", 25, 32], ["recurrence", "OBSERVATION_MODIFIER", 89, 99], ["glomerulonephritis", "OBSERVATION", 103, 121], ["reinfection", "OBSERVATION", 132, 143], ["VIRAL NEPHROPATHYDifferent", "OBSERVATION", 213, 239], ["viral nephropathies", "OBSERVATION", 278, 297]]], ["In acute glomerulonephritis, direct viral infection of the glomerulus induces proliferative changes following release of cytokines.", [["glomerulus", "ANATOMY", 59, 69], ["glomerulonephritis", "DISEASE", 9, 27], ["infection", "DISEASE", 42, 51], ["glomerulus", "MULTI-TISSUE_STRUCTURE", 59, 69], ["cytokines", "PROTEIN", 121, 130], ["acute glomerulonephritis", "PROBLEM", 3, 27], ["direct viral infection of the glomerulus", "PROBLEM", 29, 69], ["proliferative changes", "PROBLEM", 78, 99], ["cytokines", "TREATMENT", 121, 130], ["acute", "OBSERVATION_MODIFIER", 3, 8], ["glomerulonephritis", "OBSERVATION", 9, 27], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infection", "OBSERVATION", 42, 51], ["glomerulus", "ANATOMY", 59, 69], ["proliferative", "OBSERVATION_MODIFIER", 78, 91]]], ["1 The nephropathy is reversible in most cases if the virus is rapidly cleared.", [["nephropathy", "DISEASE", 6, 17], ["The nephropathy", "PROBLEM", 2, 17], ["the virus", "PROBLEM", 49, 58], ["nephropathy", "OBSERVATION", 6, 17], ["reversible", "OBSERVATION_MODIFIER", 21, 31], ["virus", "OBSERVATION", 53, 58]]], ["In chronic forms of glomerulonephritis, persistent viral infection provides continuous antigenic stimulation, resulting in antibody production and formation of immune complexes.", [["glomerulonephritis", "DISEASE", 20, 38], ["viral infection", "DISEASE", 51, 66], ["immune complexes", "PROTEIN", 160, 176], ["glomerulonephritis", "PROBLEM", 20, 38], ["persistent viral infection", "PROBLEM", 40, 66], ["continuous antigenic stimulation", "TREATMENT", 76, 108], ["antibody production", "PROBLEM", 123, 142], ["immune complexes", "PROBLEM", 160, 176], ["chronic", "OBSERVATION_MODIFIER", 3, 10], ["glomerulonephritis", "OBSERVATION", 20, 38], ["persistent", "OBSERVATION_MODIFIER", 40, 50], ["viral", "OBSERVATION_MODIFIER", 51, 56], ["infection", "OBSERVATION", 57, 66], ["antigenic stimulation", "OBSERVATION", 87, 108], ["antibody production", "OBSERVATION", 123, 142], ["immune complexes", "OBSERVATION", 160, 176]]], ["Studies indicate a role in the disease pathogenesis for these immune complexes, which can be derived from the circulation or formed in situ.", [["the disease pathogenesis", "PROBLEM", 27, 51], ["these immune complexes", "PROBLEM", 56, 78], ["disease", "OBSERVATION", 31, 38]]], ["2,3 Viral proteins cause inflammatory renal diseases via synthesis of various mediators that can cause sclerosis and worsen glomerulopathy.", [["renal", "ANATOMY", 38, 43], ["renal diseases", "DISEASE", 38, 52], ["sclerosis", "DISEASE", 103, 112], ["glomerulopathy", "DISEASE", 124, 138], ["renal", "ORGAN", 38, 43], ["Viral proteins", "PROTEIN", 4, 18], ["Viral proteins", "PROBLEM", 4, 18], ["inflammatory renal diseases", "PROBLEM", 25, 52], ["synthesis of various mediators", "TREATMENT", 57, 87], ["sclerosis", "PROBLEM", 103, 112], ["glomerulopathy", "PROBLEM", 124, 138], ["inflammatory", "OBSERVATION_MODIFIER", 25, 37], ["renal", "ANATOMY", 38, 43], ["diseases", "OBSERVATION", 44, 52], ["sclerosis", "OBSERVATION", 103, 112], ["worsen", "OBSERVATION_MODIFIER", 117, 123], ["glomerulopathy", "OBSERVATION", 124, 138]]], ["4, 5 Viral infections can cause many glomerular diseases.", [["glomerular", "ANATOMY", 37, 47], ["Viral infections", "DISEASE", 5, 21], ["glomerular diseases", "DISEASE", 37, 56], ["Viral", "ORGANISM", 5, 10], ["glomerular", "TISSUE", 37, 47], ["5 Viral infections", "PROBLEM", 3, 21], ["many glomerular diseases", "PROBLEM", 32, 56], ["glomerular diseases", "OBSERVATION", 37, 56]]], ["The diagnostic criteria for virus-related nephropathy include detailed clinical and laboratory data, and tissue molecular analysis.", [["tissue", "ANATOMY", 105, 111], ["nephropathy", "DISEASE", 42, 53], ["tissue", "TISSUE", 105, 111], ["virus", "PROBLEM", 28, 33], ["related nephropathy", "PROBLEM", 34, 53], ["laboratory data", "TEST", 84, 99], ["tissue molecular analysis", "TEST", 105, 130], ["nephropathy", "OBSERVATION", 42, 53]]], ["Several mechanisms are involved in the pathogenesis of virus-related nephropathy, including tropism of the virus in the kidney, induction of abnormal immune complexes, direct cytopathogenic effects, and multiorgan failure.", [["kidney", "ANATOMY", 120, 126], ["multiorgan", "ANATOMY", 203, 213], ["nephropathy", "DISEASE", 69, 80], ["multiorgan failure", "DISEASE", 203, 221], ["kidney", "ORGAN", 120, 126], ["abnormal immune complexes", "PROTEIN", 141, 166], ["virus", "PROBLEM", 55, 60], ["related nephropathy", "PROBLEM", 61, 80], ["the virus in the kidney", "PROBLEM", 103, 126], ["abnormal immune complexes", "PROBLEM", 141, 166], ["direct cytopathogenic effects", "PROBLEM", 168, 197], ["multiorgan failure", "PROBLEM", 203, 221], ["virus", "OBSERVATION", 55, 60], ["nephropathy", "OBSERVATION", 69, 80], ["tropism", "OBSERVATION_MODIFIER", 92, 99], ["virus", "OBSERVATION", 107, 112], ["kidney", "ANATOMY", 120, 126], ["abnormal", "OBSERVATION_MODIFIER", 141, 149], ["immune complexes", "OBSERVATION", 150, 166], ["cytopathogenic effects", "OBSERVATION", 175, 197], ["multiorgan failure", "OBSERVATION", 203, 221]]], ["Hepatitis B virus is associated with membranous nephropathy and mesangiocapillary glomerulonephritis in endemic areas.", [["Hepatitis B", "DISEASE", 0, 11], ["membranous nephropathy", "DISEASE", 37, 59], ["glomerulonephritis", "DISEASE", 82, 100], ["Hepatitis B virus", "ORGANISM", 0, 17], ["Hepatitis B virus", "SPECIES", 0, 17], ["Hepatitis B virus", "SPECIES", 0, 17], ["Hepatitis B virus", "PROBLEM", 0, 17], ["membranous nephropathy", "PROBLEM", 37, 59], ["mesangiocapillary glomerulonephritis in endemic areas", "PROBLEM", 64, 117], ["virus", "OBSERVATION", 12, 17], ["associated with", "UNCERTAINTY", 21, 36], ["membranous", "OBSERVATION_MODIFIER", 37, 47], ["nephropathy", "OBSERVATION", 48, 59], ["mesangiocapillary", "OBSERVATION_MODIFIER", 64, 81], ["glomerulonephritis", "OBSERVATION", 82, 100], ["endemic", "OBSERVATION_MODIFIER", 104, 111]]], ["Hepatitis C virus causes various forms of glomerulonephritis, including cryoglobulinemia-mediated glomerulonephritis.", [["Hepatitis C", "DISEASE", 0, 11], ["glomerulonephritis", "DISEASE", 42, 60], ["cryoglobulinemia", "DISEASE", 72, 88], ["glomerulonephritis", "DISEASE", 98, 116], ["Hepatitis C virus", "ORGANISM", 0, 17], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "SPECIES", 0, 17], ["Hepatitis C virus", "PROBLEM", 0, 17], ["glomerulonephritis", "PROBLEM", 42, 60], ["cryoglobulinemia", "PROBLEM", 72, 88], ["mediated glomerulonephritis", "PROBLEM", 89, 116], ["virus", "OBSERVATION", 12, 17], ["glomerulonephritis", "OBSERVATION", 42, 60], ["cryoglobulinemia", "OBSERVATION", 72, 88], ["glomerulonephritis", "OBSERVATION", 98, 116]]], ["Infection with HIV is associated with a collapsing focal segmental glomerulosclerosis, a distinctive disease that affects mainly Africans and African Americans.", [["Infection", "DISEASE", 0, 9], ["HIV", "DISEASE", 15, 18], ["focal segmental glomerulosclerosis", "DISEASE", 51, 85], ["HIV", "ORGANISM", 15, 18], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 15, 18], ["Infection", "PROBLEM", 0, 9], ["HIV", "PROBLEM", 15, 18], ["a collapsing focal segmental glomerulosclerosis", "PROBLEM", 38, 85], ["a distinctive disease", "PROBLEM", 87, 108], ["HIV", "OBSERVATION", 15, 18], ["collapsing", "OBSERVATION_MODIFIER", 40, 50], ["focal", "OBSERVATION_MODIFIER", 51, 56], ["segmental", "OBSERVATION_MODIFIER", 57, 66], ["glomerulosclerosis", "OBSERVATION", 67, 85], ["distinctive", "OBSERVATION_MODIFIER", 89, 100], ["disease", "OBSERVATION", 101, 108]]], ["In the course of HIV infection, other types of immune complex glomerulonephritis can occur, most frequently in whites.", [["HIV infection", "DISEASE", 17, 30], ["glomerulonephritis", "DISEASE", 62, 80], ["HIV", "ORGANISM", 17, 20], ["HIV", "SPECIES", 17, 20], ["HIV", "SPECIES", 17, 20], ["HIV infection", "PROBLEM", 17, 30], ["immune complex glomerulonephritis", "PROBLEM", 47, 80], ["infection", "OBSERVATION", 21, 30], ["complex", "OBSERVATION_MODIFIER", 54, 61], ["glomerulonephritis", "OBSERVATION", 62, 80]]], ["Recent reports indicate a role for parvovirus B19 in 'idiopathic' collapsing focal segmental glomerulosclerosis.", [["parvovirus B19", "DISEASE", 35, 49], ["focal segmental glomerulosclerosis", "DISEASE", 77, 111], ["parvovirus B19", "ORGANISM", 35, 49], ["parvovirus B19", "SPECIES", 35, 49], ["parvovirus B19", "SPECIES", 35, 49], ["parvovirus B19", "PROBLEM", 35, 49], ["'idiopathic' collapsing focal segmental glomerulosclerosis", "PROBLEM", 53, 111], ["idiopathic", "OBSERVATION_MODIFIER", 54, 64], ["collapsing", "OBSERVATION_MODIFIER", 66, 76], ["focal", "OBSERVATION_MODIFIER", 77, 82], ["segmental", "OBSERVATION_MODIFIER", 83, 92], ["glomerulosclerosis", "OBSERVATION", 93, 111]]], ["Both hantaviruses, and coronaviruses associated with severe acute respiratory syndrome, can lead to acute renal failure.", [["renal", "ANATOMY", 106, 111], ["hantaviruses", "DISEASE", 5, 17], ["coronaviruses", "DISEASE", 23, 36], ["acute respiratory syndrome", "DISEASE", 60, 86], ["acute renal failure", "DISEASE", 100, 119], ["renal", "ORGAN", 106, 111], ["Both hantaviruses", "PROBLEM", 0, 17], ["coronaviruses", "PROBLEM", 23, 36], ["severe acute respiratory syndrome", "PROBLEM", 53, 86], ["acute renal failure", "PROBLEM", 100, 119], ["hantaviruses", "OBSERVATION", 5, 17], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["acute", "OBSERVATION_MODIFIER", 60, 65], ["respiratory syndrome", "OBSERVATION", 66, 86], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["renal", "ANATOMY", 106, 111], ["failure", "OBSERVATION", 112, 119]]], ["Renal biopsy followed by appropriate serological and molecular testing is essential for defining virus-related glomerular lesions and guiding prognostic and therapeutic evaluation.VIRUSES AND MECHANISMS INVOLVED IN VIRAL NEPHROPATHYA direct cytopathic effect of viral proteins has also been postulated.", [["Renal", "ANATOMY", 0, 5], ["glomerular lesions", "ANATOMY", 111, 129], ["Renal biopsy", "MULTI-TISSUE_STRUCTURE", 0, 12], ["glomerular lesions", "PATHOLOGICAL_FORMATION", 111, 129], ["viral proteins", "PROTEIN", 262, 276], ["Renal biopsy", "TEST", 0, 12], ["appropriate serological and molecular testing", "TEST", 25, 70], ["virus", "PROBLEM", 97, 102], ["glomerular lesions", "PROBLEM", 111, 129], ["therapeutic evaluation", "TEST", 157, 179], ["viral proteins", "PROBLEM", 262, 276], ["biopsy", "OBSERVATION", 6, 12], ["glomerular", "ANATOMY", 111, 121], ["lesions", "OBSERVATION", 122, 129], ["VIRAL NEPHROPATHYA", "OBSERVATION", 215, 233], ["cytopathic", "OBSERVATION_MODIFIER", 241, 251], ["viral proteins", "OBSERVATION", 262, 276]]], ["6 In hepatitis C virus (HCV)-induced mesangiocapillary glomerulonephritis (MCGN), production of circulating cryo globulins is induced as an abnormal host response to infection.", [["hepatitis C", "DISEASE", 5, 16], ["glomerulonephritis", "DISEASE", 55, 73], ["MCGN", "DISEASE", 75, 79], ["infection", "DISEASE", 166, 175], ["hepatitis C virus", "ORGANISM", 5, 22], ["HCV", "ORGANISM", 24, 27], ["mesangiocapillary glomerulonephritis", "CANCER", 37, 73], ["MCGN", "CANCER", 75, 79], ["cryo globulins", "GENE_OR_GENE_PRODUCT", 108, 122], ["circulating cryo globulins", "PROTEIN", 96, 122], ["hepatitis C virus", "SPECIES", 5, 22], ["hepatitis C virus", "SPECIES", 5, 22], ["HCV", "SPECIES", 24, 27], ["hepatitis C virus (HCV)", "PROBLEM", 5, 28], ["mesangiocapillary glomerulonephritis", "PROBLEM", 37, 73], ["circulating cryo globulins", "PROBLEM", 96, 122], ["an abnormal host response to infection", "PROBLEM", 137, 175], ["hepatitis", "OBSERVATION", 5, 14], ["glomerulonephritis", "OBSERVATION", 55, 73], ["cryo globulins", "OBSERVATION", 108, 122], ["abnormal", "OBSERVATION_MODIFIER", 140, 148], ["host response", "OBSERVATION", 149, 162], ["infection", "OBSERVATION", 166, 175]]], ["Cryoglobulins are either type II or type III.", [["Cryoglobulins", "GENE_OR_GENE_PRODUCT", 0, 13], ["type II or type III", "GENE_OR_GENE_PRODUCT", 25, 44], ["Cryoglobulins", "TREATMENT", 0, 13], ["type II or type III", "PROBLEM", 25, 44], ["type II", "OBSERVATION_MODIFIER", 25, 32]]], ["At least two classes of immuno globulins are involved, one of which is polyclonal.", [["immuno globulins", "GENE_OR_GENE_PRODUCT", 24, 40], ["immuno globulins", "PROTEIN", 24, 40], ["immuno globulins", "TREATMENT", 24, 40], ["classes", "OBSERVATION_MODIFIER", 13, 20], ["immuno globulins", "OBSERVATION", 24, 40], ["polyclonal", "OBSERVATION", 71, 81]]], ["7 In acute renal failure associated with infection by hantavirus or severe acute respiratory syndrome coronavirus, the pathogenetic mechanisms of interstitial nephritis, disseminated intravascular coagulopathy, and multiorgan failure-rather than formation of immune complexes-are predominant.VIRUSES AND MECHANISMS INVOLVED IN VIRAL NEPHROPATHYBox 2 lists the viruses that are known to induce renal diseases.", [["renal", "ANATOMY", 11, 16], ["interstitial", "ANATOMY", 146, 158], ["intravascular", "ANATOMY", 183, 196], ["multiorgan", "ANATOMY", 215, 225], ["renal", "ANATOMY", 393, 398], ["acute renal failure", "DISEASE", 5, 24], ["infection", "DISEASE", 41, 50], ["hantavirus", "DISEASE", 54, 64], ["acute respiratory syndrome coronavirus", "DISEASE", 75, 113], ["interstitial nephritis", "DISEASE", 146, 168], ["intravascular coagulopathy", "DISEASE", 183, 209], ["multiorgan failure", "DISEASE", 215, 233], ["renal diseases", "DISEASE", 393, 407], ["renal", "ORGAN", 11, 16], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 183, 196], ["renal", "ORGAN", 393, 398], ["immune complexes", "PROTEIN", 259, 275], ["severe acute respiratory syndrome coronavirus", "SPECIES", 68, 113], ["acute renal failure", "PROBLEM", 5, 24], ["infection", "PROBLEM", 41, 50], ["hantavirus", "PROBLEM", 54, 64], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 68, 113], ["interstitial nephritis", "PROBLEM", 146, 168], ["disseminated intravascular coagulopathy", "PROBLEM", 170, 209], ["multiorgan failure", "PROBLEM", 215, 233], ["immune complexes", "PROBLEM", 259, 275], ["the viruses", "PROBLEM", 356, 367], ["renal diseases", "PROBLEM", 393, 407], ["acute", "OBSERVATION_MODIFIER", 5, 10], ["renal", "ANATOMY", 11, 16], ["failure", "OBSERVATION", 17, 24], ["infection", "OBSERVATION", 41, 50], ["hantavirus", "OBSERVATION", 54, 64], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["respiratory syndrome coronavirus", "OBSERVATION", 81, 113], ["interstitial", "ANATOMY_MODIFIER", 146, 158], ["nephritis", "OBSERVATION", 159, 168], ["disseminated", "OBSERVATION_MODIFIER", 170, 182], ["intravascular coagulopathy", "OBSERVATION", 183, 209], ["multiorgan failure", "OBSERVATION", 215, 233], ["immune complexes", "OBSERVATION", 259, 275], ["predominant", "OBSERVATION_MODIFIER", 280, 291], ["renal", "ANATOMY", 393, 398], ["diseases", "OBSERVATION", 399, 407]]], ["Globally, the most frequent and well recognized virus-related glomerulonephropathies are those associated with hepatitis B virus (HBV), in which formation of immune complexes is important.", [["glomerulonephropathies", "DISEASE", 62, 84], ["hepatitis B", "DISEASE", 111, 122], ["glomerulonephropathies", "CANCER", 62, 84], ["hepatitis B virus", "ORGANISM", 111, 128], ["HBV", "ORGANISM", 130, 133], ["immune complexes", "PROTEIN", 158, 174], ["hepatitis B virus", "SPECIES", 111, 128], ["hepatitis B virus", "SPECIES", 111, 128], ["HBV", "SPECIES", 130, 133], ["related glomerulonephropathies", "PROBLEM", 54, 84], ["hepatitis B virus", "PROBLEM", 111, 128], ["HBV", "PROBLEM", 130, 133], ["immune complexes", "PROBLEM", 158, 174], ["most frequent", "OBSERVATION_MODIFIER", 14, 27], ["virus", "OBSERVATION", 48, 53], ["hepatitis", "OBSERVATION", 111, 120], ["immune complexes", "OBSERVATION", 158, 174]]], ["HCV is the etiological agent of cryoglobulinemiarelated MCGN in most cases.", [["MCGN", "DISEASE", 56, 60], ["HCV", "ORGANISM", 0, 3], ["MCGN", "CANCER", 56, 60], ["HCV", "SPECIES", 0, 3], ["HCV", "PROBLEM", 0, 3]]], ["Infection with HIV can induce a broad spectrum of glomerular lesions via multiple pathogenic mechanisms.", [["glomerular lesions", "ANATOMY", 50, 68], ["HIV", "DISEASE", 15, 18], ["HIV", "ORGANISM", 15, 18], ["glomerular lesions", "PATHOLOGICAL_FORMATION", 50, 68], ["HIV", "SPECIES", 15, 18], ["HIV", "SPECIES", 15, 18], ["Infection", "PROBLEM", 0, 9], ["HIV", "PROBLEM", 15, 18], ["glomerular lesions", "PROBLEM", 50, 68], ["multiple pathogenic mechanisms", "PROBLEM", 73, 103], ["broad", "OBSERVATION_MODIFIER", 32, 37], ["glomerular", "ANATOMY", 50, 60], ["lesions", "OBSERVATION", 61, 68], ["multiple", "OBSERVATION_MODIFIER", 73, 81], ["pathogenic", "OBSERVATION", 82, 92]]], ["Parvovirus B19 (PVB19) is associated with non-HIV collapsing glomerulopathy, 8 idiopathic focal segmental glomerulosclerosis (FSGS), 9 and immune complex glomerulonephritis.", [["Parvovirus B19", "DISEASE", 0, 14], ["glomerulopathy", "DISEASE", 61, 75], ["focal segmental glomerulosclerosis", "DISEASE", 90, 124], ["FSGS", "DISEASE", 126, 130], ["glomerulonephritis", "DISEASE", 154, 172], ["Parvovirus B19", "ORGANISM", 0, 14], ["PVB19", "ORGANISM", 16, 21], ["Parvovirus B19", "SPECIES", 0, 14], ["Parvovirus B19", "SPECIES", 0, 14], ["PVB19", "SPECIES", 16, 21], ["Parvovirus B19", "TEST", 0, 14], ["non-HIV collapsing glomerulopathy", "PROBLEM", 42, 75], ["8 idiopathic focal segmental glomerulosclerosis (FSGS)", "PROBLEM", 77, 131], ["immune complex glomerulonephritis", "PROBLEM", 139, 172], ["associated with", "UNCERTAINTY", 26, 41], ["non-HIV", "OBSERVATION_MODIFIER", 42, 49], ["collapsing", "OBSERVATION_MODIFIER", 50, 60], ["glomerulopathy", "OBSERVATION", 61, 75], ["idiopathic", "OBSERVATION_MODIFIER", 79, 89], ["focal", "OBSERVATION_MODIFIER", 90, 95], ["segmental", "OBSERVATION_MODIFIER", 96, 105], ["glomerulosclerosis", "OBSERVATION", 106, 124], ["FSGS", "OBSERVATION", 126, 130], ["complex", "OBSERVATION_MODIFIER", 146, 153], ["glomerulonephritis", "OBSERVATION", 154, 172]]], ["10 Polyoma BK virus and hantavirus most frequently cause tubulointerstitial damage; occasionally, virus is simultaneously localized to the glomerulus.", [["tubulointerstitial", "ANATOMY", 57, 75], ["glomerulus", "ANATOMY", 139, 149], ["hantavirus", "DISEASE", 24, 34], ["tubulointerstitial damage", "DISEASE", 57, 82], ["10", "ORGANISM", 0, 2], ["Polyoma BK virus", "ORGANISM", 3, 19], ["hantavirus", "ORGANISM", 24, 34], ["tubulointerstitial", "PATHOLOGICAL_FORMATION", 57, 75], ["glomerulus", "TISSUE", 139, 149], ["Polyoma BK virus", "SPECIES", 3, 19], ["Polyoma BK virus", "SPECIES", 3, 19], ["Polyoma BK virus", "PROBLEM", 3, 19], ["hantavirus", "PROBLEM", 24, 34], ["tubulointerstitial damage", "PROBLEM", 57, 82], ["virus", "PROBLEM", 98, 103], ["Polyoma BK virus", "OBSERVATION", 3, 19], ["hantavirus", "OBSERVATION", 24, 34], ["tubulointerstitial", "OBSERVATION_MODIFIER", 57, 75], ["damage", "OBSERVATION", 76, 82], ["virus", "OBSERVATION", 98, 103], ["glomerulus", "ANATOMY", 139, 149]]], ["A rare or speculative role in glomerulonephritides is currently attributed to other viruses, such as those causing yellow fever, 11 mumps, 12 measles, 13 varicella, 14 and herpes.", [["glomerulonephritides", "DISEASE", 30, 50], ["yellow fever", "DISEASE", 115, 127], ["mumps", "DISEASE", 132, 137], ["measles", "DISEASE", 142, 149], ["varicella", "DISEASE", 154, 163], ["herpes", "DISEASE", 172, 178], ["glomerulonephritides", "CANCER", 30, 50], ["herpes", "ORGANISM", 172, 178], ["A rare or speculative role in glomerulonephritides", "PROBLEM", 0, 50], ["other viruses", "PROBLEM", 78, 91], ["yellow fever", "PROBLEM", 115, 127], ["11 mumps", "PROBLEM", 129, 137], ["12 measles", "PROBLEM", 139, 149], ["varicella", "TEST", 154, 163], ["herpes", "PROBLEM", 172, 178], ["rare", "OBSERVATION_MODIFIER", 2, 6], ["viruses", "OBSERVATION", 84, 91]]], ["15GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS B VIRUSHBV is a hepatotropic, double-stranded DNA virus of the Hepadnaviridae family.", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["Hepadnaviridae", "GENE_OR_GENE_PRODUCT", 110, 124], ["GLOMERULONEPHRITIS", "PROBLEM", 2, 20], ["HEPATITIS B VIRUSHBV", "PROBLEM", 37, 57], ["a hepatotropic", "PROBLEM", 61, 75], ["GLOMERULONEPHRITIS", "OBSERVATION", 2, 20], ["HEPATITIS", "OBSERVATION", 37, 46], ["hepatotropic", "OBSERVATION_MODIFIER", 63, 75]]], ["HBV itself is not cytopathic; hepatitis develops as a result of the host's immune reaction to infected hepatocytes.", [["hepatocytes", "ANATOMY", 103, 114], ["hepatitis", "DISEASE", 30, 39], ["HBV", "ORGANISM", 0, 3], ["hepatocytes", "CELL", 103, 114], ["infected hepatocytes", "CELL_TYPE", 94, 114], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["cytopathic", "PROBLEM", 18, 28], ["hepatitis", "PROBLEM", 30, 39], ["the host's immune reaction", "PROBLEM", 64, 90], ["infected hepatocytes", "PROBLEM", 94, 114], ["not", "UNCERTAINTY", 14, 17], ["cytopathic", "OBSERVATION_MODIFIER", 18, 28], ["hepatitis", "OBSERVATION", 30, 39], ["infected", "OBSERVATION", 94, 102], ["hepatocytes", "ANATOMY", 103, 114]]], ["HBV uses reverse transcriptase to transcribe RNA into DNA.", [["HBV", "ORGANISM", 0, 3], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["reverse transcriptase", "PROTEIN", 9, 30], ["HBV", "SPECIES", 0, 3], ["HBV", "PROBLEM", 0, 3], ["reverse transcriptase", "TREATMENT", 9, 30]]], ["Unlike retroviruses, however, HBV DNA is not integrated into host cell DNA during replication.", [["cell", "ANATOMY", 66, 70], ["retroviruses", "ORGANISM", 7, 19], ["HBV", "ORGANISM", 30, 33], ["DNA", "CELLULAR_COMPONENT", 34, 37], ["host cell", "CELL", 61, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["HBV DNA", "DNA", 30, 37], ["host cell DNA", "DNA", 61, 74], ["HBV", "SPECIES", 30, 33], ["Unlike retroviruses", "PROBLEM", 0, 19], ["HBV DNA", "PROBLEM", 30, 37], ["retroviruses", "OBSERVATION", 7, 19], ["host cell DNA", "OBSERVATION", 61, 74]]], ["After an HBV particle binds to and enters a hepatocyte, HBV DNA enters the cell's nucleus and is converted into covalently closed circular DNA.", [["hepatocyte", "ANATOMY", 44, 54], ["cell", "ANATOMY", 75, 79], ["nucleus", "ANATOMY", 82, 89], ["HBV", "ORGANISM", 9, 12], ["hepatocyte", "CELL", 44, 54], ["HBV", "ORGANISM", 56, 59], ["DNA", "CELLULAR_COMPONENT", 60, 63], ["cell", "CELL", 75, 79], ["nucleus", "CELLULAR_COMPONENT", 82, 89], ["DNA", "CELLULAR_COMPONENT", 139, 142], ["HBV DNA", "DNA", 56, 63], ["covalently closed circular DNA", "DNA", 112, 142], ["HBV", "SPECIES", 9, 12], ["HBV", "SPECIES", 56, 59], ["an HBV particle binds", "PROBLEM", 6, 27], ["a hepatocyte", "TEST", 42, 54], ["HBV DNA", "PROBLEM", 56, 63], ["HBV", "OBSERVATION", 9, 12], ["hepatocyte", "ANATOMY", 44, 54], ["HBV", "OBSERVATION", 56, 59], ["covalently closed", "OBSERVATION", 112, 129], ["circular DNA", "OBSERVATION", 130, 142]]], ["This highly stable genetic material acts as the intermediate template for transcription of RNA copies.", [["RNA copies", "RNA", 91, 101], ["stable", "OBSERVATION_MODIFIER", 12, 18]]], ["This pregenomic messenger RNA is transported to the cytoplasm.", [["cytoplasm", "ANATOMY", 52, 61], ["cytoplasm", "ORGANISM_SUBSTANCE", 52, 61], ["pregenomic messenger RNA", "RNA", 5, 29], ["This pregenomic messenger RNA", "PROBLEM", 0, 29], ["messenger RNA", "OBSERVATION", 16, 29]]], ["It has dual functions: acting as a template for synthesis of new HBV DNA, and carrying genetic information to direct synthesis of viral proteins.GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS B VIRUSToday, an estimated 350-400 million people worldwide are infected with HBV.", [["HBV", "ORGANISM", 65, 68], ["DNA", "CELLULAR_COMPONENT", 69, 72], ["people", "ORGANISM", 233, 239], ["HBV", "ORGANISM", 268, 271], ["HBV DNA", "DNA", 65, 72], ["viral proteins", "PROTEIN", 130, 144], ["people", "SPECIES", 233, 239], ["HBV", "SPECIES", 65, 68], ["HBV", "SPECIES", 268, 271], ["new HBV DNA", "PROBLEM", 61, 72], ["viral proteins", "PROBLEM", 130, 144], ["GLOMERULONEPHRITIS", "PROBLEM", 145, 163], ["HEPATITIS B VIRUSToday", "PROBLEM", 180, 202], ["HBV", "PROBLEM", 268, 271], ["HEPATITIS", "OBSERVATION", 180, 189], ["infected", "OBSERVATION", 254, 262], ["HBV", "OBSERVATION", 268, 271]]], ["In endemic areas, transmission is usually vertical-that is, from infected mother to child.", [["endemic", "OBSERVATION_MODIFIER", 3, 10], ["areas", "OBSERVATION_MODIFIER", 11, 16]]], ["Horizontal transmission occurs via direct contact with blood (e.g. during blood transfusions) or mucous membranes (e.g. during sexual contact), or via the percutaneous route upon contact with blood or body fluids (e.g. during intravenous drug use and needle sharing).", [["blood", "ANATOMY", 55, 60], ["blood", "ANATOMY", 74, 79], ["mucous membranes", "ANATOMY", 97, 113], ["percutaneous", "ANATOMY", 155, 167], ["blood", "ANATOMY", 192, 197], ["body", "ANATOMY", 201, 205], ["intravenous", "ANATOMY", 226, 237], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 74, 79], ["mucous membranes", "CELLULAR_COMPONENT", 97, 113], ["blood", "ORGANISM_SUBSTANCE", 192, 197], ["body", "ORGANISM_SUBDIVISION", 201, 205], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 226, 237], ["blood transfusions", "TREATMENT", 74, 92], ["mucous membranes", "PROBLEM", 97, 113], ["blood or body fluids", "TREATMENT", 192, 212], ["intravenous drug use", "TREATMENT", 226, 246], ["mucous membranes", "ANATOMY", 97, 113]]], ["Familial clustering of the virus occurs in some regions.GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS B VIRUSThe reported prevalence of HBV-associated nephropathy closely parallels the geographic patterns of prevalence of HBV.", [["nephropathy", "DISEASE", 150, 161], ["HBV", "ORGANISM", 135, 138], ["HBV", "ORGANISM", 221, 224], ["HBV", "SPECIES", 135, 138], ["HBV", "SPECIES", 221, 224], ["the virus", "PROBLEM", 23, 32], ["GLOMERULONEPHRITIS", "PROBLEM", 56, 74], ["HEPATITIS B VIRUSThe", "PROBLEM", 91, 111], ["HBV", "PROBLEM", 135, 138], ["associated nephropathy", "PROBLEM", 139, 161], ["HBV", "PROBLEM", 221, 224], ["virus", "OBSERVATION", 27, 32], ["HEPATITIS", "OBSERVATION", 91, 100], ["HBV", "OBSERVATION", 135, 138], ["nephropathy", "OBSERVATION", 150, 161], ["HBV", "OBSERVATION", 221, 224]]], ["16 frequently reported in Asian populations 17 and in children, 18 particularly male children.", [["children", "ORGANISM", 54, 62], ["children", "ORGANISM", 85, 93], ["children", "SPECIES", 54, 62], ["children", "SPECIES", 85, 93]]], ["16 By contrast, mesangial proliferative forms with IgA deposits seem to be most common in adults.", [["mesangial", "ANATOMY", 16, 25], ["mesangial", "CELL", 16, 25], ["IgA", "GENE_OR_GENE_PRODUCT", 51, 54], ["IgA", "PROTEIN", 51, 54], ["IgA deposits", "PROBLEM", 51, 63], ["mesangial proliferative", "OBSERVATION", 16, 39], ["IgA deposits", "OBSERVATION", 51, 63]]], ["19 Three types of glomerulonephritis with pathologic characteristics similar to the human subtypes have been described in woodchucks chronically infected with hepatitis virus.", [["glomerulonephritis", "DISEASE", 18, 36], ["woodchucks chronically infected with hepatitis virus", "DISEASE", 122, 174], ["human", "ORGANISM", 84, 89], ["woodchucks chronically", "ORGANISM", 122, 144], ["hepatitis virus", "ORGANISM", 159, 174], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["hepatitis virus", "SPECIES", 159, 174], ["glomerulonephritis", "PROBLEM", 18, 36], ["pathologic characteristics", "PROBLEM", 42, 68], ["hepatitis virus", "PROBLEM", 159, 174], ["glomerulonephritis", "OBSERVATION", 18, 36], ["pathologic", "OBSERVATION", 42, 52], ["hepatitis virus", "OBSERVATION", 159, 174]]], ["20 As in humans, the membranous pattern of injury most frequently affects young woodchucks, whereas the mesangial proliferative pattern of injury tends to affect older animals.", [["woodchucks", "ANATOMY", 80, 90], ["mesangial", "ANATOMY", 104, 113], ["humans", "ORGANISM", 9, 15], ["woodchucks", "CANCER", 80, 90], ["mesangial", "CELL", 104, 113], ["humans", "SPECIES", 9, 15], ["humans", "SPECIES", 9, 15], ["injury", "PROBLEM", 43, 49], ["injury", "PROBLEM", 139, 145], ["membranous", "OBSERVATION", 21, 31], ["injury", "OBSERVATION", 43, 49], ["mesangial proliferative", "OBSERVATION", 104, 127], ["injury", "OBSERVATION", 139, 145]]], ["The male : female ratio of affected woodchucks was significantly greater than that of the chronic carrier population.", [["woodchucks", "ANATOMY", 36, 46], ["female", "ORGANISM", 11, 17], ["woodchucks", "ORGANISM", 36, 46], ["affected woodchucks", "PROBLEM", 27, 46], ["the chronic carrier population", "PROBLEM", 86, 116], ["chronic", "OBSERVATION_MODIFIER", 90, 97]]], ["20Diagnosis and monitoringIn most reports, diagnosis of HBV-asso ciated glomerulonephritis has been based on persistence of circulating HBV or HBV DNA, absence of other causative agents, and presence of HBVspecific antigen(s) or viral genome in the glomerulus.", [["glomerulus", "ANATOMY", 249, 259], ["glomerulonephritis", "DISEASE", 72, 90], ["HBV", "ORGANISM", 56, 59], ["HBV", "ORGANISM", 136, 139], ["HBV", "ORGANISM", 143, 146], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["HBVspecific antigen", "GENE_OR_GENE_PRODUCT", 203, 222], ["glomerulus", "MULTI-TISSUE_STRUCTURE", 249, 259], ["HBVspecific antigen", "PROTEIN", 203, 222], ["viral genome", "DNA", 229, 241], ["HBV", "SPECIES", 56, 59], ["HBV", "SPECIES", 136, 139], ["HBV", "SPECIES", 143, 146], ["monitoring", "TEST", 16, 26], ["HBV", "PROBLEM", 56, 59], ["asso ciated glomerulonephritis", "PROBLEM", 60, 90], ["circulating HBV", "PROBLEM", 124, 139], ["HBV DNA", "PROBLEM", 143, 150], ["HBVspecific antigen", "PROBLEM", 203, 222], ["viral genome in the glomerulus", "PROBLEM", 229, 259], ["HBV", "OBSERVATION", 56, 59], ["glomerulonephritis", "OBSERVATION", 72, 90], ["HBV", "OBSERVATION", 136, 139], ["HBV", "OBSERVATION", 143, 146], ["viral genome", "OBSERVATION", 229, 241], ["glomerulus", "ANATOMY", 249, 259]]], ["One major difference between the human and woodchuck studies is that the hepatitis B e antigen (HBeAg) system has not been characterized in the latter.", [["hepatitis B e antigen", "CHEMICAL", 73, 94], ["HBeAg", "CHEMICAL", 96, 101], ["human", "ORGANISM", 33, 38], ["woodchuck", "ORGANISM", 43, 52], ["hepatitis B e antigen", "GENE_OR_GENE_PRODUCT", 73, 94], ["HBeAg", "GENE_OR_GENE_PRODUCT", 96, 101], ["HBeAg", "PROTEIN", 96, 101], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["the human and woodchuck studies", "TEST", 29, 60], ["the hepatitis B e antigen (HBeAg) system", "TEST", 69, 109], ["major", "OBSERVATION_MODIFIER", 4, 9], ["difference", "OBSERVATION_MODIFIER", 10, 20]]], ["In clinical practice, regression of pathology following viral eradication is not easy to demonstrate because of ethical concerns relating to repeat renal biopsies in humans subsequent to clinical remission.", [["renal", "ANATOMY", 148, 153], ["renal biopsies", "MULTI-TISSUE_STRUCTURE", 148, 162], ["humans", "ORGANISM", 166, 172], ["humans", "SPECIES", 166, 172], ["humans", "SPECIES", 166, 172], ["pathology", "PROBLEM", 36, 45], ["viral eradication", "TREATMENT", 56, 73], ["ethical concerns", "PROBLEM", 112, 128], ["repeat renal biopsies", "TEST", 141, 162], ["renal", "ANATOMY", 148, 153], ["biopsies", "OBSERVATION", 154, 162]]], ["As such, the diagnosis of HBV-associated renal disease usually relies heavily upon detection of HBV-specific antigen(s) in glomeruli.Diagnosis and monitoringLaboratory testing for diagnosis and assessment of response to treatment should include standard liver biochemistries (serum alanine aminotransferase, \u03b3-glutamyltransferase, and bilirubin levels), and HBV serologies (hepatitis B surface antigen, HBeAg, anti-hepatitis B e, and anti-hepatitis B core antigen antibodies).", [["renal", "ANATOMY", 41, 46], ["glomeruli", "ANATOMY", 123, 132], ["liver", "ANATOMY", 254, 259], ["serum", "ANATOMY", 276, 281], ["renal disease", "DISEASE", 41, 54], ["alanine", "CHEMICAL", 282, 289], ["bilirubin", "CHEMICAL", 335, 344], ["hepatitis B surface antigen", "CHEMICAL", 374, 401], ["HBeAg", "CHEMICAL", 403, 408], ["alanine", "CHEMICAL", 282, 289], ["bilirubin", "CHEMICAL", 335, 344], ["HBV", "ORGANISM", 26, 29], ["renal", "ORGAN", 41, 46], ["HBV", "ORGANISM", 96, 99], ["-specific antigen", "GENE_OR_GENE_PRODUCT", 99, 116], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 123, 132], ["liver", "ORGAN", 254, 259], ["serum", "ORGANISM_SUBSTANCE", 276, 281], ["alanine aminotransferase", "GENE_OR_GENE_PRODUCT", 282, 306], ["\u03b3-glutamyltransferase", "SIMPLE_CHEMICAL", 308, 329], ["bilirubin", "GENE_OR_GENE_PRODUCT", 335, 344], ["HBV", "ORGANISM", 358, 361], ["hepatitis B surface antigen", "GENE_OR_GENE_PRODUCT", 374, 401], ["HBeAg", "GENE_OR_GENE_PRODUCT", 403, 408], ["anti-hepatitis B e", "ORGANISM", 410, 428], ["anti-hepatitis B core antigen antibodies", "GENE_OR_GENE_PRODUCT", 434, 474], ["serum alanine aminotransferase", "PROTEIN", 276, 306], ["\u03b3-glutamyltransferase", "PROTEIN", 308, 329], ["bilirubin", "PROTEIN", 335, 344], ["HBV serologies", "PROTEIN", 358, 372], ["hepatitis B surface antigen", "PROTEIN", 374, 401], ["HBeAg", "PROTEIN", 403, 408], ["anti-hepatitis B e", "PROTEIN", 410, 428], ["anti-hepatitis B core antigen antibodies", "PROTEIN", 434, 474], ["HBV", "SPECIES", 26, 29], ["HBV", "SPECIES", 96, 99], ["HBV", "SPECIES", 358, 361], ["HBV", "PROBLEM", 26, 29], ["renal disease", "PROBLEM", 41, 54], ["HBV", "PROBLEM", 96, 99], ["Laboratory testing", "TEST", 157, 175], ["assessment", "TEST", 194, 204], ["treatment", "TREATMENT", 220, 229], ["standard liver biochemistries", "TEST", 245, 274], ["serum alanine aminotransferase", "TEST", 276, 306], ["\u03b3-glutamyltransferase", "TEST", 308, 329], ["bilirubin levels", "TEST", 335, 351], ["HBV serologies", "TEST", 358, 372], ["hepatitis B surface antigen", "TEST", 374, 401], ["HBeAg", "TEST", 403, 408], ["anti-hepatitis B e", "TEST", 410, 428], ["anti-hepatitis B core antigen antibodies", "TEST", 434, 474], ["HBV", "OBSERVATION", 26, 29], ["renal", "ANATOMY", 41, 46], ["disease", "OBSERVATION", 47, 54], ["glomeruli", "ANATOMY", 123, 132], ["liver", "ANATOMY", 254, 259]]], ["HBeAg is present in 80% of patients, who might also have high titers of anti-hepatitis B core antigen.", [["HBeAg", "CHEMICAL", 0, 5], ["anti-hepatitis B core antigen", "CHEMICAL", 72, 101], ["HBeAg", "GENE_OR_GENE_PRODUCT", 0, 5], ["patients", "ORGANISM", 27, 35], ["anti-hepatitis B core antigen", "GENE_OR_GENE_PRODUCT", 72, 101], ["anti-hepatitis B core antigen", "PROTEIN", 72, 101], ["patients", "SPECIES", 27, 35], ["HBeAg", "TEST", 0, 5], ["anti-hepatitis B core antigen", "TREATMENT", 72, 101]]], ["21 Subjects with biochemical hepatitis should be tested for circulating HBV DNA 22 and undergo liver biopsy.", [["liver", "ANATOMY", 95, 100], ["biochemical hepatitis", "DISEASE", 17, 38], ["HBV", "ORGANISM", 72, 75], ["liver biopsy", "MULTI-TISSUE_STRUCTURE", 95, 107], ["HBV", "SPECIES", 72, 75], ["biochemical hepatitis", "PROBLEM", 17, 38], ["circulating HBV DNA", "TEST", 60, 79], ["liver biopsy", "TEST", 95, 107], ["hepatitis", "OBSERVATION", 29, 38], ["liver", "ANATOMY", 95, 100], ["biopsy", "OBSERVATION", 101, 107]]], ["An \u03b1-fetoprotein assay could be an important adjunct.", [["An \u03b1-fetoprotein assay", "TEST", 0, 22]]], ["23 Serum C3 and C4 levels can be low in 20-50% of patients.Clinical characteristicsHBV-related membranous nephropathy tends to manifest slightly differently in pediatric and adult patients.", [["Serum", "ANATOMY", 3, 8], ["membranous nephropathy", "DISEASE", 95, 117], ["Serum C3", "GENE_OR_GENE_PRODUCT", 3, 11], ["C4", "GENE_OR_GENE_PRODUCT", 16, 18], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 180, 188], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 180, 188], ["Serum C3 and C4 levels", "TEST", 3, 25], ["Clinical characteristicsHBV", "PROBLEM", 59, 86], ["membranous nephropathy", "PROBLEM", 95, 117], ["C4", "ANATOMY_MODIFIER", 16, 18], ["low", "OBSERVATION_MODIFIER", 33, 36], ["membranous", "OBSERVATION_MODIFIER", 95, 105], ["nephropathy", "OBSERVATION", 106, 117]]], ["In children, there is a strong male preponderance, and the most frequent presentation is nephrotic syndrome, microscopic hematuria, and normal or mildly impaired renal function.", [["renal", "ANATOMY", 162, 167], ["nephrotic syndrome", "DISEASE", 89, 107], ["hematuria", "DISEASE", 121, 130], ["impaired renal function", "DISEASE", 153, 176], ["children", "ORGANISM", 3, 11], ["renal", "ORGAN", 162, 167], ["children", "SPECIES", 3, 11], ["nephrotic syndrome", "PROBLEM", 89, 107], ["microscopic hematuria", "PROBLEM", 109, 130], ["mildly impaired renal function", "PROBLEM", 146, 176], ["nephrotic syndrome", "OBSERVATION", 89, 107], ["hematuria", "OBSERVATION", 121, 130], ["normal", "OBSERVATION", 136, 142], ["mildly", "OBSERVATION_MODIFIER", 146, 152], ["impaired", "OBSERVATION", 153, 161], ["renal", "ANATOMY", 162, 167], ["function", "OBSERVATION", 168, 176]]], ["24 Pediatric chronic HBV carriers often do not have overt liver disease, and transaminase levels are usually normal.", [["liver", "ANATOMY", 58, 63], ["liver disease", "DISEASE", 58, 71], ["HBV", "ORGANISM", 21, 24], ["liver", "ORGAN", 58, 63], ["transaminase", "SIMPLE_CHEMICAL", 77, 89], ["HBV", "SPECIES", 21, 24], ["Pediatric chronic HBV carriers", "PROBLEM", 3, 33], ["overt liver disease", "PROBLEM", 52, 71], ["transaminase levels", "TEST", 77, 96], ["chronic", "OBSERVATION_MODIFIER", 13, 20], ["HBV", "OBSERVATION", 21, 24], ["liver", "ANATOMY", 58, 63], ["disease", "OBSERVATION", 64, 71], ["transaminase", "ANATOMY", 77, 89], ["normal", "OBSERVATION", 109, 115]]], ["In adults, proteinuria or the nephrotic syndrome are the most common manifestations.", [["proteinuria", "DISEASE", 11, 22], ["nephrotic syndrome", "DISEASE", 30, 48], ["proteinuria", "PROBLEM", 11, 22], ["the nephrotic syndrome", "PROBLEM", 26, 48], ["proteinuria", "OBSERVATION", 11, 22], ["nephrotic syndrome", "OBSERVATION", 30, 48], ["most common", "OBSERVATION_MODIFIER", 57, 68]]], ["Adult male predominance is less obvious than in pediatric populations.", [["male", "OBSERVATION_MODIFIER", 6, 10], ["predominance", "OBSERVATION", 11, 23], ["less obvious", "OBSERVATION_MODIFIER", 27, 39]]], ["Adults are more likely than children to have hypertension, renal dysfunction, and clinical evidence of liver disease.Clinical characteristicsThe prognosis of HBV-associated membranous nephropathy in children is favorable.", [["renal", "ANATOMY", 59, 64], ["liver", "ANATOMY", 103, 108], ["membranous", "ANATOMY", 173, 183], ["hypertension", "DISEASE", 45, 57], ["renal dysfunction", "DISEASE", 59, 76], ["liver disease", "DISEASE", 103, 116], ["membranous nephropathy", "DISEASE", 173, 195], ["Adults", "ORGANISM", 0, 6], ["children", "ORGANISM", 28, 36], ["renal", "ORGAN", 59, 64], ["liver", "ORGAN", 103, 108], ["HBV", "ORGANISM", 158, 161], ["children", "ORGANISM", 199, 207], ["Adults", "SPECIES", 0, 6], ["children", "SPECIES", 28, 36], ["children", "SPECIES", 199, 207], ["HBV", "SPECIES", 158, 161], ["hypertension", "PROBLEM", 45, 57], ["renal dysfunction", "PROBLEM", 59, 76], ["liver disease", "PROBLEM", 103, 116], ["HBV", "PROBLEM", 158, 161], ["membranous nephropathy", "PROBLEM", 173, 195], ["more likely", "UNCERTAINTY", 11, 22], ["hypertension", "OBSERVATION", 45, 57], ["renal", "ANATOMY", 59, 64], ["dysfunction", "OBSERVATION", 65, 76], ["liver", "ANATOMY", 103, 108], ["disease", "OBSERVATION", 109, 116], ["HBV", "OBSERVATION", 158, 161], ["membranous", "OBSERVATION_MODIFIER", 173, 183], ["nephropathy", "OBSERVATION", 184, 195], ["favorable", "OBSERVATION_MODIFIER", 211, 220]]], ["Stable renal function and high rates of spontaneous remission have been reported in several geographical areas in which disease prevalence is high.", [["renal", "ANATOMY", 7, 12], ["renal", "ORGAN", 7, 12], ["spontaneous remission", "PROBLEM", 40, 61], ["renal", "ANATOMY", 7, 12], ["function", "OBSERVATION", 13, 21], ["high", "OBSERVATION_MODIFIER", 26, 30], ["rates", "OBSERVATION_MODIFIER", 31, 36], ["spontaneous remission", "OBSERVATION", 40, 61], ["several", "OBSERVATION_MODIFIER", 84, 91], ["geographical", "OBSERVATION_MODIFIER", 92, 104], ["areas", "OBSERVATION_MODIFIER", 105, 110], ["disease", "OBSERVATION", 120, 127], ["high", "OBSERVATION_MODIFIER", 142, 146]]], ["By contrast, adults with HBVassociated membranous nephro pathy typically develop progressive disease.", [["HBVassociated membranous nephro pathy", "PROBLEM", 25, 62], ["progressive disease", "PROBLEM", 81, 100], ["membranous", "OBSERVATION_MODIFIER", 39, 49], ["nephro", "OBSERVATION", 50, 56], ["progressive", "OBSERVATION_MODIFIER", 81, 92], ["disease", "OBSERVATION", 93, 100]]], ["In Hong Kong, up to 29% of patients had progressive renal failure, and another 10% developed terminal uremia over 5 years.", [["renal", "ANATOMY", 52, 57], ["renal failure", "DISEASE", 52, 65], ["uremia", "DISEASE", 102, 108], ["patients", "ORGANISM", 27, 35], ["renal", "ORGAN", 52, 57], ["patients", "SPECIES", 27, 35], ["progressive renal failure", "PROBLEM", 40, 65], ["terminal uremia", "PROBLEM", 93, 108], ["progressive", "OBSERVATION_MODIFIER", 40, 51], ["renal", "ANATOMY", 52, 57], ["failure", "OBSERVATION", 58, 65], ["terminal", "OBSERVATION_MODIFIER", 93, 101], ["uremia", "OBSERVATION", 102, 108]]], ["21 The prognosis is even worse for patients with nephrotic-range proteinuria and abnormal liver function tests at presentation.", [["liver", "ANATOMY", 90, 95], ["nephrotic", "DISEASE", 49, 58], ["proteinuria", "DISEASE", 65, 76], ["abnormal liver function", "DISEASE", 81, 104], ["patients", "ORGANISM", 35, 43], ["liver", "ORGAN", 90, 95], ["patients", "SPECIES", 35, 43], ["nephrotic-range proteinuria", "PROBLEM", 49, 76], ["abnormal liver function tests", "PROBLEM", 81, 110], ["proteinuria", "OBSERVATION", 65, 76], ["liver", "ANATOMY", 90, 95]]], ["Over 50% of these patients require renal replacement therapy within 3 years.", [["renal", "ANATOMY", 35, 40], ["patients", "ORGANISM", 18, 26], ["renal", "ORGAN", 35, 40], ["patients", "SPECIES", 18, 26], ["renal replacement therapy", "TREATMENT", 35, 60], ["renal", "ANATOMY", 35, 40], ["replacement", "OBSERVATION", 41, 52]]], ["25 Vertical transmission is associated with poorer outcomes than horizontal transmission, as is endemic versus sporadic infection.", [["infection", "DISEASE", 120, 129], ["sporadic infection", "PROBLEM", 111, 129], ["endemic", "OBSERVATION_MODIFIER", 96, 103], ["sporadic", "OBSERVATION_MODIFIER", 111, 119], ["infection", "OBSERVATION", 120, 129]]], ["21,26Clinical characteristicsBox 2 Viral infections that cause nephropathy.", [["Viral infections", "DISEASE", 35, 51], ["nephropathy", "DISEASE", 63, 74], ["Clinical characteristicsBox 2 Viral infections", "PROBLEM", 5, 51], ["nephropathy", "PROBLEM", 63, 74], ["Viral infections", "OBSERVATION", 35, 51], ["nephropathy", "OBSERVATION", 63, 74]]], ["As mentioned above, HBV infection can also cause MCGN (with or without cryoglobulinemia), mesangial proliferative glomerulonephritis, and IgAN.", [["mesangial", "ANATOMY", 90, 99], ["HBV infection", "DISEASE", 20, 33], ["MCGN", "DISEASE", 49, 53], ["cryoglobulinemia", "DISEASE", 71, 87], ["glomerulonephritis", "DISEASE", 114, 132], ["IgAN", "DISEASE", 138, 142], ["HBV", "ORGANISM", 20, 23], ["MCGN", "CANCER", 49, 53], ["HBV", "SPECIES", 20, 23], ["HBV infection", "PROBLEM", 20, 33], ["MCGN", "PROBLEM", 49, 53], ["cryoglobulinemia", "PROBLEM", 71, 87], ["mesangial proliferative glomerulonephritis", "PROBLEM", 90, 132], ["IgAN", "PROBLEM", 138, 142], ["infection", "OBSERVATION", 24, 33], ["mesangial", "ANATOMY", 90, 99], ["proliferative", "OBSERVATION_MODIFIER", 100, 113], ["glomerulonephritis", "OBSERVATION", 114, 132], ["IgAN", "OBSERVATION", 138, 142]]], ["19,27 Polyarteritis nodosa has been reported in some patients with HBV and might respond to treatment with corticosteroids and interferon-\u03b1.", [["Polyarteritis nodosa", "DISEASE", 6, 26], ["corticosteroids", "CHEMICAL", 107, 122], ["patients", "ORGANISM", 53, 61], ["HBV", "ORGANISM", 67, 70], ["corticosteroids", "SIMPLE_CHEMICAL", 107, 122], ["interferon", "PROTEIN", 127, 137], ["patients", "SPECIES", 53, 61], ["HBV", "SPECIES", 67, 70], ["Polyarteritis nodosa", "PROBLEM", 6, 26], ["HBV", "PROBLEM", 67, 70], ["treatment", "TREATMENT", 92, 101], ["corticosteroids", "TREATMENT", 107, 122], ["interferon", "TREATMENT", 127, 137], ["Polyarteritis", "OBSERVATION_MODIFIER", 6, 19], ["nodosa", "OBSERVATION", 20, 26]]], ["28 Occasional concomitance of the pathologic subtypes can lead to 'double' glomerulopathies.", [["glomerulopathies", "CANCER", 75, 91], ["the pathologic subtypes", "PROBLEM", 30, 53], ["'double' glomerulopathies", "PROBLEM", 66, 91], ["pathologic", "OBSERVATION", 34, 44], ["glomerulopathies", "OBSERVATION", 75, 91]]], ["For instance, membranous nephropathy and IgAN have been reported to coexist in an HBV carrier.", [["nephropathy", "DISEASE", 25, 36], ["IgAN", "DISEASE", 41, 45], ["IgAN", "GENE_OR_GENE_PRODUCT", 41, 45], ["HBV", "ORGANISM", 82, 85], ["HBV", "SPECIES", 82, 85], ["membranous nephropathy", "PROBLEM", 14, 36], ["IgAN", "PROBLEM", 41, 45], ["an HBV carrier", "PROBLEM", 79, 93], ["membranous", "OBSERVATION_MODIFIER", 14, 24], ["nephropathy", "OBSERVATION", 25, 36], ["IgAN", "OBSERVATION", 41, 45], ["HBV", "OBSERVATION", 82, 85]]], ["29TreatmentUnlike affected children, who have a high rate of spontaneous remission, 30 adults with HBVassociated membranous nephropathy typically develop progressive disease.", [["membranous nephropathy", "DISEASE", 113, 135], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["spontaneous remission", "PROBLEM", 61, 82], ["HBVassociated membranous nephropathy", "PROBLEM", 99, 135], ["progressive disease", "PROBLEM", 154, 173], ["membranous", "OBSERVATION_MODIFIER", 113, 123], ["nephropathy", "OBSERVATION", 124, 135], ["progressive", "OBSERVATION_MODIFIER", 154, 165], ["disease", "OBSERVATION", 166, 173]]], ["21 Various management strategies have been tried, but an ideal agent is yet to be found.", [["Various management strategies", "TREATMENT", 3, 32]]], ["Treatment for HBVassociated renal disease should ideally achieve the following objectives: (i) amelioration of nephrotic syndrome and its complications; (ii) preservation of renal function; (iii) normalization of liver function and prevention of hepatic complications of HBV; and (iv) permanent eradication of HBV.", [["renal", "ANATOMY", 28, 33], ["renal", "ANATOMY", 174, 179], ["liver", "ANATOMY", 213, 218], ["hepatic", "ANATOMY", 246, 253], ["HBVassociated renal disease", "DISEASE", 14, 41], ["nephrotic syndrome", "DISEASE", 111, 129], ["hepatic complications", "DISEASE", 246, 267], ["renal", "ORGAN", 28, 33], ["renal", "ORGAN", 174, 179], ["liver", "ORGAN", 213, 218], ["hepatic", "ORGAN", 246, 253], ["HBV", "ORGANISM", 271, 274], ["HBV", "ORGANISM", 310, 313], ["HBV", "SPECIES", 271, 274], ["HBV", "SPECIES", 310, 313], ["Treatment", "TREATMENT", 0, 9], ["HBVassociated renal disease", "PROBLEM", 14, 41], ["nephrotic syndrome", "PROBLEM", 111, 129], ["its complications", "PROBLEM", 134, 151], ["renal function", "PROBLEM", 174, 188], ["liver function", "TEST", 213, 227], ["hepatic complications", "PROBLEM", 246, 267], ["HBV", "PROBLEM", 271, 274], ["permanent eradication", "TREATMENT", 285, 306], ["HBV", "PROBLEM", 310, 313], ["renal", "ANATOMY", 28, 33], ["disease", "OBSERVATION", 34, 41], ["nephrotic syndrome", "OBSERVATION", 111, 129], ["renal", "ANATOMY", 174, 179], ["liver", "ANATOMY", 213, 218], ["hepatic", "ANATOMY", 246, 253], ["complications", "OBSERVATION", 254, 267], ["HBV", "OBSERVATION", 271, 274], ["HBV", "OBSERVATION", 310, 313]]], ["Because of the involvement of immune complexes in the disease, immunosuppressive therapy-similar to that used in the idiopathic form of the disease-was once fashionable.", [["immune complexes", "PROTEIN", 30, 46], ["immune complexes", "PROBLEM", 30, 46], ["the disease", "PROBLEM", 50, 61], ["immunosuppressive therapy", "TREATMENT", 63, 88], ["the disease", "PROBLEM", 136, 147], ["immune complexes", "OBSERVATION", 30, 46], ["disease", "OBSERVATION", 54, 61], ["immunosuppressive therapy", "OBSERVATION", 63, 88], ["idiopathic", "OBSERVATION", 117, 127], ["disease", "OBSERVATION", 140, 147]]], ["Corticosteroids were reported to provide symptomatic relief in isolated cases.", [["Corticosteroids", "TREATMENT", 0, 15], ["symptomatic relief in isolated cases", "PROBLEM", 41, 77]]], ["The contemporary view, however, is that steroid and cytotoxic agents can cause deleterious hepatic flares or even fatal decompensation by enhancing viral replication when the drugs are withdrawn.", [["hepatic", "ANATOMY", 91, 98], ["steroid", "CHEMICAL", 40, 47], ["hepatic flares", "DISEASE", 91, 105], ["decompensation", "DISEASE", 120, 134], ["steroid", "CHEMICAL", 40, 47], ["steroid", "SIMPLE_CHEMICAL", 40, 47], ["hepatic", "ORGAN", 91, 98], ["The contemporary view", "TEST", 0, 21], ["steroid and cytotoxic agents", "TREATMENT", 40, 68], ["deleterious hepatic flares", "PROBLEM", 79, 105], ["fatal decompensation", "PROBLEM", 114, 134], ["enhancing viral replication", "TREATMENT", 138, 165], ["the drugs", "TREATMENT", 171, 180], ["hepatic", "ANATOMY", 91, 98], ["flares", "OBSERVATION", 99, 105], ["fatal", "OBSERVATION_MODIFIER", 114, 119], ["decompensation", "OBSERVATION", 120, 134], ["enhancing", "OBSERVATION_MODIFIER", 138, 147], ["viral replication", "OBSERVATION", 148, 165]]], ["31 Another approach is treatment with an antiviral agent.", [["treatment", "TREATMENT", 23, 32], ["an antiviral agent", "TREATMENT", 38, 56]]], ["Interferon-\u03b1 is a naturally occurring cytokine produced by B lymphocytes, null lymphocytes, and macrophages that exerts antiviral, antiproliferative and immuno modulatory effects.", [["B lymphocytes", "ANATOMY", 59, 72], ["lymphocytes", "ANATOMY", 79, 90], ["macrophages", "ANATOMY", 96, 107], ["Interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 0, 12], ["B lymphocytes", "CELL", 59, 72], ["null lymphocytes", "CELL", 74, 90], ["macrophages", "CELL", 96, 107], ["Interferon-\u03b1", "PROTEIN", 0, 12], ["cytokine", "PROTEIN", 38, 46], ["B lymphocytes", "CELL_TYPE", 59, 72], ["null lymphocytes", "CELL_TYPE", 74, 90], ["macrophages", "CELL_TYPE", 96, 107], ["Interferon", "TREATMENT", 0, 10], ["null lymphocytes", "PROBLEM", 74, 90], ["macrophages", "PROBLEM", 96, 107], ["antiviral, antiproliferative", "TREATMENT", 120, 148], ["immuno modulatory effects", "PROBLEM", 153, 178], ["null lymphocytes", "OBSERVATION", 74, 90], ["macrophages", "ANATOMY", 96, 107], ["antiviral", "OBSERVATION_MODIFIER", 120, 129]]], ["While reportedly useful in children, 32 interferon-\u03b1 has produced mixed results in adults with HBV-associated membranous nephropathy.", [["interferon-\u03b1", "CHEMICAL", 40, 52], ["membranous nephropathy", "DISEASE", 110, 132], ["children", "ORGANISM", 27, 35], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 40, 52], ["adults", "ORGANISM", 83, 89], ["HBV", "ORGANISM", 95, 98], ["interferon", "PROTEIN", 40, 50], ["children", "SPECIES", 27, 35], ["HBV", "SPECIES", 95, 98], ["HBV", "PROBLEM", 95, 98], ["membranous nephropathy", "PROBLEM", 110, 132], ["HBV", "OBSERVATION", 95, 98], ["membranous", "OBSERVATION_MODIFIER", 110, 120], ["nephropathy", "OBSERVATION", 121, 132]]], ["21, 26 Introduction of the nucleoside analog lamivudine has revolutionized the treatment of chronic HBV infection.", [["nucleoside", "CHEMICAL", 27, 37], ["lamivudine", "CHEMICAL", 45, 55], ["HBV infection", "DISEASE", 100, 113], ["nucleoside", "CHEMICAL", 27, 37], ["lamivudine", "CHEMICAL", 45, 55], ["nucleoside", "SIMPLE_CHEMICAL", 27, 37], ["lamivudine", "SIMPLE_CHEMICAL", 45, 55], ["HBV", "ORGANISM", 100, 103], ["HBV", "SPECIES", 100, 103], ["the nucleoside analog lamivudine", "TREATMENT", 23, 55], ["chronic HBV infection", "PROBLEM", 92, 113], ["chronic", "OBSERVATION_MODIFIER", 92, 99], ["HBV infection", "OBSERVATION", 100, 113]]], ["33 Lamivudine is the (-)-enantiomer of 3'-thiacytidine.", [["Lamivudine", "CHEMICAL", 3, 13], ["3'-thiacytidine", "CHEMICAL", 39, 54], ["Lamivudine", "CHEMICAL", 3, 13], ["3'-thiacytidine", "CHEMICAL", 39, 54], ["Lamivudine", "SIMPLE_CHEMICAL", 3, 13], ["(-)-enantiomer", "SIMPLE_CHEMICAL", 21, 35], ["3'-thiacytidine", "SIMPLE_CHEMICAL", 39, 54], ["Lamivudine", "TREATMENT", 3, 13], ["enantiomer", "TREATMENT", 25, 35], ["thiacytidine", "TREATMENT", 42, 54]]], ["This analog inhibits DNA synthesis by terminating the nascent proviral DNA chain through inter ference with the reverse transcriptase activity of HBV.", [["DNA", "CELLULAR_COMPONENT", 21, 24], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["HBV", "ORGANISM", 146, 149], ["nascent proviral DNA chain", "PROTEIN", 54, 80], ["reverse transcriptase", "PROTEIN", 112, 133], ["HBV", "SPECIES", 146, 149], ["This analog", "PROBLEM", 0, 11], ["DNA synthesis", "PROBLEM", 21, 34], ["the nascent proviral DNA chain", "TREATMENT", 50, 80], ["HBV", "PROBLEM", 146, 149], ["proviral DNA", "OBSERVATION", 62, 74], ["chain", "OBSERVATION_MODIFIER", 75, 80], ["HBV", "OBSERVATION", 146, 149]]], ["In children and adults with HBV-asso ciated membranous nephropathy, lamivudine has been anecdotally reported to induce remission of nephrotic syndrome and to suppress viral replication.", [["nephropathy", "DISEASE", 55, 66], ["lamivudine", "CHEMICAL", 68, 78], ["nephrotic syndrome", "DISEASE", 132, 150], ["lamivudine", "CHEMICAL", 68, 78], ["children", "ORGANISM", 3, 11], ["lamivudine", "SIMPLE_CHEMICAL", 68, 78], ["children", "SPECIES", 3, 11], ["HBV", "SPECIES", 28, 31], ["HBV", "PROBLEM", 28, 31], ["membranous nephropathy", "PROBLEM", 44, 66], ["lamivudine", "TREATMENT", 68, 78], ["nephrotic syndrome", "PROBLEM", 132, 150], ["viral replication", "TREATMENT", 167, 184], ["membranous", "OBSERVATION_MODIFIER", 44, 54], ["nephropathy", "OBSERVATION", 55, 66], ["nephrotic syndrome", "OBSERVATION", 132, 150]]], ["24, 34 In a recent analysis comparing 10 adult nephrotic patients with HBV-related membranous nephropathy who received lamivudine with 12 matched historical control subjects who presented in the pre-lamivudine era, lamivudine significantly improved proteinuria, aminotransferase levels, and renal outcome over a 3-year period.", [["renal", "ANATOMY", 291, 296], ["nephrotic", "DISEASE", 47, 56], ["membranous nephropathy", "DISEASE", 83, 105], ["lamivudine", "CHEMICAL", 119, 129], ["lamivudine", "CHEMICAL", 215, 225], ["proteinuria", "DISEASE", 249, 260], ["lamivudine", "CHEMICAL", 119, 129], ["lamivudine", "CHEMICAL", 215, 225], ["patients", "ORGANISM", 57, 65], ["HBV", "ORGANISM", 71, 74], ["lamivudine", "SIMPLE_CHEMICAL", 119, 129], ["lamivudine", "SIMPLE_CHEMICAL", 215, 225], ["aminotransferase", "SIMPLE_CHEMICAL", 262, 278], ["renal", "ORGAN", 291, 296], ["aminotransferase", "PROTEIN", 262, 278], ["patients", "SPECIES", 57, 65], ["HBV", "SPECIES", 71, 74], ["a recent analysis", "TEST", 10, 27], ["HBV", "PROBLEM", 71, 74], ["membranous nephropathy", "PROBLEM", 83, 105], ["lamivudine", "TREATMENT", 119, 129], ["lamivudine", "TREATMENT", 215, 225], ["aminotransferase levels", "TEST", 262, 285], ["renal outcome", "PROBLEM", 291, 304], ["HBV", "OBSERVATION", 71, 74], ["membranous", "OBSERVATION_MODIFIER", 83, 93], ["nephropathy", "OBSERVATION", 94, 105], ["proteinuria", "OBSERVATION", 249, 260], ["renal", "ANATOMY", 291, 296]]], ["25 Randomized studies in a larger cohort of patients are needed to prove this effect.TreatmentA potential limitation of prolonged treatment with lamivudine is emergence of drugresistant virus strains resulting from induction and selection of HBV variants with mutations at the tyrosine-methionine-aspartate-aspartate (YMDD) motif of DNA polymerase.", [["lamivudine", "CHEMICAL", 145, 155], ["tyrosine", "CHEMICAL", 277, 285], ["methionine", "CHEMICAL", 286, 296], ["aspartate", "CHEMICAL", 297, 306], ["aspartate", "CHEMICAL", 307, 316], ["lamivudine", "CHEMICAL", 145, 155], ["tyrosine", "CHEMICAL", 277, 285], ["methionine", "CHEMICAL", 286, 296], ["aspartate", "CHEMICAL", 297, 306], ["aspartate", "CHEMICAL", 307, 316], ["patients", "ORGANISM", 44, 52], ["lamivudine", "SIMPLE_CHEMICAL", 145, 155], ["drugresistant virus strains", "ORGANISM", 172, 199], ["HBV", "ORGANISM", 242, 245], ["tyrosine", "AMINO_ACID", 277, 285], ["methionine", "AMINO_ACID", 286, 296], ["aspartate", "AMINO_ACID", 297, 306], ["aspartate", "SIMPLE_CHEMICAL", 307, 316], ["DNA", "CELLULAR_COMPONENT", 333, 336], ["tyrosine-methionine-aspartate-aspartate (YMDD) motif", "PROTEIN", 277, 329], ["DNA polymerase", "PROTEIN", 333, 347], ["patients", "SPECIES", 44, 52], ["HBV", "SPECIES", 242, 245], ["Randomized studies", "TEST", 3, 21], ["prolonged treatment", "TREATMENT", 120, 139], ["lamivudine", "TREATMENT", 145, 155], ["drugresistant virus strains", "PROBLEM", 172, 199], ["HBV variants", "PROBLEM", 242, 254], ["mutations", "PROBLEM", 260, 269], ["the tyrosine", "TEST", 273, 285], ["methionine", "TREATMENT", 286, 296], ["aspartate-aspartate (YMDD)", "TREATMENT", 297, 323], ["DNA polymerase", "PROBLEM", 333, 347]]], ["One agent that might be useful in lamivudine-resistant cases is adefovir dipivoxil, an acyclic nucleotide analog that is effective against both lamivudineresistant HBV mutants and wild-type HBV.", [["lamivudine", "CHEMICAL", 34, 44], ["adefovir dipivoxil", "CHEMICAL", 64, 82], ["nucleotide", "CHEMICAL", 95, 105], ["lamivudineresistant", "CHEMICAL", 144, 163], ["lamivudine", "CHEMICAL", 34, 44], ["adefovir dipivoxil", "CHEMICAL", 64, 82], ["nucleotide", "CHEMICAL", 95, 105], ["lamivudine", "SIMPLE_CHEMICAL", 34, 44], ["adefovir", "SIMPLE_CHEMICAL", 64, 72], ["dipivoxil", "SIMPLE_CHEMICAL", 73, 82], ["acyclic nucleotide", "SIMPLE_CHEMICAL", 87, 105], ["lamivudineresistant HBV", "ORGANISM", 144, 167], ["wild-type HBV", "ORGANISM", 180, 193], ["HBV", "SPECIES", 164, 167], ["HBV", "SPECIES", 190, 193], ["lamivudine", "TREATMENT", 34, 44], ["adefovir dipivoxil", "TREATMENT", 64, 82], ["an acyclic nucleotide analog", "TREATMENT", 84, 112], ["both lamivudineresistant HBV mutants", "PROBLEM", 139, 175], ["type HBV", "PROBLEM", 185, 193]]], ["35 This agent does have nephrotoxic potential, and there are no clinical data on its efficacy in HBVrelated membranous nephro pathy that does not respond to lamivudine treatment.", [["nephrotoxic", "DISEASE", 24, 35], ["lamivudine", "CHEMICAL", 157, 167], ["lamivudine", "CHEMICAL", 157, 167], ["lamivudine", "SIMPLE_CHEMICAL", 157, 167], ["HBVrelated membranous nephro pathy", "PROBLEM", 97, 131], ["lamivudine treatment", "TREATMENT", 157, 177], ["nephrotoxic potential", "OBSERVATION_MODIFIER", 24, 45], ["no", "UNCERTAINTY", 61, 63], ["membranous", "OBSERVATION_MODIFIER", 108, 118], ["nephro pathy", "OBSERVATION", 119, 131]]], ["Data do indicate, however, that the recommended dose of 10 mg adefovir dipivoxil is associated with a relatively low risk of nephro toxicity.", [["nephro", "ANATOMY", 125, 131], ["adefovir dipivoxil", "CHEMICAL", 62, 80], ["toxicity", "DISEASE", 132, 140], ["adefovir dipivoxil", "CHEMICAL", 62, 80], ["adefovir", "SIMPLE_CHEMICAL", 62, 70], ["dipivoxil", "SIMPLE_CHEMICAL", 71, 80], ["nephro", "ORGANISM_SUBDIVISION", 125, 131], ["adefovir dipivoxil", "TREATMENT", 62, 80], ["nephro toxicity", "PROBLEM", 125, 140], ["nephro toxicity", "OBSERVATION", 125, 140]]], ["36 While awaiting an ideal agent for treatment of HBV-associated glomerulopathy, active immuniza tion remains the most effective means of immunoprophylaxis.", [["glomerulopathy", "DISEASE", 65, 79], ["HBV", "ORGANISM", 50, 53], ["HBV", "SPECIES", 50, 53], ["an ideal agent", "TREATMENT", 18, 32], ["treatment", "TREATMENT", 37, 46], ["HBV", "PROBLEM", 50, 53], ["associated glomerulopathy", "PROBLEM", 54, 79], ["active immuniza tion", "TREATMENT", 81, 101], ["immunoprophylaxis", "TREATMENT", 138, 155], ["HBV", "OBSERVATION", 50, 53], ["glomerulopathy", "OBSERVATION", 65, 79], ["active", "OBSERVATION_MODIFIER", 81, 87]]], ["37 In Taiwan, active immunization of all newborns since 1984 has led to a dramatic (10-fold) decline in the incidence of neonatal HBV infection and its sequelae.", [["HBV infection", "DISEASE", 130, 143], ["newborns", "ORGANISM", 41, 49], ["HBV", "ORGANISM", 130, 133], ["HBV", "SPECIES", 130, 133], ["active immunization", "TREATMENT", 14, 33], ["a dramatic (10-fold) decline", "PROBLEM", 72, 100], ["neonatal HBV infection", "PROBLEM", 121, 143], ["its sequelae", "PROBLEM", 148, 160], ["active", "OBSERVATION_MODIFIER", 14, 20], ["HBV", "OBSERVATION_MODIFIER", 130, 133], ["infection", "OBSERVATION", 134, 143]]], ["38 In the US, universal vaccination of infants began in 1991, and a 67% reduction in HBV infection was recorded 10 years later.", [["HBV infection", "DISEASE", 85, 98], ["infants", "ORGANISM", 39, 46], ["HBV", "ORGANISM", 85, 88], ["infants", "SPECIES", 39, 46], ["HBV", "SPECIES", 85, 88], ["universal vaccination", "TREATMENT", 14, 35], ["HBV infection", "PROBLEM", 85, 98], ["HBV", "OBSERVATION_MODIFIER", 85, 88], ["infection", "OBSERVATION", 89, 98]]], ["In 2003, the WHO recommended that all countries establish universal HBV immunization programs for infants and adolescents.", [["HBV", "ORGANISM", 68, 71], ["infants", "ORGANISM", 98, 105], ["infants", "SPECIES", 98, 105], ["adolescents", "SPECIES", 110, 121], ["HBV", "SPECIES", 68, 71], ["universal HBV immunization programs", "TREATMENT", 58, 93]]], ["39GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS C VIRUSHCV is a small RNA virus in the Flaviviridae family.", [["Flaviviridae", "ORGANISM", 86, 98], ["39GLOMERULONEPHRITIS", "PROBLEM", 0, 20], ["HEPATITIS C VIRUSHCV", "PROBLEM", 37, 57], ["a small RNA virus", "PROBLEM", 61, 78], ["HEPATITIS", "OBSERVATION", 37, 46], ["small", "OBSERVATION_MODIFIER", 63, 68], ["RNA virus", "OBSERVATION", 69, 78]]], ["Evolution of HCV has been characterized by the emergence of six major genotypes (based on sequence homology) and more than 50 subtypes.", [["HCV", "DISEASE", 13, 16], ["HCV", "ORGANISM", 13, 16], ["HCV", "SPECIES", 13, 16], ["HCV", "PROBLEM", 13, 16], ["HCV", "OBSERVATION", 13, 16]]], ["To date, around 170-200 million individuals worldwide are estimated by the WHO to be chronically infected with HCV.GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS C VIRUSAlthough viral replication is primarily confined to the liver, a variety of extrahepatic disease manifestations are associated with HCV infection.", [["liver", "ANATOMY", 223, 228], ["extrahepatic", "ANATOMY", 243, 255], ["HCV", "DISEASE", 111, 114], ["extrahepatic disease", "DISEASE", 243, 263], ["HCV infection", "DISEASE", 299, 312], ["individuals", "ORGANISM", 32, 43], ["HCV", "ORGANISM", 111, 114], ["liver", "ORGAN", 223, 228], ["extrahepatic", "ORGAN", 243, 255], ["HCV", "ORGANISM", 299, 302], ["HCV", "SPECIES", 111, 114], ["HCV", "SPECIES", 299, 302], ["HCV", "PROBLEM", 111, 114], ["GLOMERULONEPHRITIS", "PROBLEM", 115, 133], ["HEPATITIS C VIRUSAlthough viral replication", "PROBLEM", 150, 193], ["extrahepatic disease manifestations", "PROBLEM", 243, 278], ["HCV infection", "PROBLEM", 299, 312], ["infected", "OBSERVATION", 97, 105], ["HCV", "OBSERVATION", 111, 114], ["HEPATITIS", "OBSERVATION", 150, 159], ["viral replication", "OBSERVATION", 176, 193], ["liver", "ANATOMY", 223, 228], ["variety", "OBSERVATION_MODIFIER", 232, 239], ["extrahepatic", "ANATOMY", 243, 255], ["disease", "OBSERVATION", 256, 263], ["associated with", "UNCERTAINTY", 283, 298], ["HCV", "OBSERVATION_MODIFIER", 299, 302], ["infection", "OBSERVATION", 303, 312]]], ["The principal renal manifestation of HCV infection is MCGN type I, usually in the context of type II (mixed) cryoglobulinemia.", [["renal", "ANATOMY", 14, 19], ["HCV infection", "DISEASE", 37, 50], ["cryoglobulinemia", "DISEASE", 109, 125], ["renal", "ORGAN", 14, 19], ["HCV", "ORGANISM", 37, 40], ["HCV", "SPECIES", 37, 40], ["MCGN type I", "SPECIES", 54, 65], ["HCV infection", "PROBLEM", 37, 50], ["MCGN type I", "PROBLEM", 54, 65], ["type II (mixed) cryoglobulinemia", "PROBLEM", 93, 125], ["principal", "OBSERVATION_MODIFIER", 4, 13], ["renal", "ANATOMY", 14, 19], ["manifestation", "OBSERVATION", 20, 33], ["HCV", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 41, 50], ["type II", "OBSERVATION_MODIFIER", 93, 100], ["cryoglobulinemia", "OBSERVATION", 109, 125]]], ["40 The prevalence of MCGN in HCV type II cryoglobulinemia is approximately 30%.", [["MCGN", "DISEASE", 21, 25], ["HCV type II cryoglobulinemia", "DISEASE", 29, 57], ["MCGN", "CANCER", 21, 25], ["HCV type II", "ORGANISM", 29, 40], ["MCGN", "PROTEIN", 21, 25], ["HCV", "SPECIES", 29, 32], ["HCV type II cryoglobulinemia", "PROBLEM", 29, 57], ["cryoglobulinemia", "OBSERVATION", 41, 57]]], ["MCGN is occasionally observed in patients with hepatitis C in the absence of cryoglobulinemia.", [["MCGN", "DISEASE", 0, 4], ["hepatitis C", "DISEASE", 47, 58], ["cryoglobulinemia", "DISEASE", 77, 93], ["MCGN", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 33, 41], ["hepatitis C", "ORGANISM", 47, 58], ["patients", "SPECIES", 33, 41], ["hepatitis C", "PROBLEM", 47, 58], ["cryoglobulinemia", "PROBLEM", 77, 93], ["hepatitis", "OBSERVATION", 47, 56], ["cryoglobulinemia", "OBSERVATION", 77, 93]]], ["40 Type II MCGN (e.g. dense deposit disease) has not been described in association with HCV infection.GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS C VIRUSTwo immunologic features of HCV might underlie predisposition to extrahepatic disease manifestations.", [["extrahepatic", "ANATOMY", 219, 231], ["MCGN", "DISEASE", 11, 15], ["HCV infection", "DISEASE", 88, 101], ["HCV", "DISEASE", 182, 185], ["extrahepatic disease", "DISEASE", 219, 239], ["Type II MCGN", "CANCER", 3, 15], ["HCV", "ORGANISM", 88, 91], ["HCV", "ORGANISM", 182, 185], ["extrahepatic", "ORGAN", 219, 231], ["HCV", "SPECIES", 88, 91], ["HCV", "SPECIES", 182, 185], ["Type II MCGN (e.g. dense deposit disease", "PROBLEM", 3, 43], ["HCV infection", "PROBLEM", 88, 101], ["GLOMERULONEPHRITIS", "PROBLEM", 102, 120], ["HEPATITIS C VIRUSTwo immunologic features", "PROBLEM", 137, 178], ["HCV", "PROBLEM", 182, 185], ["extrahepatic disease manifestations", "PROBLEM", 219, 254], ["dense", "OBSERVATION_MODIFIER", 22, 27], ["deposit", "OBSERVATION_MODIFIER", 28, 35], ["disease", "OBSERVATION", 36, 43], ["HCV", "OBSERVATION_MODIFIER", 88, 91], ["infection", "OBSERVATION", 92, 101], ["HEPATITIS", "OBSERVATION", 137, 146], ["HCV", "OBSERVATION", 182, 185], ["extrahepatic", "ANATOMY", 219, 231], ["disease", "OBSERVATION", 232, 239]]], ["First, HCV is known to evade immune elimination, leading to chronic infection and accumulation of circulating immune complexes.", [["infection", "DISEASE", 68, 77], ["HCV", "ORGANISM", 7, 10], ["circulating immune complexes", "PROTEIN", 98, 126], ["HCV", "SPECIES", 7, 10], ["HCV", "PROBLEM", 7, 10], ["immune elimination", "PROBLEM", 29, 47], ["chronic infection", "PROBLEM", 60, 77], ["accumulation of circulating immune complexes", "PROBLEM", 82, 126], ["HCV", "OBSERVATION", 7, 10], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["infection", "OBSERVATION", 68, 77], ["circulating immune complexes", "OBSERVATION", 98, 126]]], ["MCGN associated with HCV infection might result from this phenomenon.", [["MCGN", "DISEASE", 0, 4], ["HCV infection", "DISEASE", 21, 34], ["MCGN", "GENE_OR_GENE_PRODUCT", 0, 4], ["HCV", "ORGANISM", 21, 24], ["HCV", "SPECIES", 21, 24], ["HCV infection", "PROBLEM", 21, 34], ["this phenomenon", "PROBLEM", 53, 68], ["HCV", "OBSERVATION_MODIFIER", 21, 24], ["infection", "OBSERVATION", 25, 34]]], ["Second, HCV stimulates production of monoclonal rheumatoid factors.", [["HCV", "ORGANISM", 8, 11], ["monoclonal rheumatoid factors", "GENE_OR_GENE_PRODUCT", 37, 66], ["monoclonal rheumatoid factors", "PROTEIN", 37, 66], ["HCV", "SPECIES", 8, 11], ["monoclonal rheumatoid factors", "PROBLEM", 37, 66], ["HCV", "OBSERVATION", 8, 11], ["monoclonal rheumatoid factors", "OBSERVATION", 37, 66]]], ["This feature causes type II cryoglobulinemia, which accounts for most symptomatic cryoglobulinemic vasculitis.", [["type II cryoglobulinemia", "DISEASE", 20, 44], ["vasculitis", "DISEASE", 99, 109], ["type II cryoglobulinemia", "PROBLEM", 20, 44], ["most symptomatic cryoglobulinemic vasculitis", "PROBLEM", 65, 109], ["type II", "OBSERVATION_MODIFIER", 20, 27], ["cryoglobulinemia", "OBSERVATION", 28, 44], ["symptomatic", "OBSERVATION_MODIFIER", 70, 81], ["cryoglobulinemic", "OBSERVATION_MODIFIER", 82, 98], ["vasculitis", "OBSERVATION", 99, 109]]], ["Although this manifestation occurs relatively infrequently, as do all the extrahepatic disease manifestations, it accounts for much of the increased morbidity and mortality that accompanies the disease.GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS C VIRUSBetween 35% and 90% of HCV-infected patients have been reported to have mixed cryoglobulinemia.", [["extrahepatic", "ANATOMY", 74, 86], ["extrahepatic disease", "DISEASE", 74, 94], ["HCV-infected", "DISEASE", 277, 289], ["cryoglobulinemia", "DISEASE", 332, 348], ["HCV", "ORGANISM", 277, 280], ["patients", "ORGANISM", 290, 298], ["patients", "SPECIES", 290, 298], ["HCV", "SPECIES", 277, 280], ["the extrahepatic disease manifestations", "PROBLEM", 70, 109], ["the increased morbidity", "PROBLEM", 135, 158], ["the disease", "PROBLEM", 190, 201], ["GLOMERULONEPHRITIS", "PROBLEM", 202, 220], ["HEPATITIS C VIRUSBetween", "PROBLEM", 237, 261], ["HCV", "PROBLEM", 277, 280], ["mixed cryoglobulinemia", "PROBLEM", 326, 348], ["extrahepatic", "ANATOMY", 74, 86], ["disease", "OBSERVATION", 87, 94], ["increased", "OBSERVATION_MODIFIER", 139, 148], ["morbidity", "OBSERVATION", 149, 158], ["disease", "OBSERVATION", 194, 201], ["HEPATITIS", "OBSERVATION", 237, 246], ["mixed", "OBSERVATION_MODIFIER", 326, 331], ["cryoglobulinemia", "OBSERVATION", 332, 348]]], ["41, 42 Prevalence increases with duration of hepatitis.", [["hepatitis", "DISEASE", 45, 54], ["hepatitis", "PROBLEM", 45, 54], ["hepatitis", "OBSERVATION", 45, 54]]], ["It should be noted, however, that the prevalence of mixed cryo globulinemia has not been determined in popula tions of unselected HCV-infected patients.", [["popula tions", "ANATOMY", 103, 115], ["HCV-infected", "DISEASE", 130, 142], ["HCV", "ORGANISM", 130, 133], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 143, 151], ["HCV", "SPECIES", 130, 133], ["mixed cryo globulinemia", "PROBLEM", 52, 75], ["unselected HCV", "PROBLEM", 119, 133], ["mixed", "OBSERVATION_MODIFIER", 52, 57], ["cryo globulinemia", "OBSERVATION", 58, 75], ["HCV", "OBSERVATION", 130, 133], ["infected", "OBSERVATION_MODIFIER", 134, 142]]], ["Frank symptomatic cryoglobulinemia affects 1% or less of patients and is usually associated with high levels of rheumatoid factor and cryo globulins.", [["cryoglobulinemia", "DISEASE", 18, 34], ["patients", "ORGANISM", 57, 65], ["rheumatoid factor", "GENE_OR_GENE_PRODUCT", 112, 129], ["cryo globulins", "GENE_OR_GENE_PRODUCT", 134, 148], ["rheumatoid factor", "PROTEIN", 112, 129], ["cryo globulins", "PROTEIN", 134, 148], ["patients", "SPECIES", 57, 65], ["Frank symptomatic cryoglobulinemia affects", "PROBLEM", 0, 42], ["high levels of rheumatoid factor", "PROBLEM", 97, 129], ["cryo globulins", "TREATMENT", 134, 148], ["symptomatic", "OBSERVATION_MODIFIER", 6, 17], ["cryoglobulinemia", "OBSERVATION", 18, 34], ["rheumatoid", "OBSERVATION", 112, 122]]], ["Testing of unselected patients with cryo globulinemia has shown that up to 90% have anti-HCV antibody.", [["patients", "ORGANISM", 22, 30], ["anti-HCV antibody", "PROTEIN", 84, 101], ["patients", "SPECIES", 22, 30], ["cryo globulinemia", "TEST", 36, 53], ["anti-HCV antibody", "TEST", 84, 101]]], ["Type I MCGN has long been regarded as idiopathic, but a consider able proportion of patients has concomitant chronic HCV infection.", [["Type I MCGN", "DISEASE", 0, 11], ["HCV infection", "DISEASE", 117, 130], ["Type I MCGN", "GENE_OR_GENE_PRODUCT", 0, 11], ["patients", "ORGANISM", 84, 92], ["HCV", "ORGANISM", 117, 120], ["Type I MCGN", "PROTEIN", 0, 11], ["patients", "SPECIES", 84, 92], ["HCV", "SPECIES", 117, 120], ["Type I MCGN", "PROBLEM", 0, 11], ["idiopathic", "PROBLEM", 38, 48], ["concomitant chronic HCV infection", "PROBLEM", 97, 130], ["idiopathic", "OBSERVATION", 38, 48], ["chronic", "OBSERVATION_MODIFIER", 109, 116], ["HCV", "OBSERVATION_MODIFIER", 117, 120], ["infection", "OBSERVATION", 121, 130]]], ["The exact proportion of patients with type I MCGN who are anti-HCV-antibody-positive is unknown.GLOMERULONEPHRITIS ASSOCIATED WITH HEPATITIS C VIRUSThe true prevalence of MCGN without detectable cryoglobulinemia is difficult to assess.", [["MCGN", "DISEASE", 171, 175], ["cryoglobulinemia", "DISEASE", 195, 211], ["patients", "ORGANISM", 24, 32], ["type I MCGN", "GENE_OR_GENE_PRODUCT", 38, 49], ["anti-HCV-antibody", "GENE_OR_GENE_PRODUCT", 58, 75], ["MCGN", "CANCER", 171, 175], ["patients", "SPECIES", 24, 32], ["anti-HCV-antibody", "TEST", 58, 75], ["GLOMERULONEPHRITIS", "PROBLEM", 96, 114], ["HEPATITIS C VIRUSThe true prevalence of MCGN", "PROBLEM", 131, 175], ["detectable cryoglobulinemia", "PROBLEM", 184, 211], ["HEPATITIS", "OBSERVATION", 131, 140], ["without", "UNCERTAINTY", 176, 183], ["detectable", "OBSERVATION_MODIFIER", 184, 194], ["cryoglobulinemia", "OBSERVATION", 195, 211]]], ["Such cases might represent a subclinical form of cryoglobulinemia in which circulating cryoglobulins have not been detected by standard laboratory techniques.", [["cryoglobulinemia", "DISEASE", 49, 65], ["cryoglobulins", "GENE_OR_GENE_PRODUCT", 87, 100], ["cryoglobulins", "PROTEIN", 87, 100], ["cryoglobulinemia", "PROBLEM", 49, 65], ["circulating cryoglobulins", "PROBLEM", 75, 100], ["might represent", "UNCERTAINTY", 11, 26], ["subclinical", "OBSERVATION_MODIFIER", 29, 40], ["cryoglobulinemia", "OBSERVATION", 49, 65], ["cryoglobulins", "OBSERVATION", 87, 100]]], ["Further, production of IgM antibodies with anti-IgG activity might induce formation of immune complexes that lack cryoprecipitable properties.", [["IgM antibodies", "GENE_OR_GENE_PRODUCT", 23, 37], ["anti-IgG", "GENE_OR_GENE_PRODUCT", 43, 51], ["IgM antibodies", "PROTEIN", 23, 37], ["anti-IgG", "PROTEIN", 43, 51], ["immune complexes", "PROTEIN", 87, 103], ["IgM antibodies", "PROBLEM", 23, 37], ["anti-IgG activity", "TREATMENT", 43, 60], ["immune complexes", "PROBLEM", 87, 103]]], ["43 Finally, these patients might develop detectable circulating cryoglobulinemia only later in the course of the disease.", [["cryoglobulinemia", "DISEASE", 64, 80], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["detectable circulating cryoglobulinemia", "PROBLEM", 41, 80], ["the disease", "PROBLEM", 109, 120], ["detectable", "OBSERVATION_MODIFIER", 41, 51], ["circulating", "OBSERVATION_MODIFIER", 52, 63], ["cryoglobulinemia", "OBSERVATION", 64, 80], ["disease", "OBSERVATION", 113, 120]]], ["44DiagnosisLaboratory testing coupled with renal biopsy establishes the diagnosis of HCV-related MCGN.", [["renal biopsy", "ANATOMY", 43, 55], ["HCV", "DISEASE", 85, 88], ["MCGN", "DISEASE", 97, 101], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 43, 55], ["HCV", "ORGANISM", 85, 88], ["MCGN", "CANCER", 97, 101], ["HCV", "SPECIES", 85, 88], ["44DiagnosisLaboratory testing", "TEST", 0, 29], ["renal biopsy", "TEST", 43, 55], ["HCV", "PROBLEM", 85, 88], ["renal", "ANATOMY", 43, 48], ["biopsy", "OBSERVATION", 49, 55], ["HCV", "OBSERVATION", 85, 88]]], ["Most patients will have anti-HCV antibody, as well as HCV RNA, in serum.", [["serum", "ANATOMY", 66, 71], ["patients", "ORGANISM", 5, 13], ["HCV", "ORGANISM", 54, 57], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["anti-HCV antibody", "PROTEIN", 24, 41], ["HCV RNA", "RNA", 54, 61], ["patients", "SPECIES", 5, 13], ["HCV", "SPECIES", 54, 57], ["anti-HCV antibody", "TEST", 24, 41], ["HCV RNA", "PROBLEM", 54, 61], ["HCV", "OBSERVATION", 54, 57]]], ["Serum transaminase levels are elevated in 70% of patients.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["Serum transaminase levels", "TEST", 0, 25], ["elevated", "PROBLEM", 30, 38], ["elevated", "OBSERVATION_MODIFIER", 30, 38]]], ["Cryoglobulins are detected in 50-70% of patients.", [["Cryoglobulins", "GENE_OR_GENE_PRODUCT", 0, 13], ["patients", "ORGANISM", 40, 48], ["Cryoglobulins", "PROTEIN", 0, 13], ["patients", "SPECIES", 40, 48], ["Cryoglobulins", "TEST", 0, 13]]], ["Serum electrophoresis and immunofixation detects type II (mixed) cryo globulins.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["type II (mixed) cryo globulins", "GENE_OR_GENE_PRODUCT", 49, 79], ["type II (mixed) cryo globulins", "PROTEIN", 49, 79], ["Serum electrophoresis", "TEST", 0, 21], ["immunofixation", "TEST", 26, 40], ["type II (mixed) cryo globulins", "PROBLEM", 49, 79]]], ["Monoclonal rheumatoid factor, almost in variably an IgM\u03ba, is a distinguishing feature of cryo globulinemic glomerulonephritis.", [["glomerulonephritis", "DISEASE", 107, 125], ["Monoclonal rheumatoid factor", "GENE_OR_GENE_PRODUCT", 0, 28], ["IgM\u03ba", "GENE_OR_GENE_PRODUCT", 52, 56], ["cryo globulinemic glomerulonephritis", "CANCER", 89, 125], ["Monoclonal rheumatoid factor", "PROTEIN", 0, 28], ["IgM\u03ba", "PROTEIN", 52, 56], ["Monoclonal rheumatoid factor", "PROBLEM", 0, 28], ["cryo globulinemic glomerulonephritis", "PROBLEM", 89, 125], ["rheumatoid", "OBSERVATION", 11, 21], ["cryo globulinemic glomerulonephritis", "OBSERVATION", 89, 125]]], ["The amount of cryoglobulins, usually measured as a cryocrit, varies between patients and with time in a given patient (range 2-70%). \u03ba Light chains are also commonly present in the urine.", [["urine", "ANATOMY", 181, 186], ["cryoglobulins", "GENE_OR_GENE_PRODUCT", 14, 27], ["patients", "ORGANISM", 76, 84], ["patient", "ORGANISM", 110, 117], ["urine", "ORGANISM_SUBSTANCE", 181, 186], ["cryoglobulins", "PROTEIN", 14, 27], ["patients", "SPECIES", 76, 84], ["patient", "SPECIES", 110, 117], ["cryoglobulins", "PROBLEM", 14, 27], ["Light chains", "TREATMENT", 135, 147], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["cryoglobulins", "OBSERVATION", 14, 27], ["chains", "OBSERVATION_MODIFIER", 141, 147]]], ["The serum complement pattern, which does not change greatly with clinical disease activity, is also discriminative.", [["serum", "ANATOMY", 4, 9], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["The serum complement pattern", "TEST", 0, 28], ["clinical disease activity", "PROBLEM", 65, 90]]], ["Characteristically, early complement components (C4 and C1q) and CH50 are present at very low or undetectable levels in these patients, whereas the C3 level tends to remain normal or is only slightly depressed.Clinical characteristicsRenal disease associated with HCV is rare in children.", [["Renal", "ANATOMY", 234, 239], ["depressed", "DISEASE", 200, 209], ["Renal disease", "DISEASE", 234, 247], ["HCV", "DISEASE", 264, 267], ["complement components", "GENE_OR_GENE_PRODUCT", 26, 47], ["C4", "GENE_OR_GENE_PRODUCT", 49, 51], ["C1q", "GENE_OR_GENE_PRODUCT", 56, 59], ["CH50", "GENE_OR_GENE_PRODUCT", 65, 69], ["patients", "ORGANISM", 126, 134], ["C3", "GENE_OR_GENE_PRODUCT", 148, 150], ["Renal", "ORGAN", 234, 239], ["HCV", "ORGANISM", 264, 267], ["children", "ORGANISM", 279, 287], ["early complement components", "PROTEIN", 20, 47], ["C4", "PROTEIN", 49, 51], ["C1q", "PROTEIN", 56, 59], ["CH50", "PROTEIN", 65, 69], ["C3", "PROTEIN", 148, 150], ["patients", "SPECIES", 126, 134], ["children", "SPECIES", 279, 287], ["HCV", "SPECIES", 264, 267], ["early complement components (C4 and C1q)", "PROBLEM", 20, 60], ["CH50", "TEST", 65, 69], ["slightly depressed", "PROBLEM", 191, 209], ["Renal disease", "PROBLEM", 234, 247], ["HCV", "PROBLEM", 264, 267], ["early", "OBSERVATION_MODIFIER", 20, 25], ["complement", "OBSERVATION_MODIFIER", 26, 36], ["components", "OBSERVATION_MODIFIER", 37, 47], ["C4", "ANATOMY_MODIFIER", 49, 51], ["CH50", "ANATOMY", 65, 69], ["normal", "OBSERVATION", 173, 179], ["slightly", "OBSERVATION_MODIFIER", 191, 199], ["depressed", "OBSERVATION", 200, 209], ["disease", "OBSERVATION", 240, 247], ["HCV", "OBSERVATION", 264, 267]]], ["The typical age of disease onset is the fifth or sixth decade of life after longstanding infection, often in association with mild subclinical liver disease.", [["liver", "ANATOMY", 143, 148], ["infection", "DISEASE", 89, 98], ["liver disease", "DISEASE", 143, 156], ["liver", "ORGAN", 143, 148], ["longstanding infection", "PROBLEM", 76, 98], ["mild subclinical liver disease", "PROBLEM", 126, 156], ["disease", "OBSERVATION", 19, 26], ["infection", "OBSERVATION", 89, 98], ["mild", "OBSERVATION_MODIFIER", 126, 130], ["subclinical", "OBSERVATION_MODIFIER", 131, 142], ["liver", "ANATOMY", 143, 148], ["disease", "OBSERVATION", 149, 156]]], ["Patients might have other symptoms of cryoglobulinemia, such as palpable purpura and arthralgias.", [["cryoglobulinemia", "DISEASE", 38, 54], ["purpura", "DISEASE", 73, 80], ["arthralgias", "DISEASE", 85, 96], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["other symptoms", "PROBLEM", 20, 34], ["cryoglobulinemia", "PROBLEM", 38, 54], ["palpable purpura", "PROBLEM", 64, 80], ["arthralgias", "PROBLEM", 85, 96], ["cryoglobulinemia", "OBSERVATION", 38, 54], ["palpable", "OBSERVATION_MODIFIER", 64, 72], ["purpura", "OBSERVATION", 73, 80], ["arthralgias", "OBSERVATION", 85, 96]]], ["Renal manifestations include nephrotic (20%) or non-nephrotic proteinuria and microscopic hematuria.", [["Renal", "ANATOMY", 0, 5], ["nephrotic", "DISEASE", 29, 38], ["proteinuria", "DISEASE", 62, 73], ["hematuria", "DISEASE", 90, 99], ["Renal", "ORGAN", 0, 5], ["Renal manifestations", "PROBLEM", 0, 20], ["nephrotic", "TEST", 29, 38], ["non-nephrotic proteinuria", "PROBLEM", 48, 73], ["microscopic hematuria", "PROBLEM", 78, 99], ["manifestations", "OBSERVATION", 6, 20], ["nephrotic", "OBSERVATION", 29, 38], ["proteinuria", "OBSERVATION", 62, 73], ["microscopic", "OBSERVATION_MODIFIER", 78, 89], ["hematuria", "OBSERVATION", 90, 99]]], ["45 Acute nephritic syndrome is the presenting feature in about a quarter of cases.", [["Acute nephritic syndrome", "DISEASE", 3, 27], ["Acute nephritic syndrome", "PROBLEM", 3, 27], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["nephritic", "OBSERVATION", 9, 18]]], ["Renal insufficiency, frequently of mild severity, occurs in about half of patients.", [["Renal", "ANATOMY", 0, 5], ["Renal insufficiency", "DISEASE", 0, 19], ["Renal", "ORGAN", 0, 5], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Renal insufficiency", "PROBLEM", 0, 19], ["mild severity", "PROBLEM", 35, 48], ["insufficiency", "OBSERVATION", 6, 19], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["severity", "OBSERVATION_MODIFIER", 40, 48]]], ["Over 80% of patients have refractory hypertension at presentation, which might be responsible for a considerable number of cardiovascular deaths.Clinical characteristicsThe clinical course of HCV-associated renal disease can vary dramatically.", [["cardiovascular", "ANATOMY", 123, 137], ["renal", "ANATOMY", 207, 212], ["hypertension", "DISEASE", 37, 49], ["cardiovascular deaths", "DISEASE", 123, 144], ["HCV", "DISEASE", 192, 195], ["renal disease", "DISEASE", 207, 220], ["patients", "ORGANISM", 12, 20], ["cardiovascular", "ANATOMICAL_SYSTEM", 123, 137], ["HCV", "ORGANISM", 192, 195], ["renal", "ORGAN", 207, 212], ["patients", "SPECIES", 12, 20], ["HCV", "SPECIES", 192, 195], ["refractory hypertension", "PROBLEM", 26, 49], ["cardiovascular deaths", "PROBLEM", 123, 144], ["HCV", "PROBLEM", 192, 195], ["associated renal disease", "PROBLEM", 196, 220], ["refractory", "OBSERVATION_MODIFIER", 26, 36], ["hypertension", "OBSERVATION", 37, 49], ["cardiovascular deaths", "OBSERVATION", 123, 144], ["HCV", "OBSERVATION", 192, 195], ["renal", "ANATOMY", 207, 212], ["disease", "OBSERVATION", 213, 220]]], ["This disease does not frequently progress to uremia, despite the persistence of urinary abnormalities in the majority of patients.", [["urinary", "ANATOMY", 80, 87], ["uremia", "DISEASE", 45, 51], ["urinary abnormalities", "DISEASE", 80, 101], ["urinary", "ORGANISM_SUBDIVISION", 80, 87], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["This disease", "PROBLEM", 0, 12], ["uremia", "PROBLEM", 45, 51], ["urinary abnormalities", "PROBLEM", 80, 101], ["disease", "OBSERVATION", 5, 12], ["uremia", "OBSERVATION", 45, 51], ["urinary", "ANATOMY", 80, 87], ["abnormalities", "OBSERVATION", 88, 101]]], ["According to an Italian series, around 15% of patients eventually require dialysis.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["dialysis", "TREATMENT", 74, 82]]], ["46 Other forms of glomerular injury, including membranous nephropathy, FSGS, mesangial proliferative glomerulonephritis, and crescentic glomerulonephritis, have been reported in HCV carriers as individual case reports and small series.", [["glomerular", "ANATOMY", 18, 28], ["mesangial", "ANATOMY", 77, 86], ["glomerular injury", "DISEASE", 18, 35], ["membranous nephropathy", "DISEASE", 47, 69], ["FSGS", "DISEASE", 71, 75], ["glomerulonephritis", "DISEASE", 101, 119], ["glomerulonephritis", "DISEASE", 136, 154], ["glomerular", "TISSUE", 18, 28], ["HCV", "ORGANISM", 178, 181], ["HCV", "SPECIES", 178, 181], ["glomerular injury", "PROBLEM", 18, 35], ["membranous nephropathy", "PROBLEM", 47, 69], ["FSGS", "PROBLEM", 71, 75], ["mesangial proliferative glomerulonephritis", "PROBLEM", 77, 119], ["crescentic glomerulonephritis", "PROBLEM", 125, 154], ["small series", "PROBLEM", 222, 234], ["glomerular", "ANATOMY", 18, 28], ["injury", "OBSERVATION", 29, 35], ["membranous", "OBSERVATION_MODIFIER", 47, 57], ["nephropathy", "OBSERVATION", 58, 69], ["FSGS", "OBSERVATION", 71, 75], ["mesangial", "OBSERVATION_MODIFIER", 77, 86], ["proliferative", "OBSERVATION_MODIFIER", 87, 100], ["glomerulonephritis", "OBSERVATION", 101, 119], ["crescentic", "OBSERVATION_MODIFIER", 125, 135], ["glomerulonephritis", "OBSERVATION", 136, 154], ["small", "OBSERVATION_MODIFIER", 222, 227]]], ["Notably, membranous nephropathy in HCV carriers is characterized by the absence of cryoglobulin and male predominance.", [["membranous nephropathy", "DISEASE", 9, 31], ["HCV", "DISEASE", 35, 38], ["HCV", "ORGANISM", 35, 38], ["cryoglobulin", "GENE_OR_GENE_PRODUCT", 83, 95], ["HCV", "SPECIES", 35, 38], ["membranous nephropathy", "PROBLEM", 9, 31], ["HCV carriers", "PROBLEM", 35, 47], ["cryoglobulin", "PROBLEM", 83, 95], ["membranous", "OBSERVATION_MODIFIER", 9, 19], ["nephropathy", "OBSERVATION", 20, 31], ["HCV", "OBSERVATION", 35, 38], ["cryoglobulin", "OBSERVATION", 83, 95], ["male", "OBSERVATION_MODIFIER", 100, 104], ["predominance", "OBSERVATION_MODIFIER", 105, 117]]], ["47TreatmentIn general, therapy can be directed at two levels: removal of cryoglobulins by plasmapheresis; and inhibition of cryoglobulin synthesis by attenuating immune responses (using steroids or cytotoxic agents) or suppressing viral replication (using interferon and ribavirin).", [["cryoglobulin", "CHEMICAL", 124, 136], ["steroids", "CHEMICAL", 186, 194], ["ribavirin", "CHEMICAL", 271, 280], ["steroids", "CHEMICAL", 186, 194], ["ribavirin", "CHEMICAL", 271, 280], ["cryoglobulins", "GENE_OR_GENE_PRODUCT", 73, 86], ["cryoglobulin", "SIMPLE_CHEMICAL", 124, 136], ["interferon", "GENE_OR_GENE_PRODUCT", 256, 266], ["ribavirin", "SIMPLE_CHEMICAL", 271, 280], ["cryoglobulins", "PROTEIN", 73, 86], ["interferon", "PROTEIN", 256, 266], ["therapy", "TREATMENT", 23, 30], ["removal of cryoglobulins", "TREATMENT", 62, 86], ["plasmapheresis", "TREATMENT", 90, 104], ["cryoglobulin synthesis", "TREATMENT", 124, 146], ["attenuating immune responses", "TREATMENT", 150, 178], ["steroids", "TREATMENT", 186, 194], ["cytotoxic agents", "TREATMENT", 198, 214], ["suppressing viral replication", "TREATMENT", 219, 248], ["interferon", "TREATMENT", 256, 266], ["ribavirin", "TREATMENT", 271, 280]]], ["Before the association between HCV and cryo globulinemic MCGN was established, steroids and cyclophosphamide were the mainstays of treatment.", [["steroids", "CHEMICAL", 79, 87], ["cyclophosphamide", "CHEMICAL", 92, 108], ["steroids", "CHEMICAL", 79, 87], ["cyclophosphamide", "CHEMICAL", 92, 108], ["HCV", "ORGANISM", 31, 34], ["steroids", "SIMPLE_CHEMICAL", 79, 87], ["cyclophosphamide", "SIMPLE_CHEMICAL", 92, 108], ["HCV", "SPECIES", 31, 34], ["HCV", "PROBLEM", 31, 34], ["cryo globulinemic MCGN", "TREATMENT", 39, 61], ["steroids", "TREATMENT", 79, 87], ["cyclophosphamide", "TREATMENT", 92, 108], ["treatment", "TREATMENT", 131, 140]]], ["Our awareness of this link has facilitated a more rational approach to management of this condition.", [["this condition", "PROBLEM", 85, 99]]], ["Controlled trials have shown that antiviral therapy with interferon-\u03b1 is asso ciated with improvements in systemic symptoms of immune complex disease.", [["interferon-\u03b1", "CHEMICAL", 57, 69], ["immune complex disease", "DISEASE", 127, 149], ["interferon-\u03b1", "GENE_OR_GENE_PRODUCT", 57, 69], ["interferon-\u03b1", "PROTEIN", 57, 69], ["antiviral therapy", "TREATMENT", 34, 51], ["interferon", "TREATMENT", 57, 67], ["systemic symptoms", "PROBLEM", 106, 123], ["immune complex disease", "PROBLEM", 127, 149], ["antiviral therapy", "OBSERVATION", 34, 51], ["immune complex disease", "OBSERVATION", 127, 149]]], ["Unfortunately, posttherapy relapse occurs in a large pro portion of patients, particularly when interferon monotherapy is administered in short courses.", [["interferon", "CHEMICAL", 96, 106], ["patients", "ORGANISM", 68, 76], ["interferon", "PROTEIN", 96, 106], ["patients", "SPECIES", 68, 76], ["posttherapy relapse", "PROBLEM", 15, 34], ["interferon monotherapy", "TREATMENT", 96, 118], ["large", "OBSERVATION_MODIFIER", 47, 52]]], ["Introduction of combination therapy with interferon-\u03b12b plus ribavirin was an important milestone in the treatment of chronic hepatitis C. 48 This cocktail has also produced favorable results in mixed cryo globulinemia, although non-responses and relapses after initial improvements still occur.", [["interferon-\u03b12b", "CHEMICAL", 41, 55], ["ribavirin", "CHEMICAL", 61, 70], ["hepatitis", "DISEASE", 126, 135], ["ribavirin", "CHEMICAL", 61, 70], ["interferon-\u03b12b", "GENE_OR_GENE_PRODUCT", 41, 55], ["ribavirin", "SIMPLE_CHEMICAL", 61, 70], ["interferon", "PROTEIN", 41, 51], ["combination therapy", "TREATMENT", 16, 35], ["interferon", "TREATMENT", 41, 51], ["ribavirin", "TREATMENT", 61, 70], ["chronic hepatitis C.", "PROBLEM", 118, 138], ["This cocktail", "TREATMENT", 142, 155], ["mixed cryo globulinemia", "PROBLEM", 195, 218], ["relapses", "PROBLEM", 247, 255], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["hepatitis", "OBSERVATION", 126, 135], ["mixed", "OBSERVATION_MODIFIER", 195, 200], ["cryo globulinemia", "OBSERVATION", 201, 218]]], ["49 The introduction of pegylated forms of interferon (peginterferon) in 2000 was another breakthrough in treatment of chronic hepatitis C. Recent data on peginterferon and ribavirin combination therapy are encouraging.", [["pegylated forms of interferon", "CHEMICAL", 23, 52], ["peginterferon", "CHEMICAL", 54, 67], ["hepatitis", "DISEASE", 126, 135], ["peginterferon", "CHEMICAL", 154, 167], ["ribavirin", "CHEMICAL", 172, 181], ["peginterferon", "CHEMICAL", 154, 167], ["ribavirin", "CHEMICAL", 172, 181], ["interferon", "GENE_OR_GENE_PRODUCT", 42, 52], ["peginterferon", "SIMPLE_CHEMICAL", 54, 67], ["peginterferon", "SIMPLE_CHEMICAL", 154, 167], ["ribavirin", "SIMPLE_CHEMICAL", 172, 181], ["interferon", "PROTEIN", 42, 52], ["The introduction of pegylated forms of interferon (peginterferon)", "TREATMENT", 3, 68], ["chronic hepatitis C.", "PROBLEM", 118, 138], ["peginterferon", "TREATMENT", 154, 167], ["ribavirin combination therapy", "TREATMENT", 172, 201], ["chronic", "OBSERVATION_MODIFIER", 118, 125], ["hepatitis", "OBSERVATION", 126, 135]]], ["50 An increased rate of treatment failure in carriers of HCV genotype 1 has been recognized.", [["HCV genotype 1", "ORGANISM", 57, 71], ["HCV", "SPECIES", 57, 60], ["An increased rate of treatment failure", "PROBLEM", 3, 41], ["HCV genotype 1", "PROBLEM", 57, 71], ["increased", "OBSERVATION_MODIFIER", 6, 15], ["rate", "OBSERVATION_MODIFIER", 16, 20], ["treatment", "OBSERVATION_MODIFIER", 24, 33], ["failure", "OBSERVATION", 34, 41]]], ["51 Observational studies support the effectiveness of peginterferon and ribavirin combination therapy in HCV-associated cryoglobulinemic MCGN.", [["peginterferon", "CHEMICAL", 54, 67], ["ribavirin", "CHEMICAL", 72, 81], ["MCGN", "DISEASE", 137, 141], ["peginterferon", "CHEMICAL", 54, 67], ["ribavirin", "CHEMICAL", 72, 81], ["peginterferon", "SIMPLE_CHEMICAL", 54, 67], ["ribavirin", "SIMPLE_CHEMICAL", 72, 81], ["HCV", "ORGANISM", 105, 108], ["cryoglobulinemic MCGN", "CANCER", 120, 141], ["HCV", "SPECIES", 105, 108], ["Observational studies", "TEST", 3, 24], ["peginterferon", "TREATMENT", 54, 67], ["ribavirin combination therapy", "TREATMENT", 72, 101], ["HCV", "PROBLEM", 105, 108], ["cryoglobulinemic MCGN", "TREATMENT", 120, 141], ["cryoglobulinemic MCGN", "OBSERVATION", 120, 141]]], ["One therapeutic drawback is the hemolytic effect that complicates ribavirin therapy, particularly in patients with functional renal impairment.", [["renal", "ANATOMY", 126, 131], ["hemolytic", "DISEASE", 32, 41], ["ribavirin", "CHEMICAL", 66, 75], ["renal impairment", "DISEASE", 126, 142], ["ribavirin", "CHEMICAL", 66, 75], ["ribavirin", "SIMPLE_CHEMICAL", 66, 75], ["patients", "ORGANISM", 101, 109], ["renal", "ORGAN", 126, 131], ["patients", "SPECIES", 101, 109], ["the hemolytic effect", "PROBLEM", 28, 48], ["ribavirin therapy", "TREATMENT", 66, 83], ["functional renal impairment", "PROBLEM", 115, 142], ["hemolytic effect", "OBSERVATION", 32, 48], ["ribavirin therapy", "OBSERVATION", 66, 83], ["renal", "ANATOMY", 126, 131], ["impairment", "OBSERVATION", 132, 142]]], ["This difficulty has been overcome by adjusting the dose according to glomerular filtration rate instead of body weight alone, and utilizing recombinant erythropoietin to combat anemia.", [["glomerular", "ANATOMY", 69, 79], ["body", "ANATOMY", 107, 111], ["anemia", "DISEASE", 177, 183], ["glomerular", "TISSUE", 69, 79], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["erythropoietin", "GENE_OR_GENE_PRODUCT", 152, 166], ["erythropoietin", "PROTEIN", 152, 166], ["glomerular filtration rate", "TEST", 69, 95], ["recombinant erythropoietin", "TREATMENT", 140, 166], ["anemia", "PROBLEM", 177, 183]]], ["Post-treatment renal biopsy showed histological improvement in two of three patients who received combination therapy for 12 months.", [["renal", "ANATOMY", 15, 20], ["renal biopsy", "MULTI-TISSUE_STRUCTURE", 15, 27], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["treatment renal biopsy", "TEST", 5, 27], ["combination therapy", "TREATMENT", 98, 117], ["renal", "ANATOMY", 15, 20], ["biopsy", "OBSERVATION", 21, 27], ["histological", "OBSERVATION_MODIFIER", 35, 47], ["improvement", "OBSERVATION_MODIFIER", 48, 59]]], ["52HIV-RELATED GLOMERULAR DISEASESThe wide spectrum of glomerulopathies occurring in the course of HIV infection can be classified into four groups.", [["glomerulopathies", "DISEASE", 54, 70], ["HIV infection", "DISEASE", 98, 111], ["glomerulopathies", "CANCER", 54, 70], ["HIV", "ORGANISM", 98, 101], ["HIV", "SPECIES", 98, 101], ["52HIV", "SPECIES", 0, 5], ["HIV", "SPECIES", 98, 101], ["GLOMERULAR DISEASESThe", "PROBLEM", 14, 36], ["glomerulopathies", "PROBLEM", 54, 70], ["HIV infection", "PROBLEM", 98, 111], ["GLOMERULAR", "OBSERVATION_MODIFIER", 14, 24], ["DISEASESThe", "OBSERVATION", 25, 36], ["wide spectrum", "OBSERVATION_MODIFIER", 37, 50], ["glomerulopathies", "OBSERVATION", 54, 70], ["infection", "OBSERVATION", 102, 111]]], ["The first group is the classical HIV-associated nephropathy (HIVAN), a distinct entity with histological features of FSGS with tuft collapse or, more rarely, mesangial hyperplasia.", [["tuft", "ANATOMY", 127, 131], ["mesangial hyperplasia", "ANATOMY", 158, 179], ["HIV-associated nephropathy", "DISEASE", 33, 59], ["HIVAN", "DISEASE", 61, 66], ["FSGS", "DISEASE", 117, 121], ["mesangial hyperplasia", "DISEASE", 158, 179], ["HIV", "ORGANISM", 33, 36], ["mesangial hyperplasia", "PATHOLOGICAL_FORMATION", 158, 179], ["HIV", "SPECIES", 33, 36], ["the classical HIV-associated nephropathy", "PROBLEM", 19, 59], ["FSGS", "PROBLEM", 117, 121], ["tuft collapse", "PROBLEM", 127, 140], ["mesangial hyperplasia", "PROBLEM", 158, 179], ["nephropathy", "OBSERVATION", 48, 59], ["FSGS", "OBSERVATION", 117, 121], ["tuft", "OBSERVATION_MODIFIER", 127, 131], ["collapse", "OBSERVATION", 132, 140], ["mesangial", "OBSERVATION_MODIFIER", 158, 167], ["hyperplasia", "OBSERVATION", 168, 179]]], ["HIVAN seems to be related to a direct effect of HIV or viral proteins on renal epithelium.", [["renal epithelium", "ANATOMY", 73, 89], ["HIVAN", "DISEASE", 0, 5], ["HIV", "ORGANISM", 48, 51], ["renal epithelium", "TISSUE", 73, 89], ["viral proteins", "PROTEIN", 55, 69], ["HIV", "SPECIES", 48, 51], ["HIVAN", "PROBLEM", 0, 5], ["HIV", "PROBLEM", 48, 51], ["viral proteins on renal epithelium", "PROBLEM", 55, 89], ["renal", "ANATOMY", 73, 78], ["epithelium", "ANATOMY_MODIFIER", 79, 89]]], ["53 The second group is a diffuse proliferative-mesangiocapillary or lupuslike glomerulonephritis, with predominantly mesangial immune deposits, also known as HIV immune-complex-mediated disease.", [["mesangiocapillary", "ANATOMY", 47, 64], ["mesangial immune deposits", "ANATOMY", 117, 142], ["glomerulonephritis", "DISEASE", 78, 96], ["HIV immune-complex", "GENE_OR_GENE_PRODUCT", 158, 176], ["HIV", "SPECIES", 158, 161], ["a diffuse proliferative-mesangiocapillary", "PROBLEM", 23, 64], ["lupuslike glomerulonephritis", "PROBLEM", 68, 96], ["predominantly mesangial immune deposits", "PROBLEM", 103, 142], ["HIV immune-complex-mediated disease", "PROBLEM", 158, 193], ["diffuse", "OBSERVATION_MODIFIER", 25, 32], ["proliferative", "OBSERVATION_MODIFIER", 33, 46], ["mesangiocapillary", "ANATOMY", 47, 64], ["lupuslike", "OBSERVATION_MODIFIER", 68, 77], ["glomerulonephritis", "OBSERVATION", 78, 96], ["predominantly", "OBSERVATION_MODIFIER", 103, 116], ["mesangial immune deposits", "OBSERVATION", 117, 142], ["complex", "OBSERVATION_MODIFIER", 169, 176], ["disease", "OBSERVATION", 186, 193]]], ["54 This group also includes other immune-complex-mediated glomerulonephritides with more-heterogeneous histological features.", [["glomerulonephritides", "ANATOMY", 58, 78], ["glomerulonephritides", "CANCER", 58, 78], ["mediated glomerulonephritides", "PROBLEM", 49, 78], ["heterogeneous", "OBSERVATION_MODIFIER", 89, 102], ["histological", "OBSERVATION", 103, 115]]], ["The third group (which includes immunotactoid glomerulonephritis) is heterogeneous with regard to glomerular lesions and pathogenic mechanisms, some of which are still undefined.", [["glomerular lesions", "ANATOMY", 98, 116], ["glomerulonephritis", "DISEASE", 46, 64], ["glomerular lesions", "PATHOLOGICAL_FORMATION", 98, 116], ["immunotactoid glomerulonephritis", "PROBLEM", 32, 64], ["glomerular lesions", "PROBLEM", 98, 116], ["pathogenic mechanisms", "PROBLEM", 121, 142], ["glomerulonephritis", "OBSERVATION", 46, 64], ["heterogeneous", "OBSERVATION_MODIFIER", 69, 82], ["glomerular", "ANATOMY", 98, 108], ["lesions", "OBSERVATION", 109, 116], ["pathogenic mechanisms", "OBSERVATION", 121, 142]]], ["The true role of HIV infection in glomerulopathies of this type is also uncertain.", [["HIV infection", "DISEASE", 17, 30], ["glomerulopathies", "DISEASE", 34, 50], ["HIV", "ORGANISM", 17, 20], ["HIV", "SPECIES", 17, 20], ["HIV", "SPECIES", 17, 20], ["HIV infection", "PROBLEM", 17, 30], ["HIV", "OBSERVATION_MODIFIER", 17, 20], ["infection", "OBSERVATION", 21, 30], ["glomerulopathies", "OBSERVATION", 34, 50]]], ["The final group includes HIV-associated thrombotic microangiopathy/hemolytic uremic syndrome, in which HIV is the main, but not sole, etiological factor.", [["thrombotic microangiopathy", "DISEASE", 40, 66], ["hemolytic uremic syndrome", "DISEASE", 67, 92], ["HIV", "ORGANISM", 25, 28], ["HIV", "ORGANISM", 103, 106], ["HIV", "SPECIES", 25, 28], ["HIV", "SPECIES", 103, 106], ["HIV", "SPECIES", 25, 28], ["HIV", "SPECIES", 103, 106], ["HIV", "PROBLEM", 25, 28], ["thrombotic microangiopathy", "PROBLEM", 40, 66], ["hemolytic uremic syndrome", "PROBLEM", 67, 92], ["thrombotic", "OBSERVATION_MODIFIER", 40, 50], ["microangiopathy", "OBSERVATION", 51, 66], ["hemolytic", "OBSERVATION_MODIFIER", 67, 76], ["uremic syndrome", "OBSERVATION", 77, 92], ["main", "OBSERVATION_MODIFIER", 114, 118]]], ["Ethnic/geographic background is an important determinant of the type of glomerulopathy associated with HIV; for example, collapsing FSGS is prevalent in patients of African descent.HIV-RELATED GLOMERULAR DISEASESThe FSGS variant of HIVAN is the most commonly reported chronic renal disease associated with HIV infection.", [["renal", "ANATOMY", 276, 281], ["glomerulopathy", "DISEASE", 72, 86], ["HIV", "DISEASE", 103, 106], ["FSGS", "DISEASE", 132, 136], ["HIVAN", "DISEASE", 232, 237], ["chronic renal disease", "DISEASE", 268, 289], ["HIV infection", "DISEASE", 306, 319], ["patients", "ORGANISM", 153, 161], ["renal", "ORGAN", 276, 281], ["HIV", "ORGANISM", 306, 309], ["HIV", "SPECIES", 103, 106], ["patients", "SPECIES", 153, 161], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 306, 309], ["HIV", "SPECIES", 103, 106], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 306, 309], ["Ethnic/geographic background", "PROBLEM", 0, 28], ["glomerulopathy", "PROBLEM", 72, 86], ["HIV", "PROBLEM", 103, 106], ["collapsing FSGS", "PROBLEM", 121, 136], ["African descent", "PROBLEM", 165, 180], ["HIV", "PROBLEM", 181, 184], ["GLOMERULAR DISEASESThe FSGS variant", "PROBLEM", 193, 228], ["HIVAN", "PROBLEM", 232, 237], ["chronic renal disease", "PROBLEM", 268, 289], ["HIV infection", "PROBLEM", 306, 319], ["geographic", "OBSERVATION_MODIFIER", 7, 17], ["glomerulopathy", "OBSERVATION", 72, 86], ["collapsing", "OBSERVATION_MODIFIER", 121, 131], ["FSGS", "OBSERVATION", 132, 136], ["GLOMERULAR", "ANATOMY", 193, 203], ["DISEASESThe FSGS", "OBSERVATION", 204, 220], ["HIVAN", "OBSERVATION", 232, 237], ["most commonly", "OBSERVATION_MODIFIER", 245, 258], ["chronic", "OBSERVATION_MODIFIER", 268, 275], ["renal", "ANATOMY", 276, 281], ["disease", "OBSERVATION", 282, 289], ["HIV", "OBSERVATION_MODIFIER", 306, 309], ["infection", "OBSERVATION", 310, 319]]], ["HIVAN affects up to 10% of HIV-infected patients of African descent-mainly males at risk of drug abuse, and often African Americans.", [["HIVAN", "DISEASE", 0, 5], ["HIV-infected", "DISEASE", 27, 39], ["drug abuse", "DISEASE", 92, 102], ["HIV", "ORGANISM", 27, 30], ["patients", "ORGANISM", 40, 48], ["HIV", "SPECIES", 27, 30], ["patients", "SPECIES", 40, 48], ["HIV", "SPECIES", 27, 30], ["HIVAN affects", "PROBLEM", 0, 13]]], ["Glomerular changes associated with this variant are capillary wall collapse of varying severity, with widening of Bowman's space.", [["Glomerular", "ANATOMY", 0, 10], ["capillary wall", "ANATOMY", 52, 66], ["Glomerular", "MULTI-TISSUE_STRUCTURE", 0, 10], ["capillary wall", "TISSUE", 52, 66], ["Glomerular changes", "PROBLEM", 0, 18], ["capillary wall collapse of varying severity", "PROBLEM", 52, 95], ["widening of Bowman's space", "PROBLEM", 102, 128], ["capillary", "ANATOMY_MODIFIER", 52, 61], ["wall", "ANATOMY_MODIFIER", 62, 66], ["collapse", "OBSERVATION", 67, 75], ["varying", "OBSERVATION_MODIFIER", 79, 86], ["severity", "OBSERVATION_MODIFIER", 87, 95], ["widening", "OBSERVATION_MODIFIER", 102, 110], ["Bowman", "ANATOMY", 114, 120], ["'s space", "OBSERVATION", 120, 128]]], ["Visceral epi thelial cells undergo hyperplasia and hypertrophy, and develop protein inclusions in their swollen cytoplasm surrounding the collapsed lobules.", [["Visceral epi thelial cells", "ANATOMY", 0, 26], ["swollen cytoplasm", "ANATOMY", 104, 121], ["lobules", "ANATOMY", 148, 155], ["hyperplasia", "DISEASE", 35, 46], ["hypertrophy", "DISEASE", 51, 62], ["Visceral epi thelial cells", "CELL", 0, 26], ["swollen cytoplasm", "ORGANISM_SUBSTANCE", 104, 121], ["lobules", "MULTI-TISSUE_STRUCTURE", 148, 155], ["Visceral epi thelial cells", "CELL_TYPE", 0, 26], ["Visceral epi thelial cells", "PROBLEM", 0, 26], ["hyperplasia", "PROBLEM", 35, 46], ["hypertrophy", "PROBLEM", 51, 62], ["protein inclusions", "PROBLEM", 76, 94], ["their swollen cytoplasm", "PROBLEM", 98, 121], ["thelial cells", "OBSERVATION", 13, 26], ["hyperplasia", "OBSERVATION", 35, 46], ["hypertrophy", "OBSERVATION", 51, 62], ["protein inclusions", "OBSERVATION", 76, 94], ["swollen cytoplasm", "OBSERVATION", 104, 121], ["collapsed lobules", "OBSERVATION", 138, 155]]], ["Sclerosis affects segments of capillary tuft or the whole glomerular surface.", [["capillary tuft", "ANATOMY", 30, 44], ["glomerular surface", "ANATOMY", 58, 76], ["Sclerosis", "DISEASE", 0, 9], ["capillary tuft", "TISSUE", 30, 44], ["glomerular surface", "CELLULAR_COMPONENT", 58, 76], ["Sclerosis affects segments of capillary tuft", "PROBLEM", 0, 44], ["segments", "ANATOMY_MODIFIER", 18, 26], ["capillary", "ANATOMY_MODIFIER", 30, 39], ["tuft", "ANATOMY_MODIFIER", 40, 44], ["whole", "ANATOMY_MODIFIER", 52, 57], ["glomerular", "ANATOMY", 58, 68], ["surface", "ANATOMY_MODIFIER", 69, 76]]], ["Tubular cells might undergo degenerative changes, necrosis or flattening.", [["Tubular cells", "ANATOMY", 0, 13], ["necrosis", "DISEASE", 50, 58], ["Tubular cells", "CELL", 0, 13], ["Tubular cells", "CELL_TYPE", 0, 13], ["Tubular cells", "PROBLEM", 0, 13], ["degenerative changes", "PROBLEM", 28, 48], ["necrosis", "PROBLEM", 50, 58], ["flattening", "PROBLEM", 62, 72], ["cells", "OBSERVATION", 8, 13], ["degenerative", "OBSERVATION", 28, 40], ["necrosis", "OBSERVATION", 50, 58], ["flattening", "OBSERVATION_MODIFIER", 62, 72]]], ["Large dense casts can develop in dilated tubules.HIV-RELATED GLOMERULAR DISEASESDetection of HIV RNA in renal tissue from patients with HIVAN, and of HIV DNA in patients with and without nephropathy, 55 raises the question of whether renal cells can be infected in vivo (tubular epithelial cells can be infected in vitro).", [["tubules", "ANATOMY", 41, 48], ["renal tissue", "ANATOMY", 104, 116], ["renal cells", "ANATOMY", 234, 245], ["tubular epithelial cells", "ANATOMY", 271, 295], ["HIVAN", "DISEASE", 136, 141], ["nephropathy", "DISEASE", 187, 198], ["dilated tubules", "MULTI-TISSUE_STRUCTURE", 33, 48], ["HIV", "ORGANISM", 93, 96], ["renal tissue", "TISSUE", 104, 116], ["patients", "ORGANISM", 122, 130], ["HIV", "ORGANISM", 150, 153], ["DNA", "CELLULAR_COMPONENT", 154, 157], ["patients", "ORGANISM", 161, 169], ["renal cells", "CELL", 234, 245], ["tubular epithelial cells", "CELL", 271, 295], ["HIV RNA", "RNA", 93, 100], ["renal cells", "CELL_TYPE", 234, 245], ["tubular epithelial cells", "CELL_TYPE", 271, 295], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 93, 96], ["patients", "SPECIES", 122, 130], ["HIV", "SPECIES", 150, 153], ["patients", "SPECIES", 161, 169], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 150, 153], ["Large dense casts", "PROBLEM", 0, 17], ["dilated tubules", "PROBLEM", 33, 48], ["HIV", "PROBLEM", 49, 52], ["GLOMERULAR DISEASESDetection", "PROBLEM", 61, 89], ["HIV RNA in renal tissue", "PROBLEM", 93, 116], ["HIVAN", "TREATMENT", 136, 141], ["HIV DNA", "PROBLEM", 150, 157], ["nephropathy", "PROBLEM", 187, 198], ["renal cells", "PROBLEM", 234, 245], ["tubular epithelial cells", "PROBLEM", 271, 295], ["dense", "OBSERVATION_MODIFIER", 6, 11], ["casts", "OBSERVATION", 12, 17], ["dilated", "OBSERVATION", 33, 40], ["GLOMERULAR", "OBSERVATION_MODIFIER", 61, 71], ["DISEASESDetection", "OBSERVATION", 72, 89], ["HIV RNA", "OBSERVATION", 93, 100], ["renal tissue", "ANATOMY", 104, 116], ["HIVAN", "OBSERVATION", 136, 141], ["HIV DNA", "OBSERVATION", 150, 157], ["renal", "ANATOMY", 234, 239], ["cells", "OBSERVATION", 240, 245], ["tubular epithelial cells", "OBSERVATION", 271, 295]]], ["4 Renal uptake of viral gene products might induce transactivation of host LAI AND LAI MAY 2006 VOL 2 NO 5 www.nature.com/clinicalpractice/neph genes.", [["Renal", "ANATOMY", 2, 7], ["NO", "CHEMICAL", 102, 104], ["NO", "CHEMICAL", 102, 104], ["Renal", "ORGAN", 2, 7], ["viral gene products", "PROTEIN", 18, 37], ["clinicalpractice/neph genes", "DNA", 122, 149], ["viral gene products", "TREATMENT", 18, 37], ["Renal", "ANATOMY", 2, 7], ["uptake", "OBSERVATION", 8, 14], ["viral gene", "OBSERVATION", 18, 28]]], ["In renal cells, HIV proteins can cause apoptosis, 4 phenotypic modifications, 56 and subsequent tubulointerstitial fibrosis.Clinical characteristicsClinical manifestations of HIVAN with FSGS are nephrotic-range proteinuria and renal insufficiency.", [["renal cells", "ANATOMY", 3, 14], ["tubulointerstitial", "ANATOMY", 96, 114], ["renal", "ANATOMY", 227, 232], ["fibrosis", "DISEASE", 115, 123], ["HIVAN", "DISEASE", 175, 180], ["FSGS", "DISEASE", 186, 190], ["nephrotic", "DISEASE", 195, 204], ["proteinuria", "DISEASE", 211, 222], ["renal insufficiency", "DISEASE", 227, 246], ["renal cells", "CELL", 3, 14], ["HIV", "ORGANISM", 16, 19], ["renal", "ORGAN", 227, 232], ["renal cells", "CELL_TYPE", 3, 14], ["HIV proteins", "PROTEIN", 16, 28], ["HIV", "SPECIES", 16, 19], ["HIV proteins", "PROBLEM", 16, 28], ["apoptosis", "PROBLEM", 39, 48], ["subsequent tubulointerstitial fibrosis", "PROBLEM", 85, 123], ["HIVAN", "PROBLEM", 175, 180], ["FSGS", "PROBLEM", 186, 190], ["nephrotic", "PROBLEM", 195, 204], ["proteinuria", "PROBLEM", 211, 222], ["renal insufficiency", "PROBLEM", 227, 246], ["renal cells", "ANATOMY", 3, 14], ["tubulointerstitial", "OBSERVATION_MODIFIER", 96, 114], ["fibrosis", "OBSERVATION", 115, 123], ["HIVAN", "OBSERVATION", 175, 180], ["FSGS", "OBSERVATION", 186, 190], ["nephrotic", "OBSERVATION", 195, 204], ["range", "OBSERVATION_MODIFIER", 205, 210], ["proteinuria", "OBSERVATION", 211, 222], ["renal", "ANATOMY", 227, 232], ["insufficiency", "OBSERVATION", 233, 246]]], ["Hypertension and edema are uncommon.", [["edema", "ANATOMY", 17, 22], ["Hypertension", "DISEASE", 0, 12], ["edema", "DISEASE", 17, 22], ["edema", "PATHOLOGICAL_FORMATION", 17, 22], ["Hypertension", "PROBLEM", 0, 12], ["edema", "PROBLEM", 17, 22], ["edema", "OBSERVATION", 17, 22]]], ["In overt cases, ultrasonography typically reveals enlarged, highly echogenic kidneys, which probably develop in response to microcystic tubular dilatation.", [["kidneys", "ANATOMY", 77, 84], ["microcystic tubular", "ANATOMY", 124, 143], ["kidneys", "ORGAN", 77, 84], ["microcystic tubular", "MULTI-TISSUE_STRUCTURE", 124, 143], ["ultrasonography", "TEST", 16, 31], ["enlarged, highly echogenic kidneys", "PROBLEM", 50, 84], ["microcystic tubular dilatation", "PROBLEM", 124, 154], ["enlarged", "OBSERVATION", 50, 58], ["highly", "OBSERVATION_MODIFIER", 60, 66], ["echogenic", "OBSERVATION", 67, 76], ["kidneys", "ANATOMY", 77, 84], ["microcystic", "OBSERVATION_MODIFIER", 124, 135], ["tubular", "ANATOMY_MODIFIER", 136, 143], ["dilatation", "OBSERVATION", 144, 154]]], ["Before effective antiretroviral treatment was available, clinical progression was rapid.", [["effective antiretroviral treatment", "TREATMENT", 7, 41]]], ["Intensive antiretroviral treatment delays progression.", [["Intensive antiretroviral treatment delays progression", "TREATMENT", 0, 53]]], ["57 Pathology of the HIV-associated disease mediated by immune complexes resembles lupus nephropathy.", [["HIV-associated disease", "DISEASE", 20, 42], ["lupus nephropathy", "DISEASE", 82, 99], ["HIV", "ORGANISM", 20, 23], ["immune complexes", "PROTEIN", 55, 71], ["HIV", "SPECIES", 20, 23], ["HIV", "SPECIES", 20, 23], ["the HIV", "PROBLEM", 16, 23], ["associated disease", "PROBLEM", 24, 42], ["immune complexes", "PROBLEM", 55, 71], ["lupus nephropathy", "PROBLEM", 82, 99], ["HIV", "OBSERVATION", 20, 23], ["disease", "OBSERVATION", 35, 42], ["immune complexes", "OBSERVATION", 55, 71], ["lupus nephropathy", "OBSERVATION", 82, 99]]], ["The clinical presentation is nephrotic syndrome with microscopic hematuria.", [["nephrotic syndrome", "DISEASE", 29, 47], ["hematuria", "DISEASE", 65, 74], ["nephrotic syndrome", "PROBLEM", 29, 47], ["microscopic hematuria", "PROBLEM", 53, 74], ["nephrotic syndrome", "OBSERVATION", 29, 47], ["microscopic", "OBSERVATION_MODIFIER", 53, 64], ["hematuria", "OBSERVATION", 65, 74]]], ["Progression to renal failure occurs, but more slowly than in HIVAN.", [["renal", "ANATOMY", 15, 20], ["renal failure", "DISEASE", 15, 28], ["HIVAN", "DISEASE", 61, 66], ["renal", "ORGAN", 15, 20], ["renal failure", "PROBLEM", 15, 28], ["HIVAN", "TREATMENT", 61, 66], ["renal", "ANATOMY", 15, 20], ["failure", "OBSERVATION", 21, 28]]], ["Patients often have HCV coinfection, but HIV seems to have the prevailing role.", [["HCV coinfection", "DISEASE", 20, 35], ["Patients", "ORGANISM", 0, 8], ["HCV", "ORGANISM", 20, 23], ["HIV", "ORGANISM", 41, 44], ["Patients", "SPECIES", 0, 8], ["HIV", "SPECIES", 41, 44], ["HCV", "SPECIES", 20, 23], ["HIV", "SPECIES", 41, 44], ["HCV coinfection", "PROBLEM", 20, 35], ["HIV", "PROBLEM", 41, 44], ["HCV", "OBSERVATION_MODIFIER", 20, 23], ["coinfection", "OBSERVATION", 24, 35]]], ["Viral antigen has been detected in glomeruli, and antibodies eluted from the kidney react with HIV antigens in circulating immune complexes (IgA-p24 antigen, IgG-p24 and IgG-gp120).", [["glomeruli", "ANATOMY", 35, 44], ["kidney", "ANATOMY", 77, 83], ["Viral", "ORGANISM", 0, 5], ["glomeruli", "TISSUE", 35, 44], ["kidney", "ORGAN", 77, 83], ["HIV", "ORGANISM", 95, 98], ["IgA-p24 antigen", "GENE_OR_GENE_PRODUCT", 141, 156], ["IgG-p24", "GENE_OR_GENE_PRODUCT", 158, 165], ["IgG-gp120", "GENE_OR_GENE_PRODUCT", 170, 179], ["Viral antigen", "PROTEIN", 0, 13], ["antibodies", "PROTEIN", 50, 60], ["HIV antigens", "PROTEIN", 95, 107], ["circulating immune complexes", "PROTEIN", 111, 139], ["IgA", "PROTEIN", 141, 144], ["p24 antigen", "PROTEIN", 145, 156], ["IgG", "PROTEIN", 158, 161], ["p24", "PROTEIN", 162, 165], ["IgG", "PROTEIN", 170, 173], ["gp120", "PROTEIN", 174, 179], ["HIV", "SPECIES", 95, 98], ["Viral antigen", "TEST", 0, 13], ["glomeruli", "TEST", 35, 44], ["antibodies", "TEST", 50, 60], ["HIV antigens", "PROBLEM", 95, 107], ["circulating immune complexes", "TEST", 111, 139], ["IgA", "TEST", 141, 144], ["p24 antigen", "TEST", 145, 156], ["IgG", "TEST", 158, 161], ["p24", "TEST", 162, 165], ["IgG", "TEST", 170, 173], ["glomeruli", "ANATOMY", 35, 44], ["kidney", "ANATOMY", 77, 83], ["HIV", "OBSERVATION", 95, 98]]], ["In cases of HIV-related IgAN, circulating immune complexes containing IgA idiotype antibodies have been detected.", [["IgAN", "DISEASE", 24, 28], ["HIV", "ORGANISM", 12, 15], ["IgA idiotype antibodies", "GENE_OR_GENE_PRODUCT", 70, 93], ["circulating immune complexes", "PROTEIN", 30, 58], ["IgA idiotype antibodies", "PROTEIN", 70, 93], ["HIV", "SPECIES", 12, 15], ["HIV", "SPECIES", 12, 15], ["HIV", "PROBLEM", 12, 15], ["IgAN", "PROBLEM", 24, 28], ["circulating immune complexes", "PROBLEM", 30, 58], ["IgA idiotype antibodies", "PROBLEM", 70, 93], ["HIV", "OBSERVATION", 12, 15], ["idiotype antibodies", "OBSERVATION", 74, 93]]], ["58 Most patients with HIV-associated thrombotic microangiopathy/hemolytic uremic syndrome present with acute renal failure, microscopic hematuria, and non-nephrotic proteinuria.", [["renal", "ANATOMY", 109, 114], ["thrombotic microangiopathy", "DISEASE", 37, 63], ["hemolytic uremic syndrome", "DISEASE", 64, 89], ["acute renal failure", "DISEASE", 103, 122], ["hematuria", "DISEASE", 136, 145], ["proteinuria", "DISEASE", 165, 176], ["patients", "ORGANISM", 8, 16], ["renal", "ORGAN", 109, 114], ["patients", "SPECIES", 8, 16], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 22, 25], ["HIV", "PROBLEM", 22, 25], ["thrombotic microangiopathy", "PROBLEM", 37, 63], ["hemolytic uremic syndrome", "PROBLEM", 64, 89], ["acute renal failure", "PROBLEM", 103, 122], ["microscopic hematuria", "PROBLEM", 124, 145], ["non-nephrotic proteinuria", "PROBLEM", 151, 176], ["thrombotic", "OBSERVATION_MODIFIER", 37, 47], ["microangiopathy", "OBSERVATION", 48, 63], ["hemolytic uremic syndrome", "OBSERVATION", 64, 89], ["acute", "OBSERVATION_MODIFIER", 103, 108], ["renal", "ANATOMY", 109, 114], ["failure", "OBSERVATION", 115, 122], ["microscopic", "OBSERVATION_MODIFIER", 124, 135], ["hematuria", "OBSERVATION", 136, 145], ["non-nephrotic proteinuria", "OBSERVATION", 151, 176]]], ["Multiorgan involvement is frequent and prognosis is poor, with a high rate of mortality.", [["Multiorgan", "ANATOMY", 0, 10], ["Multiorgan involvement", "PROBLEM", 0, 22], ["a high rate of mortality", "PROBLEM", 63, 87], ["involvement", "OBSERVATION", 11, 22]]], ["Multifactorial etiologies encompass drugs, neoplasia, lymphoma and infection.PARVOVIRUS B19PVB19 has been associated with acute glomerulonephritis.", [["neoplasia", "ANATOMY", 43, 52], ["lymphoma", "ANATOMY", 54, 62], ["neoplasia", "DISEASE", 43, 52], ["lymphoma", "DISEASE", 54, 62], ["infection", "DISEASE", 67, 76], ["B19PVB19", "CHEMICAL", 88, 96], ["glomerulonephritis", "DISEASE", 128, 146], ["neoplasia", "CANCER", 43, 52], ["lymphoma", "CANCER", 54, 62], ["B19PVB19", "PROTEIN", 88, 96], ["Multifactorial etiologies encompass drugs", "PROBLEM", 0, 41], ["neoplasia", "PROBLEM", 43, 52], ["lymphoma", "PROBLEM", 54, 62], ["infection", "PROBLEM", 67, 76], ["PARVOVIRUS", "TEST", 77, 87], ["acute glomerulonephritis", "PROBLEM", 122, 146], ["neoplasia", "OBSERVATION", 43, 52], ["lymphoma", "OBSERVATION", 54, 62], ["infection", "OBSERVATION", 67, 76], ["associated with", "UNCERTAINTY", 106, 121], ["acute", "OBSERVATION_MODIFIER", 122, 127], ["glomerulonephritis", "OBSERVATION", 128, 146]]], ["Patients present with mild proteinuria and microhematuria, with low levels of serum complement 3.", [["serum", "ANATOMY", 78, 83], ["proteinuria", "DISEASE", 27, 38], ["microhematuria", "DISEASE", 43, 57], ["Patients", "ORGANISM", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["complement 3", "GENE_OR_GENE_PRODUCT", 84, 96], ["serum complement 3", "PROTEIN", 78, 96], ["Patients", "SPECIES", 0, 8], ["mild proteinuria", "PROBLEM", 22, 38], ["microhematuria", "PROBLEM", 43, 57], ["low levels of serum complement 3", "PROBLEM", 64, 96], ["mild", "OBSERVATION_MODIFIER", 22, 26], ["proteinuria", "OBSERVATION", 27, 38], ["microhematuria", "OBSERVATION", 43, 57], ["low levels", "OBSERVATION_MODIFIER", 64, 74]]], ["The pathology of this disease is characterized by endo capillary glomerulonephritis, MCGN, or both, with sub endothelial deposits.", [["capillary", "ANATOMY", 55, 64], ["endothelial", "ANATOMY", 109, 120], ["glomerulonephritis", "DISEASE", 65, 83], ["MCGN", "DISEASE", 85, 89], ["endo capillary", "TISSUE", 50, 64], ["MCGN", "CANCER", 85, 89], ["endothelial", "TISSUE", 109, 120], ["this disease", "PROBLEM", 17, 29], ["endo capillary glomerulonephritis", "PROBLEM", 50, 83], ["sub endothelial deposits", "PROBLEM", 105, 129], ["disease", "OBSERVATION", 22, 29], ["endo capillary glomerulonephritis", "OBSERVATION", 50, 83], ["sub endothelial deposits", "OBSERVATION", 105, 129]]], ["PVB19 capsid protein is found in the glomeruli.", [["glomeruli", "ANATOMY", 37, 46], ["PVB19", "GENE_OR_GENE_PRODUCT", 0, 5], ["glomeruli", "TISSUE", 37, 46], ["PVB19 capsid protein", "PROTEIN", 0, 20], ["capsid protein", "TEST", 6, 20], ["protein", "OBSERVATION", 13, 20], ["glomeruli", "ANATOMY", 37, 46]]], ["10 Spontaneous recovery is the norm.PARVOVIRUS B19PVB19 is also associated with collapsing glomerulopathy.", [["glomerulopathy", "DISEASE", 91, 105], ["PARVOVIRUS", "TEST", 36, 46], ["collapsing glomerulopathy", "PROBLEM", 80, 105], ["also associated with", "UNCERTAINTY", 59, 79], ["collapsing", "OBSERVATION_MODIFIER", 80, 90], ["glomerulopathy", "OBSERVATION", 91, 105]]], ["Prevalence of PVB19 DNA in renal biopsies (78%) and peripheral blood (87%) is significantly higher in patients with collapsing glomerulopathy than in those with other nephropathies.", [["renal biopsies", "ANATOMY", 27, 41], ["peripheral blood", "ANATOMY", 52, 68], ["glomerulopathy", "DISEASE", 127, 141], ["nephropathies", "DISEASE", 167, 180], ["PVB19", "TISSUE", 14, 19], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["renal biopsies", "MULTI-TISSUE_STRUCTURE", 27, 41], ["peripheral blood", "ORGANISM_SUBSTANCE", 52, 68], ["patients", "ORGANISM", 102, 110], ["PVB19 DNA", "DNA", 14, 23], ["patients", "SPECIES", 102, 110], ["PVB19", "SPECIES", 14, 19], ["renal biopsies", "TEST", 27, 41], ["peripheral blood", "TEST", 52, 68], ["collapsing glomerulopathy", "PROBLEM", 116, 141], ["other nephropathies", "PROBLEM", 161, 180], ["renal", "ANATOMY", 27, 32], ["biopsies", "OBSERVATION", 33, 41], ["peripheral", "ANATOMY_MODIFIER", 52, 62], ["blood", "ANATOMY", 63, 68], ["higher", "OBSERVATION_MODIFIER", 92, 98], ["collapsing", "OBSERVATION_MODIFIER", 116, 126], ["glomerulopathy", "OBSERVATION", 127, 141], ["nephropathies", "OBSERVATION", 167, 180]]], ["10 Glomerular and tubular infection with PVB19 might trigger collapsing glomerulopathy, but only in patients with immune defects and a racial pre disposition (African descent).", [["Glomerular", "ANATOMY", 3, 13], ["tubular", "ANATOMY", 18, 25], ["infection", "DISEASE", 26, 35], ["PVB19", "CHEMICAL", 41, 46], ["glomerulopathy", "DISEASE", 72, 86], ["immune defects", "DISEASE", 114, 128], ["Glomerular", "TISSUE", 3, 13], ["tubular", "MULTI-TISSUE_STRUCTURE", 18, 25], ["patients", "ORGANISM", 100, 108], ["patients", "SPECIES", 100, 108], ["tubular infection", "PROBLEM", 18, 35], ["PVB19", "TREATMENT", 41, 46], ["collapsing glomerulopathy", "PROBLEM", 61, 86], ["immune defects", "PROBLEM", 114, 128], ["Glomerular", "OBSERVATION", 3, 13], ["tubular", "ANATOMY_MODIFIER", 18, 25], ["infection", "OBSERVATION", 26, 35], ["collapsing", "OBSERVATION_MODIFIER", 61, 71], ["glomerulopathy", "OBSERVATION", 72, 86], ["immune defects", "OBSERVATION", 114, 128]]], ["8 Most intriguingly, Tanawattanacharoen and coworkers 9 detected PVB19 DNA in 80% of patients with 'idiopathic' FSGS, and frequently also in controls.", [["idiopathic' FSGS", "DISEASE", 100, 116], ["PVB19", "ORGANISM", 65, 70], ["DNA", "CELLULAR_COMPONENT", 71, 74], ["patients", "ORGANISM", 85, 93], ["PVB19 DNA", "DNA", 65, 74], ["patients", "SPECIES", 85, 93], ["'idiopathic' FSGS", "TREATMENT", 99, 116], ["FSGS", "OBSERVATION", 112, 116]]], ["These results possibly reflect the presence of latent DNA from past infection.", [["infection", "DISEASE", 68, 77], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["latent DNA", "PROBLEM", 47, 57], ["past infection", "PROBLEM", 63, 77], ["possibly reflect", "UNCERTAINTY", 14, 30], ["latent", "OBSERVATION_MODIFIER", 47, 53], ["DNA", "OBSERVATION", 54, 57], ["infection", "OBSERVATION", 68, 77]]], ["Failure to localize PVB19 nucleic acid within kidney is evidence against ongoing, high-level viral replication.HANTAVIRUSHantaviruses are responsible for 'hemorrhagic fever with renal syndrome' , an acute inter stitial nephritis resulting from direct vascular injury of renal tissue.", [["kidney", "ANATOMY", 46, 52], ["renal", "ANATOMY", 178, 183], ["vascular", "ANATOMY", 251, 259], ["renal tissue", "ANATOMY", 270, 282], ["PVB19 nucleic acid", "CHEMICAL", 20, 38], ["hemorrhagic fever", "DISEASE", 155, 172], ["renal syndrome", "DISEASE", 178, 192], ["nephritis", "DISEASE", 219, 228], ["PVB19", "GENE_OR_GENE_PRODUCT", 20, 25], ["kidney", "ORGAN", 46, 52], ["renal", "ORGAN", 178, 183], ["vascular", "MULTI-TISSUE_STRUCTURE", 251, 259], ["renal tissue", "TISSUE", 270, 282], ["PVB19", "PROTEIN", 20, 25], ["Failure to localize PVB19 nucleic acid within kidney", "PROBLEM", 0, 52], ["high-level viral replication", "PROBLEM", 82, 110], ["'hemorrhagic fever", "PROBLEM", 154, 172], ["renal syndrome'", "PROBLEM", 178, 193], ["an acute inter stitial nephritis", "PROBLEM", 196, 228], ["direct vascular injury of renal tissue", "PROBLEM", 244, 282], ["kidney", "ANATOMY", 46, 52], ["evidence against", "UNCERTAINTY", 56, 72], ["viral replication", "OBSERVATION", 93, 110], ["hemorrhagic", "OBSERVATION_MODIFIER", 155, 166], ["fever", "OBSERVATION", 167, 172], ["renal", "ANATOMY", 178, 183], ["syndrome", "OBSERVATION", 184, 192], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["inter stitial", "OBSERVATION_MODIFIER", 205, 218], ["nephritis", "OBSERVATION", 219, 228], ["vascular", "ANATOMY", 251, 259], ["injury", "OBSERVATION", 260, 266], ["renal tissue", "ANATOMY", 270, 282]]], ["59 The severe form leads to acute renal failure in 50% of cases.", [["renal", "ANATOMY", 34, 39], ["acute renal failure", "DISEASE", 28, 47], ["renal", "ORGAN", 34, 39], ["acute renal failure", "PROBLEM", 28, 47], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["renal", "ANATOMY", 34, 39], ["failure", "OBSERVATION", 40, 47]]], ["Less severe forms occur in nonendemic areas, and present primarily as fever, hepatitis, and mild renal impairment.", [["renal", "ANATOMY", 97, 102], ["fever", "DISEASE", 70, 75], ["hepatitis", "DISEASE", 77, 86], ["renal impairment", "DISEASE", 97, 113], ["renal", "ORGAN", 97, 102], ["Less severe forms", "PROBLEM", 0, 17], ["nonendemic areas", "PROBLEM", 27, 43], ["fever", "PROBLEM", 70, 75], ["hepatitis", "PROBLEM", 77, 86], ["mild renal impairment", "PROBLEM", 92, 113], ["severe", "OBSERVATION_MODIFIER", 5, 11], ["nonendemic", "OBSERVATION_MODIFIER", 27, 37], ["fever", "OBSERVATION", 70, 75], ["hepatitis", "OBSERVATION", 77, 86], ["mild", "OBSERVATION_MODIFIER", 92, 96], ["renal", "ANATOMY", 97, 102], ["impairment", "OBSERVATION", 103, 113]]], ["In most cases, glomeruli are not affected and the pathology is tubulointerstitial.", [["glomeruli", "ANATOMY", 15, 24], ["tubulointerstitial", "ANATOMY", 63, 81], ["tubulointerstitial", "DISEASE", 63, 81], ["glomeruli", "MULTI-TISSUE_STRUCTURE", 15, 24], ["tubulointerstitial", "PROBLEM", 63, 81], ["glomeruli", "ANATOMY", 15, 24], ["pathology", "OBSERVATION", 50, 59], ["tubulointerstitial", "OBSERVATION", 63, 81]]], ["Isolated cases with immune complex glomerular disease have been described, in association with diffuse proliferative glomerulonephritis and complete recovery after remission of the systemic clinical syndrome.", [["glomerular", "ANATOMY", 35, 45], ["glomerular disease", "DISEASE", 35, 53], ["glomerulonephritis", "DISEASE", 117, 135], ["glomerular", "TISSUE", 35, 45], ["Isolated cases", "PROBLEM", 0, 14], ["immune complex glomerular disease", "PROBLEM", 20, 53], ["diffuse proliferative glomerulonephritis", "PROBLEM", 95, 135], ["the systemic clinical syndrome", "PROBLEM", 177, 207], ["immune complex", "OBSERVATION_MODIFIER", 20, 34], ["glomerular disease", "OBSERVATION", 35, 53], ["diffuse", "OBSERVATION_MODIFIER", 95, 102], ["proliferative", "OBSERVATION_MODIFIER", 103, 116], ["glomerulonephritis", "OBSERVATION", 117, 135], ["complete", "OBSERVATION_MODIFIER", 140, 148], ["recovery", "OBSERVATION_MODIFIER", 149, 157], ["systemic", "OBSERVATION_MODIFIER", 181, 189], ["clinical syndrome", "OBSERVATION", 190, 207]]], ["60SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUSSix percent of patients suffering from severe acute respiratory distress syndrome had acute renal impairment.", [["respiratory", "ANATOMY", 99, 110], ["renal", "ANATOMY", 139, 144], ["acute respiratory distress syndrome", "DISEASE", 93, 128], ["acute renal impairment", "DISEASE", 133, 155], ["patients", "ORGANISM", 62, 70], ["renal", "ORGAN", 139, 144], ["patients", "SPECIES", 62, 70], ["ACUTE RESPIRATORY SYNDROME", "PROBLEM", 9, 35], ["severe acute respiratory distress syndrome", "PROBLEM", 86, 128], ["acute renal impairment", "PROBLEM", 133, 155], ["ACUTE", "OBSERVATION_MODIFIER", 9, 14], ["RESPIRATORY SYNDROME", "OBSERVATION", 15, 35], ["severe", "OBSERVATION_MODIFIER", 86, 92], ["acute", "OBSERVATION_MODIFIER", 93, 98], ["respiratory distress", "OBSERVATION", 99, 119], ["syndrome", "OBSERVATION", 120, 128], ["acute", "OBSERVATION_MODIFIER", 133, 138], ["renal", "ANATOMY", 139, 144], ["impairment", "OBSERVATION", 145, 155]]], ["61 Despite detection of viral DNA in the urine, there was no evidence of viral tropism of the kidney.", [["urine", "ANATOMY", 41, 46], ["kidney", "ANATOMY", 94, 100], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["urine", "ORGANISM_SUBSTANCE", 41, 46], ["kidney", "ORGAN", 94, 100], ["viral DNA", "DNA", 24, 33], ["viral DNA in the urine", "PROBLEM", 24, 46], ["viral tropism of the kidney", "PROBLEM", 73, 100], ["viral DNA", "OBSERVATION", 24, 33], ["no evidence of", "UNCERTAINTY", 58, 72], ["viral tropism", "OBSERVATION", 73, 86], ["kidney", "ANATOMY", 94, 100]]], ["The pathology is exclusively tubulointerstitial nephritis.", [["tubulointerstitial", "ANATOMY", 29, 47], ["tubulointerstitial nephritis", "DISEASE", 29, 57], ["tubulointerstitial nephritis", "CANCER", 29, 57], ["The pathology", "TEST", 0, 13], ["tubulointerstitial nephritis", "PROBLEM", 29, 57], ["pathology", "OBSERVATION", 4, 13], ["exclusively", "OBSERVATION_MODIFIER", 17, 28], ["tubulointerstitial", "OBSERVATION_MODIFIER", 29, 47], ["nephritis", "OBSERVATION", 48, 57]]], ["The mechanism of disease is probably related to multiorgan failure, rhabdomyolysis, and hemodynamic disturbance.BK VIRUSRenal infection with BK virus affects kidney allograft recipients, leading to renal dysfunction and sometimes graft loss.", [["multiorgan", "ANATOMY", 48, 58], ["kidney allograft", "ANATOMY", 158, 174], ["renal", "ANATOMY", 198, 203], ["graft", "ANATOMY", 230, 235], ["multiorgan failure", "DISEASE", 48, 66], ["rhabdomyolysis", "DISEASE", 68, 82], ["hemodynamic disturbance", "DISEASE", 88, 111], ["BK", "CHEMICAL", 112, 114], ["infection", "DISEASE", 126, 135], ["renal dysfunction", "DISEASE", 198, 215], ["graft loss", "DISEASE", 230, 240], ["multiorgan", "ORGAN", 48, 58], ["BK", "ORGANISM", 112, 114], ["BK virus", "ORGANISM", 141, 149], ["kidney allograft", "MULTI-TISSUE_STRUCTURE", 158, 174], ["renal", "ORGAN", 198, 203], ["graft", "TISSUE", 230, 235], ["BK virus", "SPECIES", 141, 149], ["disease", "PROBLEM", 17, 24], ["multiorgan failure", "PROBLEM", 48, 66], ["rhabdomyolysis", "PROBLEM", 68, 82], ["hemodynamic disturbance", "PROBLEM", 88, 111], ["BK VIRUSRenal infection", "PROBLEM", 112, 135], ["BK virus", "PROBLEM", 141, 149], ["kidney allograft recipients", "TREATMENT", 158, 185], ["renal dysfunction", "PROBLEM", 198, 215], ["sometimes graft loss", "PROBLEM", 220, 240], ["disease", "OBSERVATION", 17, 24], ["probably related to", "UNCERTAINTY", 28, 47], ["multiorgan failure", "OBSERVATION", 48, 66], ["rhabdomyolysis", "OBSERVATION", 68, 82], ["hemodynamic disturbance", "OBSERVATION", 88, 111], ["infection", "OBSERVATION", 126, 135], ["BK virus", "OBSERVATION", 141, 149], ["kidney", "ANATOMY", 158, 164], ["allograft", "OBSERVATION", 165, 174], ["renal", "ANATOMY", 198, 203], ["dysfunction", "OBSERVATION", 204, 215], ["graft loss", "OBSERVATION", 230, 240]]], ["62 More rarely, acute interstitial nephritis is observed in immunocompromised patients.", [["interstitial", "ANATOMY", 22, 34], ["interstitial nephritis", "DISEASE", 22, 44], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["acute interstitial nephritis", "PROBLEM", 16, 44], ["acute", "OBSERVATION_MODIFIER", 16, 21], ["interstitial", "ANATOMY_MODIFIER", 22, 34], ["nephritis", "OBSERVATION", 35, 44], ["immunocompromised", "OBSERVATION_MODIFIER", 60, 77]]], ["63OTHER VIRUSESHepatitis A virus infection can present as acute post-infectious glomerulopnephritis with pathology resembling that of IgAN.", [["infection", "DISEASE", 33, 42], ["glomerulopnephritis", "DISEASE", 80, 99], ["IgAN", "DISEASE", 134, 138], ["63OTHER VIRUSESHepatitis A virus", "ORGANISM", 0, 32], ["VIRUSESHepatitis A virus", "SPECIES", 8, 32], ["A virus infection", "PROBLEM", 25, 42], ["acute post-infectious glomerulopnephritis", "PROBLEM", 58, 99], ["pathology", "PROBLEM", 105, 114], ["virus infection", "OBSERVATION", 27, 42], ["acute", "OBSERVATION_MODIFIER", 58, 63], ["infectious", "OBSERVATION_MODIFIER", 69, 79], ["glomerulopnephritis", "OBSERVATION", 80, 99], ["IgAN", "OBSERVATION", 134, 138]]], ["64 More commonly, hepatitis A virus induces acute renal failure secondary to acute fulminant hepatitis.", [["renal", "ANATOMY", 50, 55], ["hepatitis A", "DISEASE", 18, 29], ["acute renal failure", "DISEASE", 44, 63], ["hepatitis", "DISEASE", 93, 102], ["hepatitis A virus", "ORGANISM", 18, 35], ["renal", "ORGAN", 50, 55], ["hepatitis A virus", "SPECIES", 18, 35], ["hepatitis A virus", "SPECIES", 18, 35], ["hepatitis A virus", "PROBLEM", 18, 35], ["acute renal failure", "PROBLEM", 44, 63], ["acute fulminant hepatitis", "PROBLEM", 77, 102], ["hepatitis", "OBSERVATION", 18, 27], ["acute", "OBSERVATION_MODIFIER", 44, 49], ["renal", "ANATOMY", 50, 55], ["failure", "OBSERVATION", 56, 63], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["fulminant", "OBSERVATION_MODIFIER", 83, 92], ["hepatitis", "OBSERVATION", 93, 102]]], ["65 Acute renal failure complicating other viral infections, such as Epstein-Barr virus 66 and dengue fever, 67 is related to multiorgan failure, rhabdomyolysis, and hepatorenal syndrome.CONCLUSIONDiverse mechanisms of glomerular and tubulointerstitial injury and heterogeneous clinicopathologic patterns underlie the relationship between viral infection and glomerular disease.", [["renal", "ANATOMY", 9, 14], ["multiorgan", "ANATOMY", 125, 135], ["glomerular", "ANATOMY", 218, 228], ["tubulointerstitial", "ANATOMY", 233, 251], ["glomerular", "ANATOMY", 358, 368], ["Acute renal failure", "DISEASE", 3, 22], ["viral infections", "DISEASE", 42, 58], ["Epstein-Barr virus", "DISEASE", 68, 86], ["dengue fever", "DISEASE", 94, 106], ["multiorgan failure", "DISEASE", 125, 143], ["rhabdomyolysis", "DISEASE", 145, 159], ["hepatorenal syndrome.CONCLUSIONDiverse", "DISEASE", 165, 203], ["tubulointerstitial injury", "DISEASE", 233, 258], ["viral infection", "DISEASE", 338, 353], ["glomerular disease", "DISEASE", 358, 376], ["renal", "ORGAN", 9, 14], ["Epstein-Barr virus 66", "ORGANISM", 68, 89], ["multiorgan", "ORGAN", 125, 135], ["glomerular", "TISSUE", 218, 228], ["tubulointerstitial", "MULTI-TISSUE_STRUCTURE", 233, 251], ["glomerular", "TISSUE", 358, 368], ["Epstein-Barr virus 66", "SPECIES", 68, 89], ["Acute renal failure", "PROBLEM", 3, 22], ["other viral infections", "PROBLEM", 36, 58], ["Barr virus", "PROBLEM", 76, 86], ["dengue fever", "PROBLEM", 94, 106], ["multiorgan failure", "PROBLEM", 125, 143], ["rhabdomyolysis", "PROBLEM", 145, 159], ["hepatorenal syndrome.CONCLUSIONDiverse mechanisms", "PROBLEM", 165, 214], ["glomerular and tubulointerstitial injury", "PROBLEM", 218, 258], ["heterogeneous clinicopathologic patterns", "PROBLEM", 263, 303], ["viral infection", "PROBLEM", 338, 353], ["glomerular disease", "PROBLEM", 358, 376], ["Acute", "OBSERVATION_MODIFIER", 3, 8], ["renal", "ANATOMY", 9, 14], ["failure", "OBSERVATION", 15, 22], ["viral", "OBSERVATION_MODIFIER", 42, 47], ["infections", "OBSERVATION", 48, 58], ["multiorgan", "ANATOMY", 125, 135], ["failure", "OBSERVATION", 136, 143], ["rhabdomyolysis", "OBSERVATION", 145, 159], ["hepatorenal", "OBSERVATION", 165, 176], ["glomerular", "ANATOMY", 218, 228], ["tubulointerstitial", "OBSERVATION_MODIFIER", 233, 251], ["injury", "OBSERVATION", 252, 258], ["heterogeneous", "OBSERVATION_MODIFIER", 263, 276], ["clinicopathologic", "OBSERVATION", 277, 294], ["viral", "OBSERVATION_MODIFIER", 338, 343], ["infection", "OBSERVATION", 344, 353], ["glomerular disease", "OBSERVATION", 358, 376]]], ["The etiological role of some viruses is still un defined.", [["some viruses", "PROBLEM", 24, 36], ["some", "OBSERVATION_MODIFIER", 24, 28], ["viruses", "OBSERVATION", 29, 36]]], ["Molecular biology techniques are vital in elucidating the precise location and role of viruses in the pathogenesis of virus-related nephropathy.", [["nephropathy", "DISEASE", 132, 143], ["viruses", "PROBLEM", 87, 94], ["virus", "PROBLEM", 118, 123], ["related nephropathy", "PROBLEM", 124, 143], ["viruses", "OBSERVATION", 87, 94], ["nephropathy", "OBSERVATION", 132, 143]]]], "e152b141715401b2de26d9b172ce02972bf10288": [["IntroductionPorcine epidemic diarrhea (PED) is an acute enteric tract infectious disease of swine characterized by vomiting, watery diarrhea, dehydration, and death (Debouck et al. 1981 ).", [["diarrhea", "DISEASE", 29, 37], ["PED", "DISEASE", 39, 42], ["enteric tract infectious disease", "DISEASE", 56, 88], ["vomiting", "DISEASE", 115, 123], ["watery diarrhea", "DISEASE", 125, 140], ["dehydration", "DISEASE", 142, 153], ["death", "DISEASE", 159, 164], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["swine", "ORGANISM", 92, 97], ["swine", "SPECIES", 92, 97], ["swine", "SPECIES", 92, 97], ["IntroductionPorcine epidemic diarrhea", "PROBLEM", 0, 37], ["an acute enteric tract infectious disease of swine", "PROBLEM", 47, 97], ["vomiting", "PROBLEM", 115, 123], ["watery diarrhea", "PROBLEM", 125, 140], ["dehydration", "PROBLEM", 142, 153], ["death", "PROBLEM", 159, 164], ["acute", "OBSERVATION_MODIFIER", 50, 55], ["enteric tract", "ANATOMY", 56, 69], ["infectious", "OBSERVATION", 70, 80]]], ["These symptoms especially lead to high mortality rate in suckling piglet (90-100%), which is the main reason for the huge economic losses in the global swine industry (Li et al. 2012b; Sun et al. 2012) .", [["piglet", "ANATOMY", 66, 72], ["piglet", "ORGAN", 66, 72], ["piglet", "SPECIES", 66, 72], ["swine", "SPECIES", 152, 157], ["swine", "SPECIES", 152, 157], ["These symptoms", "PROBLEM", 0, 14], ["high mortality rate", "PROBLEM", 34, 53], ["the huge economic losses", "PROBLEM", 113, 137], ["huge", "OBSERVATION_MODIFIER", 117, 121], ["economic", "OBSERVATION_MODIFIER", 122, 130], ["losses", "OBSERVATION", 131, 137]]], ["Recently, there were one of the most severe outbreaks in the USA; about 7 million piglets (10% of total domestic pigs) died from the disease within a single year (Jung and Saif 2015; Paarlberg 2014) .IntroductionThe causative agent, PED virus (PEDV), is classified as a member of the order Nidovirales, family Coronaviridae, and genus Alphacoronavirus.", [["piglets", "ORGANISM", 82, 89], ["pigs", "ORGANISM", 113, 117], ["PED virus", "ORGANISM", 233, 242], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 290, 301], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 310, 323], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 335, 351], ["piglets", "SPECIES", 82, 89], ["pigs", "SPECIES", 113, 117], ["PED virus", "SPECIES", 233, 242], ["PEDV", "SPECIES", 244, 248], ["total domestic pigs", "TREATMENT", 98, 117], ["the disease", "PROBLEM", 129, 140], ["PED virus", "PROBLEM", 233, 242], ["Coronaviridae", "TREATMENT", 310, 323], ["most", "OBSERVATION_MODIFIER", 32, 36], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["outbreaks", "OBSERVATION", 44, 53], ["disease", "OBSERVATION", 133, 140]]], ["PEDV is an enveloped, single-stranded, and positive-sense RNA virus.", [["PEDV", "CHEMICAL", 0, 4], ["PEDV", "GENE_OR_GENE_PRODUCT", 0, 4], ["PEDV", "DNA", 0, 4], ["PEDV", "SPECIES", 0, 4], ["PEDV", "PROBLEM", 0, 4], ["positive-sense RNA virus", "PROBLEM", 43, 67], ["enveloped", "OBSERVATION_MODIFIER", 11, 20], ["RNA virus", "OBSERVATION", 58, 67]]], ["Its genome is approximately 28 kb in length and consists of a 5\u2032 untranslated region (UTR), a 3\u2032 UTR, and seven open reading frames (ORFs): ORF1a, ORF1b, S, ORF3, E, M, and N (Kocherhans et al. 2001 ).", [["ORF1a", "GENE_OR_GENE_PRODUCT", 140, 145], ["ORF1b", "GENE_OR_GENE_PRODUCT", 147, 152], ["ORF3", "GENE_OR_GENE_PRODUCT", 157, 161], ["5\u2032 untranslated region", "DNA", 62, 84], ["UTR", "DNA", 86, 89], ["UTR", "DNA", 97, 100], ["open reading frames", "DNA", 112, 131], ["ORFs", "DNA", 133, 137], ["ORF1a", "DNA", 140, 145], ["ORF1b", "DNA", 147, 152], ["S", "DNA", 154, 155], ["ORF3", "DNA", 157, 161], ["E", "DNA", 163, 164], ["a 5\u2032 untranslated region", "PROBLEM", 60, 84], ["UTR", "PROBLEM", 97, 100], ["ORF1a", "TEST", 140, 145], ["ORF1b", "TEST", 147, 152], ["ORF3", "TEST", 157, 161], ["genome", "OBSERVATION_MODIFIER", 4, 10], ["approximately", "OBSERVATION_MODIFIER", 14, 27], ["28 kb", "OBSERVATION_MODIFIER", 28, 33], ["length", "OBSERVATION_MODIFIER", 37, 43]]], ["The first two ORFs (ORF1a and ORF1b) encode two replicase polyproteins, and the remaining five code for an accessory protein (ORF3) and the following structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N) (Duarte et al. 1994) .IntroductionThe PEDV was first observed in domesticated pigs in England in 1971 (Oldham 1972) , and then spread to European countries such as Belgium (Pensaert and De Bouck 1978) , England (Pritchard et al. 1999) , Czech (Sm\u00edd et al. 1992 ) during the 1970s and 1980s.", [["membrane", "ANATOMY", 196, 204], ["ORF1a", "GENE_OR_GENE_PRODUCT", 20, 25], ["ORF1b", "GENE_OR_GENE_PRODUCT", 30, 35], ["ORF3", "GENE_OR_GENE_PRODUCT", 126, 130], ["spike (S), envelope (E)", "GENE_OR_GENE_PRODUCT", 171, 194], ["membrane", "CELLULAR_COMPONENT", 196, 204], ["pigs", "ORGANISM", 309, 313], ["ORFs", "DNA", 14, 18], ["ORF1a", "DNA", 20, 25], ["ORF1b", "DNA", 30, 35], ["replicase polyproteins", "PROTEIN", 48, 70], ["accessory protein", "PROTEIN", 107, 124], ["ORF3", "PROTEIN", 126, 130], ["structural proteins", "PROTEIN", 150, 169], ["spike (S), envelope (E), membrane (M)", "PROTEIN", 171, 208], ["pigs", "SPECIES", 309, 313], ["PEDV", "SPECIES", 269, 273], ["ORF1a", "TEST", 20, 25], ["two replicase polyproteins", "TREATMENT", 44, 70], ["an accessory protein (ORF3", "TREATMENT", 104, 130], ["envelope (E), membrane (M), and nucleocapsid (N)", "PROBLEM", 182, 230], ["The PEDV", "TREATMENT", 265, 273]]], ["In Asia, the first case of the disease was reported in China in 1973 (Sun et al. 2016) , and subsequently occurred in other Asian countries such as South Korea (Kweon et al. 1993) , Japan (Takahashi et al. 1983) , Viet Nam (Toan et al. 2011) , and Thailand (Puranaveja et al. 2009 ).", [["the disease", "PROBLEM", 27, 38], ["disease", "OBSERVATION", 31, 38]]], ["In late 2010, highly pathogenic PEDV strains appeared in China and were considered as the first pandemic strains (Sun et al. 2012) .", [["PEDV", "ORGANISM", 32, 36], ["PEDV", "SPECIES", 32, 36], ["highly pathogenic PEDV strains", "PROBLEM", 14, 44], ["the first pandemic strains", "PROBLEM", 86, 112], ["pathogenic", "OBSERVATION_MODIFIER", 21, 31], ["PEDV strains", "OBSERVATION", 32, 44]]], ["In April 2013, the highly virulent PEDV was also first reported (Stevenson et al. 2013) in the USA and spread across the nation (31 states) (Cima 2013) .", [["PEDV", "CANCER", 35, 39], ["PEDV", "SPECIES", 35, 39], ["the highly virulent PEDV", "PROBLEM", 15, 39], ["virulent", "OBSERVATION_MODIFIER", 26, 34], ["PEDV", "OBSERVATION", 35, 39]]], ["Since then, the notorious strains emerged continuously in many other countries including South Korea (Lee and Lee 2014) , Japan (Suzuki et al. 2015) , Taiwan (Chiou et al. 2014) , Canada (Pasick et al. 2014) , Mexico (Vlasova et al. 2014) .", [["the notorious strains", "PROBLEM", 12, 33]]], ["The PEDV strains detected in these countries were classified as US-like PEDV strains.", [["PEDV strains", "ORGANISM", 4, 16], ["PEDV", "ORGANISM", 72, 76], ["PEDV", "SPECIES", 4, 8], ["The PEDV strains", "PROBLEM", 0, 16], ["US", "TEST", 64, 66], ["PEDV strains", "PROBLEM", 72, 84]]], ["In December 2013, a new PEDV strain OH851 (later designated as S INDEL PEDV) causing lower mortality rate which has specific insertions and deletions in N-terminal of the S protein (S1 region) was detected in the USA (Oka et al. 2014; Vlasova et al. 2014) .", [["OH851", "CHEMICAL", 36, 41], ["N", "CHEMICAL", 153, 154], ["S protein", "GENE_OR_GENE_PRODUCT", 171, 180], ["S protein", "PROTEIN", 171, 180], ["S1 region", "PROTEIN", 182, 191], ["a new PEDV strain OH851", "PROBLEM", 18, 41], ["lower mortality rate", "PROBLEM", 85, 105], ["deletions in N", "PROBLEM", 140, 154], ["S1", "ANATOMY", 182, 184]]], ["(Grasland et al. 2015; Hanke et al. 2015; Kim et al. 2016; Lee and Lee 2014; Mesquita et al. 2015) .IntroductionTo date, there have been many investigations of the PEDV phylogenetics on the basis of particular genes-S (Li et al. 2012a ), ORF3 (Li et al. 2014 ), E , M (Chen et al. 2008) , and N (Li et al. 2013 )-and genome (Chen et al. 2014; Huang et al. 2013; Lin et al. 2016; Stevenson et al. 2013) sequences.", [["ORF3", "DNA", 238, 242], ["Stevenson et al. 2013) sequences", "DNA", 379, 411], ["the PEDV phylogenetics", "PROBLEM", 160, 182]]], ["Nevertheless, there was no time-calibrated phylogenomic study on this virus.", [["phylogenomic study", "TEST", 43, 61], ["this virus", "PROBLEM", 65, 75]]], ["In order to explore this topic, we analyzed 138 available public genome sequences that collected during the 38 years .", [["public genome sequences", "DNA", 58, 81], ["public genome sequences", "TREATMENT", 58, 81]]], ["The main focus of this study are (1) to characterize sequences of PEDV coding region; (2) to reconstruct the genome-wide phylogeny of the global PEDVs using two different analyses methods, Bayesian inference (BI) and maximum likelihood (ML); and (3) to examine the various evolutionary mechanisms including selection pressure, substitution rate, divergence times, and effective population size changes using Bayesian coalescent approach.IntroductionIn this paper, the terms \"classical\" and \"pandemic\" PEDV isolates respectively correspond to the PEDV prototype CV777-like isolates that have appeared since the 1970s and other PEDV isolates globally detected after 2010.Data collection and sequence analysisWe analyzed 138 PEDV coding genome sequences available on NCBI, collected around the world from 1978 to 2015.", [["PEDV", "ORGANISM", 501, 505], ["PEDV prototype CV777", "ORGANISM", 546, 566], ["PEDV coding region", "DNA", 66, 84], ["global PEDVs", "DNA", 138, 150], ["PEDV coding genome sequences", "DNA", 722, 750], ["this study", "TEST", 18, 28], ["PEDV coding region", "PROBLEM", 66, 84], ["selection pressure", "TREATMENT", 307, 325], ["substitution rate", "TREATMENT", 327, 344], ["effective population size changes", "TREATMENT", 368, 401], ["Bayesian coalescent approach", "TREATMENT", 408, 436], ["the PEDV prototype", "TEST", 542, 560], ["other PEDV isolates", "TEST", 620, 639], ["Data collection", "TEST", 669, 684], ["sequence analysisWe", "TEST", 689, 708], ["PEDV coding genome sequences", "TEST", 722, 750], ["main", "OBSERVATION_MODIFIER", 4, 8], ["size", "OBSERVATION_MODIFIER", 389, 393]]], ["These viruses were composed of 43 Asian (27 from China, eight from South Korea, four from Thailand, three from Viet Nam, and one from Japan), five European (two from Belgium, two from Germany, and one from France), and 90 American (87 from USA, two from Mexico, and one from Canada) viruses (Table S1 ).", [["These viruses", "PROBLEM", 0, 13], ["viruses", "OBSERVATION", 6, 13]]], ["At the first stage of making our data matrix, all known recombinant sequences were removed.", [["matrix", "CELLULAR_COMPONENT", 38, 44], ["recombinant sequences", "DNA", 56, 77], ["all known recombinant sequences", "PROBLEM", 46, 77]]], ["Namely, all sequences were screened for the presence of recombination events via the RDP 3.0b41 package (Martin et al. 2015) with the default parameters.", [["all sequences", "TEST", 8, 21], ["recombination events", "PROBLEM", 56, 76]]], ["To avert the possibility of detecting false-positive recombinants, we considered only putative recombinant sites detected by at least 3 out of 6 methods.", [["recombinant sites", "DNA", 95, 112], ["false-positive recombinants", "PROBLEM", 38, 65], ["putative recombinant sites", "PROBLEM", 86, 112], ["positive recombinants", "OBSERVATION", 44, 65]]], ["In all analyses, p < 0.05 was considered to indicate statistical significance.Data collection and sequence analysisBoth nucleotide and amino acid sequences of coding regions were aligned with MAFFT 7 (Katoh and Standley 2013) .", [["nucleotide", "CHEMICAL", 120, 130], ["amino acid", "CHEMICAL", 135, 145], ["nucleotide", "CHEMICAL", 120, 130], ["amino acid", "CHEMICAL", 135, 145], ["amino acid", "AMINO_ACID", 135, 145], ["coding regions", "DNA", 159, 173], ["MAFFT 7", "DNA", 192, 199], ["Data collection", "TEST", 78, 93], ["sequence analysisBoth nucleotide", "TEST", 98, 130], ["amino acid sequences", "TEST", 135, 155], ["MAFFT", "TEST", 192, 197]]], ["The final alignment was composed of 27,436 nucleotide positions and can be obtained from the authors.", [["nucleotide", "CHEMICAL", 43, 53], ["alignment", "OBSERVATION_MODIFIER", 10, 19]]], ["The alignment of coding genome sequences was also divided into the corresponding individual genes: ORF1a-ORF1b-S-ORF3-E-M-N.", [["coding genome sequences", "DNA", 17, 40]]], ["All gene positions quoted here are with respect to PEDV genome of prototype CV777 (GenBank accession no. AF353511).", [["AF353511", "CHEMICAL", 105, 113], ["AF353511", "CHEMICAL", 105, 113], ["PEDV genome", "DNA", 51, 62], ["CV777", "DNA", 76, 81], ["All gene positions", "TREATMENT", 0, 18]]], ["For both nucleotide and amino acid sequences of the seven individual genes, as well as the entire coding region, identical sequence were filtered primally and estimated transition-transversion ratio were calculated by Tree-Puzzle 5.3 (Schmidt et al. 2002) .", [["nucleotide", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 24, 34], ["nucleotide", "CHEMICAL", 9, 19], ["amino acid", "CHEMICAL", 24, 34], ["amino acid", "AMINO_ACID", 24, 34], ["entire coding region", "DNA", 91, 111], ["both nucleotide and amino acid sequences", "TEST", 4, 44], ["transversion ratio", "TEST", 180, 198]]], ["The transition-transversion ratio were estimated as 2.63 and it was used as input value in following recombinant detection model.", [["The transition-transversion ratio", "TEST", 0, 33]]], ["After primal filtering, following measures were estimated using BioEdit 7.2.5 (Hall 1999) , and Modeltest 3.7 (Posada 2003) : total sites (including gaps), conserved sites, and average identities, base frequencies, substitution matrix, and evolutionary models.Data collection and sequence analysisIn addition, we plotted the number of nucleotide and amino acid variations at each position throughout the 138 PEDV whole coding region alignment.", [["nucleotide", "CHEMICAL", 335, 345], ["amino acid", "CHEMICAL", 350, 360], ["nucleotide", "CHEMICAL", 335, 345], ["amino acid", "CHEMICAL", 350, 360], ["amino acid", "AMINO_ACID", 350, 360], ["138 PEDV whole coding region", "DNA", 404, 432], ["BioEdit", "TEST", 64, 71], ["Modeltest", "TEST", 96, 105], ["substitution matrix", "TREATMENT", 215, 234], ["Data collection", "TEST", 260, 275], ["sequence analysisIn", "TEST", 280, 299], ["nucleotide and amino acid variations", "TREATMENT", 335, 371], ["sites", "OBSERVATION_MODIFIER", 166, 171], ["base", "ANATOMY_MODIFIER", 197, 201], ["substitution matrix", "OBSERVATION", 215, 234]]], ["We first estimated the nucleotide differences by counting the number of minor nucleotides at each position across the sequence alignment.", [["nucleotide", "CHEMICAL", 23, 33], ["nucleotides", "CHEMICAL", 78, 89], ["the nucleotide differences", "PROBLEM", 19, 45], ["minor nucleotides", "OBSERVATION", 72, 89]]], ["Next, we defined the major nucleotide at each site as the most frequent nucleotide (A, T, C, or G), and the rest of the nucleotides were considered as minor nucleotides.", [["nucleotide", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 27, 37], ["nucleotide", "CHEMICAL", 72, 82], ["nucleotides", "CHEMICAL", 120, 131], ["nucleotides", "CHEMICAL", 157, 168], ["the nucleotides", "TREATMENT", 116, 131], ["minor nucleotides", "PROBLEM", 151, 168]]], ["For example, at a specific position of the alignment, if the nucleotide C was major in 120 samples, the nucleotides A, T, and G were considered as minor nucleotides in the remaining 18 samples; the nucleotide difference was 18.", [["samples", "ANATOMY", 91, 98], ["samples", "ANATOMY", 185, 192], ["nucleotide", "CHEMICAL", 61, 71], ["nucleotide C", "CHEMICAL", 61, 73], ["nucleotides", "CHEMICAL", 153, 164], ["nucleotide", "CHEMICAL", 198, 208], ["nucleotide C", "GENE_OR_GENE_PRODUCT", 61, 73], ["samples", "CANCER", 91, 98], ["T", "GENE_OR_GENE_PRODUCT", 119, 120], ["G", "GENE_OR_GENE_PRODUCT", 126, 127], ["nucleotide C", "DNA", 61, 73], ["the nucleotide C", "TEST", 57, 73], ["the nucleotides", "TEST", 100, 115], ["minor nucleotides", "PROBLEM", 147, 164], ["the nucleotide difference", "TEST", 194, 219]]], ["We applied the same principle for amino acid differences.Phylogenomic reconstructionsPhylogenomic trees for the PEDV coding genomes were reconstructed using two different analytical methods: Bayesian inference (BI) and maximum likelihood (ML).", [["amino acid", "CHEMICAL", 34, 44], ["amino acid", "CHEMICAL", 34, 44], ["amino acid", "AMINO_ACID", 34, 44], ["PEDV coding genomes", "DNA", 112, 131], ["amino acid differences", "TREATMENT", 34, 56], ["Phylogenomic reconstructions", "TEST", 57, 85], ["Phylogenomic trees", "PROBLEM", 85, 103], ["the PEDV coding genomes", "PROBLEM", 108, 131]]], ["We chose the best-fit model of nucleotide substitution with the standard ModelTest PAUP block in PAUP 4.0b10 (Swofford 2003 ) and Akaike's information criterion (AIC) in ModelTest 3.7 (Posada 2003) ; GTR + I + G was selected as the best evolutionary model.", [["nucleotide", "CHEMICAL", 31, 41], ["nucleotide", "CHEMICAL", 31, 41], ["GTR + I + G", "GENE_OR_GENE_PRODUCT", 200, 211], ["nucleotide substitution", "TREATMENT", 31, 54], ["the standard ModelTest PAUP block", "TREATMENT", 60, 93], ["ModelTest", "TEST", 170, 179], ["GTR + I + G", "TREATMENT", 200, 211]]], ["The uniformed BI analysis was carried out using MrBayes 3.2.5 (Ronquist and Huelsenbeck 2003) with the GTR + I + G model.", [["The uniformed BI analysis", "TEST", 0, 25], ["MrBayes", "TEST", 48, 55], ["the GTR", "TREATMENT", 99, 106]]], ["For the partitioned model approach of BI analysis, 7 genes were concatenated and the following models were applied: GTR + I + G for the ORF1a, ORF1b, and S gene regions; TrN + I for the ORF3 and M gene regions; TrN for the E gene region; GTR + G for the N gene region (Table 1) .", [["GTR + I + G", "GENE_OR_GENE_PRODUCT", 116, 127], ["ORF1a", "GENE_OR_GENE_PRODUCT", 136, 141], ["ORF1b", "GENE_OR_GENE_PRODUCT", 143, 148], ["TrN + I", "GENE_OR_GENE_PRODUCT", 170, 177], ["ORF3", "GENE_OR_GENE_PRODUCT", 186, 190], ["GTR + G", "GENE_OR_GENE_PRODUCT", 238, 245], ["ORF1a", "DNA", 136, 141], ["ORF1b", "DNA", 143, 148], ["S gene regions", "DNA", 154, 168], ["TrN", "DNA", 170, 173], ["ORF3 and M gene regions", "DNA", 186, 209], ["TrN", "DNA", 211, 214], ["E gene region", "DNA", 223, 236], ["GTR", "DNA", 238, 241], ["N gene region", "DNA", 254, 267], ["BI analysis", "TEST", 38, 49], ["GTR", "TREATMENT", 116, 119], ["the ORF1a", "TEST", 132, 141], ["ORF1b", "TEST", 143, 148], ["the ORF3", "PROBLEM", 182, 190], ["the E gene region", "TREATMENT", 219, 236], ["GTR", "TREATMENT", 238, 241], ["the N gene region", "TREATMENT", 250, 267]]], ["Each analysis was performed with the following parameters: number of substitution rate, 6; rates, gamma; the number of generation, 100,000,000; sample frequency, 500; the number of chains, 1; burn-in generation, 25% of the number of generations.", [["gamma", "PROTEIN", 98, 103], ["Each analysis", "TEST", 0, 13], ["substitution rate", "TEST", 69, 86], ["rates", "TEST", 91, 96], ["sample frequency", "TEST", 144, 160], ["burn", "TEST", 192, 196]]], ["Bayesian posterior probability (BPP) values (Erixon et al. 2003) shown on respective internal nodes indicated the robustness of the phylogenomic analysis.", [["internal nodes", "ANATOMY", 85, 99], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 85, 99], ["Bayesian posterior probability (BPP) values", "TEST", 0, 43], ["the phylogenomic analysis", "TEST", 128, 153], ["nodes", "OBSERVATION", 94, 99]]], ["Bayesian posterior probability (BPP) values are shown on internal nodes to indicate the robustness of the phylogenomic analysis.Phylogenomic reconstructionsML analysis was also conducted using PhyML 3.1 (Guindon et al. 2009 ) with the following options: model of nucleotide substitution, GTR; nonparametric bootstrap analysis, yes; number of replicates, 500; proportion of invariable site (pinvar), estimated; nst, 6; number of substitution rate categories, 6; gamma shape parameter, estimated by program; optimize tree topology, yes.", [["nucleotide", "CHEMICAL", 263, 273], ["nucleotide", "CHEMICAL", 263, 273], ["internal nodes", "MULTI-TISSUE_STRUCTURE", 57, 71], ["Bayesian posterior probability (BPP) values", "TEST", 0, 43], ["internal nodes", "PROBLEM", 57, 71], ["the phylogenomic analysis", "TEST", 102, 127], ["Phylogenomic reconstructionsML analysis", "TEST", 128, 167], ["PhyML", "TEST", 193, 198], ["nucleotide substitution", "TREATMENT", 263, 286], ["GTR", "TREATMENT", 288, 291], ["nonparametric bootstrap analysis", "TEST", 293, 325], ["substitution rate categories", "TREATMENT", 428, 456], ["posterior", "ANATOMY_MODIFIER", 9, 18], ["nodes", "OBSERVATION", 66, 71]]], ["A bootstrap test (with 1000 pseudoreplicates) (Felsenstein 1985) was performed to determine the statistical support for each node of the ML tree.Selection pressure analysisThe selection pressure is important indicators of evolutionary biology.", [["node", "ANATOMY", 125, 129], ["ML tree", "MULTI-TISSUE_STRUCTURE", 137, 144], ["A bootstrap test", "TEST", 0, 16], ["Selection pressure analysis", "TEST", 145, 172], ["The selection pressure", "TREATMENT", 172, 194], ["node", "OBSERVATION", 125, 129], ["ML tree", "OBSERVATION", 137, 144], ["pressure", "OBSERVATION_MODIFIER", 186, 194]]], ["To evaluate the selective pressure that drives PEDV evolution, we estimated the relative rates of nonsynonymous and synonymous substitution (\u03c9 = dN/dS) by using ClustalX 1.81 (Thompson et al. 1997) , PAL2NAL (Suyama et al. 2006 ) and the CodeML program in the PAML 4.7 package (Yang 2007) .", [["the selective pressure", "TEST", 12, 34], ["nonsynonymous and synonymous substitution", "TREATMENT", 98, 139], ["the CodeML program", "TREATMENT", 234, 252], ["selective", "OBSERVATION_MODIFIER", 16, 25], ["pressure", "OBSERVATION", 26, 34], ["synonymous substitution", "OBSERVATION", 116, 139]]], ["Ratio values equal to 1 indicate neutral evolution; < 1, negative selection; and > 1, positive selection.Co-estimation of substitution rates, time of the most recent common ancestor, and population size changesTo explore the evolutionary history of the global PEDVs, the substitution rates, time of the most recent common ancestor (tMRCA), and changes in population size were co-estimated using the Bayesian coalescent approaches as implemented in BEAST 2.3.1 (Bouckaert et al. 2014) .", [["Ratio values", "TEST", 0, 12], ["substitution rates", "PROBLEM", 122, 140], ["population size changes", "PROBLEM", 187, 210], ["the global PEDVs", "PROBLEM", 249, 265], ["the substitution rates", "TREATMENT", 267, 289], ["changes in population size", "PROBLEM", 344, 370], ["the Bayesian coalescent approaches", "TREATMENT", 395, 429], ["neutral evolution", "OBSERVATION_MODIFIER", 33, 50], ["substitution rates", "OBSERVATION", 122, 140], ["size", "OBSERVATION_MODIFIER", 198, 202], ["size", "OBSERVATION_MODIFIER", 366, 370]]], ["We combined three molecular clock models (strict, relaxed uncorrelated exponential, and relaxed uncorrelated lognormal) with three different demographic models (constant size, exponential growth, and Bayesian skyline) to make nine datasets.", [["size", "OBSERVATION_MODIFIER", 170, 174]]], ["These nine datasets were simulated following generalised time reversible (GTR) substitution model.", [["generalised time reversible (GTR) substitution model", "TREATMENT", 45, 97]]], ["Next, each dataset was run for 550,000,000 generations to ensure convergence of all parameters (ESS > 100) with discarded burn-in of 10%.", [["burn", "DISEASE", 122, 126], ["ESS", "TEST", 96, 99], ["burn", "OBSERVATION", 122, 126]]], ["By comparison of Bayesian factors (log 10 Bayes factors > 2 in all cases), based on the relative marginal likelihoods of the nine models, the relaxed uncorrelated exponential clock and exponential population size model were selected as the best fit for the data set.", [["Bayesian factors", "PROTEIN", 17, 33], ["Bayes factors", "PROTEIN", 42, 55], ["Bayes factors", "TEST", 42, 55], ["exponential population size model", "TREATMENT", 185, 218], ["marginal", "OBSERVATION_MODIFIER", 97, 105], ["exponential clock", "OBSERVATION", 163, 180], ["exponential", "OBSERVATION_MODIFIER", 185, 196], ["population", "OBSERVATION_MODIFIER", 197, 207], ["size", "OBSERVATION_MODIFIER", 208, 212]]], ["The resulting convergence was analyzed using Tracer 1.6 (Rambaut and Drummond 2013a), and the statistical uncertainties were summarized in the 95% highest posterior density (HPD) intervals.", [["Tracer", "TEST", 45, 51], ["posterior", "ANATOMY_MODIFIER", 155, 164], ["density", "OBSERVATION", 165, 172]]], ["Trees were summarized as maximum clade credibility (MCC) tree using TreeAnnotator Table 1 The best fit evolutionary models estimated for PEDV genomic regions with Modeltest \u2212lnL log likelihood scores, Pinvar proportion of invariable sites (Drummond et al. 2005) .Sequence analysisFor a total of 138 global PEDVs, the features of the entire coding region and their individual gene sequences are summarized in Tables 2, 3 and Fig. 1 .", [["PEDVs", "CANCER", 306, 311], ["PEDV genomic regions", "DNA", 137, 157], ["PEDV", "SPECIES", 137, 141], ["TreeAnnotator Table", "TREATMENT", 68, 87], ["evolutionary models", "TEST", 103, 122], ["PEDV genomic regions", "PROBLEM", 137, 157], ["Modeltest", "TEST", 163, 172], ["Sequence analysis", "TEST", 263, 280]]], ["Our plotting analyses also illustrated higher sequence variabilities for both nucleotides and amino acids in the S region, though both nucleotide and amino acid alterations were evenly distributed throughout the coding regions (Fig. 1 ).", [["amino acids", "CHEMICAL", 94, 105], ["nucleotide", "CHEMICAL", 135, 145], ["amino acid", "CHEMICAL", 150, 160], ["nucleotides", "CHEMICAL", 78, 89], ["amino acids", "CHEMICAL", 94, 105], ["nucleotide", "CHEMICAL", 135, 145], ["amino acid", "CHEMICAL", 150, 160], ["amino acids", "AMINO_ACID", 94, 105], ["amino acid", "AMINO_ACID", 150, 160], ["S region", "DNA", 113, 121], ["coding regions", "DNA", 212, 226], ["Our plotting analyses", "TEST", 0, 21], ["higher sequence variabilities", "PROBLEM", 39, 68], ["both nucleotides", "TREATMENT", 73, 89], ["amino acids", "TEST", 94, 105], ["both nucleotide and amino acid alterations", "PROBLEM", 130, 172], ["amino acid", "OBSERVATION", 150, 160]]], ["In addition, the group-specific conserved amino acid residues were investigated to observe difference between classical group and pandemic group.", [["amino acid", "CHEMICAL", 42, 52], ["amino acid", "CHEMICAL", 42, 52], ["amino acid", "AMINO_ACID", 42, 52], ["amino acid residues", "TREATMENT", 42, 61]]], ["As a result, within multiple alignment, 27 specific conserved amino acid residues were discovered in classical isolates and 31 for pandemic isolates through five genes: ORF1a, ORF1b, S, ORF3, and N (Table 3) .", [["amino acid", "CHEMICAL", 62, 72], ["amino acid", "CHEMICAL", 62, 72], ["amino acid", "AMINO_ACID", 62, 72], ["ORF1a", "GENE_OR_GENE_PRODUCT", 169, 174], ["ORF1b", "GENE_OR_GENE_PRODUCT", 176, 181], ["ORF3", "GENE_OR_GENE_PRODUCT", 186, 190], ["N (Table 3", "GENE_OR_GENE_PRODUCT", 196, 206], ["ORF1a", "DNA", 169, 174], ["ORF1b", "DNA", 176, 181], ["S", "DNA", 183, 184], ["ORF3", "DNA", 186, 190], ["N", "DNA", 196, 197], ["amino acid residues", "TEST", 62, 81], ["pandemic isolates", "PROBLEM", 131, 148], ["ORF3", "TEST", 186, 190]]], ["On the other hand, there were no group-specific conserved amino acid on E and M genes.Phylogenomic reconstructionsBI (both uniformed and partitioned model approaches) and ML methods produced identical tree topologies, and supported the features of the maximum clade credibility (MCC) tree ( Fig. 2 and Fig. S1 ).", [["amino acid", "CHEMICAL", 58, 68], ["amino acid", "CHEMICAL", 58, 68], ["amino acid", "AMINO_ACID", 58, 68], ["S1", "GENE_OR_GENE_PRODUCT", 307, 309], ["E and M genes", "DNA", 72, 85], ["S1", "PROTEIN", 307, 309], ["Phylogenomic reconstructionsBI", "TEST", 86, 116], ["tree topologies", "OBSERVATION", 201, 216]]], ["138 isolates of PEDV are classified as six groups except for one unclassified isolate (KM242131).", [["PEDV", "CANCER", 16, 20], ["PEDV", "SPECIES", 16, 20], ["PEDV", "PROBLEM", 16, 20]]], ["Group 1-5 were clustered with theSelection pressure analysisThe nonsynonymous/synonymous substitution ratio (\u03c9 = dN/ dS) values derived from the entire data set were estimated and indicated in Table 2 .", [["theSelection pressure analysis", "TEST", 30, 60], ["The nonsynonymous/synonymous substitution ratio", "TEST", 60, 107], ["synonymous substitution", "OBSERVATION", 78, 101]]], ["The dN/dS value of complete coding sequences was 0.167, and all the values for each component gene were also lower than 1.0.", [["complete coding sequences", "TEST", 19, 44]]], ["Among the seven PEDV genes, the dN/dS value of M gene had the highest value (0.272), while the corresponding value for ORF1b was lowest (0.077).Co-estimation of substitution rate, divergence times, and population size changesThe complete coding genome sequences of 138 PEDVs collected during the past 38 years were also analyzed using a Bayesian coalescent approach.", [["PEDV", "GENE_OR_GENE_PRODUCT", 16, 20], ["ORF1b", "GENE_OR_GENE_PRODUCT", 119, 124], ["PEDVs", "CANCER", 269, 274], ["PEDV genes", "DNA", 16, 26], ["M gene", "DNA", 47, 53], ["ORF1b", "PROTEIN", 119, 124], ["ORF1b", "TEST", 119, 124], ["substitution rate", "PROBLEM", 161, 178], ["population size changes", "PROBLEM", 202, 225], ["a Bayesian coalescent approach", "TREATMENT", 335, 365], ["substitution rate", "OBSERVATION", 161, 178], ["size", "OBSERVATION_MODIFIER", 213, 217]]], ["Under the relaxed uncorrelated exponential clock and exponential growth population size model, the 3) years ago, followed by chronological divergence of Group 5 (19.9 years ago; 95% HPD 9.9-31.6), Group 3 (13.2 years ago; 95% HPD 7.3-20.2), Group 4 (11.7 years ago; 95% HPD 6.1-18.9), Group 2 (10.0 years ago; 95% HPD 5.9-14.8) and Group 1 (5.0 years ago; 95% HPD 3.2-8.1).Co-estimation of substitution rate, divergence times, and population size changesIn Bayesian skyline plot, visualized in Fig. 3 , the effective population size of PEDV keeps consistent level except for a short period around 2012.", [["PEDV", "SPECIES", 536, 540], ["HPD", "TEST", 182, 185], ["HPD", "TEST", 226, 229], ["HPD", "TEST", 270, 273], ["HPD", "TEST", 314, 317], ["HPD", "TEST", 360, 363], ["substitution rate", "TREATMENT", 390, 407], ["Bayesian skyline plot", "PROBLEM", 457, 478], ["PEDV", "PROBLEM", 536, 540], ["exponential", "OBSERVATION_MODIFIER", 53, 64], ["growth", "OBSERVATION_MODIFIER", 65, 71], ["population", "OBSERVATION_MODIFIER", 72, 82], ["size", "OBSERVATION_MODIFIER", 83, 87], ["size", "OBSERVATION_MODIFIER", 442, 446], ["effective", "OBSERVATION_MODIFIER", 507, 516], ["population", "OBSERVATION_MODIFIER", 517, 527], ["size", "OBSERVATION_MODIFIER", 528, 532], ["PEDV", "OBSERVATION", 536, 540]]], ["In the early phase in this period, the effective population size decreased rapidly.", [["the effective population size", "PROBLEM", 35, 64], ["early phase", "OBSERVATION_MODIFIER", 7, 18], ["effective", "OBSERVATION_MODIFIER", 39, 48], ["population", "OBSERVATION_MODIFIER", 49, 59], ["size", "OBSERVATION_MODIFIER", 60, 64], ["decreased", "OBSERVATION_MODIFIER", 65, 74], ["rapidly", "OBSERVATION_MODIFIER", 75, 82]]], ["Moreover, in the latter phase of this period, the effective population size recovered its original level after a rapid increase.DiscussionThis study aimed to characterize the PEDV genome and explore its evolutionary features using protein coding genome sequences.", [["PEDV genome", "DNA", 175, 186], ["protein coding genome sequences", "DNA", 231, 262], ["PEDV", "SPECIES", 175, 179], ["a rapid increase", "PROBLEM", 111, 127], ["This study", "TEST", 138, 148], ["the PEDV genome", "PROBLEM", 171, 186], ["protein coding genome sequences", "TEST", 231, 262], ["effective", "OBSERVATION_MODIFIER", 50, 59], ["population", "OBSERVATION_MODIFIER", 60, 70], ["size", "OBSERVATION_MODIFIER", 71, 75], ["rapid", "OBSERVATION_MODIFIER", 113, 118], ["increase", "OBSERVATION_MODIFIER", 119, 127]]], ["Our pairwise comparison, of the complete coding genome sequences of 138 PEDVs, revealed that this virus had a high degree of genetic similarity compared to other porcine RNA viruses (average nucleotide identities, 77.8% for porcine reproductive and respiratory syndrome virus, 85.1% for foot-and-mouth disease virus, and 89.1% for classical swine fever virus) (Kwon et al. 2015; Yoon et al. 2013 Yoon et al. , 2011 .", [["nucleotide", "CHEMICAL", 191, 201], ["porcine reproductive and respiratory syndrome", "DISEASE", 224, 269], ["foot-and-mouth disease", "DISEASE", 287, 309], ["swine fever", "DISEASE", 341, 352], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 224, 275], ["foot-and-mouth disease virus", "ORGANISM", 287, 315], ["swine fever virus", "ORGANISM", 341, 358], ["coding genome sequences", "DNA", 41, 64], ["foot-and-mouth disease virus", "SPECIES", 287, 315], ["swine fever virus", "SPECIES", 341, 358], ["respiratory syndrome virus", "SPECIES", 249, 275], ["foot-and-mouth disease virus", "SPECIES", 287, 315], ["swine fever virus", "SPECIES", 341, 358], ["this virus", "PROBLEM", 93, 103], ["genetic similarity", "PROBLEM", 125, 143], ["other porcine RNA viruses", "PROBLEM", 156, 181], ["nucleotide identities", "TEST", 191, 212], ["porcine reproductive and respiratory syndrome virus", "PROBLEM", 224, 275], ["foot", "TEST", 287, 291], ["mouth disease virus", "PROBLEM", 296, 315], ["classical swine fever virus", "PROBLEM", 331, 358], ["high degree", "OBSERVATION_MODIFIER", 110, 121], ["RNA viruses", "OBSERVATION", 170, 181], ["respiratory syndrome", "OBSERVATION", 249, 269], ["mouth", "ANATOMY", 296, 301]]], ["Among the seven genes, our analyses showed that S was identified as the most variable, and the result was consistent with previous study (Huang et al. 2013) .", [["our analyses", "TEST", 23, 35], ["previous study", "TEST", 122, 136]]], ["Like other coronavirus S proteins, the PEDV S protein is a primary target for vaccination; it plays key roles in receptor binding for viral entry and neutralizing antibody induction for protective immunity (Huang et al. 2013; Makadiya et al. 2016 ).", [["coronavirus S proteins", "GENE_OR_GENE_PRODUCT", 11, 33], ["PEDV S", "GENE_OR_GENE_PRODUCT", 39, 45], ["coronavirus S proteins", "PROTEIN", 11, 33], ["PEDV S protein", "PROTEIN", 39, 53], ["other coronavirus S proteins", "PROBLEM", 5, 33], ["the PEDV S protein", "TEST", 35, 53], ["vaccination", "TREATMENT", 78, 89], ["viral entry", "TREATMENT", 134, 145], ["neutralizing antibody induction", "TREATMENT", 150, 181], ["coronavirus", "OBSERVATION", 11, 22]]], ["An additional finding of the present study is that, for each of classical and pandemic clade, there were a number of amino acid residues that were conserved through five genes: ORF1a, ORF1b, S, ORF3, and N. Here, as expected, S gene had the largest proportion of specific amino acid sequences in both classical and pandemic viruses.", [["amino acid", "CHEMICAL", 117, 127], ["amino acid", "CHEMICAL", 272, 282], ["amino acid", "CHEMICAL", 117, 127], ["amino acid", "CHEMICAL", 272, 282], ["amino acid", "AMINO_ACID", 117, 127], ["ORF1a", "GENE_OR_GENE_PRODUCT", 177, 182], ["ORF1b", "GENE_OR_GENE_PRODUCT", 184, 189], ["S", "GENE_OR_GENE_PRODUCT", 191, 192], ["ORF3", "GENE_OR_GENE_PRODUCT", 194, 198], ["amino acid", "AMINO_ACID", 272, 282], ["ORF1a", "DNA", 177, 182], ["ORF1b", "DNA", 184, 189], ["S", "DNA", 191, 192], ["ORF3", "DNA", 194, 198], ["S gene", "DNA", 226, 232], ["the present study", "TEST", 25, 42], ["amino acid residues", "PROBLEM", 117, 136], ["specific amino acid sequences", "PROBLEM", 263, 292], ["pandemic viruses", "OBSERVATION", 315, 331]]], ["Since only a few amino acid substitutions in its sequence can alter the biological features as well as the antigenic properties of the virus, these specific amino acid residues might be regarded as useful markers for the classification and diagnosis of PEDV.", [["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "CHEMICAL", 17, 27], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "AMINO_ACID", 17, 27], ["amino acid", "AMINO_ACID", 157, 167], ["PEDV", "CANCER", 253, 257], ["PEDV", "SPECIES", 253, 257], ["a few amino acid substitutions", "PROBLEM", 11, 41], ["the virus", "PROBLEM", 131, 140], ["these specific amino acid residues", "TREATMENT", 142, 176], ["PEDV", "PROBLEM", 253, 257], ["acid substitutions", "OBSERVATION", 23, 41]]], ["Although the phylogeny of PEDV has been studied in recent years using individual gene (S, ORF3, E, M, and N) or genome sequences, the present study provides further details on genome-wide phylogeny.", [["PEDV", "GENE_OR_GENE_PRODUCT", 26, 30], ["ORF3", "GENE_OR_GENE_PRODUCT", 90, 94], ["E", "GENE_OR_GENE_PRODUCT", 96, 97], ["PEDV", "DNA", 26, 30], ["ORF3", "DNA", 90, 94], ["E", "DNA", 96, 97], ["genome sequences", "DNA", 112, 128], ["PEDV", "SPECIES", 26, 30], ["PEDV", "PROBLEM", 26, 30], ["ORF3", "TEST", 90, 94], ["the present study", "TEST", 130, 147]]], ["Our findings revealed that there were two clearly defined top-level clades for PEDV, one containing the classical isolates and the other comprising the pandemic viruses.", [["PEDV", "CHEMICAL", 79, 83], ["PEDV", "SPECIES", 79, 83], ["Our findings", "TEST", 0, 12], ["PEDV", "PROBLEM", 79, 83], ["the classical isolates", "PROBLEM", 100, 122], ["the pandemic viruses", "PROBLEM", 148, 168], ["top", "OBSERVATION_MODIFIER", 58, 61], ["pandemic viruses", "OBSERVATION", 152, 168]]], ["This point is consistent with the previous reports (Lin et al. 2016; Suzuki et al. 2015) .", [["consistent with", "UNCERTAINTY", 14, 29]]], ["The classical isolates were prototype CV777-like isolates that have appeared worldwide since the first report in England in 1971 (Oldham 1972) .", [["CV777", "ORGANISM", 38, 43], ["The classical isolates", "TEST", 0, 22]]], ["The pandemic PEDVs have also spread worldwide since the first emergence in China in late 2010 (Sun et al. 2012) , and have caused great economic losses to the global swine industry due to its fatal mortality and morbidity.", [["swine", "SPECIES", 166, 171], ["great economic losses", "PROBLEM", 130, 151], ["its fatal mortality", "PROBLEM", 188, 207], ["morbidity", "PROBLEM", 212, 221], ["spread", "OBSERVATION_MODIFIER", 29, 35], ["worldwide", "OBSERVATION_MODIFIER", 36, 45], ["great", "OBSERVATION_MODIFIER", 130, 135], ["economic losses", "OBSERVATION", 136, 151]]], ["Within the pandemic clade, our phylogenomic trees showed two subclades (Asian and North American), and this supported the viewpoints of previous authors (Lee and Lee 2014; Suzuki et al. 2015; Vlasova et al. 2014; Yamamoto et al. 2016) .", [["subclades", "OBSERVATION_MODIFIER", 61, 70]]], ["In addition, our results show that the North American pandemic clade were divided into two groups.", [["the North American pandemic clade", "TREATMENT", 35, 68]]], ["The former consisted of only non-S INDEL PEDVs, while the latter was composed of both non-S INDEL and lower virulent S INDEL PEDVs containing insertions and deletions in the N-terminal region of the spike protein.", [["N", "CHEMICAL", 174, 175], ["-S INDEL", "PROTEIN", 89, 97], ["N-terminal region", "DNA", 174, 191], ["spike protein", "PROTEIN", 199, 212], ["both non-S INDEL", "PROBLEM", 81, 97], ["lower virulent S INDEL PEDVs containing insertions", "TREATMENT", 102, 152], ["deletions in the N-terminal region", "TREATMENT", 157, 191], ["the spike protein", "PROBLEM", 195, 212], ["lower", "OBSERVATION_MODIFIER", 102, 107], ["virulent", "OBSERVATION_MODIFIER", 108, 116], ["terminal", "ANATOMY_MODIFIER", 176, 184]]], ["This is in accord with the viewpoints of some PEDV researchers Lin et al. 2016; Suzuki et al. 2015; Vlasova et al. 2014 ).DiscussionNext, our phylogenomic results postulated that there was no immediate relationship between time and/or country of collection and the evolution of global PEDVs within each clade.", [["PEDVs", "GENE_OR_GENE_PRODUCT", 285, 290], ["collection", "PROBLEM", 246, 256], ["global PEDVs", "PROBLEM", 278, 290], ["collection", "OBSERVATION", 246, 256], ["global", "OBSERVATION_MODIFIER", 278, 284], ["PEDVs", "OBSERVATION", 285, 290]]], ["The phylogenetic groupings were consistent with the views of previous works (Lee 2015; Lee and Lee 2014; Lin et al. 2016; Yamamoto et al. 2016) , and this may be largely due to the rapid expansion and diversification of PEDVs over a relatively short period and their rapid spread via frequent international trade in livestock.", [["the rapid expansion", "PROBLEM", 177, 196], ["diversification of PEDVs", "PROBLEM", 201, 225], ["consistent with", "UNCERTAINTY", 32, 47], ["rapid", "OBSERVATION_MODIFIER", 181, 186], ["expansion", "OBSERVATION", 187, 196]]], ["Such complicated population structure can make vaccine strategies and local regulation more difficult.", [["Such complicated population structure", "PROBLEM", 0, 37], ["vaccine strategies", "TREATMENT", 47, 65]]], ["Thus, it is essential to consistently monitor for changes in the mixed population structure of this virus.DiscussionIn this study, we first analyzed the selection pressure on the genomes of PEDVs.", [["PEDVs", "CELL", 190, 195], ["changes", "PROBLEM", 50, 57], ["this virus", "PROBLEM", 95, 105], ["this study", "TEST", 119, 129], ["mixed", "OBSERVATION_MODIFIER", 65, 70], ["population", "OBSERVATION", 71, 81]]], ["Our analyses showed that the influence of purifying selection is acting on the coding genome of the global PEDVs; the mean nonsynonymous/synonymous substitution ratio (\u03c9 = dN/dS) values for individual genes as well as complete genomes were low in all cases Fig. 2 Bayesian maximum clade credibility phylogenetic tree derived from the complete coding genome sequences of 138 PEDVs.", [["PEDVs", "GENE_OR_GENE_PRODUCT", 107, 112], ["coding genome", "DNA", 79, 92], ["global PEDVs", "DNA", 100, 112], ["coding genome sequences", "DNA", 343, 366], ["Our analyses", "TEST", 0, 12], ["purifying selection", "TREATMENT", 42, 61], ["the mean nonsynonymous/synonymous substitution ratio", "TEST", 114, 166], ["individual genes", "PROBLEM", 190, 206], ["synonymous substitution", "OBSERVATION", 137, 160]]], ["The data set (27,436 bps) was also analyzed phylogenetically using Bayesian inference (BI) and maximum likelihood (ML) methods, and both of them produced identical topology.", [["The data", "TEST", 0, 8], ["bps", "TEST", 21, 24]]], ["Divergence times (in years) are positioned below the nodes, and the 95% HPD intervals are in brackets.", [["nodes", "ANATOMY", 53, 58]]], ["The credibility of the phylogenetic analysis is presented above the nodes: the left numbers represent Bayesian posterior probabilities (> 0.80) and the right ones represent ML bootstrap values (> 60%).", [["the phylogenetic analysis", "TEST", 19, 44], ["Bayesian posterior probabilities", "TEST", 102, 134], ["ML bootstrap values", "TEST", 173, 192], ["nodes", "OBSERVATION", 68, 73], ["left", "ANATOMY_MODIFIER", 79, 83], ["Bayesian", "OBSERVATION_MODIFIER", 102, 110], ["posterior", "OBSERVATION_MODIFIER", 111, 120], ["probabilities", "OBSERVATION_MODIFIER", 121, 134], ["right", "ANATOMY_MODIFIER", 152, 157], ["ML bootstrap", "OBSERVATION", 173, 185]]], ["Groups are indicated above the corresponding nodes using colored circles.", [["nodes", "ANATOMY", 45, 50], ["nodes", "MULTI-TISSUE_STRUCTURE", 45, 50], ["nodes", "OBSERVATION", 45, 50]]], ["Among them, the M gene showed the highest dN/dS value, while the ORF1b presented the lowest one.", [["M gene", "DNA", 16, 22], ["dN", "DNA", 42, 44], ["ORF1b", "DNA", 65, 70]]], ["The purifying selections of other porcine RNA viruses were also postulated in our previous publications, which were much lower than that of PEDV (0.167); 0.068 for foot-and-mouth disease (Yoon et al. 2011 ) and 0.067 for classical swine fever virus (Kwon et al. 2015) .DiscussionFinally, in order to explore the evolutionary mechanism of PEDV, we first co-estimated an overall evolutionary rate and population size changes as well as divergence times for the virus.", [["foot-and-mouth disease", "DISEASE", 164, 186], ["swine fever", "DISEASE", 231, 242], ["porcine", "ORGANISM", 34, 41], ["mouth", "ORGAN", 173, 178], ["PEDV", "GENE_OR_GENE_PRODUCT", 338, 342], ["foot-and-mouth", "SPECIES", 164, 178], ["swine fever virus", "SPECIES", 231, 248], ["classical swine fever virus", "SPECIES", 221, 248], ["PEDV", "SPECIES", 338, 342], ["other porcine RNA viruses", "PROBLEM", 28, 53], ["PEDV", "TEST", 140, 144], ["foot", "TEST", 164, 168], ["mouth disease", "PROBLEM", 173, 186], ["classical swine fever virus", "PROBLEM", 221, 248], ["PEDV", "PROBLEM", 338, 342], ["population size changes", "PROBLEM", 399, 422], ["the virus", "PROBLEM", 455, 464], ["porcine RNA viruses", "OBSERVATION", 34, 53], ["foot", "ANATOMY", 164, 168], ["mouth", "ANATOMY", 173, 178], ["population", "OBSERVATION_MODIFIER", 399, 409], ["size", "OBSERVATION_MODIFIER", 410, 414]]], ["The evolutionary rate of PEDV was computed at 3.38 \u00d7 10 \u22124 substitutions/site/year for its complete coding genome, which was within the range of 10 \u22122 -10 \u22125 nucleotide substitutions/site/year for nearly all RNA viruses (Duffy et al. 2008) .", [["nucleotide", "CHEMICAL", 158, 168], ["PEDV", "GENE_OR_GENE_PRODUCT", 25, 29], ["PEDV", "DNA", 25, 29], ["PEDV", "SPECIES", 25, 29], ["PEDV", "PROBLEM", 25, 29], ["nucleotide substitutions/site", "TREATMENT", 158, 187]]], ["These fast evolutionary rates of RNA viruses including PEDV generally arise from several factors such as short generation times, small genome size, rapid mutation, and lack of polymerase proof-reading (Elena and Sanju\u00e1n 2005) .", [["PEDV", "GENE_OR_GENE_PRODUCT", 55, 59], ["RNA viruses", "PROBLEM", 33, 44], ["PEDV", "PROBLEM", 55, 59], ["short generation times", "PROBLEM", 105, 127], ["small genome size", "PROBLEM", 129, 146], ["rapid mutation", "PROBLEM", 148, 162], ["RNA viruses", "OBSERVATION", 33, 44], ["small", "OBSERVATION_MODIFIER", 129, 134], ["genome", "OBSERVATION_MODIFIER", 135, 141], ["size", "OBSERVATION_MODIFIER", 142, 146], ["rapid mutation", "OBSERVATION", 148, 162]]], ["As a result, it is possible that RNA virus raises viral population adaptation, survival, and fitness, allowing them to spread to novel environments and hosts rapidly (Lauring and Andino 2010) .", [["RNA virus", "PROBLEM", 33, 42], ["RNA virus", "OBSERVATION", 33, 42]]], ["Our molecular dating indicates that the tMRCA of PEDV was 75.9 (95% HPD 37.01-126.65) years ago; they were derived approximately in 1940, which was about 9000 years later than the domestication of wild boar (Larson et al. 2005; Zeder 2008 ).", [["boar", "ORGANISM", 202, 206], ["boar", "SPECIES", 202, 206], ["PEDV", "SPECIES", 49, 53], ["PEDV", "TEST", 49, 53], ["HPD", "TEST", 68, 71]]], ["This configuration revealed that the tMRCA of PEDV is similar to that of transmissible gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV) which are phylogenetically related porcine RNA viruses with similar genome size (28 kb).", [["PEDV", "CHEMICAL", 46, 50], ["transmissible gastroenteritis", "DISEASE", 73, 102], ["respiratory coronavirus", "DISEASE", 128, 151], ["tMRCA", "GENE_OR_GENE_PRODUCT", 37, 42], ["PEDV", "GENE_OR_GENE_PRODUCT", 46, 50], ["transmissible gastroenteritis virus", "ORGANISM", 73, 108], ["TGEV", "ORGANISM", 110, 114], ["porcine respiratory coronavirus", "ORGANISM", 120, 151], ["PRCV", "CANCER", 153, 157], ["porcine", "ORGANISM", 194, 201], ["tMRCA", "PROTEIN", 37, 42], ["PEDV", "PROTEIN", 46, 50], ["transmissible gastroenteritis virus", "SPECIES", 73, 108], ["porcine respiratory coronavirus", "SPECIES", 120, 151], ["transmissible gastroenteritis virus", "SPECIES", 73, 108], ["TGEV", "SPECIES", 110, 114], ["porcine respiratory coronavirus", "SPECIES", 120, 151], ["PRCV", "SPECIES", 153, 157], ["the tMRCA of PEDV", "PROBLEM", 33, 50], ["transmissible gastroenteritis virus", "PROBLEM", 73, 108], ["TGEV", "PROBLEM", 110, 114], ["porcine respiratory coronavirus (PRCV)", "PROBLEM", 120, 158], ["porcine RNA viruses", "PROBLEM", 194, 213], ["PEDV", "OBSERVATION", 46, 50], ["transmissible", "OBSERVATION_MODIFIER", 73, 86], ["gastroenteritis", "OBSERVATION", 87, 102], ["respiratory coronavirus", "OBSERVATION", 128, 151], ["porcine RNA viruses", "OBSERVATION", 194, 213], ["genome", "OBSERVATION_MODIFIER", 227, 233], ["size", "OBSERVATION_MODIFIER", 234, 238]]], ["The tMRCA of TGEV and PRCV appeared in 1941 and the substitution rate was 7.5 \u00b1 2 \u00d7 10 \u22124 (substitutions/site/year) (S\u00e1nchez et al. 1992 ).", [["TGEV", "ORGANISM", 13, 17], ["PRCV", "CANCER", 22, 26], ["tMRCA", "PROTEIN", 4, 9], ["TGEV", "SPECIES", 13, 17], ["the substitution rate", "TEST", 48, 69], ["TGEV", "OBSERVATION", 13, 17]]], ["On the other hand, the origin of PEDV were relatively younger than other porcine viruses with small genome size; 786 for tMRCA of porcine reproductive and respiratory syndrome virus (15 kb) (Yoon et al. 2011) ; 481 for tMRCA of foot-and-mouth disease virus (8 kb) (Yoon et al. 2011) ; 2770 for tMRCA of classical swine fever virus (12 kb) (Kwon et al. 2015) .", [["porcine reproductive and respiratory syndrome", "DISEASE", 130, 175], ["swine fever", "DISEASE", 313, 324], ["PEDV", "GENE_OR_GENE_PRODUCT", 33, 37], ["porcine reproductive and respiratory syndrome virus", "ORGANISM", 130, 181], ["foot-and-mouth disease virus", "ORGANISM", 228, 256], ["classical swine fever virus", "ORGANISM", 303, 330], ["porcine", "SPECIES", 130, 137], ["foot-and-mouth disease virus", "SPECIES", 228, 256], ["swine fever virus", "SPECIES", 313, 330], ["porcine reproductive and respiratory syndrome virus", "SPECIES", 130, 181], ["foot-and-mouth disease virus", "SPECIES", 228, 256], ["classical swine fever virus", "SPECIES", 303, 330], ["PEDV", "PROBLEM", 33, 37], ["small genome size", "PROBLEM", 94, 111], ["porcine reproductive", "PROBLEM", 130, 150], ["respiratory syndrome virus", "PROBLEM", 155, 181], ["tMRCA of foot", "PROBLEM", 219, 232], ["mouth disease virus", "PROBLEM", 237, 256], ["classical swine fever virus", "PROBLEM", 303, 330], ["origin", "ANATOMY_MODIFIER", 23, 29], ["PEDV", "OBSERVATION", 33, 37], ["small", "OBSERVATION_MODIFIER", 94, 99], ["genome", "OBSERVATION_MODIFIER", 100, 106], ["size", "OBSERVATION_MODIFIER", 107, 111], ["respiratory syndrome", "OBSERVATION", 155, 175], ["foot", "ANATOMY", 228, 232], ["mouth", "ANATOMY", 237, 242]]], ["As above, the evolutionary rate and tMRCA of porcine RNA virus did not correspond to relationship between evolution rate and genome size.", [["tMRCA", "GENE_OR_GENE_PRODUCT", 36, 41], ["porcine RNA virus", "ORGANISM", 45, 62], ["porcine", "SPECIES", 45, 52], ["the evolutionary rate", "TEST", 10, 31], ["tMRCA of porcine RNA virus", "PROBLEM", 36, 62], ["porcine RNA virus", "OBSERVATION", 45, 62], ["genome", "OBSERVATION_MODIFIER", 125, 131], ["size", "OBSERVATION_MODIFIER", 132, 136]]], ["These conflicting result suggest that the evolution rate of porcine RNA virus was affected by other variables rather than genome size.DiscussionRegarding the effective population size changes of PEDVs, our Bayesian skyline plot analyses (BSP) indicated that the PEDV had maintained constant effective population size only excluding a short period, around 2012.", [["PEDV", "CHEMICAL", 262, 266], ["porcine", "ORGANISM", 60, 67], ["PEDV", "SPECIES", 262, 266], ["porcine RNA virus", "PROBLEM", 60, 77], ["our Bayesian skyline plot analyses", "TEST", 202, 236], ["the PEDV", "PROBLEM", 258, 266], ["porcine RNA virus", "OBSERVATION", 60, 77], ["size", "OBSERVATION_MODIFIER", 129, 133], ["size", "OBSERVATION_MODIFIER", 179, 183], ["size", "OBSERVATION_MODIFIER", 312, 316]]], ["This drastic change is visualized as a valley shape in our plot showing the effective number of infection occurrence.", [["infection", "DISEASE", 96, 105], ["This drastic change", "PROBLEM", 0, 19], ["a valley shape", "PROBLEM", 37, 51], ["our plot", "TEST", 55, 63], ["infection occurrence", "PROBLEM", 96, 116], ["drastic", "OBSERVATION_MODIFIER", 5, 12], ["change", "OBSERVATION", 13, 19], ["valley shape", "OBSERVATION_MODIFIER", 39, 51], ["effective", "OBSERVATION_MODIFIER", 76, 85], ["number", "OBSERVATION_MODIFIER", 86, 92], ["infection", "OBSERVATION", 96, 105]]], ["This feature was consistent with the history of PEDV prevalence as follows.", [["PEDV", "SPECIES", 48, 52], ["PEDV prevalence", "PROBLEM", 48, 63], ["consistent with", "UNCERTAINTY", 17, 32], ["PEDV", "OBSERVATION", 48, 52]]], ["Since the first report of PEDV in England in 1971, the virus prevailed until the 1980s in Europe.", [["PEDV", "CHEMICAL", 26, 30], ["PEDV", "SPECIES", 26, 30], ["PEDV", "PROBLEM", 26, 30], ["the virus", "PROBLEM", 51, 60], ["PEDV", "OBSERVATION", 26, 30]]], ["From the 1990s to early 2010s, the major outbreaks were also reported in East Asia.", [["major", "OBSERVATION_MODIFIER", 35, 40], ["outbreaks", "OBSERVATION", 41, 50]]], ["In 2012, the global outbreaks of PEDV actually seemed to settle down.", [["PEDV", "CHEMICAL", 33, 37], ["PEDV", "SPECIES", 33, 37], ["PEDV", "PROBLEM", 33, 37]]], ["However, unfortunately, there were recurrences of a new strain in April 2013 in the USA, and the virus spread to worldwide by 2015.", [["a new strain", "PROBLEM", 50, 62], ["the virus", "PROBLEM", 93, 102], ["new", "OBSERVATION_MODIFIER", 52, 55], ["strain", "OBSERVATION_MODIFIER", 56, 62]]], ["The additional factor of the sharp decline of PEDV population size might be the decrease in host population resulting from the outbreaks of other porcine diseases such as foot-and-mouth disease; there was a culling of > 3 million pigs in South Korea during the 2010-2011 foot-andmouth disease outbreaks.", [["porcine diseases", "DISEASE", 146, 162], ["foot-and-mouth disease", "DISEASE", 171, 193], ["porcine", "ORGANISM", 146, 153], ["foot", "ORGANISM_SUBDIVISION", 171, 175], ["mouth", "ORGAN", 180, 185], ["pigs", "ORGANISM", 230, 234], ["porcine", "SPECIES", 146, 153], ["foot-and-mouth", "SPECIES", 171, 185], ["pigs", "SPECIES", 230, 234], ["porcine", "SPECIES", 146, 153], ["the sharp decline", "PROBLEM", 25, 42], ["PEDV population size", "PROBLEM", 46, 66], ["host population", "PROBLEM", 92, 107], ["other porcine diseases", "PROBLEM", 140, 162], ["foot-and-mouth disease", "PROBLEM", 171, 193], ["andmouth disease outbreaks", "PROBLEM", 276, 302], ["sharp", "OBSERVATION_MODIFIER", 29, 34], ["decline", "OBSERVATION_MODIFIER", 35, 42], ["PEDV", "OBSERVATION", 46, 50], ["size", "OBSERVATION_MODIFIER", 62, 66], ["decrease", "OBSERVATION_MODIFIER", 80, 88], ["host population", "OBSERVATION", 92, 107], ["porcine diseases", "OBSERVATION", 146, 162], ["foot", "ANATOMY", 171, 175], ["mouth", "ANATOMY", 180, 185], ["disease", "OBSERVATION", 186, 193], ["foot", "ANATOMY", 271, 275], ["disease", "OBSERVATION", 285, 292]]], ["The effective population size change was helpful to understand PEDV evolution by complementing continuous information to the discontinuous information such as tMRCA and substitution rate on each node of phylogenetic tree.DiscussionPEDV is still one of the most acute pathogens in the global swine industry.", [["tMRCA", "DNA", 159, 164], ["swine", "SPECIES", 291, 296], ["PEDV", "SPECIES", 63, 67], ["swine", "SPECIES", 291, 296], ["The effective population size change", "PROBLEM", 0, 36], ["tMRCA and substitution rate", "TREATMENT", 159, 186], ["effective", "OBSERVATION_MODIFIER", 4, 13], ["population", "OBSERVATION_MODIFIER", 14, 24], ["size", "OBSERVATION_MODIFIER", 25, 29], ["node", "OBSERVATION", 195, 199], ["phylogenetic tree", "OBSERVATION", 203, 220], ["acute", "OBSERVATION_MODIFIER", 261, 266], ["pathogens", "OBSERVATION", 267, 276]]], ["Accordingly, global policies are necessary to prevent and control this acute disease.", [["global policies", "TREATMENT", 13, 28], ["this acute disease", "PROBLEM", 66, 84], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["disease", "OBSERVATION", 77, 84]]], ["The extensive information on evolutionary dynamics we provide from this study might be very useful for the prevention and control of this virus as well as for improving our understanding of its epidemiology and evolution.", [["this study", "TEST", 67, 77], ["this virus", "PROBLEM", 133, 143]]], ["Our study is the first genome-wide phylogenomic study on the temporal and spatial dynamics of PEDV.", [["PEDV", "SPECIES", 94, 98], ["Our study", "TEST", 0, 9], ["wide phylogenomic study", "TEST", 30, 53], ["PEDV", "PROBLEM", 94, 98]]]], "PMC2852069": [["Isatin (2,3-dioxoindole), a versatile lead molecule for potential bioactive agents, and its derivatives were reported to posses anticancer1, antibacterial activities2\u20134.", [["Isatin", "CHEMICAL", 0, 6], ["2,3-dioxoindole", "CHEMICAL", 8, 23], ["Isatin", "CHEMICAL", 0, 6], ["2,3-dioxoindole", "CHEMICAL", 8, 23], ["Isatin", "SIMPLE_CHEMICAL", 0, 6], ["2,3-dioxoindole", "SIMPLE_CHEMICAL", 8, 23], ["Isatin (2,3-dioxoindole)", "TREATMENT", 0, 24], ["a versatile lead molecule", "TREATMENT", 26, 51], ["potential bioactive agents", "TREATMENT", 56, 82], ["its derivatives", "TREATMENT", 88, 103], ["antibacterial activities2\u20134", "TREATMENT", 141, 168], ["bioactive agents", "OBSERVATION", 66, 82]]], ["Methisazone (N-methylisatin-\u03b2-thiosemicarbazone) was one of the first clinically used synthetic antiviral agent5.", [["Methisazone", "CHEMICAL", 0, 11], ["N-methylisatin-\u03b2-thiosemicarbazone", "CHEMICAL", 13, 47], ["Methisazone", "CHEMICAL", 0, 11], ["N-methylisatin-\u03b2-thiosemicarbazone", "CHEMICAL", 13, 47], ["Methisazone", "SIMPLE_CHEMICAL", 0, 11], ["N-methylisatin-\u03b2-thiosemicarbazone", "SIMPLE_CHEMICAL", 13, 47], ["Methisazone", "TREATMENT", 0, 11], ["N-methylisatin-\u03b2-thiosemicarbazone)", "TREATMENT", 13, 48], ["synthetic antiviral agent5", "TREATMENT", 86, 112]]], ["Isatin derivative were reported for antiviral activity against a verity of pathogens viruses6 and N,N-disubstitutedthiosemicarbazone derivative of isatin were tested for inhibition of HIV-1 replication7.", [["Isatin", "CHEMICAL", 0, 6], ["N,N-disubstitutedthiosemicarbazone", "CHEMICAL", 98, 132], ["isatin", "CHEMICAL", 147, 153], ["Isatin", "CHEMICAL", 0, 6], ["N,N-disubstitutedthiosemicarbazone", "CHEMICAL", 98, 132], ["isatin", "CHEMICAL", 147, 153], ["Isatin derivative", "SIMPLE_CHEMICAL", 0, 17], ["N,N-disubstitutedthiosemicarbazone", "SIMPLE_CHEMICAL", 98, 132], ["isatin", "SIMPLE_CHEMICAL", 147, 153], ["HIV-1", "ORGANISM", 184, 189], ["replication7", "ORGANISM", 190, 202], ["HIV-1", "SPECIES", 184, 189], ["HIV-1", "SPECIES", 184, 189], ["Isatin derivative", "TREATMENT", 0, 17], ["antiviral activity", "TREATMENT", 36, 54], ["pathogens viruses6", "PROBLEM", 75, 93], ["N-disubstitutedthiosemicarbazone derivative of isatin", "TREATMENT", 100, 153], ["HIV", "PROBLEM", 184, 187]]], ["Previously we reported synthesis of novel isatin derivatives and evaluated antiviral activity against HIV-1 and HIV-2 in MT-4 cells8.", [["MT-4 cells8", "ANATOMY", 121, 132], ["isatin", "CHEMICAL", 42, 48], ["isatin", "CHEMICAL", 42, 48], ["isatin derivatives", "SIMPLE_CHEMICAL", 42, 60], ["HIV-1", "ORGANISM", 102, 107], ["HIV-2", "ORGANISM", 112, 117], ["MT-4 cells8", "CELL", 121, 132], ["HIV-1", "SPECIES", 102, 107], ["HIV-2", "SPECIES", 112, 117], ["HIV-1", "SPECIES", 102, 107], ["HIV-2", "SPECIES", 112, 117], ["novel isatin derivatives", "TREATMENT", 36, 60], ["antiviral activity", "TEST", 75, 93], ["HIV", "TEST", 102, 105], ["HIV", "TEST", 112, 115]]], ["Significant antiviral activity was observed with these compounds against HIV-1 replication9.", [["HIV-1", "ORGANISM", 73, 78], ["replication9", "ORGANISM", 79, 91], ["HIV-1", "SPECIES", 73, 78], ["HIV-1", "SPECIES", 73, 78], ["Significant antiviral activity", "PROBLEM", 0, 30], ["HIV", "PROBLEM", 73, 76], ["antiviral activity", "OBSERVATION", 12, 30]]]]}